0001144204-15-065342.txt : 20151113 0001144204-15-065342.hdr.sgml : 20151113 20151113161205 ACCESSION NUMBER: 0001144204-15-065342 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20150930 FILED AS OF DATE: 20151113 DATE AS OF CHANGE: 20151113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: OPGEN INC CENTRAL INDEX KEY: 0001293818 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 061614015 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-37367 FILM NUMBER: 151229255 BUSINESS ADDRESS: STREET 1: 708 QUINCE ORCHARD ROAD STREET 2: SUITE 205 CITY: GAITHERSBURG STATE: MD ZIP: 20878 BUSINESS PHONE: 240-813-1260 MAIL ADDRESS: STREET 1: 708 QUINCE ORCHARD ROAD STREET 2: SUITE 205 CITY: GAITHERSBURG STATE: MD ZIP: 20878 10-Q 1 v423020_10q.htm FORM 10-Q

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-Q

(Mark one)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2015

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number 001-37367

OPGEN, INC.

(Exact name of registrant as specified in its charter)


Delaware		06-1614015
(State or other jurisdiction of incorporation or organization)		(I.R.S. employer identification no.)

708 Quince Orchard Road, Suite 205, Gaithersburg, MD		20878
(Address of principal executive offices)		(Zip code)

Registrant’s telephone number, including area code: (240) 813-1260

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	¨	Accelerated filer	¨
Non-accelerated filer	¨	Smaller reporting company	x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

12,539,704 shares of the Company’s common stock, par value $0.01 per share, were outstanding as of October 30, 2015.

OPGEN, INC.

TABLE OF CONTENTS FOR FORM 10-Q

INFORMATION REGARDING FORWARD-LOOKING STATEMENTS

PART I.	FINANCIAL INFORMATION

Item 1.	Unaudited Condensed Consolidated Financial Statements
	Condensed Consolidated Balance Sheets at September 30, 2015 and December 31, 2014	4
	Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2015 and 2014	5
	Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2015 and 2014	6
	Notes to Unaudited Condensed Consolidated Financial Statements	7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	19
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	26
Item 4.	Controls and Procedures	27

PART II.	OTHER INFORMATION	27

Item 1.	Legal Proceedings	27
Item 1A.	Risk Factors	27
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	30
Item 3.	Defaults Upon Senior Securities	31
Item 4.	Mine Safety Disclosures	31
Item 5	Other Information	31
Item 6.	Exhibits	31

	SIGNATURES	32

INFORMATION REGARDING FORWARD-LOOKING STATEMENTS

This quarterly report on Form 10-Q of OpGen, Inc. and certain information incorporated herein by reference contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. In this Form 10-Q, we refer to OpGen, Inc. as the “Company,” “we,” “our” or “us.” All statements other than statements of historical facts contained herein, including statements regarding our future results of operations and financial position, strategy and plans, and our expectations for future operations, are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect” or the negative version of these words and similar expressions are intended to identify forward-looking statements.

We have based these forward-looking statements on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, strategy, short- and long-term business operations and objectives, and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in Part II Item 1A “Risk Factors.” In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed included herein may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Forward-looking statements include, but are not limited to, statements about:

the commercialization of our current products, including our QuickFISH® and PNAFISH diagnostic products for infectious diseases, Acuitas® MDRO test products and completed development and commercialization of our Acuitas Lighthouse™ MDRO Management System products and services;

integration of the operations of AdvanDx, Inc. acquired by merger on July 14, 2015;

anticipated trends and challenges in our business and the competition that we face;

the execution of our business plan and our growth strategy;

our expectations regarding the size of and growth in potential markets;

changes in laws or regulations applicable to our business, including potential regulation by the FDA;

our ability to develop and commercialize new products and the timing of commercialization;

our liquidity and working capital requirements, including our long-term future cash requirements beyond the next 12 months; and

our expectations regarding future revenue and expenses.

Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance or achievements. In addition, neither we nor any other person assumes responsibility for the accuracy and completeness of any of these forward-looking statements. Any forward-looking statement made by us in this quarterly report on Form 10-Q speaks only as of the date on which it is made. We disclaim any duty to update any of these forward looking statements after the date of this quarterly report on Form 10-Q to confirm these statements to actual results or revised expectations.

These factors should not be construed as exhaustive and should be read in conjunction with our other disclosures, including but not limited to this quarterly report on Form 10-Q, including the factors described in Part II. Item 1A. “Risk Factors,” as well as our quarterly reports on Form 10-Q for the periods ended June 30, 2015 and March 31, 2015 filed with the United States Securities and Exchange Commission, or SEC. Other risks may be described from time to time in our filings made under the securities laws. New risks emerge from time to time. It is not possible for our management to predict all risks. All forward-looking statements in this quarterly report on Form 10-Q speak only as of the date made and are based on our current beliefs and expectations. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

OpGen, Inc.

Condensed Consolidated Balance Sheets

(unaudited)

	September 30, 2015			December 31, 2014
Assets
Current assets
Cash and cash equivalents	$	11,187,129		$	749,517
Accounts receivable, net		553,938			503,983
Inventory, net		1,155,488			369,742
Prepaid expenses and other current assets		538,312			90,233
Total current assets		13,434,867			1,713,475

Property and equipment, net		1,021,971			587,956
Deferred IPO issuance costs		-			296,041
Intangible assets, net		1,955,769			-
Goodwill		291,747			-
Other noncurrent assets		293,135			57,459
Total assets	$	16,997,489		$	2,654,931

Liabilities, Redeemable Preferred Stock and Stockholders' Equity (Deficit)
Current liabilities
Accounts payable	$	1,274,657		$	1,160,081
Accrued compensation and benefits		840,637			423,099
Accrued liabilities		1,232,328			993,657
Deferred revenue		158,860			339,171
Short-term notes payable		1,250			1,505,000
Current maturities of long-term capital lease obligations		227,049			100,499
Short-term convertible notes, net of discounts		-			1,500,000
Total current liabilities		3,734,781			6,021,507

Note payable		1,000,000			-
Long-term capital lease obligations and other noncurrent liabilities		317,854			134,149
Total liabilities		5,052,635			6,155,656

Commitments and contingencies (Note 10)

Redeemable convertible preferred stock
Series A redeemable convertible preferred stock, $.01 par value; 6,000,000 shares authorized; 3,999,864 shares issued and outstanding at December 31, 2014 (none at September 30, 2015); aggregate liquidation preference of $7,999,728 at December 31, 2014 (none at September 30, 2015)		-			4,564,899
Total redeemable convertible preferred stock		-			4,564,899

Stockholders' equity (deficit)
Common stock, $.01 par value; 200,000,000 shares authorized; 12,539,704 and 493,178 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively		125,397			4,932
Additional paid-in capital		121,216,140			88,701,737
Accumulated other comprehensive loss		(49	)		-
Accumulated deficit		(109,396,634	)		(96,772,293	)
Total stockholders' equity (deficit)		11,944,854			(8,065,624	)

Total liabilities, redeemable preferred stock and stockholders' equity (deficit)	$	16,997,489		$	2,654,931

See accompanying notes to unaudited condensed consolidated financial statements.

OpGen, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(unaudited)

	Three Months Ended September 30,						Nine Months Ended September 30,
	2015			2014			2015			2014

Revenue
Product sales	$	929,241		$	268,854		$	1,432,592		$	841,567
Laboratory services		23,765			88,190			87,201			379,339
Collaboration revenue		27,780			477,780			308,340			1,783,340
Total revenue		980,786			834,824			1,828,133			3,004,246

Cost of products sold (excluding depreciation and amortization)		562,694			101,425			712,016			276,831
Cost of services (excluding depreciation and amortization)		46,634			129,120			191,738			336,616
Total costs of sales (excluding depreciation and amortization)		609,328			230,545			903,754			613,447
Gross profit		371,458			604,279			924,379			2,390,799

Operating expenses
Research and development		1,724,127			1,029,650			3,741,247			3,075,420
General and administrative		1,610,828			555,444			3,687,313			1,590,085
Sales and marketing		979,681			459,064			2,815,976			1,486,801
Depreciation and amortization		185,177			141,060			392,404			461,432
Transaction expenses		525,596			-			525,596			-
Total operating expenses		5,025,409			2,185,218			11,162,536			6,613,738
Operating loss		(4,653,951	)		(1,580,939	)		(10,238,157	)		(4,222,939	)

Other income (expense)
Interest income		2,513			37			9,675			120
Interest expense		(17,482	)		(32,331	)		(1,746,853	)		(47,468	)
Change in fair value of derivative financial instruments and other		-			4,400			(647,342	)		4,400
Total other income (expense)		(14,969	)		(27,894	)		(2,384,520	)		(42,948	)
Loss before income taxes		(4,668,920	)		(1,608,833	)		(12,622,677	)		(4,265,887	)

Provision for income taxes		1,662			-			1,662			-
Net loss		(4,670,582	)		(1,608,833	)		(12,624,339	)		(4,265,887	)

Preferred stock dividends		-			(175,246	)		(244,508	)		(458,799	)
Net loss available to common stockholders	$	(4,670,582	)	$	(1,784,079	)	$	(12,868,847	)	$	(4,724,686	)

Net loss per common share - basic and diluted	$	(0.38	)	$	(4.92	)	$	(2.00	)	$	(13.03	)
Weighted average shares outstanding - basic and diluted		12,261,238			362,537			6,444,373			362,537

Net loss	$	(4,670,582	)	$	(1,608,833	)	$	(12,624,339	)	$	(4,265,887	)
Other comprehensive loss - foreign currency translation		(49	)		-			(49	)		-
Comprehensive loss	$	(4,670,631	)	$	(1,608,833	)	$	(12,624,388	)	$	(4,265,887	)

See accompanying notes to unaudited condensed consolidated financial statements.

OpGen, Inc.

Condensed Consolidated Statements of Cash Flows

Nine Months Ended September 30,

(unaudited)

	2015			2014
Cash flows from operating activities
Net loss	$	(12,624,339	)	$	(4,265,887	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		392,404			461,432
Deferred tax provision		1,662			-
Noncash interest expense		1,598,312			20,883
Share-based compensation		1,172,231			80,457
Inventory obsolescence		-			(44,595	)
Change in fair value of derivative financial instruments and other		647,342			(4,400	)
Changes in operating assets and liabilities, net of effects of acquisition:
Accounts receivable		507,066			62,251
Inventory		288,126			(159,174	)
All other assets		(306,386	)		78,311
Accounts payable		(814,855	)		29,853
Accrued compensation and other liabilities		(1,752,790	)		(42,778	)
Deferred revenue		(180,311	)		(121,551	)
Net cash used in operating activities		(11,071,538	)		(3,905,198	)

Cash flows from investing activities
Cash acquired in business combination		1,367,211			-
Purchases of property and equipment		(89,234	)		(39,537	)
Net cash provided by (used in) investing activities		1,277,977			(39,537	)

Cash flows from financing activities
Proceeds from issuance of common stock, net of issuance costs		4,958,335			-
Proceeds from issuance of preferred stock, net of issuance costs		-			1,937,902
Proceeds from issuance of convertible notes and warrants, net of issuance costs		1,388,815			1,472,386
Proceeds from issuance of promissory notes, net of issuance costs		1,741,667			-
Proceeds from exercise of stock options and warrants		214			-
Proceeds from initial public offering, net of issuance costs paid in 2015		12,408,285			-
Payments on debt		(153,750	)		(3,750	)
Payments on capital lease obligations		(112,200	)		(80,575	)
Net cash provided by financing activities		20,231,366			3,325,963

Effects of exchange rates on cash		(193	)		-
Net (decrease) increase in cash and cash equivalents		10,437,612			(618,772	)
Cash and cash equivalents at beginning of period		749,517			1,400,345
Cash and cash equivalents at end of period	$	11,187,129		$	781,573

Supplemental disclosure of cash flow information
Cash paid during the period for interest	$	201,233		$	26,088

Supplemental disclosure of noncash investing and financing activities:
Acquisition of equipment purchased through capital leases	$	429,320		$	-
Common stock issued in business combination	$	2,584,090		$	-
Exchange of demand note for convertible debt	$	300,000		$	-
Exchange of demand notes for IPO units sold in initial public offering	$	2,100,000		$	-
Conversion of convertible notes into Series A preferred stock	$	3,000,000		$	-
Conversion of Series A preferred stock into common shares	$	8,183,661		$	-

See accompanying notes to unaudited condensed consolidated financial statements.

Notes to Unaudited Condensed Consolidated Financial Statements
September 30, 2015

Note 1 - Organization

OpGen, Inc. (“OpGen”) was incorporated in Delaware in 2001. On July 14, 2015, OpGen completed the strategic acquisition (the “Merger”) of AdvanDx, Inc. and its wholly owned subsidiary AdvanDx A/S (collectively, “AdvanDx”) (see Note 4). Pursuant to the terms of a merger agreement, Velox Acquisition Corp. (OpGen’s wholly owned subsidiary formed for the express purpose of enacting the Merger) merged with and into AdvanDx, Inc. with AdvanDx, Inc. surviving as OpGen’s wholly owned subsidiary (see Note 4). OpGen, AdvanDx, Inc. and AdvanDx A/S are collectively referred to hereinafter as the “Company.” The Company’s headquarters are in Gaithersburg, Maryland, and its principal operations are in Gaithersburg, Maryland and Woburn, Massachusetts. The Company also has operations in Copenhagen, Denmark.

OpGen is an early-stage company using rapid molecular testing and bioinformatics to help guide antibiotic therapy and to assist healthcare providers to combat multi-drug resistant infections, or MDROs. OpGen’s lead products are its QuickFISH® and PNAFISH products, which are advanced in vitro diagnostic kits for the diagnosis and prevention of infectious diseases, the Acuitas® MDRO Gene Test, a CLIA lab-based test that provides a profile of MDRO resistant genes from patients screened for colonization or infection and the Acuitas Lighthouse to aid in the interpretation of MDRO diagnostic test results. The company develops, markets and sells its products principally for use in hospitals and clinical laboratories in the United States and internationally.

The Company’s operations are subject to certain risks and uncertainties. The risks include rapid technology changes, the need to manage growth, the need to retain key personnel, the need to protect intellectual property and the need to raise additional capital financing on terms acceptable to the Company. The Company’s success depends, in part, on its ability to develop and commercialize its proprietary technology as well as raise additional capital.

Note 2 – Liquidity and management’s plans

The accompanying consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Since inception, the Company has incurred, and continues to incur, significant losses from operations. The Company has funded its operations primarily through external investor financing arrangements. The Company raised significant funds in 2015, including:

$0.8 million in short-term notes (in the first quarter of 2015, $0.3 million of demand notes held by an entity controlled by our chief executive officer were settled as partial payment for a 2015 convertible note, and in the second quarter of 2015, $0.2 million of notes from a related party were repaid in cash),

$1.5 million through the issuance of convertible notes,

$12.1 million in net proceeds from its initial public offering, or IPO, as discussed further below, and

$6.0 million in net proceeds from the issuances of common stock and promissory note to Merck Global Health Innovations Fund, LLC (“Merck GHI”).

On May 8, 2015, OpGen completed its IPO pursuant to which it offered and sold 2,850,000 units, each consisting of one share of common stock and a detachable stock purchase warrant to purchase an additional share of common stock, at an initial offering price of $6.00 per unit. Of the total gross proceeds of $17.1 million, approximately $2.1 million was satisfied by exchanging outstanding demand notes. After considering the demand notes, underwriting discounts and commissions and offering expenses, the total net cash proceeds were $12.1 million. On the IPO closing date, the underwriters exercised their over-allotment option to acquire an additional 422,500 stock purchase warrants. In connection with the IPO, all of OpGen’s outstanding Series A Preferred Stock, 2014 convertible notes and 2015 convertible notes were converted into 7,374,852 shares of common stock.

In July 2015, the Company raised $6.0 million by issuing 1,136,364 shares of common stock (with a value of $5.0 million at $4.40 per share) and a $1.0 million promissory note to Merck GHI (see Note 5).

The Company’s current operating assumptions, which include management’s best estimate of future revenue and operating expenses, indicate that current cash on hand will be sufficient to fund operations through at least the end of the first quarter of 2016. In the event the Company is unable to successfully raise additional capital in 2016, the Company will not have sufficient cash flows and liquidity to finance its business operations as currently contemplated. Accordingly, in such circumstances the Company would be compelled to reduce general and administrative expenses and delay research and development projects, including the purchase of scientific equipment and supplies, until it is able to obtain sufficient financing, or pursue other strategic alternatives which may include licensing and/or partnering arrangements or mergers and acquisitions. The financial statements do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.

Note 3 - Summary of significant accounting policies

Basis of presentation and consolidation

The accompanying interim condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission, or SEC, for interim financial information. Accordingly, they do not include all the information and footnotes required by U.S. Generally Accepted Accounting Principles, or GAAP, for complete financial statements. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited financial statements and accompanying notes for the year ended December 31, 2014 previously filed with the SEC. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual financial statements included in the Company’s registration statement on Form S-1/A and, in the opinion of management, reflect all the adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company’s financial position as of September 30, 2015 and the results of operations and cash flows for the three and nine months ended September 30, 2015 and 2014. The interim condensed consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. The December 31, 2014 balance sheet included herein was derived from the audited financial statements, but may not include all disclosures including notes required by GAAP for complete financial statements.

The accompanying unaudited interim condensed consolidated financial statements include the accounts of the OpGen and its wholly owned and controlled subsidiaries; all intercompany transactions and balances have been eliminated. The Company operates in one business segment. Certain prior period information has been reclassified to conform to the current period presentation.

Foreign Currency

AdvanDx A/S is located in Copenhagen, Denmark and uses the Danish Krone as its functional currency. As a result, all assets and liabilities are translated into U.S. dollars based on exchange rates at the end of the reporting period. Income and expense items are translated at the average exchange rates prevailing during the reporting period. Translation adjustments are reported in other comprehensive loss, a component of stockholder's equity. Foreign currency translation adjustments are the sole component of accumulated other comprehensive loss at September 30, 2015.

Foreign currency transaction gains and losses, excluding gains and losses on intercompany balances where there is no current intent to settle such amounts in the foreseeable future, are included in the determination of net loss.

Unless otherwise noted, all references to “$” or “dollar” refer to the United States dollar.

Use of estimates

In preparing financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In the accompanying consolidated financial statements, estimates are used for, but not limited to, share-based compensation, allowances for doubtful accounts and inventory obsolescence, valuation of derivative financial instruments, beneficial conversion features of convertible debt, deferred tax assets and liabilities and related valuation allowance, and depreciation and amortization and estimated useful lives of long-lived assets, and the recoverability of long-lived assets. Actual results could differ from those estimates.

Fair value of financial instruments

All current assets and liabilities are carried at cost, which approximates fair value, because of the short-term maturities of those instruments. The carrying value of the Company’s debt is reflective of fair value based on instruments with similar terms available to the Company.

Cash and cash equivalents

The Company considers all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company has cash and cash equivalents deposited in financial institutions in which the balances occasionally exceed the federal government agency (FDIC) insured limits of $250,000. The Company has not experienced any losses in such accounts and management believes it is not exposed to any significant credit risk.

Accounts receivable

The Company’s accounts receivable result from revenues earned but not collected from customers. Credit is extended based on an evaluation of a customer’s financial condition and, generally, collateral is not required. Accounts receivable are due within 30 to 45 days and are stated at amounts due from customers. The Company evaluates if an allowance is necessary by considering a number of factors, including the length of time accounts receivable are past due, the Company’s previous loss history and the customer’s current ability to pay its obligation. If amounts become uncollectible, they are charged to operations when that determination is made. The allowance for doubtful accounts was $79,697 as of September 30, 2015 and December 31, 2014, respectively.

At September 30, 2015, the Company had accounts receivable from two customers which individually represented 12% and 11% of total accounts receivable. At December 31, 2014, the Company had accounts receivable from two customers which individually represented 79%, and 15% of total accounts receivable.

Inventories

Inventories are valued using the first-in, first-out method and stated at the lower of cost or market and consist of the following:

	September 30, 2015		December 31, 2014

Raw materials and supplies	$	697,414	$	40,749
Work-in process		222,031		135,625
Finished goods		236,043		193,368
Total	$	1,155,488	$	369,742

Inventories include the Argus Whole Genome Mapping Systems, reagents and supplies used for Argus consumable kits, reagents and components for QuickFISH and PNAFISH kit products, and reagents and supplies used for the Company’s laboratory services. Inventory reserves for obsolescence and expirations were $778,944 and $867,816 at September 30, 2015 and December 31, 2014, respectively.

Product warranty

A warranty reserve is established upon the sale of any Argus System or Whole Genome Mapping product that is covered by warranty based on the estimated cost of replacement parts during the warranty period. Warranty periods are twelve months. The reserve is adjusted during the warranty period to reflect the remaining estimated costs under the warranty. The reserve for warranties was $2,750 as of September 30, 2015 and December 31, 2014, respectively.

Impairment of property and equipment

Property and equipment is reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. Recoverability measurement and estimating of undiscounted cash flows is done at the lowest possible level for which we can identify assets. If such assets are considered to be impaired, impairment is recognized as the amount by which the carrying amount of assets exceeds the fair value of the assets. During the three and nine months ended September 30, 2015 and 2014, the Company determined that its property and equipment was not impaired.

Intangible assets and goodwill

Intangible assets were acquired as part of the Merger, and consist of definite-lived intangible assets and goodwill.

Definite-lived intangible assets

Definite-lived intangible assets include trademarks, developed technology and customer relationships, and are amortized over their useful lives of 10, 7 and 7 years, respectively. Definite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. If any indicators were present, the Company would test for recoverability by comparing the carrying amount of the asset to the net undiscounted cash flows expected to be generated from the asset. If those net undiscounted cash flows do not exceed the carrying amount (i.e., the asset is not recoverable), the Company would perform the next step, which is to determine the fair value of the asset and record an impairment loss, if any. During the three and nine months ended September 30, 2015 and 2014, the Company determined that its definite-lived intangible assets were not impaired.

Goodwill

Goodwill represents the excess of the purchase price for AdvanDx over the fair values of the acquired tangible or intangible assets and assumed liabilities. Goodwill is tax deductible in all relevant jurisdictions. As a result of the Merger, the Company recognized goodwill of approximately $292,000.

The Company will conduct an impairment test of goodwill on an annual basis as of October 1 of each year, and will also conduct tests if events occur or circumstances change that would, more likely than not, reduce the Company’s fair value below its net equity value.

Redeemable convertible preferred stock

All shares of Series A redeemable convertible preferred stock, or Series A Preferred Stock (including those shares issued in connection with the conversion of the 2014 and 2015 convertible debt (see Note 6)), were converted into 7,374,852 shares of common stock in connection with the Company’s IPO (see Note 7).

Prior to the IPO, the carrying value of the Series A Preferred Stock was increased by the accretion of related discounts, issuance costs and accrued but unpaid dividends so that the carrying amount would equal the redemption amount at the dates the stock becomes redeemable. At December 31, 2014, the Company had 3,999,864 shares of Series A Preferred Stock, outstanding. The Series A Preferred Stock was redeemable at the option of the holders of 70% of the outstanding shares of Series A Preferred Stock, subject to certain additional requirements. The Company’s redeemable convertible preferred stock was classified as temporary equity due to redemption provisions outside of the Company’s control.

Revenue recognition

The Company recognizes revenue primarily from sales of its products and services when the following criteria are met: persuasive evidence of an arrangement exists; delivery has occurred; the selling price is fixed or determinable; and collectability is reasonably assured. At times, the Company sells products and services, or performs software development, under multiple-element arrangements with separate units of accounting; in these situations, total consideration is allocated to the identified units of accounting based on their relative selling prices and revenue is then recognized for each unit based on its specific characteristics.

Amounts billed to customers for shipping and handling are included in revenue when the related product or service revenue is recognized. Shipping and handling costs are included in cost of sales.

Revenue from sales of the Argus System

When an Argus System is sold without the Genome Builder software, total arrangement consideration is recognized as revenue when the system is delivered to the customer. Ancillary performance obligations, including installation, limited customer training and limited consumables, are considered inconsequential and are combined with the Argus System as one unit of accounting.

When an Argus System is sold with the Genome Builder software in a multiple-element arrangement, total arrangement consideration is allocated to the Argus System and to the Genome Builder software based on their relative selling prices. Selling prices are determined based on sales of similar systems to similar customers and, where no sales have occurred, on management’s best estimate of the expected selling price relative to similar products. Revenue related to the Argus System is recognized when it is delivered to the customer; revenue for the Genome Builder software is recognized when it is delivered to the customer.

Revenue from sales of AdvanDx diagnostic products

Revenue from sales of AdvanDx diagnostic products typically is recognized when the product is delivered to the customer.

Revenue from sales of Genome Builder Software and consumables (on a stand-alone basis)

Revenue is recognized for Genome Builder Software and for consumables, when sold on a standalone basis, upon delivery to the customer.

Revenue from extended warranty service contracts

The Company recognizes revenue associated with extended warranty service contracts over the service period in proportion to the costs expected to be incurred over that same period.

Revenue from providing laboratory services

The Company recognizes revenue associated with laboratory services contracts when the service has been performed and reports are made available to the customer.

Revenue from funded software development arrangements

The Company’s funded software development arrangements generally consist of multiple-elements. Total arrangement consideration is allocated to the identified units of accounting based on their relative selling prices and revenue is then recognized for each unit based on its specific characteristics. When funded software development arrangements include substantive research and development milestones, revenue is recognized for each such milestone when the milestone is achieved and is due and collectible. Milestones are considered substantive if all of the following conditions are met: (1) the milestone is nonrefundable; (2) achievement of the milestone was not reasonably assured at the inception of the arrangement; (3) substantive effort is involved to achieve the milestone; and (4) the amount of the milestone appears reasonable in relation to the effort expended, the other milestones in the arrangement and the related risk associated with achievement of the milestone.

Share-based compensation

Share-based payments are recognized at fair value. The fair value of share-based payments to employees and directors is estimated, on the date of grant, using the Black-Scholes model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option. For all time-vesting awards granted, expense is amortized using the straight-line attribution method. Share-based compensation expense recognized is based on the value of the portion of stock-based awards that is ultimately expected to vest during the period.

Option valuation models, including the Black-Scholes model, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award.

Income taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the expected future tax consequences attributable to temporary differences between financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred income tax assets to the amount expected to be realized. The Company’s tax provision for the three and nine months ended September 30, 2015 resulted from the deductibility of goodwill for tax purposes.

Tax benefits are initially recognized in the financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions are initially, and subsequently, measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement with the tax authority, assuming full knowledge of the position and all relevant facts.

The Company had federal net operating loss, or NOL, carryforwards of $76,267,809 at December 31, 2014. Despite the NOL carryforwards, which begin to expire in 2022, the Company may have future tax liability due to alternative minimum tax or state tax requirements. Also, use of the NOL carryforwards may be subject to an annual limitation as provided by Section 382 of the Internal Revenue Code of 1986, as amended, or the Code. There can be no assurance that the NOL carryforwards will ever be fully utilized.

Loss per share

Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of shares of common stock outstanding during the period.

For periods of net income, and when the effects are not anti-dilutive, diluted earnings per share is computed by dividing net income available to common shareholders by the weighted-average number of shares outstanding plus the impact of all potential dilutive common shares, consisting primarily of common stock options and stock purchase warrants using the treasury stock method, and convertible preferred stock and convertible debt using the if-converted method.

For periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all dilutive potential common shares is anti-dilutive. The number of anti-dilutive shares, consisting of (i) common stock options, (ii) restricted stock units (in 2014), (iii) stock purchase warrants, and (iv) prior to the IPO, convertible preferred stock and convertible debt, exercisable or exchangeable into common stock which have been excluded from the computation of diluted loss per share, was 5.7 million and 6.1 million for the nine and three months ended September 30, 2015 and 2014, respectively. The Company’s convertible preferred stock, prior to its conversion, contained non-forfeitable rights to dividends, and therefore was considered to be a participating security; the calculation of basic and diluted income (loss) per share excludes net income (but not net loss) attributable to the convertible preferred stock from the numerator and excludes the impact of those shares from the denominator in periods prior to the IPO.

Recent accounting pronouncements

In May 2014, the Financial Accounting Standards Board, or FASB, issued guidance for revenue recognition for contracts, superseding the previous revenue recognition requirements, along with most existing industry-specific guidance. The guidance requires an entity to review contracts in five steps: 1) identify the contract, 2) identify performance obligations, 3) determine the transaction price, 4) allocate the transaction price, and 5) recognize revenue. The new standard will result in enhanced disclosures regarding the nature, amount, timing and uncertainty of revenue arising from contracts with customers. The standard is effective for the Company’s reporting year beginning January 1, 2018 and early adoption is permitted starting January 1, 2017. The Company is currently evaluating the impact, if any, that this new accounting pronouncement will have on its financial statements.

In August 2014, the FASB issued guidance requiring management to evaluate on a regular basis whether any conditions or events have arisen that could raise substantial doubt about the entity’s ability to continue as a going concern. The guidance 1) provides a definition for the term “substantial doubt,” 2) requires an evaluation every reporting period, interim periods included, 3) provides principles for considering the mitigating effect of management’s plans to alleviate the substantial doubt, 4) requires certain disclosures if the substantial doubt is alleviated as a result of management’s plans, 5) requires an express statement, as well as other disclosures, if the substantial doubt is not alleviated, and 6) requires an assessment period of one year from the date the financial statements are issued. The standard is effective for the Company’s reporting year beginning January 1, 2017 and early adoption is permitted. The Company is currently evaluating the impact, if any, that this new accounting pronouncement will have on its financial statements.

In April 2015, the FASB issued accounting guidance requiring that debt issuance costs related to a recognized liability be presented on the balance sheet as a direct reduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected. The standard is effective for reporting periods beginning after December 15, 2015. The Company is currently evaluating the impact, if any, that this new accounting pronouncement will have on its financial statements.

In July 2015, the FASB issued accounting guidance for inventory. Under the guidance, an entity should measure inventory within the scope of this guidance at the lower of cost and net realizable value, except when inventory is measured using LIFO or the retail inventory method. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. In addition, the FASB has amended some of the other inventory guidance to more clearly articulate the requirements for the measurement and disclosure of inventory. The standard is effective for reporting periods beginning after December 15, 2016. The amendments in this pronouncement should be applied prospectively, with earlier application permitted. The Company is currently evaluating the impact, if any, that this new accounting pronouncement will have on its financial statements.

In September 2015, the FASB issued accounting guidance to simplify the accounting for measurement period adjustments resulting from business combinations. Under the guidance, an acquirer will be required to recognize adjustments to provisional amounts identified during the measurement period in the reporting period in which the adjustments are determined. The guidance requires an entity to present separately on the face of the income statement or disclose in the notes to the financial statements the portion of the amount recorded in current-period earnings by line item that would have been recorded in previous reporting periods if the adjustment had been recognized as of the acquisition date. The standard is effective for reporting periods beginning after December 15, 2015. The amendments in this pronouncement should be applied prospectively, with earlier application permitted. The Company is currently evaluating the impact, if any, that this new accounting pronouncement will have on its financial statements.

The Company has evaluated all other issued and unadopted Accounting Standards Updates and believes the adoption of these standards will not have a material impact on its results of operations, financial position, or cash flows.

Note 4 – Business Combination

On July 14, 2015, the Company completed the Merger by acquiring 100% of the capital stock of AdvanDx in the Merger in a taxable transaction. AdvanDx researches, develops and markets advanced in vitro diagnostic kits for the diagnosis and prevention of infectious diseases, and sells its products principally to hospitals and clinical laboratories in the United States and Europe. The Company acquired AdvanDx principally to exploit AdvanDx’s diagnostic capabilities with respect to MDROs and leverage AdvanDx’s relationships with hospitals and clinical laboratories to accelerate the sales of OpGen’s products and services.

Pursuant to an Agreement and Plan of Merger (the “Merger Agreement”), Velox Acquisition Corp. merged with and into AdvanDx, Inc. with AdvanDx, Inc. surviving as a wholly owned subsidiary of the Company in accordance with the General Corporation Law of the State of Delaware. Under the terms of the Merger Agreement, the merger consideration consisted of an aggregate 681,818 shares of the Company's common stock with a value of $2.6 million (the “Merger Consideration”), which Merger Consideration was distributed in accordance with the liquidation preferences set forth in the AdvanDx, Inc. Restated Certificate of Incorporation, as amended.

The Company accounted for its acquisition of AdvanDx by recording all tangible and intangible assets acquired and liabilities assumed at their estimated fair values on the acquisition date, with the remaining unallocated purchase price recorded as goodwill. The fair value assigned to identifiable intangible assets acquired was determined using an income approach for trade names and customer relationships, and a cost approach for technology. The fair values are based on the Company’s estimates and may be adjusted from time to time, but no later than July 13, 2016, as better information becomes available. The Company received stepped-up bases in the acquired assets and liabilities and therefore did not recognize any deferred income tax assets and liabilities. The following represents the preliminary allocation of the purchase price:

Total purchase price - fair value of common stock issued	$	2,584,090

Fair value of tangible assets acquired:
Cash		1,367,211
Receivables		557,112
Inventory		1,073,855
Property and equipment		250,636
Other assets		359,587
Fair value of identifiable intangible assets acquired:
Customer relationships		1,094,000
Developed technology		458,000
Trademarks and tradenames		461,000
Fair value of goodwill		291,747

Fair value of liabilities assumed		3,329,058
	$	2,584,090

The total consideration paid in the acquisition exceeded the estimated fair value of the tangible and identifiable intangible assets acquired and liabilities assumed, resulting in approximately $0.3 million of goodwill. Goodwill, primarily related to expected synergies gained from combining operations, sales growth from future product offerings and customers, together with certain intangible assets that do not qualify for separate recognition, including assembled workforce, is tax deductible in all relevant taxing jurisdictions. The Company expensed acquisition-related costs of approximately $0.5 million related to the Merger in 2015. AdvanDx recognized approximately $0.8 million of revenue and $0.8 million of net losses from the acquisition date to September 30, 2015, which results are included in the Company’s 2015 interim condensed consolidated financial statements.

The following unaudited pro forma financial information summarizes the results of operations for the periods indicated as if the Merger had been completed as of January 1, 2014. Pro forma information primarily reflects adjustments relating to (i) elimination of the interest on AdvanDx’s outstanding debt, and (ii) the amortization of intangibles acquired. The pro forma amounts do not purport to be indicative of the results that would have actually been obtained if the acquisition occurred as of January 1, 2014 or that may be obtained in the future:

Unaudited pro forma results	Nine months ended						Three months ended
	September 30, 2015			September 30, 2014			September 30, 2015			September 30, 2014

Revenues	$	3,902,337		$	6,631,510		$	1,126,530		$	1,955,894
Net loss	$	(15,623,109	)	$	(11,784,997	)	$	(4,650,817	)	$	(4,517,541	)
Net loss per share	$	(2.29	)	$	(11.72	)	$	(0.38	)	$	(4.49	)

Note 5 – Merck GHI Financing

On July 14, 2015, as a condition to the Merger, the Company entered into a Common Stock and Note Purchase Agreement (the “Purchase Agreement”) with Merck GHI, pursuant to which Merck GHI purchased 1,136,364 shares of common stock of the Company at $4.40 per share for gross proceeds of $5.0 million. Pursuant to the Purchase Agreement, the Company also issued to Merck GHI a 8% Senior Secured Promissory Note (the “Note”) in the principal amount of $1.0 million with a two-year maturity date from the date of issuance. The Company's obligations under the Note are secured by a lien on all of the Company's assets.

The Company incurred issuance costs of approximately $50,000 related to the financing, of which approximately $8,000 was deferred as debt issuance costs and are being amortized as interest expense over the life of the Note, and $42,000 was charged to additional paid-in capital.

Note 6 - Fair value measurements

The Company classifies its financial instruments using a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:

Level 1 - defined as observable inputs such as quoted prices in active markets;

Level 2 - defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and

Level 3 - defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions such as expected revenue growth and discount factors applied to cash flow projections.

Financial assets and liabilities measured at fair value on a recurring basis

The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the hierarchy. The following tables present the fair value hierarchy for the Company’s financial assets and liabilities measured at fair value on a recurring basis at September 30, 2015 and December 31, 2014:

	Fair value at
	September 30, 2015		Level 1		Level 2		Level 3
Cash and cash equivalents	$	11,187,129	$	11,187,129	$	-	$	-

		Fair value at December 31, 2014				Level 1				Level 2				Level 3
Cash and cash equivalents	$		749,517		$		748,048		$		1,469			$	-

The Company’s Level 1 securities primarily consist of cash and cash equivalents, including money market funds and U.S. Treasury Notes; the Company determines the estimated fair value for its Level 1 securities using quoted (unadjusted) prices for identical assets or liabilities in active markets.

Prior to its IPO, certain stock purchase warrants contained cash settlement features and, accordingly, the Company considered them to be derivative financial instruments and accounted for them at fair value using level 3 inputs. As a result of the Company’s IPO and elimination of the cash settlement features pursuant to their terms, those stock purchase warrants were reclassified to equity. For periods prior to the IPO, the Company determined the fair value of these derivative liabilities using a hybrid valuation method that consisted of a probability weighted expected return method that values the Company’s equity securities assuming various possible future economic outcomes while using an option pricing method (that treated all equity linked instruments as call options on the Company’s equity value with exercise prices based on the liquidation preference of the Series A Preferred Stock ) to estimate the allocation of value within one or more of the scenarios. Using this hybrid method, unobservable inputs included the Company’s equity value, the exercise price for each option value, expected timing of possible economic outcomes such as initial public offering, risk free interest rates and stock price volatility. The following tables set forth a summary of changes in the fair value of Level 3 liabilities measured at fair value on a recurring basis for the nine months ended September 30, 2015:

Description

Balance at
December
31, 2014

Established
in 2015

Change in
Fair Value

Reclassified
to Equity

Balance at
September
30, 2015

Derivative warrant liability

72,333

647,342

(719,675

)

Financial assets and liabilities carried at fair value on a non-recurring basis

The Company does not have any financial assets and liabilities measured at fair value on a non-recurring basis.

Non-financial assets and liabilities carried at fair value on a recurring basis

The Company does not have any non-financial assets and liabilities measured at fair value on a recurring basis.

Non-financial assets and liabilities carried at fair value on a non-recurring basis

The Company measures its long-lived assets, including property and equipment and intangible assets (including goodwill), at fair value on a non-recurring basis when they are deemed to be impaired. No such fair value impairment was recognized in the three and nine month periods ended September 30, 2015 and 2014.

See Note 4 for a discussion of the fair value of assets acquired and liabilities assumed in the Merger.

Note 7 – Series A redeemable convertible preferred stock

All shares of Series A Preferred Stock (including those shares issued in connection with the conversion of the 2014 and 2015 convertible debt (see Note 6)) were converted into 7,374,852 shares of common stock in connection with the Company’s IPO (see Note 9). Prior to the Company’s IPO, the Series A Preferred Stock was classified as temporary equity due to redemption provisions outside of the Company’s control.

The Company issued 1,999,864 shares of Series A Preferred Stock in December 2013 at $1.00 per share in exchange for $1,999,864 in convertible promissory notes. In February 2014, the Company sold 1,405,096 shares of Series A Preferred Stock for gross proceeds of $1,405,096. In April 2014, the Company sold an additional 594,904 shares of Series A Preferred Stock for gross proceeds of $594,904. At December 31, 2014, the Company had a total of 3,999,864 shares of Series A Preferred Stock outstanding, convertible into 3,999,864 shares of common stock.

The holders of the Series A Preferred Stock had the right to receive non-cumulative dividends, at a rate of 8% per annum, when and if declared by the Board of Directors. The Series A Preferred Stock had preference of payment over all other classes and series of capital stock of the Company with respect to dividends, payment on liquidation and payment on redemption. The liquidation and redemption preferences were at two times the Series A Preferred Stock purchase price. The Series A Preferred Stock holders were entitled to vote on all matters that come to stockholders on an as-converted basis with holders of the common stock. In addition, the Series A Preferred Stock had broad based anti-dilution rights.

The holders of Series A Preferred Stock had the right to convert such shares, at their option and at any time, into shares of common stock at the then-applicable conversion rate, as defined. The initial conversion rate was one common share for each preferred share, which could be adjusted for specified dilutive transactions. Beginning in December 2020, the Company may have been obligated to redeem shares of Series A Preferred Stock, if requested, by holders of at least 70% of the then-outstanding shares of preferred stock. The redemption, if requested, would have taken place in three equal annual installments. Series A Preferred Stock would have been redeemed at two times the original issue price per share plus all accrued and unpaid dividends. The redemptions were subject to certain equity adjustments for specified anti-dilution transactions, as defined.

Note 8 - Debt

All the Company’s outstanding demand notes and convertible notes were exchanged for units in the Company’s IPO or otherwise were converted into Series A Preferred Stock and subsequently converted into shares of common stock in connection with the IPO. A short-term 8% promissory note for $150,000 issued in April 2015 was repaid in cash in June 2015. In July 2015, the Company issued a $1.0 million 8% senior secured promissory note to Merck GHI (see Note 5). As of September 30, 2015, the Company has a total of $1,001,250 debt outstanding.

Demand notes

In the fourth quarter of 2014 and first quarter of 2015, the Company raised a total of $2.3 million through the issuance of short-term demand notes. In the first quarter of 2015, $0.3 million of demand notes, held by an entity controlled by our chief executive officer, were settled as partial payment for a 2015 convertible note. All outstanding demand notes were tendered as payment for 350,000 units in the Company’s IPO (see Note 9). Prior to settlement, the demand notes bore interest at 8% per annum, had a first priority security interest in the assets of the Company, and a term of approximately four months.

2014 convertible debt

In July, August and September 2014, the Company raised $1.5 million through the issuance of convertible debt. All outstanding 2014 convertible debt was converted into Series A Preferred Stock and then into 1,500,000 shares of common stock in connection with the Company’s IPO (see Note 9). Prior to its conversion, the debt was convertible, at the option of the holders or in certain cases at the Company’s option, into shares of Series A Preferred Stock or other potential equity securities, bore interest at 8% and was due in full on July 11, 2015.

2015 convertible debt

In February and March 2015, the Company raised $1.5 million in capital through the issuance of 8% secured convertible notes with detachable stock purchase warrants. All outstanding 2015 convertible debt was converted into Series A Preferred Stock and then into 1,875,000 shares of common stock in connection with the Company’s IPO (see Note 9). Prior to its conversion, the 2015 convertible notes were pre-payable by the Company without penalty at any time following the three-month anniversary of the closing of the IPO (provided that before the six-month anniversary of the closing of an IPO, the 2015 convertible notes could only be prepaid out of newly issued capital subsequent to the IPO), and were puttable by the holder to the Company in the event of a defined default. The 2015 convertible notes were each convertible, at the election of the holder, into (i) shares of Series A Preferred Stock, at a conversion rate of 1.25 shares of Series A Preferred Stock for each $1.00 converted if the conversion occurs prior to closing of an IPO, or (ii) shares of common stock at a conversion rate of one share of common stock for each $1.00 converted if the conversion occurs after the closing of an IPO.

The conversion option embedded in the convertible notes was determined to contain beneficial conversion features, resulting in the bifurcation of those features as an equity instrument (resulting in an additional debt discount) at issuance. After allocation of the gross proceeds to the detachable stock purchase warrants (discussed below) and beneficial conversion feature, the total debt discount recognized was equal to the face value of the 2015 convertible notes. Upon conversion in May 2015, the remaining unamortized beneficial conversion feature of approximately $1.5 million was charged to interest expense in the accompanying condensed consolidated statement of operations. Remaining unamortized deferred financing costs of $71,421 were also charged to interest expense upon conversion.

The 2015 convertible note holders also received detachable stock purchase warrants exercisable for 225,011 shares of common stock at 110% of the IPO price and exercisable only if the IPO occurred, and then exercisable beginning on the six-month anniversary of the closing of the IPO. Prior to the IPO, as a result of net settlement features, the stock purchase warrants were considered derivative liabilities, were initially recorded at fair value (resulting in a debt discount) and were marked-to-market at each balance sheet date through earnings. As a result of the elimination of the net settlement features in the IPO, the stock purchase warrants were marked to fair value of $0.7 million on May 8, 2015 and then reclassified to equity.

Note 9 - Stockholders’ equity (deficit)

On May 8, 2015, the Company completed its IPO pursuant to which the Company offered and sold 2,850,000 units, each consisting of one share of common stock and a detachable stock purchase warrant to purchase an additional share of common stock, at an initial offering price of $6.00 per unit. Of the total gross proceeds of $17.1 million, approximately $2.1 million was satisfied by exchanging outstanding demand notes. After considering the demand notes, and underwriting discounts, commissions and offering expenses of $2.9 million (which were charged to additional paid in capital), the total net cash proceeds to the Company was $12.1 million. On the IPO closing date, the underwriters exercised a portion of their over-allotment option to acquire an additional 422,500 stock purchase warrants for cash of $4,225. In connection with the IPO, all of the Company’s outstanding Series A Preferred Stock, 2014 convertible notes and 2015 convertible notes were converted into 7,374,852 shares of common stock.

The stock purchase warrants issued as part of the units (including over-allotment option) are exercisable for 3,272,500 shares of common stock at $6.60 per share beginning six months after the closing of the IPO for five years, expiring on May 8, 2020. Additionally, the Company issued additional warrants to its investment bankers to purchase 185,250 shares of common stock, on the same terms as the warrants issued with the units. The warrants were valued using the Black-Scholes option pricing model and are classified as equity.

In July 2015, the Company issued 1,136,364 shares of common stock to Merck GHI for cash consideration of $5.0 million (see Note 5).

Stock options

In 2002, the Company adopted the 2002 Stock Option and Restricted Stock Plan, or the 2002 Plan, pursuant to which the Company’s Board of Directors could grant either incentive stock options or non-qualified stock options, shares of restricted stock, shares of unrestricted common stock, and other share-based awards to officers and employees. In 2008, the Company adopted the 2008 Stock Option and Restricted Stock Plan, or the 2008 Plan, pursuant to which the Company’s Board of Directors may grant either incentive or non-qualified stock options or shares of restricted stock to directors, key employees, consultants and advisors.

In April 2015, the Company adopted, and the Company’s stockholders approved, the 2015 Equity Incentive Plan, or the 2015 Plan; the 2015 Plan became effective upon the execution and delivery of the underwriting agreement for the Company’s IPO. Following the effectiveness of the 2015 Plan, no further grants will be made under the 2002 Plan or 2008 Plan. The 2015 Plan provides for the granting of incentive stock options within the meaning of Section 422 of the Internal Revenue Code to employees and the granting of non-qualified stock options to employees, non-employee directors and consultants. The 2015 Plan also provides for the grants of restricted stock, restricted stock units, stock appreciation rights, dividend equivalents and stock payments to employees, non-employee directors and consultants.

Under the 2015 Plan, the aggregate number of shares of the common stock authorized for issuance may not exceed (1) 1,355,000 plus (2) the sum of the number of shares subject to outstanding awards under the 2008 Plan as of the 2015 Plan’s effective date, that are subsequently forfeited or terminated for any reason before being exercised or settled, plus (3) the number of shares subject to vesting restrictions under the 2008 Plan as of the 2015 Plan’s effective date that are subsequently forfeited. In addition, the number of shares that have been authorized for issuance under the 2015 Plan will be automatically increased on the first day of each fiscal year beginning on January 1, 2016 and ending on (and including) January 1, 2025, in an amount equal to the lesser of (1) 4% of the outstanding shares of common stock on the last day of the immediately preceding fiscal year, or (2) another lesser amount determined by the Board of Directors. Shares subject to awards granted under the 2015 Plan that are forfeited or terminated before being exercised or settled, or are not delivered to the participant because such award is settled in cash, will again become available for issuance under the 2015 Plan. However, shares that have actually been issued shall not again become available unless forfeited. As of September 30, 2015, 528,890 shares remain available for issuance under the 2015 Plan.

For the three months ended September 30, 2015 and 2014, the Company recorded $261,540 and $24,977, respectively, of stock compensation expense. For the nine months ended September 30, 2015 and 2014, the Company recorded $1,172,231 and $80,457, respectively, of stock compensation expense. The allocation of share-based compensation expense by operating expenses is as follows:

	Three months ended September 30,
	2015		2014
Research and development	$	59,688	$	1,528
General and administrative		156,236		22,460
Sales and marketing		45,616		989
	$	261,540	$	24,977

	Nine months ended September 30,
	2015		2014
Research and development	$	161,819	$	3,903
General and administrative		443,267		74,032
Sales and marketing		567,145		2,522
	$	1,172,231	$	80,457

During the nine months ended September 30, 2015, the Company granted stock options to acquire 1,660,387 shares of common stock at a weighted average exercise price of $2.87 per share. The 2015 awards had a weighted average grant date fair value per share of $3.16. The Company has total stock options to acquire 1,948,249 shares of common stock outstanding at September 30, 2015.

Restricted stock units

In March 2014, the Company awarded restricted stock units to acquire 130,640 shares of common stock to its Chief Executive Officer. The restricted stock units were compensation for his service as Chief Executive Officer, or CEO, from October 2013 through June 2014 and were subject to forfeiture if he did not continue to perform management services through October 24, 2014. The restricted stock units vested on October 24, 2014 and 130,640 shares of common stock were issued to the CEO.

Stock purchase warrants

The Company has total stock purchase warrants to acquire 3,716,355 and 33,594 shares of common stock outstanding at September 30, 2015 and December 31, 2014, respectively. In the first quarter of 2015, the Company issued 225,011 warrants in connection with the issuance of its 2015 convertible debt. In the second quarter of 2015 in connection with the Company’s IPO, the Company issued 3,457,750 stock purchase warrants to investors and to its investment bankers. As of September 30, 2015, the warrants are classified as equity.

Note 10 - Commitments and contingencies

Operating leases

During the second quarter 2015, the Company extended the term of its Gaithersburg, Maryland office lease, effective May 7, 2015, through January 31, 2021, with one additional five-year renewal at the Company’s election. The Company is responsible for all utilities, repairs, insurance, and taxes under this operating lease. Effective July 1, 2015, the Company further modified its lease agreement to add additional leased space to its headquarters. The Company also leases a facility in Woburn, Massachusetts under an operating lease that expires in January 2016, and provides the Company with options to extend the lease beyond the current expiration date. Additionally, the Company leases office space in Denmark; this lease was extended in September 2015 and is currently on a month-to-month basis. Rent expense under the Company’s facility operating leases for the nine months ended September 30, 2015 and 2014 was $447,007 and $341,862, respectively.

Capital leases

The Company leases computer equipment, office furniture, and equipment under various capital leases. The leases expire at various dates through 2018. The leases require monthly principal and interest payments.

Registration and other shareholder rights

In connection with the Merger and the investment transactions (see Notes 4 and 5), the Company also entered into a Registration Rights Agreement with the AdvanDx stockholders receiving Merger Consideration and with Merck GHI, pursuant to which the investors were granted certain demand registration rights and piggyback registration rights in connection with subsequent registered offerings of the Company's common stock. Merck GHI also received rights to participate on a pro-rata basis in future securities offerings by the Company.

On December 18, 2013, the Company entered into the Third Amended and Restated Investors' Rights Agreement (the "Investors' Rights Agreement") with investors acquiring promissory notes convertible into shares of the Company's Series A Preferred Stock. Following the IPO, the holders of 20% or more of the securities subject to the Investors' Rights Agreement have demand registration rights and piggyback registration rights in connection with subsequent registered offerings of the Company's common stock.

Note 11 - License agreements, research collaborations and development agreements

OpGen is a party to two license agreements to acquire certain patent rights and technologies. Royalties are incurred upon the sale of a product or service which utilizes the licensed technology. Certain of the agreements require the Company to pay minimum royalties or license maintenance fees. The Company recognized $7,484 and $23,810 of net royalty expense for the three months ended September 30, 2015 and 2014, respectively and ($13,769) and $73,142 of net royalty (income) expense for the nine months ended September 30, 2015 and 2014, respectively. In 2015, future minimum royalty fees are $20,000 under these agreements.

In September 2013, OpGen entered into a technology development agreement in which the Company would receive fixed milestone payments for meeting development milestones under the agreement. Since the milestones are substantive, the Company recognizes revenue in the periods in which the substantive milestones are achieved; the Company attained sixteen milestones during 2014. In addition, the Company received an upfront payment of $250,000, which is recognized on a straight-line basis over the term of the technology development agreement. The Company recognized total revenue of $208,340 and $1,133,340 during the nine months ended September 30, 2015 and 2014, respectively, and $27,780 and $172,220 during the three months ended September 30, 2015 and 2014, respectively, relating to this arrangement.

In July 2003, AdvanDx entered into a non-exclusive, non-sublicensable, worldwide license agreement with Life Technologies, Inc. (“Life Technologies”) to use certain patent rights that allow it to manufacture and sell certain products. The agreement was amended multiple times through 2009 to add additional features and modify certain terms and conditions. Life Technologies is entitled to certain royalties on product sales. The Company expensed royalties of $150,570 since the Merger.

Note 12 - Related party transactions

In March 2014, the Company entered into a supply agreement with Fluidigm Corporation, or Fluidigm, under which Fluidigm supplies the Company with its microfluidic test platform for use in manufacturing the Acuitas MDRO Gene Test. The Company’s CEO and Chairman of the Board of Directors of the Company, is a director of Fluidigm.

On July 12, 2015, the Company entered into a letter agreement, or the Agreement, with Fluidigm to expand the companies' existing relationship to include collaborating on the development of test kits and custom analytic instruments for identification, screening and surveillance testing of MDROs. The Agreement also expands the existing Supply Agreement between the Company and Fluidigm, and provides for expansion of the gene targets and organisms to be tested on the Company's existing CLIA lab-based tests, the Acuitas MDRO Gene Test and the Acuitas Resistome Test, using Fluidigm technologies and products. Additionally, Fluidigm has agreed not to develop or directly collaborate with any third party to develop an FDA approved or CE marked diagnostic tests for the purpose of detecting resistome genes for identified MDROs if the Company meets certain minimum purchase commitments and other requirements. The initial term of the Agreement is five years. Both parties have the ability to extend the term for an additional five years. Under the expanded Supply Agreement, the term is extended until March 17, 2018, and the Company has the right to extend the term of the Supply Agreement for up to two additional three-year terms.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the unaudited condensed financial statements and the accompanying notes thereto included in Part I, Item 1 of this quarterly report on Form 10-Q. This discussion contains forward-looking statements, based on current expectations and related to future events and our future financial performance, that involve risks and uncertainties. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of many important factors, including those set forth under Part II. Item 1A. “Risk Factors” as well as our Form 10-Q for the periods ended March 31, 2015 and June 30, 2015 filed with the SEC.

Overview

On July 14, 2015, OpGen completed the strategic acquisition (the “Merger”) of AdvanDx, Inc. and its wholly owned subsidiary AdvanDx A/S (collectively, “AdvanDx”). AdvanDx researches, develops and markets advanced in vitro diagnostic kits for the diagnosis and prevention of infectious diseases, and sells its products principally to hospitals and clinical laboratories in the United States and Europe. The Company acquired AdvanDx principally to exploit AdvanDx’s diagnostic capabilities with respect to MDROs and leverage AdvanDx’s relationships with hospitals and clinical laboratories to accelerate the sales of OpGen’s products and services.

The Company’s headquarters are in Gaithersburg, Maryland, and its principal operations are in Gaithersburg, Maryland and Woburn, Massachusetts. The Company also has operations in Copenhagen, Denmark. The Company operates in one business segment.

Recent Developments

Since inception, the Company has incurred, and continues to incur, significant losses from operations. The Company has funded its operations primarily through external investor financing arrangements. The Company raised significant funds in 2015, including:

$1.5 million through the issuance of convertible notes,

$12.1 million in net proceeds from its initial public offering, or IPO, as discussed further below, and

$6.0 million in net proceeds from the issuances of common stock and promissory note to Merck Global Health Innovations Fund, LLC (“Merck GHI”).

On July 14, 2015, the Company completed the strategic acquisition of AdvanDx. Pursuant to the Merger Agreement, a newly formed Merger Sub merged with and into AdvanDx, with AdvanDx surviving as a wholly owned subsidiary of the Company in accordance with the General Corporation Law of the State of Delaware. Under the terms of the Merger Agreement, the Merger Consideration consisted of an aggregate 681,818 shares of the Company's common stock with a value of $2.6 million (based on the closing sales price of our common stock of $3.79 per share on July 13, 2015).

In July 2015, the Company raised $6.0 million by issuing 1,136,364 shares of common stock (with a value of $5.0 million at $4.40 per share) and a $1.0 million promissory note to Merck GHI.

On July 14, 2015, the Company entered into a Registration Rights Agreement with Merck GHI and the AdvanDx stockholders who received Merger Consideration in the Merger, which will require the Company to register such shares of Company common stock for resale by such holders in the future. Under the Purchase Agreement, Merck GHI has the right to participate in future securities offerings made by the Company. There is no assurance that Merck GHI will exercise such participation rights in the future.

The Company’s current operating assumptions, which include management’s best estimate of future revenue and operating expenses, indicate that current cash on hand will be sufficient to fund operations through at least the end of the first quarter of 2016. In the event the Company is unable to successfully raise additional capital in 2016, the Company will not have sufficient cash flows and liquidity to finance its business operations as currently contemplated. Accordingly, in such circumstances the Company would be compelled to reduce general and administrative expenses and delay research and development projects, including the purchase of scientific equipment and supplies, until it is able to obtain sufficient financing, or pursue other strategic alternatives which may include licensing and/or partnering arrangements or mergers and acquisitions. The condensed consolidated financial statements do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.

Results of operations for the nine months ended September 30, 2015 and 2014

Revenues and gross profit

	Nine months ended September 30,
	2015		2014
Revenue
Product sales	$	1,432,592	$	841,567
Laboratory services		87,201		379,339
Collaboration revenue		308,340		1,783,340
Total revenue		1,828,133		3,004,246

Cost of sales
Cost of products sold		712,016		276,831
Cost of services		191,738		336,616
Total cost of sales		903,754		613,447

Gross Profit	$	924,379	$	2,390,799

Our total revenue for the nine months ended September 30, 2015 decreased 39%, to $1.8 million from $3.0 million, when compared to the same period in 2014. This decrease is primarily attributable to:

Product Sales: an increase in revenue of 70% in 2015 as compared to 2014 is attributable to the inclusion of AdvanDx products sales subsequent to the Merger, offset in part by a reduction in the sale of our Argus products, as we transition from our legacy mapping products to the introduction of Acuitas MDRO products;

Laboratory Services: a decrease in revenue of 77% in 2015 as compared to 2014 as a result of a reduction in sales of mapping products, as we transition from our legacy mapping products to the introduction of Acuitas MDRO products; and

Collaborative Revenue: a decrease in revenue generated under a certain collaborative arrangement of 83% in 2015 as compared to 2014 as a result of nearing completion of a technology development agreement.

The Company expects revenues for the year ending December 31, 2015 to remain below 2014 levels as a result of a strategic shift from Argus and Whole Genome Mapping product sales and collaborations to a focus on its QuickFISH and PNAFISH diagnostic products, Acuitas MDRO test products and Acuitas Lighthouse Management System products and services.

Gross profit for the nine months ended September 30, 2015 decreased 61%, to $0.9 million from $2.4 million, when compared to the same period in 2014. This decrease is primarily attributable to the inclusion of AdvanDx cost of sales subsequent to the Merger, along with a decrease in the cost of generating collaboration revenue.

Operating expenses

	2015		2014

Research and development	$	3,741,247	$	3,075,420
General and administrative		3,687,313		1,590,085
Sales and marketing		2,815,976		1,486,801
Depreciation and amortization		392,404		461,432
Transaction expenses		525,596		-
Total operating expenses	$	11,162,536	$	6,613,738

The Company’s total operating expenses for the nine months ended September 30, 2015 increased 69%, to $11.2 million from $6.6 million, when compared to the same period in 2014. This increase is primarily attributable to:

Research and Development: an increase in expenses of $0.7 million primarily due to the inclusion of $0.7 million of AdvanDx expenses subsequent to the Merger;

General and Administrative: an increase in expenses of $2.1 million primarily due the inclusion of $0.3 million of AdvanDx expenses subsequent to the Merger, salaries of $0.5 million, public company costs of $0.8 million and share-based compensation costs of $0.4 million;

Sales and Marketing: an increase in expenses of $1.3 million primarily due to the inclusion of $0.3 million of AdvanDx expenses subsequent to the Merger, clinical outcome cost benefit studies costs of $0.6 million, and share-based compensation costs of $0.6 million;

Depreciation and Amortization: a decrease in expenses due to higher depreciation in the first half of 2014, offset in part by additional amortization expense related to intangible assets recognized subsequent to the Merger; and

Transaction Expenses: the Company incurred $0.5 million of transaction expenses in connection with the Merger.

Other income (expense)

	Nine months ended September 30,
	2015			2014

Interest income	$	9,675		$	120
Interest expense		(1,746,853	)		(47,468	)
Change in fair value of derivative financial instruments and other		(647,342	)		4,400
Total other income (expense)	$	(2,384,520	)	$	(42,948	)

Other income (expense) for the nine months ended September 30, 2015 increased to a net expense of $2.4 million from a net expense of $42,948 in 2014, and was primarily the result of $1.5 million of non-cash interest expense related to the conversion of our convertible notes in May 2015 and the final mark-to-market adjustment related to our warrant liabilities, which were reclassified to stockholders’ equity on May 8, 2015 when their net cash-settlement features lapsed.

Results of operations for the three months ended September 30, 2015 and 2014

Revenues and gross profit

	Three months ended September 30,
	2015		2014
Revenue
Product sales	$	929,241	$	268,854
Laboratory services		23,765		88,190
Collaboration revenue		27,780		477,780
Total revenue		980,786		834,824

Cost of sales
Cost of product sales		562,694		101,425
Cost of services		46,634		129,120
Total cost of sales		609,328		230,545

Gross Profit	$	371,458	$	604,279

Our total revenue for the three months ended September 30, 2015 increased 17%, to $1.0 million from $0.8 million, when compared to the same period in 2014. This increase is primarily attributable to:

Product Sales: an increase in revenue of 245% in 2015 as compared to 2014 was primarily due the inclusion of AdvanDx subsequent to the Merger;

Laboratory Services: a decrease in revenue of 73% in 2015 as compared to 2014 as a result of a reduction in sales of mapping products, as we transition from our legacy mapping products to the introduction of Acuitas MDRO products; and

Collaborative Revenue: a decrease in revenue generated under certain Collaborative Arrangements of 94% in 2015 as compared to 2014 as a result of nearing completion of a technology development agreement.

Gross profit for the three months ended September 30, 2015 decreased 39%, to $0.4 million from $0.6 million, when compared to the same period in 2014. This decrease is primarily attributable to the inclusion of AdvanDx cost of sales subsequent to the Merger.

Operating expenses

	Three months ended September 30,
	2015		2014

Research and development	$	1,724,127	$	1,029,650
General and administrative		1,610,828		555,444
Sales and marketing		979,681		459,064
Depreciation and amortization		185,177		141,060
Transaction expenses		525,596		-
Total operating expenses	$	5,025,409	$	2,185,218

The Company’s total operating expenses for the three months ended September 30, 2015 increased 130%, to $5.0 million from $2.2 million, when compared to the same period in 2014. This increase is primarily attributable to:

Research and Development: an increase in expenses of $0.7 million primarily due to the inclusion of $0.7 million of AdvanDx expenses subsequent to the Merger;

General and Administrative: an increase in expenses of $1.1 million primarily due to the inclusion of $0.3 million of AdvanDx expenses subsequent to the Merger, salary expenses of $0.2 million, public company costs of $0.3 million and share-based compensation costs of $0.2 million;

Sales and Marketing: an increase in expenses of $0.5 million primarily due to the inclusion of $0.3 million of AdvanDx expenses subsequent to the Merger, and $0.2 million for clinical outcome cost benefit studies;

Depreciation and Amortization: an increase in expenses due to amortization of intangible assets recognized subsequent to the Merger; and

Transaction Expenses: the Company incurred $0.5 million of transaction expenses in connection with the Merger.

Other income (expense)

	Three months ended September 30,
	2015			2014

Interest income	$	2,513		$	37
Interest expense		(17,482	)		(32,331	)
Change in fair value of derivative financial instruments		-			4,400
Total other income (expense)	$	(14,969	)	$	(27,894	)

Other income (expense) for the three months ended September 30, 2015 decreased to a net expense of $14,969 from a net expense of $27,894 in 2014.

Liquidity and capital resources

At September 30, 2015, the Company had cash and cash equivalents of $11,187,129, compared to $749,517 at December 31, 2014.

The Company raised significant funds in the first nine months of 2015, including:

$1.5 million through the issuance of convertible notes,

$12.1 million in net proceeds from its IPO, as discussed further below, and

$6.0 million in net proceeds from the issuances of common stock and promissory note to Merck GHI.

In May 2015, the Company completed its IPO pursuant to which the Company offered and sold 2,850,000 units, each consisting of one share of common stock and a detachable stock purchase warrant to purchase an additional share of common stock, at an initial offering price of $6.00 per unit. Of the total gross proceeds of $17.1 million, approximately $2.1 million was satisfied by exchanging outstanding demand notes. After considering the demand notes, underwriting discounts and commissions and offering expenses, the total net cash proceeds to the Company was $12.1 million. In connection with the IPO, all of the Company’s outstanding Series A Preferred Stock, 2014 convertible notes and 2015 convertible notes were converted into 7,374,852 shares of common stock.

In July 2015, the Company raised $6.0 million by issuing 1,136,364 shares of common stock (with a value of $5.0 million at $4.40 per share) and a $1.0 million promissory note to Merck GHI.

The Company’s primary cash requirements are to fund operations as well as research and development programs and collaborations, including those related to AdvanDx acquired in July 2015, and to support general and administrative activities, and to fund acquisitions of products or businesses. The Company’s current operating assumptions, after the IPO and July acquisition of AdvanDx and the funding provided by Merck GHI, which include management’s best estimate of future revenue and operating expenses, indicate that current cash on hand will be sufficient to fund operations through at least the end of the first quarter of 2016. The Company does not currently have any bank credit lines. In the event the Company is unable to successfully raise additional capital in 2016, the Company may not have sufficient cash flows and liquidity to finance its business operations as currently contemplated. Accordingly, in such circumstances the Company would be compelled to reduce general and administrative expenses and delay research and development projects, including the purchase of scientific equipment and supplies, until it is able to obtain sufficient financing, or pursue other strategic alternatives which may include licensing and/or partnering arrangements or mergers and acquisitions.

Sources and uses of cash

The following table summarizes the net cash and cash equivalents provided by (used in) operating activities, investing activities and financing activities for the periods indicated:

	Nine months ended September 30,
	2015			2014

Net cash used in operating activities	$	(11,071,538	)	$	(3,905,198	)
Net cash provided by (used in) investing activities		1,277,977			(39,537	)
Net cash provided by financing activities		20,231,366			3,325,963

Net cash used in operating activities

Net cash used in operating activities for the nine months ended September 30, 2015 consists primarily of our net loss of ($12.6 million), reduced by certain non-cash items, including depreciation and amortization expense of $0.4 million, share-based compensation expense of $1.2 million, change in the fair value of our warrant liability of $0.6 million, non-cash interest expense including that associated with the conversion of our convertible notes in May 2015 of $1.5 million, and the net change in operating assets and liabilities of ($2.3 million). Net cash used in operating activities for the nine months ended September 30, 2014 consists primarily of our net loss of ($4.3 million), reduced by certain non-cash items, including depreciation and amortization expense of $0.5 million and share-based compensation expense of $0.1 million.

Net cash provided by (used in) investing activities

Net cash provided by (used in) investing activities in 2015 included cash on hand at AdvanDx at the date of the Merger, along with the purchase of property and equipment. Net cash used in investing activities in 2014 included solely the purchase of property and equipment.

Net cash provided by financing activities

Net cash provided by financing activities for the nine months ended September 30, 2015 of $20.2 million consisted primarily of net proceeds from the issuance of debt instruments of $3.1 million, net proceeds from our IPO of $12.1 million, and the net proceeds from the issuance of common stock of Merck GHI of $5.0 million. Net cash provided by financing activities for the nine months ended September 30, 2014 of $3.4 million consisted primarily of net proceeds from the issuance of preferred stock and convertible notes.

Critical accounting policies and use of estimates

This Management's Discussion and Analysis of Financial Condition and Results of Operations is based on our unaudited condensed consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. In our unaudited condensed financial statements, estimates are used for, but not limited to, share-based compensation, allowances for doubtful accounts and inventories, valuation of derivative financial instruments, deferred tax assets and liabilities and related valuation allowance, and depreciation and amortization and estimated useful lives of long-lived assets. Actual results could differ from those estimates.

A summary of our significant accounting policies is included in Note 3 to the accompanying unaudited condensed consolidated financial statements. Certain of our accounting policies are considered critical, as these policies require significant, difficult or complex judgments by management, often requiring the use of estimates about the effects of matters that are inherently uncertain.

Revenue Recognition

The Company recognizes revenue primarily from sales of the Argus System, sales of extended warranty service contracts for the Argus System, sales of AdvanDx diagnostic products, providing laboratory services, and from “funded software development” arrangements with collaborative parties. Revenue is recognized when the following criteria are met: persuasive evidence of an arrangement exists; delivery has occurred; the selling price is fixed or determinable; and collectability is reasonably assured. At times, the Company sells products and services, or performs software development, under multiple-element arrangements with separate units of accounting; in these situations, total consideration is allocated to the identified units of accounting based on their relative selling prices and revenue is then recognized for each unit based on its specific characteristics.

When an Argus System is sold without the Genome Builder software, total arrangement consideration is recognized as revenue when the System is delivered to the customer. Ancillary performance obligations, including installation, limited customer training and limited consumables, are considered inconsequential and are combined with the Argus System as one unit of accounting. When an Argus System is sold with the Genome Builder software in a multiple-element arrangement, total arrangement consideration is allocated to the Argus System and to the Genome Builder software (considered multiple elements) based on their relative selling prices. Selling prices are determined based on sales of similar systems to similar customers and, where no sales have occurred, on management’s best estimate of the expected selling price relative to similar products. Revenue related to the Argus System is recognized when it is delivered to the customer; revenue for the Genome Builder software is recognized when it is delivered to the customer. Revenue is recognized for Genome Builder software and for consumables, when sold on a stand-alone basis, upon delivery to the customer.

Revenue for the sales of AdvanDx’s diagnostic products typically is recognized when the product is delivered to the customer.

The Company recognizes revenue associated with laboratory services contracts when the service has been performed and reports are made available to the customer.

The Company recognizes revenue associated with extended warranty service contracts over the service period in proportion to the costs expected to be incurred over that same period. The Company’s funded software development arrangements generally consist of multiple elements. Total arrangement consideration is allocated to the identified units of accounting based on their relative selling prices and revenue is then recognized for each unit based on its specific characteristics. When funded software development arrangements include substantive research and development milestones, revenue is recognized for each such milestone when the milestone is achieved and is due and collectible. Milestones are considered substantive if all of the following conditions are met: (1) the milestone is nonrefundable; (2) achievement of the milestone was not reasonably assured at the inception of the arrangement; (3) substantive effort is involved to achieve the milestone; and (4) the amount of the milestone appears reasonable in relation to the effort expended, the other milestones in the arrangement and the related risk associated with achievement of the milestone.

Impairment of Long-Lived Assets

Definite-lived intangible assets include trademarks, developed technology and customer relationships. If any indicators were present, the Company would test for recoverability by comparing the carrying amount of the asset to the net undiscounted cash flows expected to be generated from the asset. If those net undiscounted cash flows do not exceed the carrying amount (i.e., the asset is not recoverable), the Company would perform the next step, which is to determine the fair value of the asset and record an impairment loss, if any.

Goodwill represents the excess of the purchase price for AdvanDx over the fair values of the acquired tangible or intangible assets and assumed liabilities. The Company will conduct an impairment test of goodwill on an annual basis as of October 1 of each year, and will also conduct tests if events occur or circumstances change that would, more likely than not, reduce the Company’s fair value below its net equity value.

Derivative Financial Instruments

The Company accounts for its derivative financial instruments, consisting solely of certain stock purchase warrants that contain non-standard anti-dilution provisions and/or cash settlement features, at fair value using level 3 inputs. Fair value of these derivative liabilities is determined using a hybrid valuation method that consists of a probability weighted expected return method that values the Company’s equity securities assuming various possible future economic outcomes while using an option pricing method (that treats all equity linked instruments as call options on the Company’s equity value with exercise prices based on the liquidation preference of the Series A Preferred Stock) to estimate the allocation of value within one or more of the scenarios. Using this hybrid method, unobservable inputs included the Company’s equity value, the exercise price for each option value, expected timing of possible economic outcomes such as initial public offering, risk free interest rates and stock price volatility. The Company’s sole derivative financial instrument, a warrant liability, was reclassified to equity in May 2015 as its net-cash settlement features lapsed.

Share-Based Compensation

Share-based payments to employees, directors and consultants are recognized at fair value. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option. The estimated fair value of equity instruments issued to nonemployees is recorded at fair value on the earlier of the performance commitment date or the date the services required are completed.

For all time-vesting awards granted, expense is amortized using the straight-line attribution method. For awards that contain a performance condition, expense is amortized using the accelerated attribution method. Share-based compensation expense recognized is based on the value of the portion of stock-based awards that is ultimately expected to vest during the period. The fair value of share-based payments is estimated, on the date of grant, using the Black-Scholes model. Option valuation models, including the Black-Scholes model, require the input of highly subjective estimates and assumptions, and changes in those estimates and assumptions can materially affect the grant-date fair value of an award. These assumptions include the fair value of the underlying and the expected life of the award.

See additional discussion of the use of estimates relating to share-based compensation, and a discussion of management’s methodology for developing each of the assumptions used in such estimates, in Note 3 to the accompanying unaudited condensed consolidated financial statements.

Recently issued accounting pronouncements

In August 2014, the FASB issued guidance requiring management to evaluate on a regular basis whether any conditions or events have arisen that could raise substantial doubt about the entity’s ability to continue as a going concern. The guidance 1) provides a definition for the term ‘‘substantial doubt,’’ 2) requires an evaluation every reporting period, interim periods included, 3) provides principles for considering the mitigating effect of management’s plans to alleviate the substantial doubt, 4) requires certain disclosures if the substantial doubt is alleviated as a result of management’s plans, 5) requires an express statement, as well as other disclosures, if the substantial doubt is not alleviated, and 6) requires an assessment period of one year from the date the financial statements are issued. The standard is effective for the Company’s reporting year beginning January 1, 2017 and early adoption is permitted. The Company is currently evaluating the impact, if any, that this new accounting pronouncement will have on its financial statements.

Contractual obligations and off-balance sheet arrangements

As of September 30, 2015 and December 31, 2014, we did not have any off-balance sheet arrangements, as defined in Item 303(a)(4)(ii) of Regulation S-K promulgated by the SEC.

JOBS Act

On April 5, 2012, the JOBS Act was enacted. Section 107 of the JOBS Act provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act, for complying with new or revised accounting standards. In other words, an “emerging growth company” can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act. This election allows us to delay the adoption of new or revised accounting standards that have different effective dates for public and private companies until those standards apply to private companies. As a result of this election, our financial statements may not be comparable to companies that comply with public company effective dates.

We are in the process of evaluating the benefits of relying on other exemptions and reduced reporting requirements provided by the JOBS Act. Subject to certain conditions set forth in the JOBS Act, as an “emerging growth company,” we intend to rely on certain of these exemptions, including without limitation, (i) providing an auditor’s attestation report on our system of internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act of 2002 and (ii) complying with any requirement that may be adopted by the PCAOB regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements, known as the auditor discussion and analysis. We will remain an “emerging growth company” until the earliest of (i) the last day of the fiscal year in which we have total annual gross revenues of $1 billion or more; (ii) December 31, 2019; (iii) the date on which we have issued more than $1 billion in nonconvertible debt during the previous three years; or (iv) the date on which we are deemed to be a large accelerated filer under the rules of the SEC.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

As a smaller reporting company, we are not required to provide the information required by this Item.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is accumulated and communicated to management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

Our management has carried out an evaluation, under the supervision and with the participation of our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act), as of September 30, 2015. Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were effective. In designing and evaluating our disclosure controls and procedures, we recognize that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives.

Changes in Internal Control over Financial Reporting

On July 14, 2015, the Company completed the Merger by acquiring 100% of the capital stock of AdvanDx in the Merger. The Company has not yet completed an assessment of the design and/or operating effectiveness of AdvanDx’s internal control over financial reporting. As of September 30, 2015, AdvanDx had total assets of $2.6 million and AdvanDx generated revenues of $0.8 million for the period subsequent to the Merger. There were no changes in the Company’s internal control over financial reporting during the last quarter that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

Part II — OTHER INFORMATION

Item 1. Legal Proceedings

None.

Item 1A. Risk Factors

In addition to the Risk Factors included in our Form 10-Q for the first quarter ended March 31, 2015, which are incorporated herein by reference, the Company adds the following risk factors:

We have a history of losses, and we expect to incur losses for the next several years. The report of our independent registered public accounting firm on our financial statements for the years ended December 31, 2014 and 2013 contains explanatory language that substantial doubt exists about our ability to continue as a going concern.

We have incurred substantial losses since our inception, and we expect to continue to incur additional losses for the next several years. For the nine month periods ended September 30, 2015 and 2014 we had a net loss of $12.6 million and $4.3 million, respectively. From our inception through September 30, 2015, we had an accumulated deficit of $109.4 million. The report of our independent registered public accounting firm on our financial statements for the years ended December 31, 2014 and 2013 contains explanatory language that substantial doubt exists about our ability to continue as a going concern. During the first nine months of 2015, the Company raised $3.1 million in short-term notes and convertible debt (including $1.0 million from Merck GHI, discussed below). In May 2015, the Company completed its IPO pursuant to which the Company offered and sold 2,850,000 units, each consisting of one share of common stock and a detachable stock purchase warrant to purchase an additional share of common stock, at an initial offering price of $6.00 per unit. Of the total gross proceeds of $17.1 million, approximately $2.1 million was satisfied by exchanging outstanding demand notes. After considering the demand notes, underwriting discounts and commissions and offering expenses, the total net cash proceeds to the Company was $12.1 million. In connection with the IPO, all of the Company’s outstanding Series A Preferred Stock, 2014 convertible notes and 2015 convertible notes were converted into 7,374,852 shares of common stock. In July 2015, we received an additional investment of $6.0 million as a result of an investment made in our common stock and a secured promissory note by Merck GHI. In addition, on July 14, 2015, we acquired AdvanDx pursuant to consummation of the Merger under the Merger Agreement.

We expect to continue to incur significant operating expenses and anticipate that our expenses will increase due to costs relating to, among other things:

commercializing our Acuitas MDRO test products, Acuitas Lighthouse MDRO Management System and QuickFISH products, and potential future diagnostic and screening products and services;

integration of the AdvanDx operations;

developing, presenting and publishing additional clinical and economic utility data intended to increase clinician adoption of our current and future products and services;

expansion of our operating capabilities;

maintenance, expansion and protection of our intellectual property portfolio and trade secrets;

future clinical trials;

expansion of the size and geographic reach of our sales force and our marketing capabilities to commercialize potential future products and services;

employment of additional clinical, quality control, scientific, customer service, laboratory, billing and reimbursement and management personnel; and

employment of operational, financial, accounting and information systems personnel, consistent with expanding our operations and our status as a newly public company.

Even if we achieve significant revenues, we may not become profitable, and even if we achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain consistently profitable could adversely affect the market price of our common stock and could significantly impair our ability to raise capital, expand our business or continue to pursue our growth strategy. We anticipate that we will need to raise additional capital to support our operations, including the operations of AdvanDx. While Merck GHI has the right to participate in future capital raising transactions, there is no assurance that it will invest further in the Company. We have no committed sources of capital and may find it difficult to raise money on terms favorable to us or at all. The failure to obtain sufficient capital to support our operations could have an adverse effect on our business, financial condition and results of operations.

We may fail to realize some or all of the anticipated benefits of the business combination of OpGen and AdvanDx, which may adversely affect the value of our common stock.

The success of the integration of AdvanDx will depend, in part, on our ability to realize the anticipated benefits and cost savings from combining the respective business and operations of OpGen and AdvanDx. To realize these anticipated benefits and cost savings, we must successfully combine the acquired business with our legacy operations and integrate our respective operations, technologies and personnel, which is particularly challenging given the geographic and cultural differences between the personnel and facilities based in Maryland and Massachusetts, plus the European operations of AdvanDx, and the lack of experience we have in combining businesses. If we are not able to achieve these objectives within the anticipated time frame or at all, the anticipated benefits and cost savings of the acquisition may not be realized fully or at all or may take longer to realize than expected, and the value of our common stock may be adversely affected. In addition, the overall integration of the businesses is a complex, time-consuming and expensive process that, without proper planning and effective and timely implementation, could significantly disrupt our operations. Further, it is possible that the integration process could adversely affect our ability to maintain our research and development operations, result in the loss of key employees and other senior management, or to otherwise achieve the anticipated benefits of the acquisition.

Risks in integrating AdvanDx into our operations in order to realize the anticipated benefits of the acquisition include, among other factors:

coordinating research and development activities to enhance the introduction of new diagnostic tests and technology acquired in the acquisition;

failure to successfully integrate and harmonize financial reporting and information technology systems of the two companies;

retaining each company’s relationships with its partners;

retaining and integrating key employees from OpGen and AdvanDx;

managing effectively the diversion of management’s attention from business matters to integration issues;

combining research and development capabilities effectively and quickly;

integrating partnership efforts so that new partners acquired can easily do business with us; and

transitioning all facilities to a common information technology environment.

In addition, the actual integration may result in additional and unforeseen expenses, and the anticipated benefits of the integration plan may not be realized. Actual cost synergies, if achieved at all, may be lower than we expect and may take longer to achieve than anticipated. If we are not able to adequately address these challenges, we may be unable to successfully integrate the operations of the business acquired from AdvanDx into our own, or to realize the anticipated benefits of the integration. The anticipated benefits and synergies assume a successful integration and are based on projections, which are inherently uncertain, and other assumptions. Even if integration is successful, anticipated benefits and synergies may not be achieved. An inability to realize the full extent of, or any of, the anticipated benefits of the acquisition, as well as any delays encountered in the integration process, could have an adverse effect on our business and results of operations, which may affect the value of the shares of our common stock.

We have incurred significant costs related to the Merger. If we are unable to offset the costs of the acquisition through realization of efficiencies, our financial condition, liquidity and results of operations will suffer.

We have incurred, and expect to continue to incur, various non-recurring costs associated with combining the operations of OpGen and AdvanDx, including, but not limited to, legal, accounting and financial advisory fees. The substantial majority of non-recurring expenses have been composed of these costs and expenses related to the execution of the acquisition, facilities and systems consolidation costs and employment-related costs. We have also incurred fees and costs related to formulating and implementing integration plans. Additional unanticipated costs may be incurred in the integration of the businesses. Although we expect that the elimination of duplicative costs, as well as the realization of other efficiencies related to the integration of the businesses, should allow us to offset incremental acquisition and acquisition-related costs over time, this net benefit may not be achieved in the near term, or at all.

We expect to make significant additional investment in the future related to the acquisition of AdvanDx.

We anticipate that we will need to make significant investments in the AdvanDx business in order to make it profitable. We will require additional capital to advance the AdvanDx line of products. Investing in the AdvanDx business could distract management attention and resources from the Company’s current products and product development efforts. There can be no assurance that we can obtain sufficient resources or capital from operations or future financings to support the combined business operations. In the event the Company is unable to successfully raise additional capital, we will not have sufficient cash flows and liquidity to finance our business operations as currently contemplated. Accordingly, in such circumstances the Company would be compelled to reduce general and administrative expenses and delay research and development projects, including the purchase of scientific equipment and supplies, until it is able to obtain sufficient financing, or pursue other strategic alternatives which may include licensing and/or partnering arrangements or mergers and acquisitions.

If we cannot enter into and maintain new clinical collaborations, our efforts to commercialize our existing products, and to further develop our products in development could be delayed.

We have an existing collaboration with Hitachi High Technology related to the development of new products using our Whole Genome Mapping technology in human chromosome applications. We also seek collaborations with MDRO-related industry participants, which may include companies developing rapid diagnostic tests for MDROs, and partner with acute care hospitals in conducting clinical evaluations of our Acuitas MDRO test products. In addition, AdvanDx is likely to seek collaborative arrangement in the future as well. These collaborations are important to us. If any of our collaborators decides not to work with us in the future, or to curtail the scope of our collaboration, it could materially adversely affect our business.

A number of the AdvanDx products are regulated by the FDA and non-U.S. regulatory authorities. If we or our suppliers fail to comply with ongoing FDA, or other foreign regulatory authority, requirements, or if we experience unanticipated problems with the products, these products could be subject to restrictions or withdrawal from the market.

We do not have significant experience in complying with the rules and regulations of the FDA and foreign regulatory authorities. The AdvanDx products regulated as medical devices, and the manufacturing processes, reporting requirements, post-approval clinical data and promotional activities for such products, are subject to continued regulatory review, oversight and periodic inspections by the FDA and other domestic and foreign regulatory bodies. In particular, we and our suppliers are required to comply with FDA’s Quality System Regulations, or QSR, and International Standards Organization, or ISO, regulations for the manufacture, labeling, distribution and promotion of the AdvanDx products and other regulations which cover the methods and documentation of the design, testing, production, control, quality assurance, labeling, packaging, storage and shipping of any product for which we obtain clearance or approval. Regulatory bodies, such as the FDA, enforce the QSR and other regulations through periodic inspections. The failure by us or one of our suppliers to comply with applicable statutes and regulations administered by the FDA and other regulatory bodies, or the failure to timely and adequately respond to any adverse inspectional observations or product safety issues, could result in, among other things, any of the following enforcement actions: (1) untitled letters, warning letters, fines, injunctions, consent decrees and civil penalties; (2) unanticipated expenditures to address or defend such actions; (3) customer notifications for repair, replacement and refunds; (4) recall, detention or seizure of our products; (5) operating restrictions or partial suspension or total shutdown of production; (6) refusing or delaying our requests for 510(k) clearance or premarket approval of new products or modified products; (7) operating restrictions; (8) withdrawing 510(k) clearances or PMA approvals that have already been granted; (9) refusal to grant export approval for our products; or (10) criminal prosecution.

We are an early commercial stage company and our products may never achieve significant commercial market acceptance.

Currently, we rely principally on the commercialization of our QuickFISH and Acuitas MDRO test products, and will rely on the launch and commercialization of our Acuitas Lighthouse MDRO Management System products and services, to generate future revenue growth. To date, the Acuitas MDRO test products have delivered only minimal revenue. We believe that our commercialization success is dependent upon our ability to significantly increase the number of hospitals, long-term care facilities and other inpatient healthcare settings that use our products. We have experienced very limited revenue and customer adoption for our Acuitas MDRO products to date. If demand for products does not increase as quickly as we have planned, we may be unable to increase our revenue levels as expected. We are currently not profitable. Even if we succeed in increasing adoption of our products by our target markets, maintaining and creating relationships with our existing and new customers and developing and commercializing additional molecular testing products, we may not be able to generate sufficient revenue to achieve or sustain profitability.

Our products may never achieve significant commercial market acceptance.

Our Acuitas MDRO test products and Acuitas Lighthouse MDRO Management System products and services may never gain significant acceptance in the marketplace and, therefore, may never generate substantial revenue or profits for us. Our ability to achieve commercial market acceptance for our products will depend on several factors, including:

•

our ability to convince the medical community of the clinical utility of our products and services and their potential advantages over existing tests;

•

our ability to convince the medical community of the accuracy and speed of our products and services, as contrasted with the current methods available;

•

the willingness of hospitals and physicians to use our products and services; and

•

the recognition by inpatient health care facilities of the patient safety, improved outcome and cost-effectiveness benefits of using our products and the willingness to pay for them without reimbursement.

If any of these actions were to occur it could harm our reputation and cause our product sales and profitability to suffer and may prevent us from generating revenue. Furthermore, our key component suppliers may not currently be or may not continue to be in compliance with all applicable regulatory requirements which could result in our failure to produce our products on a timely basis and in the required quantities, if at all.

Some of the clearances obtained are subject to limitations on the intended uses for which the product may be marketed, which can reduce our potential to successfully commercialize the product and generate revenue from the product. If the FDA determines that our promotional materials, labeling, training or other marketing or educational activities constitute promotion of an unapproved use, it could request that we cease or modify our training or promotional materials or subject us to regulatory enforcement actions. It is also possible that other federal, state or foreign enforcement authorities might take action if they consider our training or other promotional materials to constitute promotion of an unapproved use, which could result in significant fines or penalties under other statutory authorities, such as laws prohibiting false claims for reimbursement.

In addition, we may be required to conduct costly post-market testing and surveillance to monitor the safety or effectiveness of our products, and we must comply with medical device reporting requirements, including the reporting of adverse events and malfunctions related to our products. Later discovery of previously unknown problems with our products, including unanticipated adverse events or adverse events of unanticipated severity or frequency, manufacturing problems, or failure to comply with regulatory requirements such as QSR, may result in changes to labeling, restrictions on such products or manufacturing processes, withdrawal of the products from the market, voluntary or mandatory recalls, a requirement to repair, replace or refund the cost of any medical device we manufacture or distribute, fines, suspension of regulatory approvals, product seizures, injunctions or the imposition of civil or criminal penalties which would adversely affect our business, operating results and prospects.

If we were to lose, or have restrictions imposed on, the FDA clearances received to date, our business, operations, financial condition and results of operations is likely to be significantly adversely affected.

Item 2. Unregistered Sales of Equity and Use of Proceeds

Unregistered Sales of Equity Securities

On July 14, 2015, the Company completed the strategic acquisition of AdvanDx, through consummation of the Merger. Under the terms of the Merger Agreement, the Merger Consideration consisted of an aggregate 681,818 shares of the Company's common stock with a value of $2.6 million (based on the closing sales price of our common stock of $3.79 per share on July 13, 2015), which Merger Consideration was distributed in accordance with the liquidation preferences set forth in the AdvanDx Restated Certificate of Incorporation, as amended. The issuance of the Merger Consideration was effected as a private placement of securities deemed exempt from registration under Section 4(a)(2) of the Securities Act, and Rule 506 of Regulation D promulgated thereunder, regarding transactions by an issuer not involving a public offering. All stockholders of AdvanDx receiving Merger Consideration represented to us that they were accredited investors and were acquiring the shares for investment purposes only and not with a view to, or for sale in connection with, any distribution thereof and that they could bear the risks of the investment and could hold the securities for an indefinite period of time. The stockholders received written disclosures that the securities had not been registered under the Securities Act and that any resale must be made pursuant to a registration statement or an available exemption from such registration. The Company entered into a Registration Rights Agreement with the AdvanDx stockholders receiving Merger Consideration.

On July 14, 2015, the Company also entered into the Purchase Agreement, with Merck GHI, pursuant to which Merck GHI purchased 1,136,364 shares of common stock of the Company at $4.40 per share for gross proceeds of $5,000,000. Pursuant to the Purchase Agreement, the Company also issued to Merck GHI a Senior Secured Promissory Note, or the Note, and together with the shares of common stock purchased, the Securities, in the principal amount of $1,000,000 with a two-year maturity date from the date of issuance. The Company's obligations under the Note are secured by a lien on all of the Company's assets pursuant to the terms of a Security Agreement, dated as of July 14, 2015, by and among the Company and AdvanDx, as debtors, and Merck GHI as the secured party. The sale of the Securities was effected as a private placement transaction deemed to be exempt from registration under Section 4(a)(2) of the Securities Act regarding transactions by an issuer not involving a public offering. Merck GHI, the sole purchaser of securities deemed to be exempt, represented to us that it was an accredited investor and was acquiring the shares for investment purposes only and not with a view to, or for sale in connection with, any distribution thereof and that it could bear the risks of the investment and could hold the securities for an indefinite period of time. The purchaser received written disclosures that the securities had not been registered under the Securities Act and that any resale must be made pursuant to a registration statement or an available exemption from such registration. The Company intends to use the proceeds from the sale of the Securities for working capital and other general corporate purposes, including funding AdvanDx’s capital requirements in 2015 and 2016.

Use of Proceeds

On May 4, 2015 our registration statement on Form S-1 (File No. 333-202478) was declared effective by the SEC for our IPO. Maxim Group LLC acted as the sole book-running manager and National Securities Corporation acted as co-manager for the offering. On May 8, 2015, we completed our IPO pursuant to which we offered and sold 2,850,000 units, each consisting of one share of common stock and a detachable stock purchase warrant to purchase an additional share of common stock, at an IPO price of $6.00 per unit. Of the total gross proceeds of $17.1 million, approximately $2.1 million was satisfied by exchanging outstanding demand notes. After considering the demand notes, underwriting discounts and commissions and offering expenses, the total net cash proceeds to the Company was $12.1 million.

The principal purposes of our IPO were to obtain additional capital to support our operations, establish a public market for our common stock and to facilitate our future access to the public capital markets. We currently intend to use the net proceeds from this offering as follows:

approximately $5.0 million for sales and marketing activities, including expansion of our sales force to support the ongoing commercialization of our Acuitas MDRO Gene Test products and, when development is completed, our Acuitas Lighthouse MDRO Management System, and for working capital and general and administrative purposes;

approximately $4.0 million for research and development related to the continued support of our completion of the development of our Acuitas Lighthouse MDRO Management System and future products in our pipeline; and

the remainder for general and administrative expenses (including compensation of our officers and directors and other personnel-related costs and costs of operating as a public company), and for working capital and other general corporate purposes.

There has been no material change in the planned use of proceeds from our IPO as described in our final prospectus filed with the SEC on May 5, 2015. No payments were made by us to directors, officers or persons owning ten percent or more of our common stock or to their associates, or to our affiliates, other than payments in the ordinary course of business to officers for salaries.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

Item 6. Exhibits

The exhibits listed in the Exhibit Index, which is incorporated herein by reference, are filed or furnished as part of this quarterly report on Form 10-Q.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	OPGEN, INC.

	By:	/s/ Timothy C. Dec
		Timothy C. Dec
		Chief Financial Officer

	Date: November 13, 2015

EXHIBIT INDEX

Exhibit Number		Description
2.1		Agreement and Plan of Merger, dated as of July 14, 2015, among OpGen, Inc., Velox Acquisition Corp, AdvanDx, Inc., Stockholder Parties and Representatives (incorporated by reference to Exhibit 2.1 of Current Report on Form 8-K, File No. 001-37367, filed on July 16, 2015)

10.1		Agreement and Plan of Merger, dated as of July 14, 2015, among OpGen, Inc., Velox Acquisition Corp, AdvanDx, Inc., Stockholder Parties and Representatives (incorporated by reference to Exhibit 2.1 of Current Report on Form 8-K, File No. 001-37367, filed on July 16, 2015)

10.2		Common Stock and Note Purchase Agreement, dated as of July 14, 2015, between OpGen, Inc. and Merck Global Health Innovation Fund, LLC (incorporated by reference to Exhibit 10.1 of Current Report on Form 8-K, File No. 001-37367, filed on July 16, 2015)

10.3		Senior Secured Promissory Note, dated as of July 14, 2015, between OpGen, Inc. and Merck Global Health Innovation Fund, LLC (incorporated by reference to Exhibit 10.1 of Current Report on Form 8-K, File No. 001-37367, filed on July 16, 2015)

10.4		Registration Rights Agreement, dated as of July 14, 2015, among OpGen, Inc., Merck Global Health Innovation Fund, LLC, SLS Invest AB and LD Pensions (incorporated by reference to Exhibit 10.1 of Current Report on Form 8-K, File No. 001-37367, filed on July 16, 2015)

10.5+		Letter Agreement, dated July 12, 2015, between OpGen, Inc. and Fluidigm Corporation (incorporated by reference to Exhibit 10.5 to the Quarterly Report on Form 10-Q, File No. 001-37367, filed on August 14, 2015)

10.6*		Eighth Amendment to Lease Agreement, dated September 8, 2015, between ARE-708 Quince Orchard, LLC, as Landlord, and OpGen, Inc., as Tenant

31.1*		Certification of Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a)

31.2*		Certification of Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14(a)

32.1*		Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101*		Interactive data files pursuant to Rule 405 of Regulation S-T; (i) the Balance Sheets, (ii) the Statements of Operations, (iii) the Statements of Cash Flows and (iv) the Notes to Unaudited Condensed Financial Statements.

Filed herewith

Confidential treatment has been granted through July 12, 2020 for certain portions of this agreement pursuant to an application for confidential treatment filed with the Securities and Exchange Commission on August 14, 2015. Such provisions have been filed separately with the Commission.

EX-10.6 2 v423020_ex10-6.htm EXHIBIT 10.6

EXHIBIT 10.6

EIGHTH AMENDMENT TO LEASE AGREEMENT

This EIGHTH AMENDMENT TO LEASE AGREEMENT (“this Eighth Amendment”) is dated as of September 8, 2015 (“Effective Date”), by and between ARE-708 QUINCE ORCHARD, LLC, a Delaware limited liability company, having an address at 385 E. Colorado Blvd., Suite 299, Pasadena, California 91101 (“Landlord”), and OPGEN, INC., a Delaware corporation, having an address at Suite 220, 708 Quince Orchard Road, Gaithersburg, Maryland 20878 (“Tenant”).

RECITALS

A. Landlord and Tenant have entered into that certain Lease Agreement (“Original Lease”) dated as of June 30, 2008, as amended by a First Amendment to Lease dated as of April 4, 2011 (“First Amendment”), a Second Amendment to Lease Agreement dated as of August 15, 2012 (“Second Amendment”), a Third Amendment to Lease Agreement dated as of December 30, 2013 (“Third Amendment”), a Fourth Amendment to Lease Agreement dated as of March 21, 2014 (“Fourth Amendment”), a Fifth Amendment to Lease Agreement dated as of March 20, 2015 (“Fifth Amendment”), a Sixth Amendment to Lease Agreement (And Amendment to Reimbursement Agreement) dated as of April 30, 2015 (“Sixth Amendment”), and a Seventh Amendment to Lease Agreement dated as of June 30, 2015 (“Seventh Amendment”; the Original Lease, the First Amendment, the Second Amendment, the Third Amendment, the Fourth Amendment, the Fifth Amendment, the Sixth Amendment, and the Seventh Amendment are hereinafter collectively referred to as the “Lease”), wherein Landlord leased to Tenant certain premises located on the first and second floors of the building located at 708 Quince Orchard Road, Gaithersburg, Maryland 20878, as more particularly described in the Lease.

B. Landlord and Tenant desire to amend the Lease, among other things, to provide an additional tenant improvement allowance to Tenant in an amount not to exceed $65,000 (“2015 TI Allowance”) and to set forth the terms for Tenant’s repayment of the 2015 TI Allowance to Landlord.

AGREEMENT

Now, therefore, the parties hereto agree that the Lease is amended as follows:

1. 2015 TI Allowance. Landlord shall provide the 2015 TI Allowance to Tenant, which amount Tenant shall use as set forth in this Eighth Amendment. Landlord’s obligations with respect to the 2015 TI Allowance shall cease upon disbursement in full of the 2015 TI Allowance to or on behalf of Tenant. The 2015 TI Allowance shall be used to reimburse Tenant only for modifications of or improvements to the Premises of a fixed and permanent nature desired by Tenant previously approved by Landlord (“Tenant Improvements”) but shall not be used to purchase any furniture, personal property, or other non-Building Systems materials or equipment. Tenant shall have no right to the use or benefit (including any reduction to Base Rent) of any portion of the 2015 TI Allowance not required for the Tenant Improvements. As of the Effective Date, Tenant is in the process of constructing the Tenant Improvements in accordance with the terms and conditions of the Lease. Upon submission by Tenant to Landlord of a single request for payment (“Payment Request”) containing written evidence (including invoices and receipts) of the expenses incurred by Tenant with respect to the Tenant Improvements, Landlord shall promptly reimburse Tenant for such expenses from the 2015 TI Allowance, but only to the extent of the funds are available therefrom. Tenant shall submit such Payment Request not later than the first anniversary of the Effective Date. Landlord shall have no obligation to so reimburse Tenant for the expenses incurred by Tenant in connection with the Tenant Improvements if Tenant submits such Payment Request after the first anniversary of the Effective Date.

Copyright © 2012. Alexandria Real Estate Equities, Inc. ALL RIGHTS RESERVED. Confidential and Proprietary. Do Not Copy or Distribute. Alexandria and Alexandria Logo are registered trademarks of Alexandria Real Estate Equities, Inc.

Eighth Amendment to Lease Agreement – OpGen, Inc.

Page - 2

2. Repayment of 2015 TI Allowance. Base Rent shall be increased as of the date on which Landlord reimburses Tenant pursuant to the Payment Request (such increase to be calculated based on the amount of the 2015 TI Allowance used by Tenant and as set forth in the Payment Request, such amount to be amortized over the remaining portion of the Second Extension Term based on an interest rate of 9% per annum; the resulting amount so amortized shall be added to the monthly installments of Base Rent).

3. Amended Definition of “Termination Fee.” As of the Effective Date, the definition of “Termination Fee” set forth in the second sentence of Section 43(c) is hereby deleted and replaced with the following sentence:

For purposes of this Section, “Termination Fee” means an amount equal to the unamortized amounts of (i) 2015 Landlord’s Work (as defined in the Fifth Amendment) and 2015 Expansion Premises Work (as defined in the Seventh Amendment), (ii) the leasing commissions paid by Landlord in connection with the Fifth Amendment and Seventh Amendment, (iii) the Rental Abatement (as defined in the Fifth Amendment), and (iv) the 2015 TI Allowance (as defined in the Eighth Amendment).

Miscellaneous.

a. Terms used in this Eighth Amendment and not otherwise defined shall have the meanings ascribed to them in the Lease.

b. This Eighth Amendment is the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior and contemporaneous oral and written agreements and discussions. This Eighth Amendment may be amended only by an agreement in writing, signed by the parties hereto.

c. This Eighth Amendment is binding upon and shall inure to the benefit of the parties hereto, their respective agents, employees, members, representatives, officers, directors, divisions, subsidiaries, affiliates, assigns, heirs, successors in interest and shareholders.

d. This Eighth Amendment may be executed in any number of counterparts, each of which shall be deemed an original, but all of which when taken together shall constitute one and the same instrument. The signature page of any counterpart may be detached therefrom without impairing the legal effect of the signature(s) thereon provided such signature page is attached to any other counterpart identical thereto except having additional signature pages executed by other parties to this Eighth Amendment attached thereto.

Eighth Amendment to Lease Agreement – OpGen, Inc.

Page - 3

e. Except as amended and/or modified by this Eighth Amendment, the Lease is hereby ratified and confirmed and all other terms of the Lease shall remain in full force and effect, unaltered and unchanged by this Eighth Amendment. In the event of any conflict between the provisions of this Eighth Amendment and the provisions of the Lease, the provisions of this Eighth Amendment shall prevail. Regardless of whether specifically amended by this Eighth Amendment, all of the terms and provisions of the Lease are hereby amended to the extent necessary to give effect to the purpose and intent of this Eighth Amendment.

[Signatures on Next Page]

Eighth Amendment to Lease Agreement – OpGen, Inc.

Page - 4

IN WITNESS WHEREOF, the parties hereto have executed this Eighth Amendment under seal as of the day and year first above written.

TENANT:

OPGEN, INC.,
a Delaware corporation

By:	/s/ Timothy C. Dec		(SEAL)
Name: Timothy C. Dec
Title: Chief Financial Officer

LANDLORD:

ARE-708 QUINCE ORCHARD, LLC,
a Delaware limited liability company

By:	ARE-GP 708 Quince Orchard QRS CORP.,
	a Maryland corporation,
	managing member

	By:	/s/ Jennifer Banks	(SEAL)
	Name: Jennifer Banks
	Title: EVP, General Counsel

EX-31.1 3 v423020_ex31-1.htm EXHIBIT 31.1

Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO RULE 13A-14(A)/15D-14(A)

I, Evan Jones, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of OpGen, Inc.

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 13, 2015

/s/ Evan Jones
Evan Jones
Chief Executive Officer (principal executive officer)

EX-31.2 4 v423020_ex31-2.htm EXHIBIT 31.2

Exhibit 31.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO RULE 13A-14(A)/15D-14(A)

I, Timothy C. Dec, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of OpGen, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting

Date: November 13, 2015

/s/ Timothy C. Dec
Timothy C. Dec
Chief Financial Officer (principal financial officer and principal accounting officer)

EX-32.1 5 v423020_ex32-1.htm EXHIBIT 32.1

Exhibit 32.1

CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report on Form 10-Q of OpGen, Inc. (the “Company”) for the quarterly period ended September 30, 2015 (the “Report”) as filed with the Securities and Exchange Commission on the date hereof, the undersigned Chief Executive Officer and Chief Financial Officer of the Company hereby certify that, to such officer’s knowledge:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

This certification is provided solely pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

Date: November 13, 2015	By:	/s/ Evan Jones
		Evan Jones Chief Executive Officer (principal executive officer)

Date: November 13, 2015	By:	/s/ Timothy C. Dec
		Timothy C. Dec Chief Financial Officer (principal financial officer and principal accounting officer)

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

GRAPHIC 6 image_002.jpg GRAPHIC begin 644 image_002.jpg M_]C_X 02D9)1@ ! 0 0 ! #_VP!# $! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_ MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P 1" !4 *D# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#^_BBBH7^\ M?P_D* )J*KT4 6**KT4 6**KTC?*5VX,D@9$+?=51EFX'7) .,C<<#(Q0!9H MK\X?C_\ M\6/A/XH:E^S3^S%\)_$?[7O[55AIVDZCXH^&W@+6--\&_#OX+Z) MXA6"32-=_:2^._B'3M>\#_">'7+:*.\T;P3#HOC3XS^(] NM.UWPE\+M:T34 M]-U2[\X\._#S_@IQ\<[ :YXN_;?_ &>_V>(9[N_LY? _[*?[.I^+=QX?NK1Y M(M1\.:K\6/VD];O]/UC7M%E62TN7N_@;X06XE22=_#.FQ[;90#]9:*_(SP;\ M&/VT_$VA/XR^!'_!8/\ X7/IMCJVN:,TWQ3_ &7_ -E/XF?#T:YX6U?4= U_ M1-1G_9STG]F?7[*?2-=TG4M$UB"+Q?/=Z'J%E>Z;6$WF9%M^WK^T#^S M0RZI^WW\&O!,GP7&I-HEU^V[^R%>^,O'_P !O"%TM_)8F[^.WPP\3Z)#\5_@ MUX;BO_.TW5O'VE:K\6/A%I>JV]POB+QKX1O([J*T /V*HKG?#>MZ3XF\/Z)X MDT#6=)\1:!XATNQUS0?$&@ZA::MH>NZ'J]M'J&D:SHVJ6$MQ8ZCI6IZ=<6U[ MI][9W5[:W5I/#-!?WT3K>3[5 %BBJ]% %BBJ]% %BBJ]% %BBFI]T?C_ #-. MH CE^X?Q_D:A3[H_'^9J:7[A_'^1J%/NC\?YF@!U%%% !1110 5^?/\ P4$^ M.?Q)^'G@WX:?!#]GF?2K3]J/]KSXDP? CX(ZYJ^G1:WI/PV6X\-ZYXL^+7QX MU_09)(UU?2O@9\)?#_B7QA!IDLD4/B;Q3-X.\$NP'B7_%7QWK]UZ[KVM7^CQO%W?BCXVU+X9Z'\5OB3+X2\+V?C3P7\%_'/CV+3_#OB'Q+KFM^(=-\':+ M'V^ O\ @JO\61^QY_P32_:G^,'@^U_M+Q3HWAOPS;.^IZE=QZEXMUGQGX^\ M&^ [J'5-:LHX;R+K?1?#^DZY9GPAHVAV>E:'L%O8%U_?"ZO_ !>UA+I&H_#&TU/33ISZ M<^F^'_$'A/5;:[L[NVFL)+>TL/%NG^#K-D2'[9:6]O>0V>CZIIT]Y [/&T32 M?RK?\&V?[=^N_M3?%K]J3X+>+/ &B^$= TSX6^"?B/;Z%IGB#7/$VG:U<7GB M74?!^OR7^F^(E&;5I[( !4-J^=Q4_P!4MQ;:S\-'EGT2WOO$/P^" MM/>^']M]J_B+P8JK(!J.@Q7ERLWB'PPDD:3W_A8/#KVAS//>Z->ZM826/A^U M /S(_9^MY/V"/VL_"W[*>DZ;K/A[]C?]L&/XA>+_ -F#P=KL_P!H3]F;]HGP M.B^/?B%\ ?#;V^K:KIVG_!CXO>#CK_Q;^"OA72-5N-*\*>+?"'Q7\&:':66D MZCHUI#^SD3!D#*S,K%BK,V[*EB5*O_''C'E/SOCV,2)[Z'X,^-/"?PR^+E]9Z5F]T[PM MX+\;ZUH43:ZEL6_6&L?4K>&[2:SGABFM[L+!>6\UO8W<-]:744VGR6EU!>A; M;[*YO%=XY9&NK^&.]M(87C"K( ?%/[6/[;7[/G["O[-7AS]H3QC?:'-\'=8U MKP5X5\+:EX5U/0;+0M4'CB"[U'PG+X>U2S"^'+O1+_3X;N]M;O3Y?LMW:RK< M0NPE=S^,7_!P9^U)\'?CQ_P3C\;_ +^!OQM^!WQ!^,'C#XF?!"3Q'\)=(^. MOPDM_&FA^'-"\66WQ$U^XU;2;OQKI-S UG'X>L@//M('=!#*@FCE$Q[']L'_ M ()1^)_"OP]'PO\ AW\)KK]MC]@"+QKI7Q#M?V"-<^*GC'X5_$#]F36])O-; MN-6U+]D#QA#X_P#AMX7\8^ )8O$.L6&D_L]_%;Q/H%IX7MM2/_"MO%SV<6E> M#[;X-\;_ 7_ ."#?BOQUXTN/VC/@6G[//Q6\8?V3>>.+']JOPO^U_\ 7QC MX8NK*"VTXW?@_7OC!\9_"GA_QRFH16EOHVJ:QX$NFTZ\NX9KNXO[^6:YO+D M_.W_ (-RO$:_L=?MW>._&/[1_C+X2?!WX8^.OV<_&'@2^\:>./CI\$+72(_% M?_":^ _$^C6%S';?$274EN=;?1=2@MQ+&1,NF1A62"17']I?PW_X*4?LU?%O M]K>7]C_X9^./#?CWQP_P@C^-.D^)_"OBO0/$OA;7/!>IVNE2Z?J.C7^GW^HQ M7=K/+>!2\5],D)/YL/%7[/7_!N'H8OY'\+?LPZAJ>K6EGI5EX9^ M$GQ+^,7Q7\1Z<]RK_37P2_8GU#QU\6?"?Q)_X)Q_L=^(?V+H= ^%FC?!G2?V\/VAX_CW MX#\1>#_A-9:)IN@6H_9__8[\?_&?Q?XD^(7B7_A&K>#3-+UCXX>$?!O@N![7 M1M5OK[Q7=Z*UI<@'ZB_%Z#0OVGO^"AOP9^ 7PWLSJ'@3]C'Q98?M@?M%LD[HT8EDFC;) )WQ7(%S%("2)([G-Q&^Y)RTJNQ^:OV7_V7 MOA;^R9\*+/X5_"Z#Q-+%)JFL^*O%_C;Q_KEQXJ^)GQ4^)?B@QW'BWXF_%/Q= M=I&_C?XC^*+Z"?4M6U"V@L]%M@T.D>'=,TGP_8:396?TTGW<@, Q9L-D-\[% MLL&"E6;.XH5&PG9@;<4 .HHHH **** "BBB@"9/NC\?YFG4U/NC\?YFG4 1R M_(/$NLW3E(-) M\/Z%IMUJNM:G<2E9)8[+2M+LY]3D2Q3SB]L[JK.7#?C/^P)\:O&>F_M0_$/X M?_%*7XEZ=)^VM\*='_;>\ :1\0_!WC3P58^#?B=I-S!X&_: ^#W@FX\9R)=: MIX:\!^ ]1_9GU#19/#&^PN&U;QQ?S[;AG8 '[=[XT)9Y=O8C/3TXYZX].:> ML6Q8U:VCG(^S'8KM%'$6&[<#YQ_P3S@CM_V!OV)%C@AMC+^R3^SI=SPP#$2W ME]$O"%Y?,O)_P!9>3SR-_M.W Z4 ?87FQ+PTFTCJ,XQW]/3FCN M>W\^*_+G_@J]IMO??!;X"RR>%;3QK>6_[>?["$6G>%[N2RMT\1G5OVFOA]H6 MI^%[F?48GTP:7XCT/4]6TJ9=3+6GFW4AFCD0((_LK]GSPSI7A7P%>V&C_!'3 M?V>A=^)_%U[^>;$O#2;2.HSC'?T].:-RMRK;@>AZY[?SXK\B/^"GEO=_ BX^$G[<_ MP;\-W'B/]I3X,:]KWA'3?AIHNG:IJNL?M+?!WQ?X;O\ 4_BY\*9-"TN:.[UB M;X<>&?"U]^TCX>U*V6:^\.S?";6](T,)+X[U\3?;'[)W@_X7^&_@GX0\3?"W MQ1IGQ#TCXL6S?'#5OBY911./B_XD^*B2>,=5^)]_=1$Q06WB:^UFZU#2=*MW M^Q^']'EL=$T]([/38U4 ^GZS=3TW3=6MI+#5M/L=5LIP3+9:G907UJX "X,% M]NM7!&21MZDY!.37Y)?\%0/%GQ"\2:3H?P5^"UW\2!\5/A[X'US]L'2(?AEX M5\<^*]5\0?$+X!ZWX=U;]F_X3>)5\#>%_$RZ9X-^.GQ-L_$D%]<^('TVVDTS MX:>(\.(E4O\ I/\ CXQ^$OVAO@K\*/COX"NA=^#?C!\/?"7Q'\-2&6&:6/2 M?%^B66N6EG\MI[>XCBN(I8U .M\.^#O!GAEI)?"_A M;P[X>\XE9/\ A'M#TW3,G+!S(=,B2V 9][/MY+,3)^\+UU7G*244@\GE3N!R M>?F])-%\%V-U/;Z?X0_:3\+_V+=:U\'/B3J$L6D>([ ME+[X.^*9;;PWXGNO$/A3K_V:OBS$/VEOVNQ^T7\&M0M]3\)^._V-/"^CB\N M=)N-!\8>'O%/AWXY_$/2O%/@;QOXEWO@OQAX8U6&+5?#G MB7P_JN@ZG%%>V$\:@'ZCF1(SF22)4]&P&'YD?AP>#]* Z2#?&RLC?=9>AQP< M?0@@^XK\R_\ @K_9P7G_ 3<_:[N"D!EC^%(_#\NEW<-[- MAHH[(W5S++'."9#J-S'$ZK(JMYA_P4D^!O@?X)_LP?%[]K/]GS2-+_9]_:)_ M9I^'^N_&+X<^//AI9KX2B\4W7@A[3Q+=?"+XF^%M&M1H'Q.\$_%^VTJX^''B M;1/&&E>)6MCKEGXA\*+9>,XM FA /V$HK#T:XN]0T72K_4M-CT_4[ZQTY]0T MR5M[V#W'E/>V9W,Y*V]R\T2(X1E1$26**57A7^:[X>6'@6;QI9^&])LO$7P9 M^->J?\%L/V@H_AY^T6=!U'PKX/FTCPM\==7\?>/_ (/ZA\2=&6.Q\5Q_&KX2 M>&O'/PJT?X6>+KA5\7>)-9N+>S5+?1(9* /Z;:*K0JQACWADC$2(Z7C^8[!@ MQVSR%Y TR[@DQ#NHE#JI9 ,_FU_P3UTZQLO'7_!2Q[:QAMF;_@H_\283Y2X1 M[:X^ G[,<\Y & -\TLTDB@#$F<<4 ?I=17Q9^W#XT.@_!MO EI+XRM]6^/WB MO0/@)8S?#S0];\0^,M-\/^.FOU^)GC#PWI'A32M0\5WNK> _A!IGC;QA9RZ0 MDWV?4=#TLE5;S ?._P#@F;\5=6\-/&'[+7Q(N/%=A MK>@Z_>O\';AM.^'_ (XUK2?$5K::W97GQ)^#>I^ /B1-_:=O%-(WBDRCS8A' M*X!^CJ?='X_S-.JM9W-O>VT-W:3Q7-MA6FK:_P"'I)+: M76?!4\NO^'?$Z#0_%>GVMQH_B6#3[73[FY\.WNJQ+>V^^:<\K\;?V#/&W[.WQ#U7XE?#CQUX#O\ 0K+697\3^$=8\ ^)_!>KW&O^ M'_%>EZI\//'_ (:\3WMKXBT+R[&>74=*\*:I8/;-H5K+#]044 >:>.O NG_$ M/P!XU\ :K>ZOIFF>.O#'B;P;=ZCXZETXZM:ZM8V.L1Z? M>7'V._N])-MIRO;V<4'V>--_A?[/?[+T?[/?AGX;^#])^/'QS^(/@#X5_"S2 M?A+X,\#_ !(N_A.?#T?AW0=&T;P]X;U&\D^'GPL\#ZIXFURRT/0[73;6_P!8 MU?5F^SW\VV"&$O!?@_P 2>-?B+X"3P1\7?AM\ M;/#^O_#NY\%:=KB^.?A%XJM_'7@:;4X_&G@3QGI5SI,7B'3;34+NSG\.YEN- M,C!F9099O2/AMX%U?P98WMIKWQ)\?_%+5-0UJ76KCQ'\0G$6FJ606PM=*MM M'TO2O 7@;X>>$[/1((+3RT72O">EF[=I-1U&74]7N[[5+GU>B@#P*Z^"&CWG MQWT?X\ZKXB\7ZWKGA?X?ZS\/O!'@V\D\*GP+X*MO$NIZ'>^*_$'AFP/ANU\0 MV7B[Q/%X>T[2K_79_$.HLGABPN]+MA;6E^(!S?[-/[,WA#]EOPCK_@'X;^(? M&$_A_KT_AMO"7PEC\:^+-5\9ZKX.^%-OH^@Z/K&D?#2/6M> MU&X\.>%];\2^*(?"^EW%OX=TI[#1["'2;3ZAHH \'\&_!?2O!'Q1^+_Q;3Q9 MXW\2>*?BW%X*@U.W\3WFA7&C^&]$^'FGZQ:^$O#/A"'P_HFD:M9^%H=1\3^* M=:&C:O?ZW)<^(_$GB;4(F1;Z*&' _9O_ &;_ K^S#X-UWX%/%-WH=WI?PYF^(?C+7?B#KWA3P+)H'A3PKJD7@:/Q#XBU6ZTC M3=>U;Q&VDV\T>EVM^;.$1#Z7HH \4TCX466B_&3QO\9$\6^+)]9\=>"OA_X# MU'PM<+X4D\'Z1I7P_P!2\9:IX)/MPU/XD>)9&FUGQ#?+)YS+ M%'#9PQ1IY]X$_90^"?PU^/\ \7_VB_ 7A>Z\*?$3X\>'O"6D?%"ULM1EA$^ M)]5\':IJ+P>,6\,1SOI%IXPO['6+;1?%^O61%WXKT/2_#FDW[//H.6^K** / MF_\ ::_9Z\,?M4_ ?XC? +Q[XD\:>$?"?Q1T!]"\2:IX!NO#.F>*K;2Y[TZ@ M]O;:GK_ASQ-HL)M9(A%(S6%V)XHYW8NURS-RVK?LL6'C.Y\-VGQ@^+_QF^.' MA+0?$&@^)[?X>?$&7X7:;X$U/Q)X2UG3-=\,:MXMTCX<_#KX=WWC+_A'-6T7 M2-;TG1==O]6\+#7M(C\1:AH&H7S1S/\ 7-% &.\4ODM ;@_:"/,#2&(22E#' MYLKRW%M /#O@7Q+X4USP MKXV72/$?P[\4V=U<>*?!>M:%X=UCPKJ>DZCI]M7_#7PCJ7@SP7H MGAK4?'GC#XDW&AV<.GQ>,/B$_A!/%=^VF)'9JNO-\/?"G@S0Y9Y$M%-W,VF+ M/+< -?PFY!@7S/X(?L[>&_@-XD^.OB+P[XP\<^)A^T%\8-9^.WC&S\8WGAB: MSL?&.M>%?#7@^\M_"=IHO@S0KNVTFW\.^!?#UK;V]SJ%].8[?S7NY&+22?3E M% '@7BWX+Z9XI^,WPS^-.J^+_%1U7X1Z'XYTOPAX,MXO"S>!3JWCZTT_1K_Q M/J\%QX=;QI+XDLM/LI-'T"2Q\=:;8KIFL>*M,>RN8?$$\2^:7'[(7P\F^)O[ M07Q1L?%'Q TB[_:>\">#_"_Q2$6&M>&O^$&UW5/ &B:EX5\/_%+2+:Y\+ZM MXBT7QXWA*\TKPEKFHC7M1$ZWX3TCPW::[X5U#4(+JZD^R** /+_ (,?#+PY M\&_AIX9^&OA*[UB^\/\ A=-5AL+O7[BQN=7F;4-GV^GP+%81V=NML(E]0HHH **** "BBB@ HHHH **** "BBB@ HHHH 7 **** "BBB@ HHHH **** "BBB@#_]D! end EX-101.INS 7 opgn-20150930.xml XBRL INSTANCE DOCUMENT 0001293818 2014-01-01 2014-09-30 0001293818 2015-01-01 2015-09-30 0001293818 2015-03-31 0001293818 2014-04-01 2014-06-30 0001293818 2015-05-01 2015-05-31 0001293818 2015-05-02 2015-05-08 0001293818 2014-07-01 2014-09-30 0001293818 2015-07-01 2015-09-30 0001293818 2015-07-14 0001293818 2013-09-01 2013-09-30 0001293818 2015-09-30 0001293818 2015-10-30 0001293818 2014-12-31 0001293818 2014-09-30 0001293818 2013-12-31 0001293818 us-gaap:RedeemableConvertiblePreferredStockMember 2015-09-30 0001293818 us-gaap:RedeemableConvertiblePreferredStockMember 2014-12-31 0001293818 us-gaap:ConvertibleNotesPayableMember 2015-01-01 2015-09-30 0001293818 us-gaap:IPOMember 2015-05-02 2015-05-08 0001293818 us-gaap:CommonStockMember 2015-05-02 2015-05-08 0001293818 opgn:AdvandxIncMember opgn:MerckGlobalHealthInnovationFundLlcMember 2015-07-01 2015-07-14 0001293818 us-gaap:CommonStockMember opgn:MerckGlobalHealthInnovationFundLlcMember 2015-07-01 2015-07-14 0001293818 us-gaap:CommonStockMember opgn:MerckGlobalHealthInnovationFundLlcMember 2015-07-14 0001293818 us-gaap:CommercialPaperMember opgn:MerckGlobalHealthInnovationFundLlcMember 2015-07-14 0001293818 us-gaap:MinimumMember 2015-01-01 2015-09-30 0001293818 us-gaap:MaximumMember 2015-01-01 2015-09-30 0001293818 us-gaap:CommonStockMember 2015-06-30 0001293818 us-gaap:RedeemableConvertiblePreferredStockMember 2015-01-01 2015-09-30 0001293818 us-gaap:FairValueInputsLevel3Member 2015-09-30 0001293818 us-gaap:FairValueInputsLevel1Member 2015-09-30 0001293818 us-gaap:FairValueInputsLevel2Member 2015-09-30 0001293818 us-gaap:FairValueInputsLevel1Member 2014-12-31 0001293818 us-gaap:FairValueInputsLevel2Member 2014-12-31 0001293818 us-gaap:FairValueInputsLevel3Member 2014-12-31 0001293818 us-gaap:SeriesAPreferredStockMember 2015-01-01 2015-09-30 0001293818 us-gaap:SeriesAPreferredStockMember 2014-02-28 0001293818 us-gaap:SeriesAPreferredStockMember 2014-02-01 2014-02-28 0001293818 us-gaap:SeriesAPreferredStockMember 2014-04-30 0001293818 us-gaap:SeriesAPreferredStockMember 2014-04-01 2014-04-30 0001293818 us-gaap:SeriesAPreferredStockMember 2014-12-31 0001293818 us-gaap:SeriesAPreferredStockMember 2013-12-31 0001293818 us-gaap:SeriesAPreferredStockMember 2013-12-01 2013-12-31 0001293818 opgn:ConvertibleNotes2015Member 2015-02-01 2015-03-31 0001293818 opgn:ConvertibleNotes2015Member 2015-03-31 0001293818 opgn:BeforeClosingIpoMember opgn:ConvertibleNotes2015Member 2015-02-01 2015-03-31 0001293818 opgn:AfterClosingIpoMember opgn:ConvertibleNotes2015Member 2015-02-01 2015-03-31 0001293818 us-gaap:CommonStockMember opgn:ConvertibleNotes2015Member 2015-03-31 0001293818 us-gaap:IPOMember 2015-05-01 2015-05-31 0001293818 us-gaap:CommonStockMember 2015-03-31 0001293818 us-gaap:CommonStockMember 2015-05-08 0001293818 opgn:DemandNotesPayableMember 2015-05-02 2015-05-08 0001293818 us-gaap:OverAllotmentOptionMember 2015-05-08 0001293818 us-gaap:OverAllotmentOptionMember 2015-05-02 2015-05-08 0001293818 opgn:TwoThousandFifteenPlanMember 2015-09-30 0001293818 opgn:TwoThousandFifteenPlanMember 2015-01-01 2015-09-30 0001293818 us-gaap:ResearchAndDevelopmentExpenseMember 2015-01-01 2015-09-30 0001293818 us-gaap:GeneralAndAdministrativeExpenseMember 2015-01-01 2015-09-30 0001293818 us-gaap:SellingAndMarketingExpenseMember 2015-01-01 2015-09-30 0001293818 us-gaap:ResearchAndDevelopmentExpenseMember 2014-01-01 2014-09-30 0001293818 us-gaap:GeneralAndAdministrativeExpenseMember 2014-01-01 2014-09-30 0001293818 us-gaap:SellingAndMarketingExpenseMember 2014-01-01 2014-09-30 0001293818 us-gaap:EquityIssuedInBusinessCombinationMember opgn:AdvandxMember 2015-07-01 2015-07-14 0001293818 opgn:AdvandxMember 2015-01-01 2015-09-30 0001293818 opgn:AdvandxMember 2015-09-30 0001293818 opgn:MerckGhiFinancingAgreementMember 2015-07-01 2015-07-14 0001293818 opgn:MerckGhiFinancingAgreementMember 2015-07-14 0001293818 us-gaap:WarrantMember 2014-12-31 0001293818 us-gaap:WarrantMember 2015-01-01 2015-09-30 0001293818 us-gaap:WarrantMember 2015-09-30 0001293818 opgn:ConvertibleNotes2015Member 2015-06-30 0001293818 opgn:ConvertibleNotes2015Member 2015-04-01 2015-06-30 0001293818 opgn:ConvertibleNotes2015Member 2015-07-01 2015-07-31 0001293818 opgn:ConvertibleNotes2015Member 2015-07-31 0001293818 opgn:ConvertibleNotes2015Member 2015-09-30 0001293818 us-gaap:LoansPayableMember 2014-10-01 2015-03-31 0001293818 us-gaap:IPOMember us-gaap:CommonStockMember 2015-05-01 2015-05-31 0001293818 us-gaap:LoansPayableMember 2015-09-30 0001293818 opgn:ConvertibleNotes2014Member 2014-07-01 2014-09-30 0001293818 opgn:ConvertibleNotes2014Member 2014-09-30 0001293818 us-gaap:LoansPayableMember 2015-01-01 2015-09-30 0001293818 us-gaap:LoansPayableMember 2015-04-01 2015-06-30 0001293818 us-gaap:AccountsReceivableMember opgn:CustomerOneMember 2015-01-01 2015-09-30 0001293818 us-gaap:AccountsReceivableMember opgn:CustomerTwoMember 2015-01-01 2015-09-30 0001293818 us-gaap:AccountsReceivableMember opgn:CustomerOneMember 2014-01-01 2014-12-31 0001293818 us-gaap:AccountsReceivableMember opgn:CustomerTwoMember 2014-01-01 2014-12-31 0001293818 us-gaap:ResearchAndDevelopmentExpenseMember 2015-07-01 2015-09-30 0001293818 us-gaap:GeneralAndAdministrativeExpenseMember 2015-07-01 2015-09-30 0001293818 us-gaap:SellingAndMarketingExpenseMember 2015-07-01 2015-09-30 0001293818 us-gaap:ResearchAndDevelopmentExpenseMember 2014-07-01 2014-09-30 0001293818 us-gaap:GeneralAndAdministrativeExpenseMember 2014-07-01 2014-09-30 0001293818 us-gaap:SellingAndMarketingExpenseMember 2014-07-01 2014-09-30 0001293818 us-gaap:EmployeeStockOptionMember 2015-07-01 2015-09-30 0001293818 us-gaap:EmployeeStockOptionMember 2014-07-01 2014-09-30 0001293818 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-09-30 0001293818 us-gaap:EmployeeStockOptionMember 2014-01-01 2014-09-30 0001293818 opgn:MerckGlobalHealthInnovationFundLlcMember 2015-07-01 2015-07-31 0001293818 us-gaap:EmployeeStockOptionMember 2015-09-30 0001293818 us-gaap:RestrictedStockUnitsRSUMember 2014-03-01 2014-03-31 0001293818 us-gaap:RestrictedStockUnitsRSUMember 2014-10-01 2014-10-24 0001293818 opgn:TwoThousandFifteenPlanMember 2015-04-01 2015-06-30 0001293818 us-gaap:CommonStockMember us-gaap:OverAllotmentOptionMember 2015-05-08 0001293818 opgn:LifeTechnologiesMember 2015-07-01 2015-09-30 0001293818 us-gaap:LoansPayableMember 2015-01-01 2015-03-31 0001293818 us-gaap:CommercialPaperMember us-gaap:CommonStockMember opgn:MerckGlobalHealthInnovationFundLlcMember 2015-01-01 2015-09-30 0001293818 opgn:AdvandxMember us-gaap:EquityIssuedInBusinessCombinationMember 2015-07-14 0001293818 us-gaap:TrademarksMember 2015-01-01 2015-09-30 0001293818 us-gaap:DevelopedTechnologyRightsMember 2015-01-01 2015-09-30 0001293818 us-gaap:CustomerRelationshipsMember 2015-01-01 2015-09-30 0001293818 us-gaap:IPOMember 2015-01-01 2015-09-30 0001293818 us-gaap:IPOMember 2014-01-01 2014-09-30 0001293818 us-gaap:SeriesAPreferredStockMember 2014-01-01 2014-09-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure 10-Q false 2015-09-30 2015 Q3 OPGEN INC 0001293818 --12-31 Smaller Reporting Company OPGN 12539704

553938

538312

369742

1155488

503983

749517

11187129

587956

1021971

1713475

13434867

90233

1232328

993657

158860

339171

296041

293135

57459

16997489

2654931

6021507

317854

134149

5052635

6155656

4564899

125397

4932

121216140

88701737

-109396634

-96772293

11944854

-8065624

16997489

1274657

1160081

840637

423099

227049

100499

3734781

2654931

4564899

1250

1505000

1500000

1432592

841567

87201 379339 308340 1783340

1828133

3004246

712016

276831

191738

336616

3741247

3075420

3687313

1590085

2815976

-10238157

-4222939

9675

-4400

647342

47468

1746853

120

6613738

11162536

1486801

6444373

362537

-2384520

-42948

-2.00

-13.03

929241

268854

23765 88190 27780 477780

980786

834824

562694

101425

46634

129120

1724127

1029650

1610828

555444

979681

-4653951

-1580939

2513

-4400

32331

17482

2185218

5025409

459064

12261238

362537

-14969

-27894

-0.38

-4.92

-4670582

-1608833

-12624339

-4265887

175246

244508

458799

-4670582

-1784079

-12868847

-4724686

-78311

-814855

29853

-1752790

-42778

-180311

-121551

-11071538

-3905198

89234

39537

1277977

-39537

1937902

1388815 1472386

1741667

-507066

-62251

3750

112200 80575

20231366

3325963

-288126

159174

306386

1172231

80457

153750

10437612

-618772

429320

214 0

392404

461432

1598312

20883

201233

26088

781573

1400345

12408285

1500000

12100000 2850000 6.00 17100000

7374852

422500 6000000

1136364

5000000

4.40

1000000

250000

79697

P30D P45D

697414

40749

222031

135625

236043

193368

778944

867816

2750

7374852

3999864

0.7

11187129

749517

748048

1469

7374852

1405096

594904

3999864

1999864

1.00

1999864

0.08

0.7

1500000

0.08

1.25

1.00

1875000

1500000

71421

225011

700000

6.00

2100000

2900000

422500

4225

7374852

3272500

6.60

2020-05-08

1355000

0.04

528890

20000 -7484 -23810 13769 -73142 250000

208340

1133340

27780

172220

-49

371458

604279

924379

2390799

-4668920

-1608833

-12622677

-4265887

1662

525596

-49

-4670631

-1608833

-12624388

-4265887

0.01

6000000

3999864

7999728

0.01

200000000

12539704

493178

12539704

1367211

-193

4958335

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><font style="FONT-SIZE: 10pt">Note 1 - Organization</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">OpGen, Inc. (“OpGen”) was incorporated in Delaware in 2001. On July 14, 2015, OpGen completed the strategic acquisition (the “Merger”) of AdvanDx, Inc. and its wholly owned subsidiary AdvanDx A/S (collectively, “AdvanDx”) (see Note 4). Pursuant to the terms of a merger agreement, Velox Acquisition Corp. (OpGen’s wholly owned subsidiary formed for the express purpose of enacting the Merger) merged with and into AdvanDx, Inc. with AdvanDx, Inc. surviving as OpGen’s wholly owned subsidiary (see Note 4). OpGen, AdvanDx, Inc. and AdvanDx A/S are collectively referred to hereinafter as the “Company.” The Company’s headquarters are in Gaithersburg, Maryland, and its principal operations are in Gaithersburg, Maryland and Woburn, Massachusetts. The Company also has operations in Copenhagen, Denmark.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">OpGen is an early-stage company using rapid molecular testing and bioinformatics to help guide antibiotic therapy and to assist healthcare providers to combat multi-drug resistant infections, or MDROs. OpGen’s lead products are its QuickFISH® and PNAFISH products, which are advanced <i>in vitro</i> diagnostic kits for the diagnosis and prevention of infectious diseases, the Acuitas® MDRO Gene Test, a CLIA lab-based test that provides a profile of MDRO resistant genes from patients screened for colonization or infection and the Acuitas Lighthouse to aid in the interpretation of MDRO diagnostic test results. The company develops, markets and sells its products principally for use in hospitals and clinical laboratories in the United States and internationally.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company’s operations are subject to certain risks and uncertainties. The risks include rapid technology changes, the need to manage growth, the need to retain key personnel, the need to protect intellectual property and the need to raise additional capital financing on terms acceptable to the Company. The Company’s success depends, in part, on its ability to develop and commercialize its proprietary technology as well as raise additional capital.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-SIZE: 10pt">Basis of presentation and consolidation</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">The accompanying interim condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission, or SEC, for interim financial information. Accordingly, they do not include all the information and footnotes required by U.S. Generally Accepted Accounting Principles, or GAAP, for complete financial statements. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited financial statements and accompanying notes for the year ended December 31, 2014 previously filed with the SEC. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual financial statements included in the Company’s registration statement on Form S-1/A and, in the opinion of management, reflect all the adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company’s financial position as of September 30, 2015 and the results of operations and cash flows for the three and nine months ended September 30, 2015 and 2014. The interim condensed consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. The December 31, 2014 balance sheet included herein was derived from the audited financial statements, but may not include all disclosures including notes required by GAAP for complete financial statements.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">The accompanying unaudited interim condensed</font> consolidated financial statements include the accounts of the OpGen and its wholly owned and controlled subsidiaries; all intercompany transactions and balances have been eliminated. The Company operates in one business segment. Certain prior period information has been reclassified to conform to the current period presentation.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-SIZE: 10pt">Foreign Currency</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">AdvanDx A/S is located in Copenhagen, Denmark and uses the <font style="WIDOWS: 1; TEXT-TRANSFORM: none; TEXT-INDENT: 0px; LETTER-SPACING: normal; DISPLAY: inline !important; FONT: 13px 'Times New Roman', Times, serif; WHITE-SPACE: normal; FLOAT: none; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"> Danish Krone as</font> its functional currency. As a result, all assets and liabilities are translated into U.S. dollars based on exchange rates at the end of the reporting period. Income and expense items are translated at the average exchange rates prevailing during the reporting period. Translation adjustments are reported in other comprehensive loss, a component of stockholder's equity. Foreign currency translation adjustments are the sole component of accumulated other comprehensive loss at September 30, 2015.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><strong><font style="FONT-SIZE: 10pt">  </font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">Foreign currency transaction gains and losses, excluding gains and losses on intercompany balances where there is no current intent to settle such amounts in the foreseeable future, are included in the determination of net loss.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">Unless otherwise noted, all references to “$” or “dollar” refer to the United States dollar.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-SIZE: 10pt">Use of estimates</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">In preparing financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In the accompanying consolidated financial statements, estimates are used for, but not limited to, share-based compensation, allowances for doubtful accounts and inventory obsolescence, valuation of derivative financial instruments, beneficial conversion features of convertible debt, deferred tax assets and liabilities and related valuation allowance, and depreciation and amortization and estimated useful lives of long-lived assets, and the recoverability of long-lived assets. Actual results could differ from those estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-SIZE: 10pt">Fair value of financial instruments</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">All current assets and liabilities are carried at cost, which approximates fair value, because of the short-term maturities of those instrument<font style="WIDOWS: 1; TEXT-TRANSFORM: none; TEXT-INDENT: 0px; LETTER-SPACING: normal; DISPLAY: inline !important; FONT: 13px 'Times New Roman', Times, serif; WHITE-SPACE: normal; FLOAT: none; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"> s. The carrying value of the Company’s debt is</font> reflective of fair value based on instruments with similar terms available to the Company.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-SIZE: 10pt">Cash and cash equivalents</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company considers all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company has cash and cash equivalents deposited in financial institutions in which the balances occasionally exceed the federal government agency (FDIC) insured limits of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">250,000</font>. The Company has not experienced any losses in such accounts and management believes it is not exposed to any significant credit risk.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-SIZE: 10pt">Accounts receivable</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company’s accounts receivable result from revenues earned but not collected from customers. Credit is extended based on an evaluation of a customer’s financial condition and, generally, collateral is not required. Accounts receivable are due within <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">30</font> to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">45</font> days and are stated at amounts due from customers. The Company evaluates if an allowance is necessary by considering a number of factors, including the length of time accounts receivable are past due, the Company’s previous loss history and the customer’s current ability to pay its obligation. If amounts become uncollectible, they are charged to operations when that determination is made. The allowance for doubtful accounts was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">79,697</font></font> as of September 30, 2015 and December 31, 2014, respectively.</font></div> <font style="FONT-SIZE: 10pt">  </font></div> <font style="FONT-SIZE: 10pt">At September 30, 2015, the Company had accounts receivable from two customers which individually represented <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 12</font>% and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 11</font>% of total accounts receivable. At December 31, 2014, the Company had accounts receivable from two customers which individually represented <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 79</font>%, and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 15</font>% of total accounts receivable.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-SIZE: 10pt"> Inventories</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Inventories are valued using the first-in, first-out method and stated at the lower of cost or market and consist of the following:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both; size: 8.5in 11.0in" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">September 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">December 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div style="CLEAR:both;CLEAR: both">Raw materials and supplies</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">697,414</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">40,749</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div style="CLEAR:both;CLEAR: both">Work-in process</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">222,031</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">135,625</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div style="CLEAR:both;CLEAR: both">Finished goods</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">236,043</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">193,368</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div style="CLEAR:both;CLEAR: both">Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,155,488</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">369,742</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="center"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> Inventories include the Argus Whole Genome Mapping Systems, reagents and supplies used for Argus consumable kits, reagents and components for QuickFISH and PNAFISH kit products, and reagents and supplies used for the Company’s laboratory services. Inventory reserves for obsolescence and expirations</font> were $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">778,944</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">867,816</font> at September 30, 2015 and December 31, 2014, respectively.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-SIZE: 10pt">Product warranty</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">A warranty reserve is established upon the sale of any Argus System or Whole Genome Mapping product that is covered by warranty based on the estimated cost of replacement parts during the warranty period. Warranty periods are twelve months. The reserve is adjusted during the warranty period to reflect the remaining estimated costs under the warranty. The reserve for warranties was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,750</font></font> as of September 30, 2015 and December 31, 2014, respectively.</font></div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-SIZE: 10pt">Impairment of property and equipment</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">Property and equipment is reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. Recoverability measurement and estimating of undiscounted cash flows is done at the lowest possible level for which we can identify assets. If such assets are considered to be impaired, impairment is recognized as the amount by which the carrying amount of assets exceeds the fair value of the assets. During the three and nine months ended September 30, 2015 and 2014, the Company determined that its property and equipment was not impaired.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-SIZE: 10pt">Redeemable convertible preferred stock</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">All shares of Series A redeemable convertible preferred stock, or Series A Preferred Stock (including those shares issued in connection with the conversion of the 2014 and 2015 convertible debt (see Note 6)), were converted into <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 7,374,852</font> shares of common stock in connection with the Company’s IPO (see Note 7).</font></div> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Prior to the IPO, the carrying value of the Series A Preferred Stock was increased by the accretion of related discounts, issuance costs and accrued but unpaid dividends so that the carrying amount would equal the redemption amount at the dates the stock becomes redeemable. At December 31, 2014, the Company had <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3,999,864</font> shares of Series A Preferred Stock, outstanding. The Series A Preferred Stock was redeemable at the option of the holders of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 70</font>% of the outstanding shares of Series A Preferred Stock, subject to certain additional requirements. The Company’s redeemable convertible preferred stock was classified as temporary equity due to redemption provisions outside of the Company’s control.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-SIZE: 10pt">Revenue recognition</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">The Company recognizes revenue primarily from sales of its products and services when the following criteria are met: persuasive evidence of an arrangement exists; delivery has occurred; the selling price is fixed or determinable; and collectability is reasonably assured. At times, the Company sells products and services, or performs software development, under multiple-element arrangements with separate units of accounting; in these situations, total consideration is allocated to the identified units of accounting based on their relative selling prices and revenue is then recognized for each unit based on its specific characteristics.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">Amounts billed to customers for shipping and handling are included in revenue when the related product or service revenue is recognized. Shipping and handling costs are included in cost of sales.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><u><font style="FONT-SIZE: 10pt">Revenue from sales of the Argus System</font></u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">When an Argus System is sold without the Genome Builder software, total arrangement consideration is recognized as revenue when the system is delivered to the customer. Ancillary performance obligations, including installation, limited customer training and limited consumables, are considered inconsequential and are combined with the Argus System as one unit of accounting.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">When an Argus System is sold with the Genome Builder software in a multiple-element arrangement, total arrangement consideration is allocated to the Argus System and to the Genome Builder software based on their relative selling prices. Selling prices are determined based on sales of similar systems to similar customers and, where no sales have occurred, on management’s best estimate of the expected selling price relative to similar products. Revenue related to the Argus System is recognized when it is delivered to the customer; revenue for the Genome Builder software is recognized when it is delivered to the customer.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"></font> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><u>Revenue from sales of AdvanDx diagnostic products</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Revenue from sales of AdvanDx diagnostic products typically is recognized when the product is delivered to the customer.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><u><font style="FONT-SIZE: 10pt">Revenue from sales of Genome Builder Software and consumables (on a stand-alone basis)</font></u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">Revenue is recognized for Genome Builder Software and for consumables, when sold on a standalone basis, upon delivery to the customer.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><u><font style="FONT-SIZE: 10pt">Revenue from extended warranty service contracts</font></u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">The Company recognizes revenue associated with extended warranty service contracts over the service period in proportion to the costs expected to be incurred over that same period.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><u><font style="FONT-SIZE: 10pt">Revenue from providing laboratory services</font></u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">The Company recognizes revenue associated with laboratory services contracts when the service has been performed and reports are made available to the customer.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><u><font style="FONT-SIZE: 10pt">Revenue from funded software development arrangements</font></u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">The Company’s funded software development arrangements generally consist of multiple-elements. Total arrangement consideration is allocated to the identified units of accounting based on their relative selling prices and revenue is then recognized for each unit based on its specific characteristics. When funded software development arrangements include substantive research and development milestones, revenue is recognized for each such milestone when the milestone is achieved and is due and collectible. Milestones are considered substantive if all of the following conditions are met: (1) the milestone is nonrefundable; (2) achievement of the milestone was not reasonably assured at the inception of the arrangement; (3) substantive effort is involved to achieve the milestone; and (4) the amount of the milestone appears reasonable in relation to the effort expended, the other milestones in the arrangement and the related risk associated with achievement of the milestone.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-SIZE: 10pt">Share-based compensation</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">Share-based payments are recognized at fair value. The fair value of share-based payments to employees and directors is estimated, on the date of grant, using the Black-Scholes model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option. For all time-vesting awards granted, expense is amortized using the straight-line attribution method. Share-based compensation expense recognized is based on the value of the portion of stock-based awards that is ultimately expected to vest during the period.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">Option valuation models, including the Black-Scholes model, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-SIZE: 10pt">Income taxes</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the expected future tax consequences attributable to temporary differences between financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred income tax assets to the amount expected to be realized. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">The Company’s tax provision for the three and nine months ended September 30, 2015 resulted from the deductibility of goodwill for tax purposes.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">Tax benefits are initially recognized in the financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions are initially, and subsequently, measured as the largest amount of tax benefit that is greater than <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 50</font>% likely of being realized upon ultimate settlement with the tax authority, assuming full knowledge of the position and all relevant facts.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">The Company had federal net operating loss, or NOL, carryforwards of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">76,267,809</font> at December 31, 2014. Despite the NOL carryforwards, which begin to expire in 2022, the Company may have future tax liability due to alternative minimum tax or state tax requirements. Also, use of the NOL carryforwards may be subject to an annual limitation as provided by Section 382 of the Internal Revenue Code of 1986, as amended, or the Code. There can be no assurance that the NOL carryforwards will ever be fully utilized.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-SIZE: 10pt">Loss per share</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of shares of common stock outstanding during the period.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">For periods of net income, and when the effects are not anti-dilutive, diluted earnings per share is computed by dividing net income available to common shareholders by the weighted-average number of shares outstanding plus the impact of all potential dilutive common shares, consisting primarily of common stock options and stock purchase warrants using the treasury stock method, and convertible preferred stock and convertible debt using the if-converted method.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">For periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all dilutive potential common shares is anti-dilutive. The number of anti-dilutive shares, consisting of (i) common stock options, (ii) restricted stock units (in 2014), (iii) stock purchase warrants, and (iv) prior to the IPO, convertible preferred stock and convertible debt, exercisable or exchangeable into common stock which have been excluded from the computation of diluted loss per share, was <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 5.7</font></font> million and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 6.1 </font></font> million for the nine and three months ended September 30, 2015 and 2014, respectively. The Company’s convertible preferred stock, prior to its conversion, contained non-forfeitable rights to dividends, and therefore was considered to be a participating security; the calculation of basic and diluted income (loss) per share excludes net income (but not net loss) attributable to the convertible preferred stock from the numerator and excludes the impact of those shares from the denominator in periods prior to the IPO.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-SIZE: 10pt">Recent accounting pronouncements</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">In May 2014, the Financial Accounting Standards Board, or FASB, issued guidance for revenue recognition for contracts, superseding the previous revenue recognition requirements, along with most existing industry-specific guidance. The guidance requires an entity to review contracts in five steps: 1) identify the contract, 2) identify performance obligations, 3) determine the transaction price, 4) allocate the transaction price, and 5) recognize revenue. The new standard will result in enhanced disclosures regarding the nature, amount, timing and uncertainty of revenue arising from contracts with customers. The standard is effective for the Company’s reporting year beginning January 1, 2018 and early adoption is permitted starting January 1, 2017. The Company is currently evaluating the impact, if any, that this new accounting pronouncement will have on its financial statements.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">In August 2014, the FASB issued guidance requiring management to evaluate on a regular basis whether any conditions or events have arisen that could raise substantial doubt about the entity’s ability to continue as a going concern. The guidance 1) provides a definition for the term <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> “substantial doubt,” 2)</font> requires an evaluation every reporting period, interim periods included, 3) provides principles for considering the mitigating effect of management’s plans to alleviate the substantial doubt, 4) requires certain disclosures if the substantial doubt is alleviated as a result of management’s plans, 5) requires an express statement, as well as other disclosures, if the substantial doubt is not alleviated, and 6) requires an assessment period of one year from the date the financial statements are issued. The standard is effective for the Company’s reporting year beginning January 1, 2017 and early adoption is permitted. The Company is currently evaluating the impact, if any, that this new accounting pronouncement will have on its financial statements.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">In April 2015, the FASB issued accounting guidance requiring that debt issuance costs related to a recognized liability be presented on the balance sheet as a direct reduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected. The standard is effective for reporting periods beginning after December 15, 2015. The Company is currently evaluating the impact, if any, that this new accounting pronouncement will have on its financial statements.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">In July 2015, the FASB issued accounting guidance for inventory. Under the guidance, an entity should measure inventory within the scope of this guidance at the lower of cost and net realizable value, except when inventory is measured using LIFO or the retail inventory method. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. In addition, the FASB has amended some of the other inventory guidance to more clearly articulate the requirements for the measurement and disclosure of inventory. The standard is effective for reporting periods beginning after December 15, 2016. The amendments in this pronouncement should be applied prospectively, with earlier application permitted. The Company is currently evaluating the impact, if any, that this new accounting pronouncement will have on its financial statements.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">In September 2015, the FASB issued accounting guidance to simplify the accounting for measurement period adjustments resulting from business combinations. Under the guidance, an acquirer will be required to recognize adjustments to provisional amounts identified during the measurement period in the reporting period in which the adjustments are determined. The guidance requires an entity to present separately on the face of the income statement or disclose in the notes to the financial statements the portion of the amount recorded in current-period earnings by line item that would have been recorded in previous reporting periods if the adjustment had been recognized as of the acquisition date. The standard is effective for reporting periods beginning after December 15, 2015. The amendments in this pronouncement should be applied prospectively, with earlier application permitted. The Company is currently evaluating the impact, if any, that this new accounting pronouncement will have on its financial statements.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">The Company has evaluated all other issued and unadopted Accounting Standards Updates and believes the adoption of these standards will not have a material impact on its results of operations, financial position, or cash flows.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-SIZE: 10pt">Intangible assets and goodwill</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">Intangible assets were acquired as part of the Merger, and consist of definite-lived intangible assets and goodwill.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><u><font style="FONT-SIZE: 10pt">Definite-lived intangible assets</font></u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">Definite-lived intangible assets include trademarks, developed technology and customer relationships, and are amortized over their useful lives of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7</font> and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7</font> years, respectively. Definite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. If any indicators were present, the Company would test for recoverability by comparing the carrying amount of the asset to the net undiscounted cash flows expected to be generated from the asset. If those net undiscounted cash flows do not exceed the carrying amount (i.e., the asset is not recoverable), the Company would perform the next step, which is to determine the fair value of the asset and record an impairment loss, if any. During the three and nine months ended September 30, 2015 and 2014, the Company determined that its definite-lived intangible assets were not impaired.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><u><font style="FONT-SIZE: 10pt"> Goodwill</font></u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">Goodwill represents the excess of the purchase price for AdvanDx over the fair values of the acquired tangible or intangible assets and assumed liabilities. Goodwill is tax deductible in all relevant jurisdictions. As a result of the Merger, the Company recognized goodwill of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">292,000</font>.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> <strong>  </strong></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">The Company will conduct an impairment test of goodwill on an annual basis as of October 1 of each year, and will also conduct tests if events occur or circumstances change that would, more likely than not, reduce the Company’s fair value below its net equity value.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

76267809

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Inventories are valued using the first-in, first-out method and stated at the lower of cost or market and consist of the following:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both; size: 8.5in 11.0in" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">September 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">December 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div style="CLEAR:both;CLEAR: both">Raw materials and supplies</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">697,414</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">40,749</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div style="CLEAR:both;CLEAR: both">Work-in process</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">222,031</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">135,625</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div style="CLEAR:both;CLEAR: both">Finished goods</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">236,043</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">193,368</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div style="CLEAR:both;CLEAR: both">Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,155,488</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">369,742</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-SIZE: 10pt">Note 3 - Summary of significant accounting policies</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><strong><font style="FONT-SIZE: 10pt">  </font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><strong><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Basis of presentation and consolidation</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">The accompanying interim condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission, or SEC, for interim financial information. Accordingly, they do not include all the information and footnotes required by U.S. Generally Accepted Accounting Principles, or GAAP, for complete financial statements. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited financial statements and accompanying notes for the year ended December 31, 2014 previously filed with the SEC. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual financial statements included in the Company’s registration statement on Form S-1/A and, in the opinion of management, reflect all the adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company’s financial position as of September 30, 2015 and the results of operations and cash flows for the three and nine months ended September 30, 2015 and 2014. The interim condensed consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. The December 31, 2014 balance sheet included herein was derived from the audited financial statements, but may not include all disclosures including notes required by GAAP for complete financial statements.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">The accompanying unaudited interim condensed</font> consolidated financial statements include the accounts of the OpGen and its wholly owned and controlled subsidiaries; all intercompany transactions and balances have been eliminated. The Company operates in one business segment. Certain prior period information has been reclassified to conform to the current period presentation.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><strong><font style="FONT-SIZE: 10pt">  </font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><strong><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Foreign Currency</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">AdvanDx A/S is located in Copenhagen, Denmark and uses the <font style="WIDOWS: 1; TEXT-TRANSFORM: none; TEXT-INDENT: 0px; LETTER-SPACING: normal; DISPLAY: inline !important; FONT: 13px 'Times New Roman', Times, serif; WHITE-SPACE: normal; FLOAT: none; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"> Danish Krone as</font> its functional currency. As a result, all assets and liabilities are translated into U.S. dollars based on exchange rates at the end of the reporting period. Income and expense items are translated at the average exchange rates prevailing during the reporting period. Translation adjustments are reported in other comprehensive loss, a component of stockholder's equity. Foreign currency translation adjustments are the sole component of accumulated other comprehensive loss at September 30, 2015.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><strong><font style="FONT-SIZE: 10pt">  </font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">Foreign currency transaction gains and losses, excluding gains and losses on intercompany balances where there is no current intent to settle such amounts in the foreseeable future, are included in the determination of net loss.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">Unless otherwise noted, all references to “$” or “dollar” refer to the United States dollar.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><strong><font style="FONT-SIZE: 10pt">  </font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><strong><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Use of estimates</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">In preparing financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In the accompanying consolidated financial statements, estimates are used for, but not limited to, share-based compensation, allowances for doubtful accounts and inventory obsolescence, valuation of derivative financial instruments, beneficial conversion features of convertible debt, deferred tax assets and liabilities and related valuation allowance, and depreciation and amortization and estimated useful lives of long-lived assets, and the recoverability of long-lived assets. Actual results could differ from those estimates.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><strong><font style="FONT-SIZE: 10pt">  </font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><strong><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Fair value of financial instruments</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">All current assets and liabilities are carried at cost, which approximates fair value, because of the short-term maturities of those instrument<font style="WIDOWS: 1; TEXT-TRANSFORM: none; TEXT-INDENT: 0px; LETTER-SPACING: normal; DISPLAY: inline !important; FONT: 13px 'Times New Roman', Times, serif; WHITE-SPACE: normal; FLOAT: none; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"> s. The carrying value of the Company’s debt is</font> reflective of fair value based on instruments with similar terms available to the Company.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><strong><font style="FONT-SIZE: 10pt">  </font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><strong><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Cash and cash equivalents</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company considers all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company has cash and cash equivalents deposited in financial institutions in which the balances occasionally exceed the federal government agency (FDIC) insured limits of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">250,000</font>. The Company has not experienced any losses in such accounts and management believes it is not exposed to any significant credit risk.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><strong> <font style="FONT-SIZE: 10pt"> </font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><strong><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Accounts receivable</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company’s accounts receivable result from revenues earned but not collected from customers. Credit is extended based on an evaluation of a customer’s financial condition and, generally, collateral is not required. Accounts receivable are due within <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">30</font> to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">45</font> days and are stated at amounts due from customers. The Company evaluates if an allowance is necessary by considering a number of factors, including the length of time accounts receivable are past due, the Company’s previous loss history and the customer’s current ability to pay its obligation. If amounts become uncollectible, they are charged to operations when that determination is made. The allowance for doubtful accounts was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">79,697</font></font> as of September 30, 2015 and December 31, 2014, respectively.</font></div> <font style="FONT-SIZE: 10pt">  </font></div> <font style="FONT-SIZE: 10pt">At September 30, 2015, the Company had accounts receivable from two customers which individually represented <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 12</font>% and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 11</font>% of total accounts receivable. At December 31, 2014, the Company had accounts receivable from two customers which individually represented <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 79</font>%, and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 15</font>% of total accounts receivable.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><strong><font style="FONT-SIZE: 10pt">  </font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><strong><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Inventories</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Inventories are valued using the first-in, first-out method and stated at the lower of cost or market and consist of the following:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both; size: 8.5in 11.0in" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">September 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">December 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div style="CLEAR:both;CLEAR: both">Raw materials and supplies</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">697,414</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">40,749</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div style="CLEAR:both;CLEAR: both">Work-in process</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">222,031</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">135,625</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div style="CLEAR:both;CLEAR: both">Finished goods</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">236,043</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">193,368</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div style="CLEAR:both;CLEAR: both">Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,155,488</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">369,742</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="center"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> Inventories include the Argus Whole Genome Mapping Systems, reagents and supplies used for Argus consumable kits, reagents and components for QuickFISH and PNAFISH kit products, and reagents and supplies used for the Company’s laboratory services. Inventory reserves for obsolescence and expirations</font> were $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">778,944</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">867,816</font> at September 30, 2015 and December 31, 2014, respectively.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><strong> <font style="FONT-SIZE: 10pt"> </font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><strong><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Product warranty</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">A warranty reserve is established upon the sale of any Argus System or Whole Genome Mapping product that is covered by warranty based on the estimated cost of replacement parts during the warranty period. Warranty periods are twelve months. The reserve is adjusted during the warranty period to reflect the remaining estimated costs under the warranty. The reserve for warranties was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,750</font></font> as of September 30, 2015 and December 31, 2014, respectively.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><strong> <font style="FONT-SIZE: 10pt"> </font></strong></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><strong><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Impairment of property and equipment</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">Property and equipment is reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. Recoverability measurement and estimating of undiscounted cash flows is done at the lowest possible level for which we can identify assets. If such assets are considered to be impaired, impairment is recognized as the amount by which the carrying amount of assets exceeds the fair value of the assets. During the three and nine months ended September 30, 2015 and 2014, the Company determined that its property and equipment was not impaired.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><strong><font style="FONT-SIZE: 10pt">  </font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><strong><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Intangible assets and goodwill</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">Intangible assets were acquired as part of the Merger, and consist of definite-lived intangible assets and goodwill.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><u><font style="FONT-SIZE: 10pt">Definite-lived intangible assets</font></u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">Definite-lived intangible assets include trademarks, developed technology and customer relationships, and are amortized over their useful lives of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7</font> and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7</font> years, respectively. Definite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. If any indicators were present, the Company would test for recoverability by comparing the carrying amount of the asset to the net undiscounted cash flows expected to be generated from the asset. If those net undiscounted cash flows do not exceed the carrying amount (i.e., the asset is not recoverable), the Company would perform the next step, which is to determine the fair value of the asset and record an impairment loss, if any. During the three and nine months ended September 30, 2015 and 2014, the Company determined that its definite-lived intangible assets were not impaired.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><u><font style="FONT-SIZE: 10pt"> Goodwill</font></u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">Goodwill represents the excess of the purchase price for AdvanDx over the fair values of the acquired tangible or intangible assets and assumed liabilities. Goodwill is tax deductible in all relevant jurisdictions. As a result of the Merger, the Company recognized goodwill of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">292,000</font>.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> <strong>  </strong></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">The Company will conduct an impairment test of goodwill on an annual basis as of October 1 of each year, and will also conduct tests if events occur or circumstances change that would, more likely than not, reduce the Company’s fair value below its net equity value.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><strong><font style="FONT-SIZE: 10pt">  </font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><strong><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Redeemable convertible preferred stock</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">All shares of Series A redeemable convertible preferred stock, or Series A Preferred Stock (including those shares issued in connection with the conversion of the 2014 and 2015 convertible debt (see Note 6)), were converted into <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 7,374,852</font> shares of common stock in connection with the Company’s IPO (see Note 7).</font></div> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Prior to the IPO, the carrying value of the Series A Preferred Stock was increased by the accretion of related discounts, issuance costs and accrued but unpaid dividends so that the carrying amount would equal the redemption amount at the dates the stock becomes redeemable. At December 31, 2014, the Company had <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3,999,864</font> shares of Series A Preferred Stock, outstanding. The Series A Preferred Stock was redeemable at the option of the holders of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 70</font>% of the outstanding shares of Series A Preferred Stock, subject to certain additional requirements. The Company’s redeemable convertible preferred stock was classified as temporary equity due to redemption provisions outside of the Company’s control.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><strong> <font style="FONT-SIZE: 10pt"> </font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><strong><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Revenue recognition</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">The Company recognizes revenue primarily from sales of its products and services when the following criteria are met: persuasive evidence of an arrangement exists; delivery has occurred; the selling price is fixed or determinable; and collectability is reasonably assured. At times, the Company sells products and services, or performs software development, under multiple-element arrangements with separate units of accounting; in these situations, total consideration is allocated to the identified units of accounting based on their relative selling prices and revenue is then recognized for each unit based on its specific characteristics.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">Amounts billed to customers for shipping and handling are included in revenue when the related product or service revenue is recognized. Shipping and handling costs are included in cost of sales.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><u><font style="FONT-SIZE: 10pt">Revenue from sales of the Argus System</font></u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">When an Argus System is sold without the Genome Builder software, total arrangement consideration is recognized as revenue when the system is delivered to the customer. Ancillary performance obligations, including installation, limited customer training and limited consumables, are considered inconsequential and are combined with the Argus System as one unit of accounting.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">When an Argus System is sold with the Genome Builder software in a multiple-element arrangement, total arrangement consideration is allocated to the Argus System and to the Genome Builder software based on their relative selling prices. Selling prices are determined based on sales of similar systems to similar customers and, where no sales have occurred, on management’s best estimate of the expected selling price relative to similar products. Revenue related to the Argus System is recognized when it is delivered to the customer; revenue for the Genome Builder software is recognized when it is delivered to the customer.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"></font> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><u>Revenue from sales of AdvanDx diagnostic products</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Revenue from sales of AdvanDx diagnostic products typically is recognized when the product is delivered to the customer.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><u><font style="FONT-SIZE: 10pt">Revenue from sales of Genome Builder Software and consumables (on a stand-alone basis)</font></u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">Revenue is recognized for Genome Builder Software and for consumables, when sold on a standalone basis, upon delivery to the customer.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><u><font style="FONT-SIZE: 10pt">Revenue from extended warranty service contracts</font></u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">The Company recognizes revenue associated with extended warranty service contracts over the service period in proportion to the costs expected to be incurred over that same period.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><u><font style="FONT-SIZE: 10pt">Revenue from providing laboratory services</font></u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">The Company recognizes revenue associated with laboratory services contracts when the service has been performed and reports are made available to the customer.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><u><font style="FONT-SIZE: 10pt">Revenue from funded software development arrangements</font></u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">The Company’s funded software development arrangements generally consist of multiple-elements. Total arrangement consideration is allocated to the identified units of accounting based on their relative selling prices and revenue is then recognized for each unit based on its specific characteristics. When funded software development arrangements include substantive research and development milestones, revenue is recognized for each such milestone when the milestone is achieved and is due and collectible. Milestones are considered substantive if all of the following conditions are met: (1) the milestone is nonrefundable; (2) achievement of the milestone was not reasonably assured at the inception of the arrangement; (3) substantive effort is involved to achieve the milestone; and (4) the amount of the milestone appears reasonable in relation to the effort expended, the other milestones in the arrangement and the related risk associated with achievement of the milestone.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><strong><font style="FONT-SIZE: 10pt">  </font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><strong><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Share-based compensation</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">Share-based payments are recognized at fair value. The fair value of share-based payments to employees and directors is estimated, on the date of grant, using the Black-Scholes model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option. For all time-vesting awards granted, expense is amortized using the straight-line attribution method. Share-based compensation expense recognized is based on the value of the portion of stock-based awards that is ultimately expected to vest during the period.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">Option valuation models, including the Black-Scholes model, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><strong><font style="FONT-SIZE: 10pt">  </font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><strong><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Income taxes</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the expected future tax consequences attributable to temporary differences between financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred income tax assets to the amount expected to be realized. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">The Company’s tax provision for the three and nine months ended September 30, 2015 resulted from the deductibility of goodwill for tax purposes.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">Tax benefits are initially recognized in the financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions are initially, and subsequently, measured as the largest amount of tax benefit that is greater than <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 50</font>% likely of being realized upon ultimate settlement with the tax authority, assuming full knowledge of the position and all relevant facts.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">The Company had federal net operating loss, or NOL, carryforwards of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">76,267,809</font> at December 31, 2014. Despite the NOL carryforwards, which begin to expire in 2022, the Company may have future tax liability due to alternative minimum tax or state tax requirements. Also, use of the NOL carryforwards may be subject to an annual limitation as provided by Section 382 of the Internal Revenue Code of 1986, as amended, or the Code. There can be no assurance that the NOL carryforwards will ever be fully utilized.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><strong><font style="FONT-SIZE: 10pt">  </font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><strong><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Loss per share</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of shares of common stock outstanding during the period.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">For periods of net income, and when the effects are not anti-dilutive, diluted earnings per share is computed by dividing net income available to common shareholders by the weighted-average number of shares outstanding plus the impact of all potential dilutive common shares, consisting primarily of common stock options and stock purchase warrants using the treasury stock method, and convertible preferred stock and convertible debt using the if-converted method.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">For periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all dilutive potential common shares is anti-dilutive. The number of anti-dilutive shares, consisting of (i) common stock options, (ii) restricted stock units (in 2014), (iii) stock purchase warrants, and (iv) prior to the IPO, convertible preferred stock and convertible debt, exercisable or exchangeable into common stock which have been excluded from the computation of diluted loss per share, was <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 5.7</font></font> million and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 6.1 </font></font> million for the nine and three months ended September 30, 2015 and 2014, respectively. The Company’s convertible preferred stock, prior to its conversion, contained non-forfeitable rights to dividends, and therefore was considered to be a participating security; the calculation of basic and diluted income (loss) per share excludes net income (but not net loss) attributable to the convertible preferred stock from the numerator and excludes the impact of those shares from the denominator in periods prior to the IPO.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><strong><font style="FONT-SIZE: 10pt">  </font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><strong><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Recent accounting pronouncements</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">In May 2014, the Financial Accounting Standards Board, or FASB, issued guidance for revenue recognition for contracts, superseding the previous revenue recognition requirements, along with most existing industry-specific guidance. The guidance requires an entity to review contracts in five steps: 1) identify the contract, 2) identify performance obligations, 3) determine the transaction price, 4) allocate the transaction price, and 5) recognize revenue. The new standard will result in enhanced disclosures regarding the nature, amount, timing and uncertainty of revenue arising from contracts with customers. The standard is effective for the Company’s reporting year beginning January 1, 2018 and early adoption is permitted starting January 1, 2017. The Company is currently evaluating the impact, if any, that this new accounting pronouncement will have on its financial statements.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">In August 2014, the FASB issued guidance requiring management to evaluate on a regular basis whether any conditions or events have arisen that could raise substantial doubt about the entity’s ability to continue as a going concern. The guidance 1) provides a definition for the term <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> “substantial doubt,” 2)</font> requires an evaluation every reporting period, interim periods included, 3) provides principles for considering the mitigating effect of management’s plans to alleviate the substantial doubt, 4) requires certain disclosures if the substantial doubt is alleviated as a result of management’s plans, 5) requires an express statement, as well as other disclosures, if the substantial doubt is not alleviated, and 6) requires an assessment period of one year from the date the financial statements are issued. The standard is effective for the Company’s reporting year beginning January 1, 2017 and early adoption is permitted. The Company is currently evaluating the impact, if any, that this new accounting pronouncement will have on its financial statements.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">In April 2015, the FASB issued accounting guidance requiring that debt issuance costs related to a recognized liability be presented on the balance sheet as a direct reduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected. The standard is effective for reporting periods beginning after December 15, 2015. The Company is currently evaluating the impact, if any, that this new accounting pronouncement will have on its financial statements.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">In July 2015, the FASB issued accounting guidance for inventory. Under the guidance, an entity should measure inventory within the scope of this guidance at the lower of cost and net realizable value, except when inventory is measured using LIFO or the retail inventory method. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. In addition, the FASB has amended some of the other inventory guidance to more clearly articulate the requirements for the measurement and disclosure of inventory. The standard is effective for reporting periods beginning after December 15, 2016. The amendments in this pronouncement should be applied prospectively, with earlier application permitted. The Company is currently evaluating the impact, if any, that this new accounting pronouncement will have on its financial statements.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">In September 2015, the FASB issued accounting guidance to simplify the accounting for measurement period adjustments resulting from business combinations. Under the guidance, an acquirer will be required to recognize adjustments to provisional amounts identified during the measurement period in the reporting period in which the adjustments are determined. The guidance requires an entity to present separately on the face of the income statement or disclose in the notes to the financial statements the portion of the amount recorded in current-period earnings by line item that would have been recorded in previous reporting periods if the adjustment had been recognized as of the acquisition date. The standard is effective for reporting periods beginning after December 15, 2015. The amendments in this pronouncement should be applied prospectively, with earlier application permitted. The Company is currently evaluating the impact, if any, that this new accounting pronouncement will have on its financial statements.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">The Company has evaluated all other issued and unadopted Accounting Standards Updates and believes the adoption of these standards will not have a material impact on its results of operations, financial position, or cash flows.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-SIZE: 10pt">Note 9 - Stockholders’ equity (deficit)</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On May 8, 2015, the Company completed its IPO pursuant to which the Company offered and sold <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,850,000</font> units, each consisting of one share of common stock and a detachable stock purchase warrant to purchase an additional share of common stock, at an initial offering price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6.00</font> per unit. Of the total gross proceeds of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">17.1</font> million, approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.1</font> million was satisfied by exchanging outstanding demand notes. After considering the demand notes, and underwriting discounts, commissions and offering expenses of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.9</font> million (which were charged to additional paid in capital), the total net cash proceeds to the Company was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">12.1</font> million. On the IPO closing date, the underwriters exercised a portion of their over-allotment option to acquire an additional <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 422,500</font> stock purchase warrants for cash of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4,225</font>. In connection with the IPO, all of the Company’s outstanding Series A Preferred Stock, 2014 convertible notes and 2015 convertible notes were converted into <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 7,374,852</font> shares of common stock.</font></div> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The stock purchase warrants issued as part of the units (including over-allotment option) are exercisable for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3,272,500</font> shares of common stock at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6.60</font> per share beginning six months after the closing of the IPO for five years, expiring on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">May 8, 2020</font>. Additionally, the Company issued additional warrants to its investment bankers to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 185,250</font> shares of common stock, on the same terms as the warrants issued with the units. The warrants were valued using the Black-Scholes option pricing model and are classified as equity.</font></div> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In July 2015, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,136,364</font> shares of common stock to Merck GHI <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">for cash consideration of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5.0</font> million (see Note 5).</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-SIZE: 10pt">  </font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-SIZE: 10pt">Stock options</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In 2002, the Company adopted the 2002 Stock Option and Restricted Stock Plan, or the 2002 Plan, pursuant to which the Company’s Board of Directors could grant either incentive stock options or non-qualified stock options, shares of restricted stock, shares of unrestricted common stock, and other share-based awards to officers and employees. In 2008, the Company adopted the 2008 Stock Option and Restricted Stock Plan, or the 2008 Plan, pursuant to which the Company’s Board of Directors may grant either incentive or non-qualified stock options or shares of restricted stock to directors, key employees, consultants and advisors.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In April 2015, the Company adopted, and the Company’s stockholders approved, the 2015 Equity Incentive Plan, or the 2015 Plan; the 2015 Plan became effective upon the execution and delivery of the underwriting agreement for the Company’s IPO. Following the effectiveness of the 2015 Plan, no further grants will be made under the 2002 Plan or 2008 Plan. The 2015 Plan provides for the granting of incentive stock options within the meaning of Section 422 of the Internal Revenue Code to employees and the granting of non-qualified stock options to employees, non-employee directors and consultants. The 2015 Plan also provides for the grants of restricted stock, restricted stock units, stock appreciation rights, dividend equivalents and stock payments to employees, non-employee directors and consultants.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Under the 2015 Plan, the aggregate number of shares of the common stock authorized for issuance may not exceed (1) <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,355,000</font> plus (2) the sum of the number of shares subject to outstanding awards under the 2008 Plan as of the 2015 Plan’s effective date, that are subsequently forfeited or terminated for any reason before being exercised or settled, plus (3) the number of shares subject to vesting restrictions under the 2008 Plan as of the 2015 Plan’s effective date that are subsequently forfeited. In addition, the number of shares that have been authorized for issuance under the 2015 Plan will be automatically increased on the first day of each fiscal year beginning on January 1, 2016 and ending on (and including) January 1, 2025, in an amount equal to the lesser of (1) <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4</font>% of the outstanding shares of common stock on the last day of the immediately preceding fiscal year, or (2) another lesser amount determined by the Board of Directors. Shares subject to awards granted under the 2015 Plan that are forfeited or terminated before being exercised or settled, or are not delivered to the participant because such award is settled in cash, will again become available for issuance under the 2015 Plan. However, shares that have actually been issued shall not again become available unless forfeited. As of September 30, 2015, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 528,890</font> shares remain available for issuance under the 2015 Plan.</font></div> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">For the three months ended September 30, 2015 and 2014, the Company recorded $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">261,540</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">24,977</font>, respectively, of stock compensation expense. For the nine months ended September 30, 2015 and 2014, the Company recorded $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,172,231</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">80,457</font>, respectively, of stock compensation expense. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The allocation of share-based compensation expense by operating expenses is as follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="22%" colspan="4"> <div>Three months ended September 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Research and development</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>59,688</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,528</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>General and administrative</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>156,236</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>22,460</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Sales and marketing</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>45,616</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>989</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>261,540</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>24,977</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Nine months ended September 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Research and development</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>161,819</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,903</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>General and administrative</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>443,267</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>74,032</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Sales and marketing</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>567,145</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,522</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,172,231</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>80,457</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">During the nine months ended September 30, 2015, the Company granted stock options to acquire <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,660,387</font> shares of common stock at a weighted average exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.87</font> per share. The 2015 awards had a weighted average grant date fair value per share of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3.16</font>. The Company has total stock options to acquire <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,948,249</font> shares of common stock outstanding at September 30, 2015.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-SIZE: 10pt">  </font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-SIZE: 10pt">Restricted stock units</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In March 2014, the Company awarded restricted stock units to acquire <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 130,640</font> shares of common stock to its Chief Executive Officer. The restricted stock units were compensation for his service as Chief Executive Officer, or CEO, from October 2013 through June 2014 and were subject to forfeiture if he did not continue to perform management services through October 24, 2014. The restricted stock units vested on October 24, 2014 and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 130,640</font> shares of common stock were issued to the CEO.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-SIZE: 10pt">  </font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-SIZE: 10pt">Stock purchase warrants</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company has total stock purchase warrants to acquire <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3,716,355</font> and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 33,594</font> shares of common stock outstanding at September 30, 2015 and December 31, 2014, respectively. In the first quarter of 2015, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 225,011</font> warrants in connection with the issuance of its 2015 convertible debt. In the second quarter of 2015 in connection with the Company’s IPO, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3,457,750</font> stock purchase warrants to investors and to its investment bankers. As of September 30, 2015, the warrants are classified as equity.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The allocation of share-based compensation expense by operating expenses is as follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="22%" colspan="4"> <div>Three months ended September 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Research and development</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>59,688</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,528</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>General and administrative</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>156,236</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>22,460</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Sales and marketing</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>45,616</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>989</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>261,540</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>24,977</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Nine months ended September 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Research and development</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>161,819</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,903</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>General and administrative</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>443,267</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>74,032</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Sales and marketing</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>567,145</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,522</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,172,231</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>80,457</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

1172231

80457

161819

443267

567145

3903

74032

2522

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-SIZE: 10pt">Note 4  Business Combination</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On July 14, 2015, the Company completed the Merger by acquiring <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 100</font>% of the capital stock of AdvanDx in the Merger in a taxable transaction. AdvanDx researches, develops and markets advanced <i>in vitro</i> diagnostic kits for the diagnosis and prevention of infectious diseases, and sells its products principally to hospitals and clinical laboratories in the United States and Europe. The Company acquired AdvanDx principally to exploit AdvanDx’s diagnostic capabilities with respect to MDROs and leverage AdvanDx’s relationships with hospitals and clinical laboratories to accelerate the sales of OpGen’s products and services.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Pursuant to an Agreement and Plan of Merger (the “Merger Agreement”), Velox Acquisition Corp. merged with and into AdvanDx, Inc. with AdvanDx, Inc. surviving as a wholly owned subsidiary of the Company in accordance with the General Corporation Law of the State of Delaware. Under the terms of the Merger Agreement, the merger consideration consisted of an aggregate <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 681,818</font> shares of the Company's common stock with a value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.6</font> million (the “Merger Consideration”), which Merger Consideration was distributed in accordance with the liquidation preferences set forth in the AdvanDx, Inc. Restated Certificate of Incorporation, as amended.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company accounted for its acquisition of AdvanDx by recording all tangible and intangible assets acquired and liabilities assumed at their estimated fair values on the acquisition date, with the remaining unallocated purchase price recorded as goodwill. The fair value assigned to identifiable intangible assets acquired was determined using an income approach for trade names and customer relationships, and a cost approach for technology. The fair values are based on the Company’s estimates and may be adjusted from time to time, but no later than July 13, 2016, as better information becomes available. The Company received stepped-up bases in the acquired assets and liabilities and therefore did not recognize any deferred income tax assets and liabilities. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following represents the preliminary allocation of the purchase price:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>Total purchase price - fair value of common stock issued</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,584,090</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>Fair value of tangible assets acquired:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>Cash</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,367,211</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>Receivables</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>557,112</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>Inventory</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,073,855</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>Property and equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>250,636</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>Other assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>359,587</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>Fair value of identifiable intangible assets acquired:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>Customer relationships</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,094,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>Developed technology</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>458,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>Trademarks and tradenames</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>461,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>Fair value of goodwill</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>291,747</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>Fair value of liabilities assumed</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,329,058</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,584,090</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The total consideration paid in the acquisition exceeded the estimated fair value of the tangible and identifiable intangible assets acquired and liabilities assumed, resulting in approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.3</font> million of goodwill. Goodwill, primarily related to expected synergies gained from combining operations, sales growth from future product offerings and customers, together with certain intangible assets that do not qualify for separate recognition, including assembled workforce, is tax deductible in all relevant taxing jurisdictions. The Company expensed acquisition-related costs of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.5</font> million related to the Merger in 2015. AdvanDx recognized approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.8</font> million of revenue and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.8</font> million of net losses from the acquisition date to September 30, 2015, which results are included in the Company’s 2015 interim condensed consolidated financial statements.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following unaudited pro forma financial information summarizes the results of operations for the periods indicated as if the Merger had been completed as of January 1, 2014. Pro forma information primarily reflects adjustments relating to (i) elimination of the interest on AdvanDx’s outstanding debt, and (ii) the amortization of intangibles acquired. The pro forma amounts do not purport to be indicative of the results that would have actually been obtained if the acquisition occurred as of January 1, 2014 or that may be obtained in the future:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="white-space:nowrap; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"> <div>Unaudited pro forma results</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Nine months ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Three months ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>September 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>September 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>September 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>September 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Revenues</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,902,337</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6,631,510</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,126,530</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,955,894</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Net loss</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(15,623,109)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(11,784,997)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(4,650,817)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(4,517,541)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="36%"> <div>Net loss per share</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>(2.29)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>(11.72)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>(0.38)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>(4.49)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The following unaudited pro forma financial information summarizes the results of operations for the periods indicated as if the Merger had been completed as of January 1, 2014. Pro forma information primarily reflects adjustments relating to (i) elimination of the interest on AdvanDx’s outstanding debt, and (ii) the amortization of intangibles acquired. The pro forma amounts do not purport to be indicative of the results that would have actually been obtained if the acquisition occurred as of January 1, 2014 or that may be obtained in the future:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="white-space:nowrap; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"> <div>Unaudited pro forma results</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Nine months ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Three months ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>September 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>September 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>September 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>September 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Revenues</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,902,337</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6,631,510</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,126,530</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,955,894</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Net loss</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(15,623,109)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(11,784,997)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(4,650,817)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(4,517,541)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="36%"> <div>Net loss per share</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>(2.29)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>(11.72)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>(0.38)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>(4.49)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

681818

500000

800000

1367211

2584090

557112

1073855

250636

359587

1094000 458000 461000

291747

3329058

2584090

3902337

6631510

1126530

1955894

-15623109

-11784997

-4650817

-4517541

1136364

4.40

5000000

1000000

50000

8000

42000

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-SIZE: 10pt">Note 6 - Fair value measurements</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company classifies its financial instruments using a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <table style="LINE-HEIGHT: 115%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt"> ·</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Level 1 - defined as observable inputs such as quoted prices in active markets;</font></div> </td> </tr> </table> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="DISPLAY: none; FONT-SIZE: 10pt"> </font></div> <table style="LINE-HEIGHT: 115%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt"> ·</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Level 2 - defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and</font></div> </td> </tr> </table> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="DISPLAY: none; FONT-SIZE: 10pt"> </font></div> <table style="LINE-HEIGHT: 115%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt"> ·</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Level 3 - defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions such as expected revenue growth and discount factors applied to cash flow projections.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><u><font style="FONT-SIZE: 10pt">Financial assets and liabilities measured at fair value on a recurring basis</font></u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the hierarchy. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following tables present the fair value hierarchy for the Company’s financial assets and liabilities measured at fair value on a recurring basis at September 30, 2015 and December 31, 2014:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Fair value at</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>September 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Level 1</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Level 2</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Level 3</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Cash and cash equivalents</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>11,187,129</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>11,187,129</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Fair value at</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Level 1</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Level 2</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Level 3</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Cash and cash equivalents</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>749,517</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>748,048</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,469</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company’s Level 1 securities primarily consist of cash and cash equivalents, including money market funds and U.S. Treasury Notes; the Company determines the estimated fair value for its Level 1 securities using quoted (unadjusted) prices for identical assets or liabilities in active markets.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Prior to its IPO, certain stock purchase warrants contained cash settlement features and, accordingly, the Company considered them to be derivative financial instruments and accounted for them at fair value using level 3 inputs. As a result of the Company’s IPO and elimination of the cash settlement features pursuant to their terms, those stock purchase warrants were reclassified to equity. For periods prior to the IPO, the Company determined the fair value of these derivative liabilities using a hybrid valuation method that consisted of a probability weighted expected return method that values the Company’s equity securities assuming various possible future economic outcomes while using an option pricing method (that treated all equity linked instruments as call options on the Company’s equity value with exercise prices based on the liquidation preference of the Series A Preferred Stock ) to estimate the allocation of value within one or more of the scenarios. Using this hybrid method, unobservable inputs included the Company’s equity value, the exercise price for each option value, expected timing of possible economic outcomes such as initial public offering, risk free interest rates and stock price volatility. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following tables set forth a summary of changes in the fair value of Level 3 liabilities measured at fair value on a recurring basis for the nine months ended September 30, 2015:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="29%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Balance at</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Balance at</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="29%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Established</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Change in</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Reclassified</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>September</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="29%"> <div>Description</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>31, 2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>in 2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Fair Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>to Equity</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>30, 2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="29%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="29%"> <div>Derivative warrant liability</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>72,333</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>647,342</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(719,675)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><u><font style="FONT-SIZE: 10pt">Financial assets and liabilities carried at fair value on a non-recurring basis</font></u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company does not have any financial assets and liabilities measured at fair value on a non-recurring basis.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><u><font style="FONT-SIZE: 10pt">Non-financial assets and liabilities carried at fair value on a recurring basis</font></u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company does not have any non-financial assets and liabilities measured at fair value on a recurring basis.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><u><font style="FONT-SIZE: 10pt">Non-financial assets and liabilities carried at fair value on a non-recurring basis</font></u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company measures its long-lived assets, including property and equipment and intangible assets (including goodwill), at fair value on a non-recurring basis when they are deemed to be impaired. No such fair value impairment was recognized in the three and nine month periods ended September 30, 2015 and 2014.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">See Note 4 for a discussion of the fair value of assets acquired and liabilities assumed in the Merger.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The following tables present the fair value hierarchy for the Company’s financial assets and liabilities measured at fair value on a recurring basis at September 30, 2015 and December 31, 2014:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Fair value at</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>September 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Level 1</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Level 2</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Level 3</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Cash and cash equivalents</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>11,187,129</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>11,187,129</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Fair value at</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Level 1</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Level 2</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Level 3</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Cash and cash equivalents</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>749,517</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>748,048</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,469</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The following tables set forth a summary of changes in the fair value of Level 3 liabilities measured at fair value on a recurring basis for the nine months ended September 30, 2015:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="29%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Balance at</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Balance at</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="29%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Established</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Change in</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Reclassified</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>September</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="29%"> <div>Description</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>31, 2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>in 2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Fair Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>to Equity</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>30, 2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="29%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="29%"> <div>Derivative warrant liability</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>72,333</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>647,342</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(719,675)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

72333

647342

719675

150000

1000000

0.08

1001250

2300000

350000

0.08

1500000

0.08

800000

200000

2100000

12100000

0.12

0.11

0.79

0.15

2750

5700000

6100000

5700000

6100000

261540

24977

59688

156236

45616

1528

22460

989

261540

24977

1172231

80457

1136364

1660387

2.87

3.16

1948249

130640

3716355

33594

3457750

185250

-150570

1662

79697

300000

6000000

2600000

0.08

2850000 0.08 17100000 12100000

1955769

291747

1000000

-44595

447007

341862

5000000

-2.29

-11.72

-0.38

-4.49

P10Y

P7Y

2584090

300000

2100000

3000000

609328 230545 903754 613447

185177

141060

EX-101.SCH 8 opgn-20150930.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink 102 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 103 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 104 - Statement - Condensed Consolidated Statements of Operations and Other Comprehensive Loss link:presentationLink link:definitionLink link:calculationLink 105 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 106 - Disclosure - Organization link:presentationLink link:definitionLink link:calculationLink 107 - Disclosure - Liquidity and management's plans link:presentationLink link:definitionLink link:calculationLink 108 - Disclosure - Summary of significant accounting policies link:presentationLink link:definitionLink link:calculationLink 109 - Disclosure - Business Combination link:presentationLink link:definitionLink link:calculationLink 110 - Disclosure - Merck GHI Financing link:presentationLink link:definitionLink link:calculationLink 111 - Disclosure - Fair value measurements link:presentationLink link:definitionLink link:calculationLink 112 - Disclosure - Series A redeemable convertible preferred stock link:presentationLink link:definitionLink link:calculationLink 113 - Disclosure - Debt link:presentationLink link:definitionLink link:calculationLink 114 - Disclosure - Stockholders' equity (deficit) link:presentationLink link:definitionLink link:calculationLink 115 - Disclosure - Commitments and contingencies link:presentationLink link:definitionLink link:calculationLink 116 - Disclosure - License agreements, research collaborations and development agreements link:presentationLink link:definitionLink link:calculationLink 117 - Disclosure - Related party transactions link:presentationLink link:definitionLink link:calculationLink 118 - Disclosure - Summary of significant accounting policies (Policies) link:presentationLink link:definitionLink link:calculationLink 119 - Disclosure - Summary of significant accounting policies (Tables) link:presentationLink link:definitionLink link:calculationLink 120 - Disclosure - Business Combination (Tables) link:presentationLink link:definitionLink link:calculationLink 121 - Disclosure - Fair value measurements (Tables) link:presentationLink link:definitionLink link:calculationLink 122 - Disclosure - Stockholders' equity (deficit) (Tables) link:presentationLink link:definitionLink link:calculationLink 123 - Disclosure - Liquidity and management's plans (Details Textual) link:presentationLink link:definitionLink link:calculationLink 124 - Disclosure - Summary of significant accounting policies (Details) link:presentationLink link:definitionLink link:calculationLink 125 - Disclosure - Summary of significant accounting policies (Details Textual) link:presentationLink link:definitionLink link:calculationLink 126 - Disclosure - Business Combination (Details) link:presentationLink link:definitionLink link:calculationLink 127 - Disclosure - Business Combination (Details 1) link:presentationLink link:definitionLink link:calculationLink 128 - Disclosure - Business Combination (Details Textual) link:presentationLink link:definitionLink link:calculationLink 129 - Disclosure - Merck GHI Financing (Details Textual) link:presentationLink link:definitionLink link:calculationLink 130 - Disclosure - Fair value measurements (Details) link:presentationLink link:definitionLink link:calculationLink 131 - Disclosure - Fair value measurements (Details 1) link:presentationLink link:definitionLink link:calculationLink 132 - Disclosure - Series A redeemable convertible preferred stock (Details Textual) link:presentationLink link:definitionLink link:calculationLink 133 - Disclosure - Debt (Details Textual) link:presentationLink link:definitionLink link:calculationLink 134 - Disclosure - Stockholders' equity (deficit) (Details) link:presentationLink link:definitionLink link:calculationLink 135 - Disclosure - Stockholders' equity (deficit) (Details Textual) link:presentationLink link:definitionLink link:calculationLink 136 - Disclosure - Commitments and contingencies (Details Textual) link:presentationLink link:definitionLink link:calculationLink 137 - Disclosure - License agreements, research collaborations and development agreements (Details Textual) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 9 opgn-20150930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 10 opgn-20150930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 11 opgn-20150930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information [Abstract] Document Information [Table] Class of Stock [Axis] Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Filer Category Trading Symbol Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] Statement [Table] Class of Stock [Domain] Statement [Line Items] Assets [Abstract] Assets Assets, Current [Abstract] Current assets Cash and Cash Equivalents, at Carrying Value, Total Cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Accounts Receivable, Net, Current, Total Accounts receivable, net Inventory, Net, Total Inventory, net Total Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Property, Plant and Equipment, Net, Total Property and equipment, net Deferred Offering Costs Deferred IPO issuance costs Indefinite-Lived Intangible Assets (Excluding Goodwill) Intangible assets, net Goodwill Goodwill Fair value of goodwill Other Assets, Noncurrent Other noncurrent assets Income Statement [Abstract] Liabilities, Current [Abstract] Current liabilities Accounts Payable, Current Accounts payable Employee-related Liabilities, Current Accrued compensation and benefits Accrued Liabilities, Current Accrued liabilities Revenues [Abstract] Revenue Deferred Revenue, Current Deferred revenue Notes Payable, Current, Total Short-term notes payable Sales Revenue, Goods, Gross Product sales Capital Lease Obligations, Current Current maturities of long-term capital lease obligations Convertible Notes Payable, Current Short-term convertible notes, net of discounts Laboratory Services Revenue Laboratory services Aggregate revenue during the period from Laboratory services rendered in the normal course of business, after deducting allowances and discounts. Notes Payable, Noncurrent, Total Note payable Capital Lease Obligations, Noncurrent Long-term capital lease obligations and other noncurrent liabilities Liabilities, Total Total liabilities Collaborations Revenue Collaboration revenue Aggregate revenue earned during the period from collaboration agreements entered into in the normal course of business. Statement of Cash Flows [Abstract] Sale of Stock [Axis] Commitments and Contingencies Commitments and contingencies (Note 10) Revenues, Total Total revenue Temporary Equity, Carrying Amount, Attributable to Parent Redeemable convertible preferred stock Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Cash flows from operating activities Temporary Equity [Abstract] Redeemable convertible preferred stock Common Stock, Value, Issued Common stock, $.01 par value; 200,000,000 shares authorized; 12,539,704 and 493,178 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively Cost of Goods Sold, Excluding Depreciation, Depletion, and Amortization Cost of products sold (excluding depreciation and amortization) Additional Paid in Capital Additional paid-in capital Net Income (Loss) Attributable to Parent Net loss Net loss Accumulated Other Comprehensive Income (Loss), Net of Tax, Total Accumulated other comprehensive loss Retained Earnings (Accumulated Deficit) Accumulated deficit Stockholders' Equity Attributable to Parent Total stockholders' equity (deficit) Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Depreciation, Depletion and Amortization Depreciation and amortization Depreciation and amortization Deferred Income Tax Expense (Benefit) Deferred tax provision Cost of Services, Excluding Depreciation, Depletion, and Amortization Cost of services (excluding depreciation and amortization) Cost Of Sales Excluding Depreciation Depletion And Amortization Total costs of sales (excluding depreciation and amortization) The aggregate cost of goods and services produced and sold during the reporting period, excluding depreciation, depletion, and amortization. Temporary Equity, Par or Stated Value Per Share Preferred stock, par value (in dollars per share) Other Noncash Expense Noncash interest expense Research and Development Expense Research and development Temporary Equity, Shares Authorized Preferred stock, shares authorized Temporary Equity, Shares Issued Preferred stock, shares issued Increase (Decrease) in Accounts Receivable Accounts receivable Temporary Equity, Shares Outstanding Preferred stock, shares outstanding General and Administrative Expense General and administrative Selling and Marketing Expense Sales and marketing Temporary Equity, Liquidation Preference Preferred stock, liquidation preference Increase (Decrease) in Inventories Inventory Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Increase (Decrease) in Other Operating Assets All other assets Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Increase (Decrease) in Accounts Payable, Trade Accounts payable Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Accrued compensation and other liabilities Gross Profit, Total Gross profit Increase (Decrease) in Deferred Revenue Deferred revenue Redeemable Convertible Preferred Stock [Member] Series A Convertible Redeemable Preferred Stock Series A Convertible Redeemable Preferred Stock Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net cash used in operating activities Investment Income, Interest Interest income Interest Expense Interest expense Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Cash flows from investing activities Fair Value Adjustment of Warrants Change in fair value of derivative financial instruments and other Change in fair value of derivative financial instruments and other Cash Acquired from Acquisition Cash acquired in business combination Nonoperating Income (Expense) Total other income (expense) Other Comprehensive Income (Loss), before Tax, Total Loss before income taxes Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment Income Tax Expense (Benefit) Provision for income taxes Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Cash flows from financing activities Redeemable Preferred Stock Dividends Preferred stock dividends Proceeds from Issuance of Common Stock Proceeds from issuance of common stock, net of issuance costs Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Organization Proceeds from Issuance of Preferred Stock and Preference Stock Proceeds from issuance of preferred stock, net of issuance costs Proceeds from Issuance of Convertible Notes and Warrants, Net of Issuance Costs Proceeds from issuance of convertible notes and warrants, net of issuance costs Represents the information pertaining to cash inflow from issuance of convertible notes and warrants, net of issuance costs. Proceeds from Notes Payable Proceeds from issuance of promissory notes, net of issuance costs Proceeds from Stock Options and Warrant Exercises Proceeds from exercise of stock options and warrants The cash inflow associated with the amount received from holders exercising their stock options and warrants. Proceeds from Issuance Initial Public Offering Proceeds from initial public offering, net of issuance costs paid in 2015 Repayments of Debt Payments on debt Effect of Exchange Rate on Cash and Cash Equivalents, Total Effects of exchange rates on cash Cash and Cash Equivalents, Period Increase (Decrease) Net (decrease) increase in cash and cash equivalents Liquidation Basis Of Accounting Abstract [Abstract] Liquidity and management’s plans Interest Paid, Total Cash paid during the period for interest Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Supplemental disclosure of noncash investing and financing activities: Capital Expenditures Incurred but Not yet Paid Acquisition of equipment purchased through capital leases Stock Issued During Period, Value, Acquisitions Common stock issued in business combination Substantial Doubt about Going Concern [Text Block] Liquidity and management’s plans Conversion of Stock [Table] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Debt Instrument [Axis] Short-term Debt, Type [Axis] Debt Instrument, Name [Domain] Accounting Policies [Abstract] Significant Accounting Policies [Text Block] Summary of significant accounting policies Proceeds from Convertible Debt Repayments of Notes Payable Short-term Debt, Type [Domain] Convertible Notes Payable [Member] Convertible Notes Payable Loans Payable [Member] Short-term Demand Notes Stock And Warrants Issued During Period Shares Initial Public Offering Warrants acquired by underwrites on the exercise of over-allotment option in connection with IPO. Basis of Accounting, Policy [Policy Text Block] Basis of presentation Foreign Currency Transactions and Translations Policy [Policy Text Block] Foreign Currency Use of Estimates, Policy [Policy Text Block] Use of estimates Income Statement Location [Axis] Sale of Stock [Domain] IPO [Member] Initial public offering Fair Value of Financial Instruments, Policy [Policy Text Block] Fair value of financial instruments Cash and Cash Equivalents, Policy [Policy Text Block] Cash and cash equivalents Trade and Other Accounts Receivable, Policy [Policy Text Block] Accounts receivable Stock And Warrants Issued During Period Shares Initial Public Offering Purchase Price Per Unit Represents the purchase price per unit (common stock and warrants) issued during the period pursuant to initial public offering. Inventory, Policy [Policy Text Block] Inventories Standard Product Warranty, Policy [Policy Text Block] Product warranty Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Impairment of long-lived assets Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block] Intangible assets and goodwill Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block] Redeemable convertible preferred stock Revenue Recognition, Policy [Policy Text Block] Revenue recognition Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Share-based compensation Income Tax, Policy [Policy Text Block] Income taxes Schedule of Inventory, Current [Table Text Block] Schedule of inventories Proceeds From Issuance Of Units Under Initial Public Offering Gross The cash inflow associated with the amount received from entity's issuance of units under initial public offering. Proceeds From Issuance Of Units Under Initial Public Offering Net The net cash inflow associated with the amount received from entity's issuance of units under initial public offering. Significant Accounting Policies [Table] Significant Accounting Policies [Line Items] Inventory, Raw Materials and Supplies, Net of Reserves Raw materials and supplies Inventory, Work in Process, Net of Reserves Work-in process Inventory, Finished Goods, Net of Reserves Finished goods Debt Conversion, Original Debt, Amount Conversion of Stock, Shares Issued Equity Components [Axis] Income Statement Location [Domain] Related Party [Axis] Equity Component [Domain] Common Stock [Member] Common Stock Fair Value Disclosures [Abstract] Fair value measurements Fair value measurements Fair Value Disclosures [Text Block] Fair value measurements Fair Value, Assets Measured on Recurring Basis [Table Text Block] Schedule of financial assets and liabilities measured at fair value on a recurring basis Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Summary of change in fair value classified as Level 3 liabilities measured at fair value on a recurring basis Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Hierarchy [Axis] Fair Value Hierarchy [Domain] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair value measurements on recurring basis Cash and Cash Equivalents, Fair Value Disclosure Cash and cash equivalents Fair Value, Inputs, Level 1 [Member] Level 1 Fair Value, Inputs, Level 2 [Member] Level 2 Fair Value, Inputs, Level 3 [Member] Level 3 Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Warrant [Member] Warrant Warrant Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value Balance at the begining of the period Balance at the end of the period Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances Established in 2015 Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract] Series A redeemable convertible preferred stock Range [Axis] Range [Domain] Maximum [Member] Maximum Minimum [Member] Minimum Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Preferred Stock [Text Block] Series A redeemable convertible preferred stock Accounts Receivable [Member] Accounts Receivable Concentration Risk Type [Axis] Concentration Risk Type [Domain] Customer [Axis] Customer [Domain] EX-101.PRE 12 opgn-20150930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EXCEL 13 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0````(`+R!;4>)6B0\O`$``"88```3````6T-O;G1E;G1?5'EP97-= M+GAM;,V9S4[#,!"$7Z7*%36N;?Y%>P&N@`0O8))M8S6.+=N4\O;8*2"H"FJ! M2G/)3V>],\DZWZ47#R^.PF!IVBZ,BR9&=\Y8J!HR*I3649>4J?5&Q73K9\RI M:JYFQ,1H=,PJVT7JXC#F'L7DXG9!WNN:!I%\JY5EO=1W: MZ5175-OJR:0E94S6=)#T8G"G?+Q1)K5@RY;UPNK(RZRS_S$,SI.J0T,435N& M^-)2V.2_4MZ=KVBJGMJXD_';NRL]M7U-:+1[L[I>IBXA_38NDAJV]89>DXKND!I9:_\G[?:=4UM-6AKEPCQ]%HSS5]]&G^6[^-CX7 M["]'GFM__=W0>S&P_K1'2.R40X#DD"`Y#D%R'('D.`;)<0*2XQ0DQQE(#CY" M"8)"5(Z"5(["5(X"58Y"58Z"58["58X"5HY"5H%"5H%"5H%"5H%"5H%"5H%" M5H%"5H%"5H%"5H%"5HE"5HE"5HE"5HE"5HE"5HE"5HE"5OE!5M;_/3!Y!5!+ M`P04````"`"\@6U'2'4%[L4````K`@``"P```%]R96QS+RYR96QSK9++;L)` M#$5_)9I]<4HE%A%AQ88=0OR`.^,\E,QXY#$B_?N.V(#"0ZW$TJ][CZZ\#JFL M#C2B]AQ2U\=43'X,JQW8OG*\M"_V/Z'D4X$G1H>)%]2-F`Q+M*;V"^GH`A3&^.R6: ME((C-Z."N[_8_`)02P,$%`````@`O(%M1\3+)$.4`0``/!<``!H```!X;"]? M&?/ODKC;671NJN@^S]^;: MANWP?Y]5,?9;8T)1N<:&AZYW[;!Z[GQCX_#I2]/;XF)+9SC/E\9/YV2'W<_9 ML^-IG_GCB;+9B_6EB_OLK?.74#D7@QE?]#!L,"S?>O>?[;OSN2[<8U>\-JZ- M?U28KPTRDP[B=!!#@B0=))"@>3IH#@E:I(,6D*!E.F@)"5JE@U:0H'4Z:`T) MVJ2#-I`@RA49C-&;%;T9HSC-&;U;T M9HS>K.C-&+U9T9LQ>K.B-V/T%D5OP>@MBMZ"T5L4O05T5Z)=EF#T%D5OP>@M MBMZ"T5L4O06CMRAZ"T9OF>@=*NO=Z3GZNBW#O6N^#5>+)GB'>+NZ^Z>,4]7[ MR(G6<=C)F?%Y=Q3'J9\AYM=%^>$#4$L#!!0````(`+R!;4>EXKTIV`(``($* M```0````9&]C4')O<',O87!P+GAM;+U646_:,!#^*Q8O[:2MH="M&Z*16FC7 M2E2M!NN>#^<(%HZ=V0Z"_OI=DL)"YT1M'L8+E\M]]MWWW=D9*ML=/!J=HG$" M+=LD4MD!.2\Z2^?201!8OL0$[`F%*'J[T"8!1X\F#O1B(3B.-<\25"[H=;M? M`MPX5!%&G]+]HIUPF.]RF:92<'!"J_!><*.M7CAVO>$HA\'K@`)!*T^19T:X M;=@M8ZJN(F;*0>*(]@H7("V647^=1.EJ!BC*JQ_[[<*T%Z48[\BSG-5TLM(SH#CA@2?43><83$@G`?:I1+$N&*_`J: M:6]'=2%5A_Z,)S0")#6#V&!9V$=*WB(8OB2X%_,#9=$0*4W?ECD#R@+/>:XA MI4G%TZ\M,-_>K#P[GN4B6#]=-=+N0"U4\0]N8^_W_(/;R$#OK`7&/[A^UL;H M0,@:VAHA[+0%9O;6":U`_--4*VF)>S^F[Z^G<=+[O=I)KQ:P<1E(/\6-7=:O M4;\1XU>_\H70/4J?W5Q!X] M$[,2/@$``&D#```1````9&]C4')O<',O8V]R92YX;6S-DTU/PS`,AO\*ZKW+ MTFH[1%T/@#@Q"8DA$+>0>%M8\Z'$4]=_3Y9U+0,NNW&K:[^/7\=))1P3UL.3 MMPX\*@@W!]V8P(1;9%M$QP@)8@N:ATFL,#&YMEYSC*'?$,?%CF^`%-/IG&A` M+CER<@3F;B!F=24%$QXX6M_CI1CP;N^;!)."0`,:#`9")Y1D]8O9&=N:BHSZ MNHJ.&QYP::5:*Y"WW5CV.Q4[(W@=3G*00_OT]T\/*4.ROO(0U%#5MNVD+5-= M')B2M^7C&UL[5I;<]HX M%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M3A^%$5B-;'EDD81_OTV2 M3;J;/`0LZ?O.14?GZ#AY\^XN8NB&B)3R> +]O6N[!3+UES@6QHO(];JM-O=5H1I;*$81V1@ M?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!$U=!)KF(M/+Y;,7\VMX^9<_I.ATR M@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9KQ]'22(""R7V4!;I)]J/3%0@R#3LZ MG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2BW`A(5M>5`TR``6'!VULS2`Y9>*?IUE!K9';O=05SP M6.XYB1'^QL4$UFG2&98T1G*=D`4.`#?$T4Q0?*]!MHK@PI+27)#6SRFU4!H( MFLB!]4>"(<7K;YH]5Z%82=J$^!!&&N*<<^9ST6S[!Z5& MT?95O-RCEU@5`9<8WS2J-2S%UGB5P/&MG#P=$Q+-E`L&08:7)"82J3E^34@3 M_BNEVOZKR2.FJW"$2M"/F(9-AIRM1:!MG&IA&!:$L;1>$[2M!'\ M6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+D!&_'H8X2IKMHG%8!/V>7L-)P>B" MRV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y M'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+`.7\N?<^E[[GT/:'2MSAD6R4)RU3393>*$IY"&V[I4_5*E=?EK[DHN#Q;Y.FO MH70^+,_Y/%_GM,T+,T.WF)&Y"M-2D&_#^>G%>!KB.=D$N7V85VWG MV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_#0X=Y>U^89Y7&4#04;6RL)"Q&MV"X MU_$L%.!D8"V@!X.O40+R4E5@,5O&`RN0HGQ,C$7H<.>77%_CT9+CVZ9EM6ZO M*7<9;2)2.<)IF!-GJ\K>9;'!51W/55ORL+YJ/;053L_^6:W(GPP13A8+$DAC ME!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SCYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F M\M\M#`DL6XA9$N)-7>W5YYNTB42%(JP#`4A%W+C[^^3:G>,U_HL@6V$5#)DU1?* M0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF8$O#>FZ=+2?_VU[4/;07/4;SHYG@ M'K.'YA,L0Z1^P7V*BH`1JV*^NJ]/^26< M.[1[\8$@F_S6VZ3VW>`,?-2K6J5D*Q$_2P=\'Y(&8XQ;]#1?CQ1BK::QK<;: M,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]!U4#E/]O4#6CV#30,9FV-J/D M3@H\W/[O#;#"Q([A[8N_`5!+`P04````"`"\@6U'O)!'KU("``!Z"@``#0`` M`'AL+W-T>6QEEJ&T8A,.C*H'GH6Y%M MV1'HPY/ES.FOGSX\.EMBANJIJ##7*X60#"D]E:575Q*CO#:;&/5FOA]Z#!$.DX@W;,Y4#3+1 MSGIU-_/J]=VJ,,#U'=XA>D>S>.U_^J^,N1>EZ`D*@0?\C2##DBB^AFL$-7^ M@7'/!!42*'T16H5%.&+8>=PB2E))#%@@1NC:P3,#V+OK_!CA0MK8+L)NG*D_ M1))E&D._^[T\7#JPV\$G#<<&Q$VG]#GB7 M$JV#V>5H@QUTW%3(',L^<@`W4!)17"B]09)R:48E*B-=*"68-G*"2L$1-92; M'9VA:3-,Z8/Y4AZ++>ZV`,['W+$/@5&Q,74B.G,H`YM4;\SFN,>TQ_&"MN@# MZ-VHJNCZ!R4E9]B)==!<=+-#],$>^B1"&U:P%)(\:W]3")D&L(1@A:4BV1CY M*U&UP*WJ*MAKBWT*CSWR>VHZ?=8&-;H$/SH]1P>WT'W#4BSG]J_Q]9(NK@Y? MF?TZX8[,CZV:(R2<(#FFL7U::>'GE?8^-76*:K]^HS*O:PRC[K/5>WH4I`VA MBO"-!&1>"_=&-MUJ"T/?T9QY.[0Z]%3Q'#P?Z%<]*P:ZM@>&TF_P!02P,$%`````@`O(%M1W-`:_N[`P`` MW`P```\```!X;"]W;W)K8F]O:RYX;6R5EMMNVS@00'^%T$NSP**V*-M)C+I` MTS1M@/2"VN@^T]+8'H0B59)*TGQ]AW*\'<>L$#_IRB-QYG`X;_STWKK;I;6W MXJ'6QD_=+-N$T$P'`U]NH%;^M6W`T+.5=;4*=.G6`[M:80F7MFQK,&$@A\/) MP(%6`:WQ&VQ\]D3S+Z'YQH&J_`8@U'H+JQ6:[.T;/UVAAA_@/(&%:IHOJH99 M]J`SH94/'RH,4,VR$5W:>]B[X=KFHD4=+\;#<3:(L-U4OSE1V@JVL,4&_7]/ M#S)1P4JU.BSH9W??G66Y'$DYV3+B:S\0[CT'QAM"E0'O8*&6LVR8"=4&>X4Z M@+M4`3XZVS9HUL3*Q`J=#_,XW>[-&@W6^!C_FZ[\QMY_L@X?K0E*STMGM>Y& MQ0?=(/J"__\._6/`1G;!1D\-1-_BSQ2HF1E&.:F74.OY_>.5%0S%AH%,&.CT$S=NZ M5NZ7L"OA<6V0EKBBS*NRM"UEGH'.&.CL$'31>C3@/<6C7J)Y/I]S-OK\ MO!,.*J"B12N&ZH6YBTLMKAZ&XK+F"5LO81GX^]S)/"'E/-CR=F-U1:7GE0#* M+.7UA(H2EAC^X20N99ZTLJXQ='/OQ*`)!`HE4$!A+QIK);J+6# M;2S_IIJ?<107 M-4^8VH\ZYRAN;9[0-B6].%E$>3Q/G.0"RY<+O&-Q%!=9ID3NM6FOZ.Y5W83( MO55&\K(KN>,RY7A?T.6(H[CD,B%Y/XJ77LDUEPG-T_F[A*!0[R>06RX3EO>2 M1,Y17'694+T?M>`HKKI,J)XHJXS$BYKDJLN$ZG\U=(OC6S"7O3A&]H@J>*P* M+GMQ;-4N)$=QV8N_5&T>G(?0*LT=*/9ZBV/K>,$=+[CC1_<$<<)17/(BV77T[`K%*4=QR8O3I][S3[L99V*@BLVX[SY#W6P9.W0Z;/?8 MT3A6WWC]F;KV619;:^JB6ZW?T[VOYL:JK@'=DG<]^=O?4$L#!!0````(`+R! M;4>E.]E`3P(``/0'```8````>&PO=V]R:W-H965T&ULC97; MCILP$(9?Q>(!%FQ.R8H@):FJ]J+2:B_::R=Q`EJ#J>V$[=O7)]A$ZP5N`G;^ M?[X9X[&+GO$W41$BP7M#6[$)*BF[YS`4QXHT6#RQCK3JGS/C#99JR"^AZ#C! M)V-J:(BB*`L;7+=!69BY%UX6["IIW9(7#L2U:3#_MR.4]9L`!L/$:WVII)X( MRR(Z(:VH60LX.6^"+7S>PT1+C.)W37IQ]PYT\@?&WO3@YVD31#H'0LE1 MZA!8/6YD3RC5D13YKPOZP=3&^_&17F%QRO0K)FL`2@P>_V6;?FV=M_$NAL?@-R!C0:4#9IB)TA M'@UVZ4*;F:GK&Y:X+#CK@>BP_MKP6`O57$\X#X$6`GM[&Q)_/VY-&>6'MB[*DO M/ZO8644V#TB]@-38\T=`:Q2I!5@%1.MX!5?SF,R+R4R0U40=5K&>!^1>0&ZS M]&X51W"2!7MEY46LW$),()QDP6Y9>Q%KZT\F$$Z2SB-@Y&68:14AFX`,FGP! M!?HIKC&G/OF@6?#1(?)37/]&7^_?O=-`E,;K/%K0B3#VLVPK(^BK*',5.0U: M0/$W/+3]C.*)CAPTT:==$-X=L@WA%W/Y"'!DUU;:,W:<'2^X+3*'](>\+#I\ M(;\PO]2M``Y*NF%>@0``,X5```8````>&PO=V]R:W-H965T M&ULC9C;;N,V$(9?Q?!]5B2'Q\`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`*=,EZI21RF482O.81X@"T>H-:KAV`2:6'"S$ MNU;2042.$ M89):L*CC+,@RYI%((U9$+$H*L>(:G0DS?.X?EM<_:<:*R$5),18U8$(!8*F= M&84Z;.&*94QKD<:LB&"D-I<-:CB[;'["$^3N0B)=](K(5TE5O:@!;JPB9EJ) MNE!)<9DS@]*\%A&QZ;F*YP+4A-4C-+DQHE"'&EGGU%,BS6N!M>W54)QK-K,F M`R_BBL'S@2IB4V44Z2*-3&&O,R3ZSMY??4A>I<,>GS.2+MT>AR>"C!-BFF\0 MF43-N@UJ`G#!4?LDZD(UDM&_D*8;<#P`4GX072)\-*>V^!*EUAK<@!=*8 M`RS_*,RAYH'<`U"4@1.X<:8'+$0I)U'SP)D#IS5U-BAGK=/&B%`&9QA+U?A_&G&?L^OFZ,%T-[G-^>?K["7?\/4$L#!!0````(`+R! M;4=WK3IS.@(``",(```8````>&PO=V]R:W-H965T&ULE9;= MDIHP&(9OA>$"A/"/@\QTZ73:@\[L[$%['#4*LX'0),KV[IODB]9U`NMZ("0^ M[Y>#F+CMU*.ZR`0NY;T6*S82`;UR8'Q'DO5Y,=`C)S@ MO0GU-(C",`MZW`U^79F^9UY7["1I-Y!G[HE3WV/^]XE0-FU\Y%\Z7KIC*W5' M4%?!-;?O>C*(C@T>)X>-_P6M&V000_SJR"1N[CTMOV7L53=^[#=^J!T()3NI M2V!U.9.&4*HKJ9'_V*+_Q]3!V_M+]6]FNDI_BP5I&/W=[66K;$/?VY,#/E'Y MPJ;OQ,XAU05WC`KS[NU.0K+^$O&]'K_!M1O,=8)/LL3&W('(!J)K`"T'8AN( M[P(!F)EY?<42UQ5GDR=&K+]MM%8XUT5494]-1JAU,C6Y6:FZ.M<9JH*SKO,. MB0SR!$@T3S262*](H,9W2D3O)1*0B$#B;HC!(`5(`!*N0C0/-0YHUB1VFL1@ M$KL&2<$$$/6;@-<\V MWC6!(5.%=.M7,H%%\LLR5CD<1ODMH$G M7NX<*K```8````>&PO=V]R:W-H965T&ULC9E-;]LX$(;_ MBN%[8G*&GX%CH):UV#TL4/2P/:N)DABUK:RE--U_OY0X5)R$'NO0)E8>#OF2 M],Q+:OG:''^V3W7=S7[O=X?V=O[4=<\WBT5[]U3OJ_:Z>:X/X2\/S7%?=>'C M\7'1/A_KZGYHM-\M0`BSV%?;PWRU')Y]/:Z6S4NWVQ[JK\=9^[+?5\?_UO6N M>;V=RWEZ\&W[^-3U#Q:KY6)L=[_=UX=VVQQFQ_KA=OY%WI2H>F0@_MG6K^W) M[[-^\#^:YF?_X:_[V[GHQU#OZKNN#U&%'[_JHM[M^DBAYW\IZ%N??8?`@*P)@?/()B)O01:A_^P@8)[K`8;F3`=%)"PR8[@8I/P4Y.PP\?TP M,:E16:WE!%#-$9.6#8ILMJ&QT$<\\U>$V.$1V`&5!`'*+3BEHXX+]#F4RH) M3/U*5&I"KI0RKS`63)=-RDFAI.0EE6852IH)!=Q6WQ`7*@MR7$DR%.AGA>9-X< M2"K7G#L@QEMON&]^09P*0S*L1K(;+@R>LR4E@5(YX\2$A"SS/D$:LB2<1JK: M3DO.4!2)4U(8=K.260A?:L%F+?(>IO>"$Q3FW8*D(L_9!6(T:.TYOT`<*VY: MJ/)3J/.Z\CY!QH+L.*-`C!:@E6#`@D`(:QS^5G(`Q[%?17*RFDP*5GP*=UY3W")#N"SA--BV?%9I/,7;R\MFWY5/(U:-R M['[R\N5M`\2R[#G;0`R[15U*C_KTKB,CD4!02@ON$)[`<&Z<=(*#O%\`.O/G M\Q]=6(*_N)9T9YE(:9T2^1,H75N.)`1'[O*',+JY'+L/!T#C)EPY8/[*`46Z MX!F4Z^S([-4$A M^4G@[G@*(K&WK9RI(3#O<#!=9G`VCJ`KQ;D`O.B#-E/BE)_BG)>4MS9(%PWY8VQ: M/O6V?";O.=/RJ. M$XPGW#VL;>7E\.6'GAF)J]?N^+U_:MMA]G._._37\Z=A>+Y:+ON[IW;?]%^Z MY_80__+0'??-$'\>'Y?]\[%M[J=&^]T2E*J6^V9[F*]7T[6OQ_6J>QEVVT/[ M]3CK7_;[YOC?IMUUK]=S/<\7OFT?GX;QPG*]6I[:W6_W[:'?=H?9L7VXGM_H MJ]J$43(I_MZVK_W9]]EH_K;KOH\__KR_GJO10[MK[X8Q1!,_?K1UN]N-D6+/ M_U+0MS['AN??<_3?I^%&^[=-W];=[I_M_?`4W:KY[+Y]:%YVP[?N]8^6QF#' M@'?=KI_^G]V]]$.WSTWFLWWS,WUN#]/G:_J+5]2,;P#4`$X-3OWP#9`:X%L# M,XTT.9O&]5LS-.O5L7N=]<_-N-KZ*LJ/8Y`8>18'T\=YFF(>IYE:KWZLM;*K MY8\QT#L-3)H-:4Z*98S.=@%SKCE,S>%R!W52./R\!WS?0[IX@S2(ZO,`YGT` MDP*8*4#P[ST>)HE+HTB2A88*#&*XK*Q)::"RWKO/+5EV3);&5!"@8L=430'. M#)PYM6E,28(!C#*79762F4H;A,_=.-:-H^&P4TQV2%-5()A)(O6Y#\_Z\.2# M74#R01H;/&K)2M*!\KY@YP;63DA=:278R1H'@%JPDW1>&5NP9[1B_4R7Q\Z$ MCC8D$CS7)%D88X,M<*-Y-XD\0=B<&])4QJ&1%HMTT9$JV#P:V)M2`TU/P7V@ MD1\3P4JC-*@DLLJIJI(&E705@"W`L^;AIPTY$J:D#=J9`D^6 M]T3XTU;RE$0+5!5ZT502NG@_ETP3SU.=:2DY2IJ%U\9;P7I-0@C>%K!#\TS5 M!$PMC'U#HH5V%EP0[UF7$Y=SOL`4#UB=J"C=BQO2++17*)&F/@E!VZ(=SE-6 MGQ`JF0K45\RYVJ*0J.HLQ:"L#@5S!8K%"63:EH3@$0E4G&EI6V815@[$^29A M`2`!>#L$2)`2&HD6/@!*=4?68;!8D-*`!RX0<$%*:2>1<\$)NZ0F8;$GPR\\ M(1<*\@CPA`0B)$AYA$0F6(\H\8B$)0O/TQ$JLB,E$1))$,IQ`D98E MSL)WLLN6>+(BD14ELI(HYC``)5K*"%;6%=3GR*,5B9K28\F&1*#BTPN*U2PI M$<&&JN1E`%_/(L$5I1($*/$QB(0E=G@J&J*BD:A((E3C M/\D-%KNY\&J3:&@*<&'X5Y'&_L*&X8ECJI(YH8=B_>FD?*PC+]OA86-R05>` M!L.CP?A?F!0>#29(DY+?.X>SC<).2G[MS!=AR[-3@7U[?)Q.2_K97?=R&-(; M^]/5TXG,#8RG"A^N;_15G6CG-"\V![`D5U#9?=,<:%I5<;:DZE*')T4&IX,L:-2W/P[@L3I0#=T*3R+KG>AP*J2K;Q& M*-!6H"8&V@-]V.R/14!$P&\!D[V(2?!^0GP)R<_F0+-@`234+BAPOYSA$:0, M0K[QWUGSK64@7L:+^O4?X1C>N]V8R2!EH^2O>,TP^81]@%P1JE MC5]2C]:A6BB4*/Z:5J'C.J4_7[.9=IN0SX3\'8&E1M'F-^YX51J+@57FN-D51LG,0NL(DXG'&K`CFU6^VR.DM>A[I^>?T M[35]FQQN9X>[SP6*:X$B"10?C9@PQP5S_ZX)N]A3!::+5\>2&D?MTI:NU?5V M/N3Q3-[@53GP#GYQTPEMR0F=/]EX`"VB`]\^N]M1TOOWLR826A?"+SXVZ4JE MQ.&P/)#UE5;_`5!+`P04````"`"\@6U'U1TM-:8!``"Q`P``&````'AL+W=O M;`_@R+N2VNYH[]RP9]"@54E6WB-4*"M0$T,M#MZO]KNBX"(@%4/X5 MC>N]V8R2!EH^2O>"TR/,(VR"8(W2QB^I1^M0G2B4*/Z>5J'C.J4_FWRF72?D M,R%?"'=9-)X:19N_N.-5:7`B=N#A[%9;#S=!Q"L3[\WZL:.FB8-7Y;%:%;_6J+G%ZCYY&>?T]?7]+7R>%Z=GCWO4!Q*5`D@6(6^'EM MQ(39SYA-]J4).]M3!::+5\>2&D?MTI8NU>5VWL=#9)_PJAQX!W^XZ82VY(#. MGVP\@!;1@6^?W6PHZ?W[61()K0OAK8]-NE(I<3B<'LCR2JL/4$L#!!0````( M`+R!;4<\ICQ=H@$``+$#```8````>&PO=V]R:W-H965T&UL MC5/+;MLP$/P5@A\0ZN6V,&0!<8J@/10(C$6U4BA1_"VN8@CK'/\4^4*[3<@60K81OB3!>&P4;'[EEE>EQIF8 MD?NS2_<.KKV(4R;.FW%C!TT=!J_**M!=N#J&U#@--F[I M5MUNYWT6SN0=7I4C[^`'UYT8##FA=2<;#J!%M.#:)W<[2GKW?K9$0FM]^-G% M.EZIF%@RO=+J#U!+`P04````"`"\@6U'V;=&?:,!``"Q`P``&````'AL M+W=OK#[K,#`UBU&6J;T/W[]05HLHJV+WAF..?,&5^*"?6[Z0`L^52R-WO:63OL M&#-5!XJ;&QR@=W\:U(I;E^J6F4$#KP-)298FR2U37/2T+$+M59<%CE:*'EXU M,:-27/\Y@,1I3S=T*;R)MK.^P,J"K;Q:*.B-P)YH:/;T;K,[Y!X1`+\$3.8L M)M[[$?'=)\_UGB;>`DBHK%?@;CG!/4CIA5SCCUGSJZ4GGL>+^F.8UKD_<@/W M*'^+VG;.;$))#0T?I7W#Z0GF$;9>L$)IPI=4H[&H%@HEBG_&5?1AG>*?+)MI MUPGI3$A7PL\D&(^-@LT';GE9:)R(&;@_N\W.P;47<3-N[*"IP^!E<2HW MV[Q@)R]T@8G$PXQ9$]0C64I@$``+$#```9````>&PO=V]R:W-H965THD(4M/5:O=AI:H/[;,#`UBU/:QM0O?OZPNAR2I2 M7_#,<,Z9,[Z4$YIWVP,X\J&DMCO:.S=L&;-U#XK;&QQ`^S\M&L6=3TW'[&"` M-Y&D),NS[)8I+C2MREA[-E6)HY-"P[,A=E2*FW][D#CMZ(J>"B^BZUTHL*ID M"Z\1"K05J(F!=DBX3NG/IIAIUPGY3,@7PGT6C:=&T>8/[GA5&IR( M'7@XN]76PTT0\[-^[*AIXN!5>:Q6F[N2'8/0!281]S-F03"O?K5%3J_1 M\TC/OZ>O+^GKY'`].[S_7J"X%"B20#$+/%P;,6'V,^8V^Z\).]M3!::+5\>2 M&D?MTI8NU>5V/N;Q3+[@53GP#OYPTPEMR0&=/]EX`"VB`]\^N]E0TOOWLR02 M6A?".Q^;=*52XG`X/9#EE5:?4$L#!!0````(`+R!;4?UAN-_H@$``+$#```9 M````>&PO=V]R:W-H965T36I;IC9M3`FT"2@F5)TY2NA;>AZZTOL*ID&Z\9)"@SH"(:VCV]3W>'PB," MX/L`LSF+B?=^1'SWR7.SIXFW``)JZQ6X6T[P`$)X(=?XYZ+YV=(3S^-5_3%, MZ]P?N8$'%#^&QO;.;$))`RV?A'W#^0F6$6Z]8(W"A"^I)V-1KA1*)/^(ZZ#" M.L<_>;'0KA.RA9!MA*]),!X;!9O?N.55J7$F9N3^[-*=@VLOXI2)\V;S];(J"U/OSB8AVO5$PLCNL#V5YI]1M02P,$ M%`````@`O(%M1U.G(?:C`0``L0,``!D```!X;"]W;W)K&ULA5/;;J,P$/T5RQ]0$T+2*B)(3:NJ?:A4]6'WV8$!K-H,M4WH_OWZ M`C191=L7/#.<<^:,+_F(^L.T`)9\*=F9/6VM[7>,F;(%Q5@+*J90HGB7W$575C'^.?V;J)=)Z03(5T(=TDP'AL%FX_< M\B+7.!+37]'5TN)X<;GX6R"X%LBB0_6_$B#G,F.T_3=C9GBK03;@Z MAI0X=#9NZ5)=;N=]&L[D&U[D/6_@E>M&=(8S]+ M(J&V/KQUL8Y7*B86^_F!+*^T^`M02P,$%`````@`O(%M1Z)QVBRD`0``L0,` M`!D```!X;"]W;W)K&ULA5/+;MLP$/P5@A\0RK(3 MIX8L($X1M(<"00[MF996$A&2JY"4E?Y]^9`4.S":B[B[FIF=Y:,8T;S:#L"1 M=R6UW=/.N7['F*TZ4-S>8`_:_VG0*.Y\:EIF>P.\CB0E69YE=TQQH6E9Q-JS M*0LQ:3X/V(^!J2G_6>9L$"2*A<4.!^.<$C2!F$?..W2?.C92">Q[/Z M4YS6NS]R"X\H_XC:==YL1DD-#1^D>\'Q!TPCW`;!"J6-7U(-UJ&:*90H_IY6 MH>,ZIC_Y=J)=)^03(5\(]UDTGAI%F]^YXV5A<"2VY^'L5CL/-T'$*Q/OS?JQ MHZ:)@Y?%J5S=;0MV"D(7F$0\3)@%P;SZU18YO4;/(SW_FKZ^I*^3P_7D\/YK M@&PO=V]R:W-H965T[0#@R)N2VA[HX-RX9\PV`RAN'W`$[?]T M:!1W/C4]LZ,!WD:2DBS/LD],<:%I7<7:LZDKG)P4&IX-L9-2W/PY@L3Y0#?T M4G@1_>!"@=456WFM4*"M0$T,=`?ZN-D?RX"(@)\"9GL5D^#]A/@:DN_M@6;! M`DAH7%#@?CG#$T@9A'SCWXOF>\M`O(XOZE_CM-[]B5MX0OE+M&[P9C-*6NCX M)-T+SM]@&6$;!!N4-GY),UF'ZD*A1/&WM`H=USG]*78+[3XA7PCY2OB<1>.I M4;3YA3M>5P9G8D<>SFZS]W`31+PR\=ZL'SMJFCAX79WK;5&Q<]"Y@23>,4$V M*X)Y\;L=\0'?CVV<.6 MDL&_GC61T+D0[GQLTH5*BP)%W);4]T-ZY8<^8K7M0W-[A`-K_:=$H[GQJ.F8'`[R))"59GF5?F.)" MTZJ,M6=3E3@Z*30\&V)'I;CYPV>P\W0<0K M$^_-^K&CIHF#5^6YVMSG)3L'H2M,(AYGS(I@7OUFBYS>HN>1GG].WU[3M\GA M=G:X_5R@N!8HDD#QOQ$3YKA@BG^:L(L]56"Z>'4LJ7'4+FWI6EUOYT,\1/8! MK\J!=_"3FTYH2T[H_,G&`V@1'?CVV=V.DMZ_GS61T+H0WOO8I"N5$H?#\D#6 M5UK]!5!+`P04````"`"\@6U'<1*^"Z$!``"Q`P``&0```'AL+W=O#;MS\/8+$ M\4!7="Z\B+9SH<#*@BV\6BC05J`F!IH#?5CMCYN`B(#?`D9[$9/@_83X&I*? M]8%FP0)(J%Q0X'XYPR-(&81\X[=)\Z-E(%[&L_I3G-:[/W$+CRC_B-IUWFQ& M20T-'Z1[P?$'3"-L@V"%TL8OJ0;K4,T42A1_3ZO0<1W3GV_91+M-R"="_HG` M4J-H\SMWO"P,CL3V/)S=:N_A)HAX9>*]63]VU#1Q\+(XEZO=MF#G('2%2<3C MA%D0S*O?;)'36_0\TO.OZ>MK^CHY7$\.[[\6V%P+;)+`YG\C)LQQQNP^-6$7 M>ZK`M/'J6%+AH%W:TJ6ZW,Z'/)[)![PL>M["+VY:H2TYH?,G&P^@073@VV=W M6THZ_WZ61$+C0KCSL4E7*B4.^_F!+*^T_`=02P,$%`````@`O(%M1[[[?RND M`0``L0,``!D```!X;"]W;W)K&ULA5/;3N,P$/T5 MRQ^`T[1`J=)(%(1V'Y`0#\NSFTP2"]L3;*>!OU]?TM"NJN4EGIF<<^:,+\6( MYMUV`(Y\*JGMEG;.]1O&;-6!XO8*>]#^3X-&<>=3TS+;&^!U)"G)\BR[88H+ M3#@I-#P8H@=E.+F:P<2QRU=T&/A5;2="P56%FSFU4*!M@(U,=!L MZ?UBLUL%1`3\$3#:DY@$[WO$]Y#\KKWV'BX"2)> MF7AOUH\=-4T)V7;!#$#K#).)NPLP(YM4OMLCI)7H>Z?G/].4Y?9D< M+B>'=S\+K,X%5DE@];\1$V8W8=;9/TW8R9XJ,&V\.I94.&B7MG2NSK?S/H]G M\@TOBYZW\,Q-*[0E>W3^9.,!-(@.?/OLZIJ2SK^?.9'0N!#>^MBD*Y42A_WQ M@I"Q+2=@(``+D)```9````>&PO=V]R:W-H M965TK%=NTD M3D`%S&PG=&\_?]*DLHQO`G;.__QL\1_;?''9EV$8QLQUM[:;CLB.LJGNM.;8\'UI(!4'S>1<]PNX>EE"C%[Q9/ M[.X=R,$?"'F7C9^G793(,>`.'[FT0.)QPR^XZZ23(/\UII],67C_;MV_J^F* MX1\0PR^D^].>>"-&FT3@A,_HVO$W,OW`9@ZY-#R2CJE?<+PR3GI;$H$>?>AG M.ZCGI/_)5Z;,79":@G0NV"1JX!JDAOD-<517E$R`C4A^/+@5Z.9%;%P=R+2R%6>JO)TN3Q[+,_T"#--SP,, M5H\&*VVP,E-,75/4FKW59,N0W`G)C<'*`[&:?!FR=D+6QF#M@5A-L0PIG)#" M&&P\$*LIER$;)V2C,U%X&%H"RV2943H9I3:`F0=B-&5`N&'BI*AN:>&+URP* MR!>$;HY9A:4O8;,H(&(P=7-28^$+V2P*2!G,W!RSKDM?SF910-"@>_5#O;1S M[^?1&G%L!6#R.`9B=(O'&SHI"XN3<#6!H+;]RLZ&O#Z9)U[ MYUO*FD'!@Z$BP->G<-G0C@6_.0ICT`C[E%SH\-G+E\+ M\4[US4(W.!GM16F^K=7_`5!+`P04````"`"\@6U'!"=%Z:0!``"Q`P``&0`` M`'AL+W=OF8W8PP)M(4I(567;/%!>:5F6LO9JJQ-%) MH>'5$#LJQ!DOZM_CM+[[ M$[?PB/*G:%SOF\TH::#EHW1O.#W!/,(N"-8H;?R2>K0.U4*A1/&/M`H=URG] MV14S[3:AF`G%2OB:Q<:346SS&W>\*@U.Q`X\G%V^]W`31+PR\;U9/W;4-''P MJCQ719Z5[!R$KC")>$R8?$4PKW[3HJ"WZ$6R^#=]CL?XB&R3WA5#KR#%VXZ MH2TYH?,G&P^@173@[;.['26]?S]K(J%U(?SB8Y.N5$H<#LL#65]I]0=02P,$ M%`````@`O(%M1VK;93:Q`0``%@0``!D```!X;"]W;W)K&ULC539;J,P%/T5RQ]0`PE-%1&DIJ-JYF&DJ@_MLP,7L.J%VB9T_KY> M@"8C-)T7O)WMZMH4H])OI@.PZ$-P:0ZXL[;?$V*J#@0U-ZH'Z4X:I06U;JE; M8GH-M`XDP4F6)+=$4"9Q682])UT6:K"<27C2R`Q"4/WG"%R-!YSB>>.9M9WU M&Z0LR,*KF0!IF))(0W/`]^G^F'M$`+PP&,W%'/GL)Z7>_.)7?<")CP`<*NL5 MJ!O.\`"<>R%G_#YI?EEZXN5\5G\,U;KT)VK@0?%75MO.A4TPJJ&A`[?/:OP) M4PDA8:6X"5]4#<8J,5,P$O0CCDR&<8PG^6ZBK1.RB9`MA+LD!(]&(>8/:FE9 M:#4BTU/?NW3OX-J+.&7DLAE7=M#4H?"R.)=9NBG(V0M=82+Q&#'I@B!.?=4B MPVOT+%I\3]]I_NCSN/"(!?`D9SL2>^]A/BBP]^5`>:^!)`0FF]`G?+&1Y` M2B_DC%\GS7=+3[SN^A,W$#RMZALZXI-**F@YH.TSSA^AZF%4&&) MTH0O*0=C4^]FE M>P?77L0I$U>;<6T'31T:+_)SD:5W.3M[H2M,)!XC)ET0S*FO6F1TC9Y%B\_I MFVOZ)E:XB>ZW_R&PO1;81H'MU.+7M18CYCAALN1SD]VJR6X22/]A,F,^=L(N M!J=`-^%^&E+BT-DXMR6[/('[+`S^'5[D/6_@)]>-Z`PYH777)TRY1K3@[).; M'26M>Z1+(*&V?OO%[76\MS&PV,^O0*(U5 MI@$``+$#```9````>&PO=V]R:W-H965TZ"]<\.>,5OWH+B]PP&T_].B4=SYU'3,#@9X$TE*LCS+OC#% MA:95&6O/IBIQ=%)H>#;$CDIQ\_<($J<#W="E\"*ZWH4"JTJV\AJA0%N!FAAH M#_1ALS\6`1$!OP5,]B(FH?<3XFM(?C8'FH460$+M@@+WRQD>081<$:Y0V?DD]6H=J MH5"B^'M:A8[KE/[LOLVTVX1$N0KX6L6&T]&LE:76_G M0Q[/Y`->E0/OX!^]BD*Y42 MA\/R0-976OT#4$L#!!0````(`+R!;4>!H';]OP,``+43```9````>&PO=V]R M:W-H965TJK-NKR;;K M=I=QW#YM396W%W9GZOZ7C6VJO.L?F^>XW34F7X]&51GS)-%QE1?U9#X;W]TW M\YE][^^TXW#[\Q[PU2UO^*M;=MH\VF41KL\E?R^[![N\,C$$- M#I]LV8[?T=-KV]G*FTRB*G]WUZ(>KWOW2Y:`&6[`P8`?#)@,&@@P$%0#"0:2 M:J#`0%$--!AHJD$*!BG5(`.#[(M![-(Q)O,Z[_+YK+'[J-WEPQ)GESV\&9ST MGJ,^@VV_.$:?S;@\YK.W.>=Z%K\-CCYA^(A9>$QZ'+/TF.PXYMICIL.?YXYX6:.0Q3LM`/QV8%T#@0X^!)D/6)2 M-PR'8:ED6J?'<7<.EYP.1:*A2`A%8!3*91@PF4KZSVDBA1(I()+'Q[)T&'V: M0J,4&BA4@$+#M+*$-I@494J!20=FS6$8IS)E*%,&3($EL`0,E6B*$DV!*`L, M:0K"266F^&DBEJ!,X^N!:GJ<:@4@.569P!.J0,P)50",X>&X"/6)X56!@>3Q.4FA.3B03HCKCN&%@4%E MD)05I?$1ZS-&C"N:>4F'"B&`).>*-&!5S4'9DM):&9I*SNBIY+B$N)<0VFJ/`NSD%G,E">%@!B3&BA M*5RX(+GOTVC-!$$"2%$%R7%!"2OBY39;CDN09 MH0=PO,_^OR4#("4<7+0<1"O3TRY$@F9`)/0,"+PQ"I"B#&P)5@!BBI@`@6M6 M>,U."2[PMB?.:'L"5YGP*@MLS&\/H!-[@14`,^K,X&H4H$856''7'D2EPO?/ M0H=4X*AN`"2H5+BZ!:A;49*5X?G.SL@WKC,!.E.!?"\`Q*A55>*]48(@%:$W M2KPWRC-ZH\1U)D%G*O`W;`4@?&,7?SAKV.7/YD?>/!=U&SW:KK/5>+JPL;8S MO:/DHE?"UN3KPT-I-MUPFPX2<:=*[J&S.W](=CBIF_\%4$L#!!0````(`+R! M;4?P,[)(\@$``&(%```9````>&PO=V]R:W-H965T-Q"J?-F?T[^Z:@W]CBI6"?ZKJW5K8.,(U*RA1Z[?Q/2- MA1(R&[@77+E?L#\J+?K9$H&>?OBV&UP[^2\$!]NR`04#.AN2]*X!!P/^9("> MS-7UA6I:%E),0(W4'G:R,7)I0TPR,,4HLT\N4[J=*HM3B;*L@"<;=*5!3O,2 M-+<5U9QRED`#L$B!KBG\Y#-R_F2-'@?@ZX#4!^``0*XA!Z?)?1E>0]9YFJ2W M9967I7&>KA_3I(LT::#)EY;)/$W0(!3CY+:L\K($9^1_=C=;Q,D"SNH.3M!@ M$J?X#DX6#@ICLGJ,0Q9Q2,!9WSDKKTF2+$M7B]CAL+P.VT/]_-^!%]=AI`?V M@\I#-RBP$]K<+'>*E4]M&O/EY1WX^\(LU*-UEV8]^K9*DN.L]*^;UR MZDM1I-6_E=#O@)4MOL-MGA2SK3)5.)0]/[F>R>&&BA72( MGYF\UN_NG9;\JU*_VX>O^R?7;SG(7.YTZR)M+F]R+?.\]=1$_@-.;S%;P_?W MO?=MEVY#_S6MY5KEO[*]/C5L?=?9RT-ZR?4/=7V1D$/8.MRIO.[^.[M+K571 MF[A.D?XUUZSLKE?SB_#!##>@8$`'@R$.;L#`@-T,@DF#``P"VP@A&(2V$2(P MB&X&T:0!!P-N&T&`@;@S\,SKZ%[F)M5ILJS4U:G/:3O%R:*!5ZV3QK/3O,&Z MF1R=SZJ;'LGR+:&1O_3>6DQ[ST&#%?$?:Q(LR\.P8EI?,.@H\. M`N,@``=WR98=AINR&PR/HYB/HS96J"V&&J4&ULC5;;1"OPG,@5G"C>R4>T:; MD]*RGT+BJ.?O_MT.[GWV7TJ"8>$`B@'T$@#9;$"*`>E_`8EWYO+ZPC5OZE&> M(W7D=K7AWL!'2V*8(Y.,,O/D.$=!!C@3!))F?"\2P,B/5@E2+H-,"A%(%:QLE@@E08W%:3+:P&$CR!DZ#:=^5[\X..^'53T M(K7Y7;N_ZDY*+0P1N3/F#^8:=>ET8J=ML[!9^8N%[VAYG.Y)E\M:\Q=02P,$ M%`````@`O(%M1^8R@GE@`@``.P<``!D```!X;"]W;W)K&ULC55-DZ(P%/PK%/<1$A(0"ZD:T:W=PU9-S6'G'#4J-4#8)`ZS_W[S M!>HLXEZ$A.Y^W0]\R3K&W\6)4NE]UE4CEOY)RG81!&)WHC41,];21CTY,%X3 MJ9;\&(B64[(WI+H*8!C&04W*QL\SL_?"\XR=954V](5[XES7A/]9T8IU2Q_X M_<9K>3Q)O1'D63#P]F5-&U&RQN/TL/2?P6(3:X0!_"II)Z[N/>U]R]B[7OS8 M+_U06Z`5W4FM0-3E@Q:TJK20*OS;:5Y*:N+U?:_^S:15[K=$T()5;^5>GI39 MT/?V]$#.E7QEW7?J(F`MN&.5,+_>[BPDJWN*[]7DTU[+QEP[^P0A1QLG0$>` M`V&H,TZ('"&Z$*8K($=`_UL!.P+^4B&PV4WGUD22/..L\T1+].<$%@K.M8A2 M]E2[A'H31I.;=Y%G'WD4SK/@0PO=8*#!K"PF@?'(IM_1.[:C&YM1K99D6M6^E@`W0H@*X"L``AO338&D]A>6`P` M,,;1!*YPN!3C>8KNX]:N9AK"*$KNXS86%\<1P%?^[@;$HP&Q$4GG$_DLY`G% M.)R#"4-%#\0@P0A,)'1`@&.H6IM.9.R1()FC-$T>IXQ'4\;N-8Z:FMN8%O,4 MSJ+19EA4X5!HAD9M6]3:H>`,3J`V<1]N=O57MY`@````L``!D```!X;"]W;W)K&ULE5;+N]K(6^40?9V"];U=;"V&:[2_2AE6+3 MD>HJ(0BQI!9E$Q?SKN^I+>;J:*JRD4]MI(]U+=K?2UFITR+&<=_Q7.[VQG4D MQ3PY\S9E+1M=JB9JY781?\6WCY@Y2(=X*>5)?WJ/G/E7I=YF(WY^[]4?NG2M_5>AY4I5/\N-V5NW*(XVM.L^U&NYB_%RDF\^3="5U@2(=9>@PA^3!F!9AAQ)U'Y.DPY'Y4 MY&%/V/C`NFE`/4"*90T:-)CECV&C@>AP2#4 M"V27,9H.XGDK"HG@G.;#L/MIL$!( M07H>\X6R'&6<7$D0@)@ASL/6(<4>2!BA:3J[DF0?F[",\WP\2Q[,DL.4G+"& M9\$U/)N^AC$*6NBZ1Q888(:7#I0OC!MVA,..\/C4O@<0G[B&,`F'(M>F&>P; M`)H<*KQ9XGXGY!,D:'"P,?V/T0[O3KC?GH)S.X-CT(,8QWR2V_`&A6$?(&BX MMDL`$18J;O+IG#^(G?PAVEW9Z.A5&7MEZ$[VK5)&6B%T8[WO[77TW*CDUKC7 MW"7E+VB^8=2AOV^>+[W%'U!+`P04````"`"\@6U'QR;4X3@"``#.!P``&0`` M`'AL+W=OB'/;$OY[31LVK$(0CA/O]:F2>B(JB^C*.]0M[43-NH#3XRI\!S^J?S'EJO@[(NB&-3_K@ZQ4VC@,#O1(SHU\9\-7ZFI(M.">-<+\!_NSD*P= M*6'0DD][K3MS'>R3##J:GP`=`5X)`#\E($=`( MK45DZ`J)5$AO4GB?%-FDT"6%TP+H7L!.OB(;$2WN0W8&D]DR+`8ODARAY#%N M:W'Q=!3LC8)=+3.:D7B;DZ$\&.2;4GFZWSR)BD2B9^4;DK=;A>!PT]2GV;Z8+L<6,' MDO7CZ7D]PLL_4$L#!!0````(`+R!;4?"13/<$@(``-H&```9````>&PO=V]R M:W-H965TO7DP'B'I5KR(Q`#)[@VI(X"%`0)Z'#;^V5A:J^\+-A)TK8GK]P3 MIZ[#_,\+H6S<^M"_%-[:8R-U`90%F'EUVY%>M*SW.#EL_6>XJ2#2$(/XV9)1 M7,T];7['V+M>?*^W?J`]$$KV4DM@-9Q)12C52FKGWY/HOSTU\7I^4?]JVE7V M=UB0BM%?;2T;Y3;PO9H<$G*-S9^(U,/L1;<,RK,K[<_"SR-WYI&O MYV$AP9T@+`)&2;YN`P;.'$Q9=?*``'0F`>'C44#DS`*B]8]EPCC3F#Z3_R#6 M![@ZA09$#\P/[:]\'9,J@/-G#L'QB11$L&3"K91%\V\H.0@]335B=NCURXD M&RXWR7R=E7\!4$L#!!0````(`+R!;4=8@%ACZ0$``$P%```9````>&PO=V]R M:W-H965T5HERT MUUX8#HJ-J6V6].WKTY)="2V]P0?^^;\9S+B8&?\0'8!$GY0,XN!U4HY[WQ=5 M!Q2+!S;"H-XTC%,LU9*WOA@YX-H$4>*'09#Z%/>#5Q9F[XV7!9LDZ0=XXTA, ME&+^]PB$S0=OYUTVWONVDWK#+PM_B:M["H/HV8`X-`?O:;<_YEIA!+]ZF,75 M'.G<3XQ]Z,6/^N`%.@4@4$GM@-5PAF<@1!LI\!_G^874@=?SB_NKJ59E?$" MGAGYW=>R4\D&'JJAP1.1[VS^#JZ$1!M6C`CS1-4D)*.7$`]1_&G'?C#C;-_D M@0M;#PA=0+@$A#9Q"S)IOF")RX*S&8D1Z[/;[96<:Q/EC%1N0I5M/+DIO"S. M912%A7_61C<:&WBTFMVB$7[*B+TUL)#AXBV#:);@\CF&#F#>-L@OC6(K4'L M#)+;(@>CR6R65A-L(Y)51.(0Z1HBL0BKR<+_^A3I*B9UF.P.QFK2.(OB<)N3 MK7(RQ\GO<*SF6[9[3+-D&Y2O@G('>KQS-/GJT?A7OSL%WIJN%JABTR#MW[[L M+A?'4VC:Y4M>%B-NX2?F;3\(=&)2-9WIC88Q"0H>/*AJ.W6U+0L"C=333'\& MV^UV(=EXN;N6"[3\!U!+`P04````"`"\@6U']?B'O:\"```M"P``&0```'AL M+W=O&X#=:YKWOYY$)6\+$,<]@]^E(>CM@^B8A%=>;NR%HTJ91.T8K\, MO^#[)YQ92(?X68J+^G`?V.)?I'RU@V^[98AL#:(26VTEN+F\B96H*JMDG'^# MZ#]/2_QXWZMONNF:\E^X$BM9_2IW^FBJ16&P$WM^KO0/>?DJ8`[,"FYEI;K_ M8'M66M8])0QJ_NZN9=-=+^Y-AH#F)Q`@D"L!TU%"#(1X+H$"@K-`-AG28!X`,&ND,@T MQ-L5YUDRH^[,6W<&=8_LA;7#X&F+W&N13V^W=?ZYN6#D=>H>V]EX-UP* M88`FEB&%0$#>=1BN"?MK@L\]S8>7\@E`\>SY$[]7'PVC7N237OX0P2XA8N8- M9PIA""`RIW_^#,$4?/#PG#8`FI$?V!\@F$U'U09`,SX$G/A=$M@+Z5C/>E`V MP\^L/I]81<_`502P,$%`````@` MO(%M1S]O/6@N!```,1<``!D```!X;"]W;W)K&UL ME9A=E>K70FFIZ+\4>V-J;U?>7:H;B;[NCY>^W[UM#=Y4ET51W-H?MD5 M99[4S67Y[%?'TB3;SBC/?!X$H9\GZ6$RFW;WOI:S:?%29^G!?"V]ZB7/D_+W MK\&=3?[#;IKDY5&EQ\$JSNYE\9M<;V2$=\7]J3M6; M[UXK_K$H?K07]]N;2=!J,)EYJEL72?/Q:N8FRUI/S<@_P>G?,5O#M]][[\LN MW$;^8U*9>9%]3[?UOE$;3+RMV24O6?VM.*T,Q*!:AT]%5G7_O:>7JB[RWF3B MYNL^3_24*P`PWX&#`!P/.G`8"#`350(*!_&N@G08*#-1@(-P&(1B$ M5$D:##35(`*#B"HI!H.8.D*;?-Q++]) M))Y-_CZ;PF:3@P=&\"#>>Y#6@^@\<,'?ZSQTC+:Q6(9IR<)0CW,;RU&BD:@6 M:<>1#!M#62V6$4'[-XYM)%F*0J4HF%C'M-Q:1H]*L=A2_2/E`W%OB4]2ND)Z ML%0HM9"H*H@<?8A&'T+T8ESTG668.I<)G!M7I%%%&A1)QP191C/)*>40 MH>-$,`[:^BRS`(:CK<\R*P*S_LB,JXU1M;$M7JT('EB`=I#N-K6%,(;*8'TC M"\>SLP"(PP5N(15K1BIOA_8;U#2>B^-!X$O0E2<"KGT64H`%2Q(;& M\-IE,8P5$WQPO'CY)<7+\>+E4+SRD2>ROBNAIZGVE4,W:_!0=L5)$C/<`$;I" MA@,D0*1A\&(5?;%2MEP1X>%&EX2+;_TB/O_0O1Z@,YWL`<"(NAE*O%9EX#J` M0B$"),ACX:4F"6>.I22<.1X0R*KQW[P=.R;/YK^D?$X/E?=8U'61=Z_#=D51 MF\9)<-6LL+U)ML-%9G9U^U6W2\^^T;47=7'L7U`/;\EG?P!02P,$%`````@` MO(%M1\BZ=(:G`@``E0D``!D```!X;"]W;W)K&UL ME9;;;ILP',9?!?$``Y\P1`2I.4S;Q:2J%]NUFS@)*N`,.TWW]O,IM.D2=KT44]W\WC!S!;`V002_RL^5E^>(],\<]"O)C&]^T\ M3DT-O.$;92R8?KSR)6\:XZ1'_NU-W\O=KJZ_&I)G+]Q/P=B##>BD?8WVIRD$NU%$DW//NK//L_N'%EX6%D`O M@(-@&"O?T65?E:(9J7R:LQNF*@91:.H?`VLG((&(A$%Q"L`L:A$:"5 MCPRP=`1%(S7<-5G_8W*S3'1=)G)A(1]6<=\`7QM@9X"=09Y>%]E9AKHL'`,S M0/`(MO08+BB]3:T8H)O3\W$IP;<1;XOCX+AIM-#Y<&"Z!C MX3KAPC&DR/+\-K5T%"!P!%IY*`,Y*&YC:U]5D4Y8=7EP7KD+EMS7%\%@B^G! M@C18@>V^%ZV'`,D@RD;"]1R$.!NQ6WD,8P2SX`KW^7J.XA3!"1,$X0GZ;3"? ML(,!&$P9P/^(&86K0!.V!P]ADH%@RGY[\%B1!]>FWQT\1#(*,!G9'3P'"?P< MGO8PVXM0IMXL.O<.-X@&:,^M3_P+,EB#0OS(W$'O&O=M7Y9'M M^0_6[^M.1L]"Z9/2'F@[(137!:=?=,X'?4<:&@W?*?-*S0=PMP;74.)XN00- M-['J+U!+`P04````"`"\@6U'`HL>O?4$``#)&P``&0```'AL+W=O>SX=GW M>CZKWMMRLRN^UY/F?;O-ZW^NB[(Z7$W9U#_XL7E;M_V#9#Y+CG:KS;;8-9MJ M-ZF+UZOI%W;YI%0/&1`_-\6A.7D_Z8-_KJI?_8>'U=4T[6,HRN*E[5WDW5,LJO*OS:I==]&FT\FJ>,W?R_9' M=;@O8`Q#A"]5V0S_)R_O35MMO MBF,^^Y@+PV?)1^_I$X8/F&N'X5R',0N/,6',C><287`8'0EX>9;H\;R3;^!$I&',$V#^##KILHRGFG].M7OXA;MITY;@ M07SV()T'`1.??0YS-V"TFWB'X1E3,@W#'@`FK=9AU-*A&-.<"Q;&/3J<2:72 MA,%)='#2<4F41[EX'$:D_5\8]NA@*2$4A8:B8)[1J7$<"X>1G*N40I2A1!D0 MF?#<+K(C$8%&HS0:EK>*C,=AF&:?)S=,95`J`U21);IP&,;)5!:ELC!Y-K*` M+12MD:F-K1A+7C$L18,9'G?16)(/A@H$8R,4@G$\#E`9&RFC&P`Q)C*120H9 MKD<,!,ERB@^)#UJ.&31>KPP*UHK(`O<@KHDER_":95"T5F)D!L@<*+O(*$1X MU3(-1.@^*X'(@TA$>,TR`SXHXLTLGD8[(HTQK8`$`\`T<6#,YP,BLT: MBH_`CCYF2^=X#7%?0ZB,N;5[!R`FE(KN?,L`,!(5OAES5Y4R1G8'(,6-B8GK M$L=%8L*KG,.6F[)P/2R/((HD<;S".6RY:41.[@$DNI9'*]*H\"KG&L@H.LP- MO@[-F'6([Z;<;Z>QYA)`9[M+CSO37@+L?'\)0&J#*7!]$2E,=:0/6@*(95EZ MV@!&R'!]$0S(T/DT0`:'B@L:$[[E"PY,Z%1[)I"J"T;9*$3@_"&`">U7014` MQ*PT7?YC,XT#(U'A6B6\5I%\*+2"A!IS.,-E0X!LL(@6W@*(B323%-40N&H( M4`T6:?.^`HC.A;<'P@`715(%WAZ(,>V!Q,M70OFRB"S?`4AHEG5[8.PH200^ M>:!0EB+1$I<#"96N*:H54&$#>*V&/)P)$>*I.A M\PL-'8`HLB3QQD#ZSCYR$EP`B%MJWRCQ*I<9)!+5=3^!#J2%ED;Q,/`^`(Q$ MA>N!],>`2&U\`U!_97&B&Q$N7`^D/^-'LVK&WB=(O"^1EG"C`*`15PH*UQCE M-8:R'!5^C%=CCO$*W],5/W^Y<0V@H4AI@\8U07E-H#0A"C_&JS''>!6X=J,< MXP'$NG+Y7]N=G%S![_.WXBFOWS:[9O)[<7ZNJ+3H_Z47G;UWDJ^.' MLGAM^[>Z)W*_-+D/;;7W/YP=?[V;_PM02P,$%`````@`O(%M1\V1H$W-`0`` M1P0``!D```!X;"]W;W)K&ULA539;J,P%/T5BP^H MP9#2B0A20C6:>1BIZL/,LP.71?7"V"9T_GZ\$))4J?J"KZ_/.7>S*6:IWG0/ M8-`[9T+OHMZ8<8NQKGO@5#_($80]::7BU-BMZK`>%=#&DSC#)(X?,:>#B,K" M^UY46>A!"J2@W47[ M9%ME#N$!OP>8]96-7.Y'*=_SBV*7`C"HC5.@=CE!!8PY(1OX[Z)Y">F( MU_99_;NOUF9_I!HJR?X,C>EMLG&$&FCIQ,RKG'_`4L+&"=:2:?]%]:2-Y&=* MA#A]#^L@_#J'D\W30KM/(`N!K(0USGU"NA#2"\&W#H?,?%W/U-"R4')&>J1N MV,G6PI43LH`J(//TZ0GH;(3CWZ5+$MZ\%LEN!+`AD08#$MTD*C\E#&0LFR^,X_QQ6 M!5AJ._I(/J2#KP;$077^XFI4RTF8T+S5N[Z-/7$#_N`_V#<3KOA%IBQ&VL$O MJKI!:'24QEX?/^562@,VL_AA$Z'>ONIUPZ`USLRMK<)%#QLCQ_.S7?\=Y7]0 M2P,$%`````@`O(%M1VN,2L.+`@```0D``!D```!X;"]W;W)K&ULC5;)*NV.ZD[HK*(>MZZ:F@K*M8&G&ZFX1.8+$&L(0;QJZ(GJ-?>3?9/'CN8G M0$>`/:'W\1.0(Z!["8DC)&=",DI('2&]EY`Y0G9O).P(^,8ALE_7C,T+D:0L M.#L%8D_TC`43!>=:1"D':D"$&FNCR$9EW1LE(+5\:+?\S&BP779>+ M[,`@ER+]6B"Y%DBL0.($LNN0K<%8XLQBU!X5Q\.HA0\U&";UADE=&#QL\VPQ M,+W/)_/Z9,XG]_FDMFB+P4F>#(=YL2"(PK`KS&OC"K,8B'$^,IISBP(80C@VZ$XLSE$R`ELZ-8#0)6ZPN-Q;7&Z+ M0W<(/'H7R^/]BP7$W@BF>W#FN.7B0""-4WR;-;K8?1O*M^9D%<&*'5IIUWC? MVY_>3U#OWC?],S"9`T__0I_V9K<_RY?%GFSI3\*W52N"=R;5F6&V]@UCDJK( M\8.:&SOU/](W:KJ1^A'K26-/:-N0;-_]4_4$L#!!0````(`+R!;4=4 MDP#_[%,``,L]`0`4````>&PO7"P)@'1@0EL9)!ADF&,F7T@[]B@`$\ MOS"O\]Z?XB^9L]Z%O`R%5.6>&LS`**\_DY3%DE./2'W@^NTBHK$;:KZ")I M.M\JJ/[YG_XI!(\S&&-%X[S.D]OVTYLDKSLCGF^KBC[(ZB5LZ;^D2=4[^]'1 M:'PT&?5`Y766IU5T#M_=EE4')-?K),?G'])-6359<1N=E^M-4G1>_%@E*WQ\ M_;!>E'G@:-[UG4JY7L/Q7S?E\E,<71,B1N^W3=TD!8[8"W/9NH#^-?RY@\!_ MF#SV-0$N^.UY"6A2U.D*5EC499ZM`$2KZ+LD3XIE"@N%VU;#U?GA^B(Z>''8 MF2A=PI&/Z`),^TXOJ6L8I/,TJ>\BV'RTQ!_2/V^S^R2'USLOGBV72"[JJ$J7 M*;RTR-,X*M*F_=YE<0^?P^D&GUY5Z2;)5E'Z98/[K6GJLKF#4U_N7.?'L@$( M[G[GJ@)Z5<$QXZ"XE0U"/[B.B_0FA:%6T>75^RBKZRW!>5G6W5$O"T".VPSV M*],&!_R^+%>?L[R+C+2WHBSVV5[/$98LLCQKLB[Q-(>S21[P9`+/JRWL M=@GW">#.1!"AM$B+]"8+GC9]L&-.`\(JA1/?=NG0'5SBHR:MUK#])NU=FVX/ M2/.VHIFB\B;*R^*6/UXFFPR!DZ=)G4;E(L]N:?V=!3D3+DO`0B`A>&@T.9T9 MCKN"JTB@VHU@._;]#L;KV\N;QU?M8+R#%3OFXX7M>`&)6M8@JO/@L'DDGFFQ M1%@>T'I'PS;10([_LMXDR_1?OP*67J?5??K5;Z/VX!_250JB``+2!2I\(:=? M(RWM'`7^\:[,5VE5?TU7$6[EP0I0;9DU'?(E5+EFJOQB,!P!?*L("-$V_19H MVC`>\G\B.D3)MH&SSOZ2KKZ-1N-X-CF-Y\,I;7YZ.HE'\Q-]$Z\V+))@;LE\ ME#01L$E@_PLX!I4]29=-=I_F'4YTMEIE>*QP0DC7CK)" M3SYPH[;K;4YT70@>7,8JO8/["$,#PM>A6VB^$>"%L:-^$KP[&(5[-,?<.EJ" MRM/&OP8N";`_0V9F,,9!I"LSPW4(>?9CA@=7"=Z]C-''[L,8D4' M<%:K,L^3"D@3'`=AS"-?=_!OK]<9"?=ZM>R71:[\P)WK1YS) MWAI)1^;Z$&:)(*"LMLLFJD'$ZESV-\FBA`6#Y!0A,4F29&<6 M$)Y0QZ/EK-9900HC,HH.LM!V\+UU4GU*FY"JL6N#`04(I+@EO=NW"X9H^>AN M+3Q"+(BO358`LTKQ/&B,#KQ!1H:;"KC`+_8^EN\[:'0'$G8*'TPHZP`*&^MN$/,M&?S>RV>J,`BO2FK5-]MDB]=0,'MO<]J M!#F\NO/-=R!KAH#9(G<@C-YG0,A6O0-$R7V2Y<0TFQ(%!L,QA!GW?KAA`8/> M1S(,9&Z1U-F2<3K+MT@P]^,;/Z;9[1V^G@`S3^"_# M6MGJIVTM@CD<'UQO$/@S5$GTE."O^#/IWEM<)8`L-/++7N4+\`_I'"-F5U4I M:.CLD?M'AI`C.,&6BMBKVX-"`\!,ZV60.]-MKEM[(=66\,,3/$4M2V]NTB6? M1K($$:`FJ;JS[8`1HG>-G6]S)0AA-;M71^:/=FF$^QSA8PB5P;KK?;XA^%0\ MT6);9T4*B`2+7@"%#!W:U19865*S6KT)FDAZ-T28!<)/M`!Q7W9WN/]2G>T) M_=[Y#1#899JN%"!JE8%E+SU967!FM]FF?[!-6^C\F>-UC`T$W,])A<;C^A=8 M;KF&W_'6^::,IPR8?DFK95;3@,Q[RHV5C76MCRRJ@%-#17>[R('4EW!E*SC0 MGO60/HPX&C)"7R4/0GV!`:6+KIG0>;ZW_2>(M?O@W2M+?$#@9%D$[F\JT]=W MH9E`^UU6N"2\#_Q3E/'K>]E3>PVO:)Q8I+=94>"J$0'(Z/RD[U,D6WU?7F\W MFYRX'T`5[6'`BK85H[+>6MB*\98$9Z;376T1`2*@CS*52$;,;9XP;V$8E:$L ML(/0V058@F$7=(!*TP!-F>X!C[RKRNWMG8])03.:TABU&^U)8B\`A<78@6PX M5L,'VI>-M!I'9VMD7AV&=?4^^M-;,CIU?%'&DM(RF?1^\+ZZ38H>I<%]%COR MD/*Y*[0"PN$H*%\;D=L1E_YTMD`E9]FTI^ZQ)[+U$>0J=W;0S4%WB@$XRT%T M\/>__HU^__M?_\?$Y+.T1HX&D3OB^CWV_PA0O,< MTI>81R3>G:<-G3G(J:B-P4U:NC)%=("/8,ZW:76;5C0I;/9L=9\4%U]D30B. M#';[&<1LF*;\7""WV"[J;)4E0(CE[>CLF^OH8`GOJ'TPQI'E*0U]4*(WCU?9*AF%PT!Q6$1M,V`"E6V8;JU$3 M[]SU+7WZ8PE_+/"/->CK=R!"-4T]<%<4)7D-FX"5.P-G>-8@A=Z!N@5?7Z0% MV@T$6D"<8.PH3:K\X0@TL-N4\!['0EIU"[QK`\1Y#0+Z<@NZ'6"9I:F+K#2D M?5DS_/)-=+L%A@DO@!23E?`$P0C#L)P(+\'R,]`?`')Y<[?$?0N3K6K13!?` M=M;;O,F.5M7V%HWF&6J':!)`[HK;BB/`Q[<7'][7`P=/@!JOK#V*0`K__F&; M+3^]OKS^W7_\3R9.[\[P-_-B#/B5H8D&WD\0599,*X!+5&7GQ%MG!MCX$ZR) M5@YD.H'OJJS^Q,+0MI"_(;OAH^*'@`#Y=I4*>)MT>5>4>7G[$+'(`$M"W"M2 M1LMU4N#)W%;EY^;.?U2E-.6G]`'99ET619K[;\`N&UP@LE)"^RW*7:[L[HV7 MH&276%>$,CK+0(%X,*U)ELMTTZA%H;%P&G2`5F_A7:`:JW2#-HH8P;N!6Q/C M:'A&K!`]X$!B)1/_TWJ-TF:29W])Y?*4<']@UW#]';@!SG^&[>&_?5L8=(PU M9"#.!`H,9"277\,L<.NZ5E7'H/Q=`C@9O0=BSVHD`D;963]CZYV2@!2:=!DPX"SXN/`A2Y=^X6UAM66-=\E]RE(CBE9SN&@T-$$G#VZA1M_ M>X2VA[0JR$YC;@^Z"E-@F23L(C*`')LKDT:V9+5V5(CK&[$YHH/6ZL.(&(2/ M2%;0B`MI;8@`\/EW%46^V:+HG''1(`.`BD-,,^(A*AND7N!T%&1=1``4R MYJ!OQ^;1F(*1=>0O#"6O5>F(A&3#*R^@__E?T(AH.3N"_"?PWYC^,!C/Y M83P8\4_'@R'*-V^3A^BD3[K!#:'9-X?QRI<#J:QS/XZSR>S*?PXAA8,`M7/'73W3"O<12/)L?QY'@:S>"WZ6`* M?X(?VE1$/=R>*6B[W@A'D%4+:6U=A079K(!Y`;" M?07'`9\T=\"5=`6D80#RWI'*FP'A62`KN$$G9LHPQ.-S,47Q`T9!I:%A:8J5 M*_SQ)JO@CR)+X!\!9L<#A""]>$_#.@`$\K,ME/@*?;W9HIC42\,9EX[]@Z#5 M%V7#=][9P]*:7=C4IH0&-TMQ*,-J0`2S0CQ&"1?-NELD M'EFUW*Z1R2^%>ICEE=L<8TO8E@8,3-@><&[@B+U>$S\J:`52/TIZ85\,\A3D MX;5SR5@1%;6/+!T$%+R;CEY(UP)54;(_(AO(\=:@4"4'4RZ(/SM@-=2`1!BZ M=:G8!1TE(R$C$E+[C2Q423^(!Z(W: MRN(0ROIK^%N7-]`57*,'`1&B2!'E40ZH[PA)7+2!Y_9V*`M`=$N_`(Z@J;DC M#EQOUVL<#0_;(<.)9?`;8)K+_I`I?.5*7GF>A5@`%6`]74\8LW;^\*PA`](#0#ZABT]D@S0_DA&VZLRLTMMM+M1#*.(/ M168<+'5T#1J(Q'3A^Z_4ND8A2S7;2@"CKE^=Q]9TE*T];Y^Q0[7($,SVT,%Z M((NX"NT+7,<.D4848B`.-C&4%##P`-&I*8D M(W4"GQ`/[K-R6^=H1X%8SUK')F$EB<(6XS]3=OGOH4$`4`7!!Y/0F8=1?NMWKIA0#4$+WK"=T MC>7W&G1P>JOTXU\LY"*7"0& M""B#B["&_%]HB'[+K`-8:+D$4)IEH\`$P*&0:D1@7D\7?Q<2,$:Y"A9)V%Y$ MAD:*+T#L1#WBL;L4@]#$RVE3'&O+KAUAI$MOD'KL23S\2[OKFKEV,K@N>;E4 MLVG`@L0&CEK$M8L$9*^[Z-^JLL#89KP1`=>[J'RW(!*)4$G*5QS9X)SV,S(0 MX$K5+B5'@6(10)^,2RFNMBB-=([OLQ".-K(\91E3Y0RYG!@<4*D=_[]KW][@>9# M.##XD>,D\'=Z2ZTG/K_CET@!8)*&T.FA67B&R*50!"/*RLS%$AT$D$$?LBA] M2HTV)*3=JE)\6Q)R9+[RA'BUGD,81-[W?\4PKT,`N!XEBJ3#<(^)J->/I>@F MQ4AY]N>[OF=TI,88)VPC0W:<-RD$\)I=DME9+,K6CH`T/BT!*)$4A$%.JH]& M[^=$6S5GPN*`IWR$7D9!CRR>R@B6)`BM,C1L*+%&/X8Y4?@B;V>'='>-7@30 MM#*"P8I[-:0?F'A2DVT#-@.$Q4O MW4VZ(GO`+:)%P2KZ+;&?@]<7E^?H7D>*M.+[27M[$8W%H-6V-B7=`"'!(L8; M0VU`;D"_E-Y]\2ZI++`$>:T$)1Q`Q_-(Y&(Y@Y`M'0G[4MBLU8 M'ON0?$83XW@XG42CTTD\.3Z).`#T!5HI9[-X>G(" M/T^.3V%H-'`R=^18H`V<:UI@LBGH`(F?3 M6K\R$QD"[^^6.7.;KN3=7PR.H[.-%S(#$*7HT:G$I_(=F/4 MN)QH'B(>0X;AB/0H"&;9,9SFM\K[10/H-TI:W/I:L>X;&1CA9%Y'J9(DXW:6R]: M@U=IY0WASX>G(T_PM%%I`>(7SV?#*)SMR$+C?99^%KS(`"6RBAZ!\%T`_:O8 M,$U<86EC-7USKF]";UQ6QL(;GZM8!U4K6CC\/4\'T8<.LQ?>S(SH+LU7JI*L M<.7K-&%:#P>>L%>[RFJFK8^M@A"(M90,`0+"&8??,JHQSCG3:BP+&\+S.TQAA2&'-XH MPZ-#8.7)F$_SEWYLO@$6K/#"WH1GVA1$J7J&TD(2`G$AQQ`=[P1I(\+`)#& MM?)U`;`8)*!ALTE-=$'WP+$OQNU(80XDG-]@O&,J@FG6&13?OY6D7X#`8Z\_ M^H)A1%6R2E%7KV/U=Z1>M`$M5)BTF/5AV7?91O@$142PJ(YT\I[I"QQ=6T@? M#:,Y_$\SE^T/ALO7$CU$#%C@9?PKFPIX"C,],4'H7`ZFF,\,^,V^V=P;@"HI MM:DGNP_LX@"I4;-9H3.)]9ZL$.4=+A1:W7\";*R!>HG'Y`Q&51FP=>:>;]/> M%#U6N@=6,P#Y!VCOZ;@M>+(W#B4\9%UX@^T5Q-`;',8.25*C6#.-A1/3U99- MB5=C1-%9"=Q,M&WQD=*7%">DL^"X@#,WAI23A0P)ND?%Q=Q.EXB<.!Z]U#'\A-[V8Q2I"V;N*,MRY&3!"K49M91FYV@M./#PY@IQM($<5(< MG'607P&/-P:@RZOWL4]$/1+9NS$)=*3`8T M!=1DM@6'Y6I:4527_?R;G;1PD$DN0@K0G0WK*/R&8]ZI):`25PXZ,=">VCG> M`6H>@W;(`U233@A$*/,F1=(M!B*PII[ MB.*-6`G1DD%6(="'4=\@HKA.FY<4<+5-*%\H)2@M4Y4BK`^6'8[UM^B#ACU^0WE;6^`B0^5;X"FF7*DT07TY`K($WB,UO M6=L#<&=KC2-3T.`\/3MF9W1:H141S_JFH2A9QTL>BX!)@7F;/#U*I&0R5B61Q1N,.98(Y,_:XHH''KRE:I*\N;40R6 MUG`D&*',B$%JH?[)7D2RF+'CJ"CE6W(=*T&F@-3'0L=8DA7ESR?>9CO.]$IP M[?W22QT"H8_ZA.]L,^S%\V_-[5#C32\*/'GL/IJ@I+6!<*S!42Y/[&QU0A"NE(1\E.=Y!DJD/S;#^VA#6 MNX9FYZQ#'F@S=%7M1,X\,=NZC)BP>W?&@&S,19>F](!*2LFWJRO09J3]OS:1M@<)=,ZCK"5L56EJ* M.H=JJZ<!S7=M#Y1XUA7VU#=SD3D&SN-!3Q, M,#GT-I#>`.R(H&?%?9G?,ZK)$ORY6?$YF!ZZ1L?.`I/-)L7B$V:!*3X?$[(+@(')+(VPT*SFI4D_4 M;1Q#B83H>K;2.C0(;`X#K,N'5`.>,Q@32%TM_A1V%,3JZM`HBUND\[&D>N&# M[_)D^>GH>HD.E3I:E\"-C!,!"0F&H-CE^'AA>$1Y'Q$!V^+6YA(?9=D MX0>:L"M,12#(V>4##"GBD#E0;(],;B]<]U7-&\$-2M0'W39CN+3[P_`]C!\^ MRC,RIC=5MB!/,]Z4NW+E'Y)7OD%'=G8,DW@>),]:H\Q0L^1E3%FP>J40J&(0 M=!DE;J^;$HVI;C2F=133$74"UP/'&*LO6.[J9DLH*@$!DL6&%]-+J2#J9/TZ M8J@W<4+D:T%'@_IBD2K8L"$ZE:.5QB5:^*")!.&@P:WNF*X7%2_9T0UZ`2K! M6$T(CRVXU$05/61IOG(>`%D!()FX=$]JS[,;ZWK@I5PZ57C8\KU41PR2>>M> MDRAV)R3DP:#/Q3XA,_Z5=S)K)6R`74\X@M$@B7L*NAIA`^X\2#0@SW`X"[^U M2)O/*+8$`I?:=CLI4R#AIKL#NHBK:_%"6AM)K?OOV/CC^#92TK!\Q0427/P' M8IZS")Q\$5).AR,X^$"4WHD-06MN&!PX=4L$%;G7L$@E@;!?O",*$#@KOS"`Z"T54M3WD)&IXDIPTH[X*%LRU4WB],K$/3=,70.AHO2'_A=!N"9*VJ5TUYO%H0$+Z)3$1H6)N)^AR M]4/V,EVC1$B+E\%:ZXTE^&(A)B+\B[DCXF#-D^H6.8$C\]C]&QYR"R?6L#)5 M1+-A*P)K9:*BJ+:*5Z&-K+[OWK^)F3(`N)D[45S4_#@>8YS&\)2R79>V&!A7 M`:.8BO5F*QYO(L,4K+RSX!A^*@7'%'2?VT7!BBVAC$H[=;MLCU;XF,8WP53[+MWN6Y/W?U1_^Z= MW6[R+:,&.@:7;"',,:J_$2NC+M^;LHY5)11E3-PA';@ZA7SX+\9%JW5]'&&J MJ0A='^159H'&^]WGH^L\)Z>9'36[.;+>,F6K@1-E_-4S"N!FDB^EWJT8XIBC M+$*XK+&97<@:>%H0>Y#E"@H.WC#9M(?H/0P=![QSD!T&#R*&)_`(!1Y0H!L# M0E;!#SB?-7ZQ402P5^4QE;+/$1AIE<<9$%&.D'%SW("!>C_%9CAV+0FD1 MT9IT4[^,0/4W04#BS:87@1D[3WJ](Z"T&Z.[W'F;QD%&G3@"O5S-17VO("+- M#BV'5H#)78$-U')6D42-4(@%IFL6=UR/PTV,J=+;I#*G4"22O$%,,D;]4-TT MMO[&@Y,?$&$@&*FR%)]K38!X.DZX[D=2&&5=*'41N\CNTV"0I,TMH$PX6W;K M]TFQ1,+C^!_._=#JS,VPULAA):%$P6(R M$A64WD@F&K3Z`*C=3-*J+$H$$L<_(>C9&\)&MW!*$5R^L^TM@,F]?W"M.K>* M,1;G<1)1T%3!JTW9#LZ)GY4$L`!O)F.,A*ZK+:LT@8:T/CQ`XN$4>X^Q!YSS M;@Q,R`@QFR)*%NJ+Y#O#D=VVV(A)#4YJ+6\127F+UOT;'6J=&GQ38KH\.1A# M^?_^U[]U%A%CI@]<-P0<7(C<":5VX>:<2P"$M%<)\/<"-QQ?4N+*P%8W71"E MDE!K,57X"6VT>;89L?;`&S,4NAO39Y=CYC%,C7$)[A(]-R$G:DBR))(JECCA MD!X]#NW5"&IT$U5%Z;^C[7R?VKF67.7)1)K@B>"Y_(IN6:MRQF.XPDG/$I2- MR6EJK]`W8H=U2$*P0-]),I)<`#*6+4%;X,-&+4/G<4)0*Y8@:[:&H%0F15]0 M%I"T%PSYVS2B=IEIW`!=EOW>7+Y^KR4!J*I1[KRN`!@->AU22[)2,CR$-4DN1P. M3\MO.&>''J5DG8JG8FWL3UI:6C=K((V)>JBB+G/A%X#++--:^ZI(&(8*M<.+ M_3P\!S]^Z9MS+,FFVA-*#(99W<)_FXJ>4-X!A;;8KABQ."-APQGR`7Q'JD$8 M%ODKNJ/6P+'_1>70`-C7C8G4TW=NJ&"'/4$Q%?G5-XPE'NESJ*9DW7O[)72V M,H8--RG4BF>)7VW:V'S0;:A9M-8AZ&C@@;5G&L?D(Y2?V>5.Z$=Z["4%"WLS M@6>HVHH)*%F:>R:*N9.Y7^GU,%2",ZU%00K:CUJV?<>.9LJ<9)KWW!S)9HT) M88')=^B!PU`/&TOK*$CN*(Z"T;Z.V4T+<&3J,2/8R"DW:%JL6FQ=_`>QSO^7 M"(!O::N-9+MBYRS3==LV:%N0Q)^NPEKJ#YN5R<9>I#EZ$B7/0O4$/LO:GEO= M*M^4&$^,,6/P^H,U%.)`70C2DFWB2:=*SG=*;\[[:]B&WGEF19PIUK@+C1>H MV^IH9*WJK1RD3YE`2Q6H1\.A+?+H%E/%`#NMG,IY="`J(^!D%+_HJWT7:[3V M5UK]!>JA)KUU4/U#X[]&J:>UXW,_'Y99@TD6SP( MK23PH&/8)(`4P2P;D[73]DY)D@@+MEGE2))>]DD1)*2Q4\W(Y.9M"QM!T\IR M<8IA.4D_+4<_5L&Z+9@M*Z=5`UO?MK@*B8F0W$I],&./QNP3#%4A21$S@Z(B M60NYV9D$)!*^][W)(6HOG?FWYQ9WK21^S0G,]5ND-@V2-[-#`WVG%4= MY=;#P;=^$DLM.PK3:AJ2H&VE)DTL,%;X03M<+*7D*323;=+5T79#:[9>;IOB MM<4&7RWE0[@WD) MUZ?'(WK#7Y;Q-XY/1_%\VEYUB%9,XLGX-![.3KP#0!0+93)H_X(V_>"42&%2 M(:JC%-C(6?ICX_CV81_/IW- MXI/3:62:&;V(#D:8]3^)1\/30_H5SAS.[_1T3K].XV-`Z).1_C8;S>/9='08 M>?V0V&T$+XP'8QUF,!_33P#!$_YX,(5G;>D(N"=BVX#+[>W,!TC MR4+:?<413_HK#>\_Q,?T2Q-]!]SJTU,$LQD*9H&M!.0R$EULU0I1KD*)DRE% M]XAPE$1[[T%%LNXC;@2`#-JL-0Z4NK4;L:T>;%%:*DB+E6E/VF5I;3ASRU(9 M2/>4,B-,HJ:4^MD^-(?N.)ITI]XDO?9'>NW"<8L\2\`^!B[3,ZU?1T8J5%^%[A9(90TN*2_1W_>EDS3,BY1P'U!4FFJ5W]K MAQS[0\HXK-R10/+(4*QS4AP2U?870SO*\1751M#?S%HYX-4L8.(O8%MT=V6, M*4#J&_;+%J4L`*741-(08T=HL;X%SY:BY=AM,3UAI.0N&ZNL][9'VK)Q,8W''-E_I+41V8/D(JWJXRZ^ M]DSAU/&_Z;D.P>D(8JZ'E*X]X`+J.%R6`8T\;.DJ]1J1X6_-H>/=HF0?[S(K MRFN#3K%[N>12"[DYT9L_;5>W8D8S9BQ;1G8I1F#OFNE$K>!>B92II'J>?`0G MZ;H(S)4>N$0DW!)9+ZC>*D7N_NY#P,"!")^`1#H^;?]R1/_YDW;K-CYGSOGT M%)D^_03$>GI"@L3TF&=MQ\3I#+4M3VOC:YP\C-XR6&[L+G"[]$&O+==_QT^H MN.Q'C;9!LEU_ZR&"P<"V)\0Y3]6F`PMFLBUD[`"M5*R/'2I-HV])ZES:&U1Z MC>RZ=&]@D]NEQGQL6F3T!1>A.Y;C[`A,')Q)+-Y4JJ,4OJ15O;=3[HQEZK6$ M-.[5_-,W/-#7/KEA,.6"0GPA@C4A7/S`TOJD+V'*J"TBR6[5GBUN_-8^6<7F MEU@"7?N`1Y4&@#XIIR:2R]45_`BJ;A10$)FDIEI;&:D]>+HHH.S_[F%196XY M0';?J;_>M0@A(UBHH]H$`CK\!2#B?R]6AHYA@:M(.%A-C(N+*%1D1#?55$K*YX">AV\BH.V(9,09=LZ)6Y\ZSXE/I5]:C^ M'9J"A8&&+").^0M-Q),&>W+[/&-*N*OUHR4B#@D7-(>5^!0;J`0?[?38<[(@ M"8)\CUJM<`D:-(`174L2J@<\2@Y:(__"DHG$>^W:-R.@OV^;6U7:I(?4">^7 M.!]8H#G8[HFJQ-+;<)#R>"C%P'0VK8Q]2FX:+<=F$PQ,_WC``^='PWY>.>'9 MMA_Q!_=F6OYXD=;+*N,M&KXE73\B1]*'\WO%(#,<]<)>0R$"3M0'L\@YJL@3 M5)&G\W@R':-:.A^=QL?SV2%ST,<$(Z?,95OT*LKB:)?XM2K3VO%-%`^/BV&[ M)+W`=`/@AL71HZ/NV,/3UE_L,]L3I-6?O_['SD`6PUI;H):J%3YZJF*%C>E. M+1VUGAW&^ZY/`[`?Q->;KDWR@:V]]:[DR^OFFSGUYY)VC@69R0*I"(;K[5&, M_-JTDR/JDY`RLZW=XC^M1*8]70NR/K9Y=#M//*W*47\K\&LN@O3.!!]?2[CQ M5:)D!%?(EMJ?;3J8HPGHB6OOJ^_T:ZC5]$BI)M_E3,L8F2)$(^J&9'^-I\-9 M/#P]=GZ:G4[CT^'4_&LK&-F?<`[-#WB,I:._G[Q.U!"%XS?0J4%7;KE=;R4' MVY1PHON9F%2Z$ZK1VIIQ_]D$3GQ)-:S=N-"$9Y-1G^O&!HV%0SE]\/B MJQSJE!7N+I:(-X;K/)-C8Q)-U!#+(W9H@D1>QAKEC%-Z85[3X%S<@&V$#=#L M\`&2`\._3A<517;CT&^I],".!FDX+$+K9#X3Z(UG0F\&4CW0I7M\\7"Q*Z>+ M00"Q?'>QQ$*CGK/F![X8JW(YE M7N3P89382&!`*F[/ZJDO%.A6D7-&^XR+>@M;!!V""$F?WGP@7#Y=<67"0XG` MV0$%/BI&+F^M7O6:I-::>*4-1O/\>AT4H;,!'6O#L1,Z;6827@1+O%`#D^B^ M<\TAGP3BUAQ8U'A$>!1,[W`*R;*82$:SP&#!Z-X!;..R(0#B$3 M?:V*#A'39U'@4VRDY0P)Y%$Q\&!%(`*L>M_JC!B.'^KOC^B^OW>CQ/'@U&^6 M.(T!+"TQHP^@&DOFEYTUV6`J,6%V\Q%>$`X,9))P**G0_I%,XO&(QAR2T8CN6; M]U:>^&"SX?@9QF?%&CI.W_!?=IX8,4S*"Z.0)U,O@]-)J'*!^FNPL`D7+?&S M),G)4ASA#6>EOI6[9QEF.X'/?;8MG*?J8` MR$``>[(3L"?/`.S)SP$LQOKT@'4W("E+OQ>4Y(#126)JA&P@P1DIP&,28^-= MW6=U64D64RL9IP4IVV?$ZV3L4!4FI_=:1H:HIY"N2[.Y%A#A%?S+M_ZOE("Z M3IT87%/X'F[L7=AGOMQ3&_JKTZ%'5-'CO&L MO6GBFN&=]]"&<+IOK%K2QNFE0]H8I4%+#137E>58,$.%@O;?T`_..1O<(!NR MB>8,I>RSW.DJ>%P?08N>F)`)+?DOG5RP7M4HGLQ8W`6%>7P2GV!XFU=PXGGE MX$WT)>@#QR"L3X?1&-3Q^1RY&'#"\604G0SCZ6S^>"B3&Y;44T$,V-YI?'S" M+D38AXG!96+D=:P=S8YA^F.0DN(IL.+K1%MCLC\-T74ZBX]'Q]'IR:FS_A>Z M@VXTUC/6.SK&L-Q3";":[%KP=#K!"A$1""[#R3BXX-GQ/!Y-9Q@B-QYS<)8` M^86"V2GXOT_]$/\XI>Y3]]J*10XF/#X>QI.3.0A>\'^3P0A-,J?3DW@\/74Y MGIM83^GEHI6U\(>8+SFF@E^Z,\.*C[&1M?Q[W2/3N6:E.W+:-Y1E$'[;F6`2 MST?'>$VBR22>G4Z->#U!N&)?CU!,6-98CZ?IRA9J:MM^^=Q]^6>;2$9#D-!W MK@`5W*'/2:X&+L\+ MEC,CZV2T8+$E%*)54$#L%V6N/J5_29"7'!)QD.IT# M48=[.`4J/G+6J">#QKS];T/M(8:$2G*$Z6>OD(?C0=1^2V6`'5ZQK;D>98B MA8"4K//=4/HH>>C3LTNX(Y0ZR5BI%UT@1,9%ZO7<%8OCW379[ M^[!(8(K0&P';I+5PRA=<"$S\P49N$;!]77L2S,`)%/6M(3(AYB)2EB[@A!8X M`-GO"&LCBO,+"W1P_($3JV#G7WC->P=HI+")=FRJF.P(FL4''^\R4+[.)--8 M-3N*5KA48'_=/6\*HOUJQQM?222M/3&;306;Q"["O&PW_I!"I8H#HA?:P?].^='+R_+E1K\^,W0/(*EP"S)9;E..K\ MMRC=)LU>"5SS3=^H!A2U%0[/_4'/BI6F7="@SB?/$P$P5O>7V17("M^G7+B8 M[A^7#OQ<1GEG>%>"4AJ#=Q4/R9ZU22JAY)P/Y4.2FT*&)N2[VYLNU*6!*1VQ M;HUSEE6MO#2J`(F9'Y\>1O,)2.]CN&:DB;73W8$.,=Q; M;,7)R`D>EY_Z;3H?<1T7\6%R!Q1;W==HL)PAS]I%N%:S6ZE3IQQ$UUFQ;-45 MYN-TBA+W='&R]9V\`HZMYJ1N<>/6%%KWV0_:3!H)=:PS$%8!C,Y7DE+/40F= M:A*=++:D`&2\J_=9Y1[@;,C(79PE>5(^MS[B;%X=#%%N/.MU*$'RN!V&]-'X:/=][* MG+H<6BZ=V^F\;(Y\Z- M-BO7-BWN-9:RQ"OW`SQZ]+7.YAT5\(.VDV$JZ8B0?6]>T9L?76'S>>0>\RCZ MI]^E=+?PD!J6/K11ZW6^S5;9[=I-;^:2;_)`&QCQE36OF_:G'C$B.0_V M(8Q6Q"\;54F6-"Q`\&M;U/LJUIDV:/G,)_%-9(87:LO#>R&)F'M<]#707F2K9;5+<"Q7FM+ M4UQOVLZB_KJVRSI_T2'T,HEY&B;;T6`O!VW-VZ91L M2"CHF2&"&"EAOJ`21P@ESH=VTHE*)^_)8D&J!1%0ZT&MQ4AO^AU,VZA@M?`YMF.YS,C99N9%A[ M>1K(UKY$1$`W*JH[J^?T03*=$1?M!DQNUVNI>V&3FQJOG$L)$@C"[^!*?CKL M5"DA=1S#Q[EZ4*B420]#"WYJ_"8PH03HDYRQ9`+YP($N6)V%BDZNF&W;#]`K M$BHXE%`;8DG"UOQ'\X=G#6FK#6W0D,C,(%@SI-JJ49_K-(I'ED_TAR)C9S$9 MS:Z=U`MX_Y7$K+&5EV)HN3WGJ_-8:M7QPMV,'%/`@1O6NRD^&([-[7F%ER02 M7.>6?:#PL+)LV`9ABELM'CB'ZGO3;@)&3]N5>*[8F)=+-\3OS\ZN8BD!R\$@ M_56`?O:)V*)(59IH?.M/VZ)E#=0IPH@B24P&VQ@*2A/I/O'%[B;*::4I[)&9 MH2AJIH3S8AKVBZ.7<@Z7$?71Z-O MSCA_3&L";H`P,T>V)4K1`,']UA7#W.ID!W[EY@)1+W?"^IUW#_VR_+0@BA_/ M'SI+[Q9BDMI=/9Y-NINAFDXVQY`;AS^S2K^-B6?VM?/`>Q8BQ3H5")@0*:W@ M*>CCQML$J7+H".;VP[KLFRVV`D-4H\]B8=_:7=I^]"YQ4*!2HJ%VK#K/'T,5R( M*E>;SB.PCK__]6\OL/@OH`'\N$*QM\+?Z2VU2_M]WMMNTR=OIXYA]2ZJTU`SY%MG*4KNU+KMY^Y=:X<>Y MSH]RQM@%'8IZ-8?':.FKQC2;;2BWK M5"YJ;`ZU3,EU;%-U26/:G2T=/Q(A+F?4:ANP3T<=EC/91!1H?1.+"\`)@")D MX_AG^P>;_P[`1!A@S!PM*Y``9W&`N@(EM@U-YV442IMMDANFQ<&BW&Y(&0NJ MG>9$._?8KRP5!.^>5/SQ@2C]1(GCCLY,3G8A%J_1ZBQ.K'CMI+W%IEF&>MQL MBL<:$<`T1V)8.!'_PN["W>U=:4AJ?^\'B?Y:#JZ=5".2J;>EMCWC9&H/9AS) M`;ILAIIH>T-.1!@Z6I`-L*VF/7>W-FAO`0A$:)3YF/?X)YDU6^V*YK@:#"\$ M62FIQ0JCT7-$[*3CSRUB="'>%^+'!Z\O+L\/.6HDE3[6M>W@[QT3"PHT',K_:YL5?_1&-VI\]-H-&M3'*WDUPWQZCE: MYX/6#MIBMT83)I]-V5F).E6;^HL(0!%/X:47T708SZ>GT8]E]>F(O3&H%T3C M\3@>3D;1:()EV6:8D,Z9\YA7#(\GQ_%P.HE&IY-XLK MY,<@!ZME^@_;;/GI]>7U[^CAU;LS^AF^,V;46!C>SIG;M#'0QGC@E&N4<^0E MN$Q>Y9A,];/Y_"0^G4ZC$VSR-3KN9A6SSTF[0>^'/.VOHC/[H[S5;F#7=:/# MU?!:HL-.@H>G;C%MA*9M_4#],I-ZQ3.L8$`E34G*V^2)%'U&DZLGX9E!5,#[ MT?\#L\_F61#2WRU^OZ]G6(?SY\,SE228I M?EB>,A`*>FE3Z4.2SIZ4PANDIWY`3]50TB&P=Y$&@SNY_7=`D;&)K+1\027: M]B!=9M5RNT97.U=;(X-"&DEA[V"SDJ20GIVJT"\<<0]+PW[HR'ZV42*\>Y?F M*]5[5U[K"JPHS0ZP*JO=RC[]:\`"8QS_!:WF#X(_8JORYG/FPF)CI+_;QA[HY]2B*ESPB%"+F-#GE%J^FN91*AM? MWFBU%98T_>;5?GF'V#UOOUVFV@`9I;=-ETIXYKL3*U-?;EW+O&"#RFB$NGU+&75J@%.M6M M(87,I/-1*O0B4'_6F9/:P^Y^_=$7#"Y6BSN(P;M&HW5>Y_SC8IN,+H'_L)\+_&OC8F8BR][810YB]O(I9%FV$M/7GZW]C*+\&+Z-^X`>./]LBDI^I5,65@0 M"@W!TLH3OR2_O<["?N#LQC`/,B..-@--HZDF6['7F^)#.6, MT]U'&NZ6M6I?\IYK^^%G54[9K^X*N]Y^3=56XD?*K5P%B]2%;0>]&_M,I;^6 M%2IJQ*5)?]T@='-4H5`)+4 M@(9)RBV_X=@JF:KP:6L!>WN\`U0I.YZ/KD9IJ\F$PK\ZC2KWQ=%NA\N/(2)A M@R5M&4S29REV3;-P5`.2(#U68VQCWAL3^;VL,E(LI85X\Q)E9C@>#$&$*XXG ML#0MY5'P%1,UE[O]UN;+H@F&:$&E<9BM+F&UQ)Q2ZSFQ_9M:O&*24#DK\YJ% M(5EF$T'#88/^F>`\/3NF6RG--Q&/;IK/7!'+!$1IT)K&)1ZE4BS2V:P8K;3Y MD:2B(4R,;_M;<6O@UMSN->D&X6D M762:MTJO8.L@-[#!@Z.4BB+4\Y![\#C<=P&=9+"=MW>O8^G<2'_QA?E[WS+V MNZ)8`<^_LEXO-CN*P5)IK2V(44MO._J3O8AD9F6_;5'*M]Q<2PARC&-:!R-) M6`L4$$W%4KD01BWVB;?9CC.]C56TO"OO!:&/^MRLLMF)Y]^:VZ%6NEX4>/+8 M?31!]0DG[M'PE:=_T3QLL)YS_A!:(6DT0OV>L]06,*X5&*:X`-_?Z(!RY*@B MVA$VR990H$,SK+\VA/6NH:5CMR4/M!FZJG8B9YZ8S8]&3-B].^-U,!8\Y0JV MB_0C4A$("R4Z+Y42[3.D41_UD6VAB.8&:4:H2R>6T[(?F9PE&2II..Q*#9O> M+CELF5*&N[;FI^XO-(33E*Q`;<)=,C*CUB^CH]&X.5)57PT* MFP85AX4MNV*R-]HD,8--]D\(5!M(;@!T1]*RX+_-[1C59@C\W*SX'TT/7'-M98++98)2Y76#*\C0+ M=(K',BU%T:RT7!+'RCM);]H@R[DB-CB#63=5ZVZ3F%T0W-,$<]T35N,],#F( M295Z@G+3;E#3LD'7H4$ZA8EL`9[,]LECT<@-9J($>4W5P`??Y&LG>3,"\=D<;J^..%V8J^W_C)Q@)AP//)AH0-'7?9(4VQT'IW* MT4I#E9U2UP7#0>/=W3%=9SM>T2,JJ*^%AK4LAE.[W]2K>LC2?.4\L%7VS=TW MSW+,G50J1TOI.E&TT>+^P0[V"_\73MQU6X(X><7DR7-CJ6R+^HM]XMQ\`J(* MA-FI.`AQ!*/-$B<7Y#>"#U`0D*Y`MN(8-'Y+D],"T89M^R1)%":?;'<4)DD8 MVJ>9UB8E[/?=L?&:\MU.BX2O#GS%+1?-@8:DES95_(E()'M\51QF9#@]V)UF[.KV_>O7[$T'A MNR,>)80)'13WZ#X+A4&V`RA([/%2#<1IL:,!J3!F8>L=\"0Y6[7:4C&.8+K! M/S>W@/E2ZH3BJ\_*N-^-5XBFP$DYH0_E:$0\BC\UEC7*KAFPU;LXGI?5HOQ193,O5S3"NA!,,C;L,%"KWBA%Y=]BX7=_LG238`WRIQ1*KJ MP03$9K^@X'VTRO(M%YB@GV!9&/)(16#VV[OV<'[B[H_Z=^_L=I-OI?^BM(QG M+6=3-F)#U>5[4TIU56$=UMG3@>O&YB7U5;6SPEZC7<[X5>TL)%:C7M]H^SFY M&^VHV.`=PZRP^!!Q/`$'O44,#S@SD/30WH-WNLY,CZ2@^S^,-!- M[*DG%7MEJ2E7GIFJ=C@N_9TPS[<9A9Q&Y#(4OD@VHR%XHC&IU[/!/#H>C#IM M>K$K=BNGN"H+^'D9K*34ZS?=/0J7O7AP7+FV(9.3FGI-9DLDS%08@NM:G%U_ M%ZN+_A:;@A42=E(%G+5B&&6[6XQQID`O4J-]:/YG\%LWGQT334KXB#3O-3JR MC/B8%2M@DM7#D3$;Z:H8?\T:33-+K_$HAP,ZQD&*AJ=ZP.FF?AF-#FW,F80? MT(L@53A/>EU.D\-6HTXW-8TL97$T/30VN+Y7N+:>%3448')%80.UG%4D(4,4 M7Y/A3N]P52LOA1#+YU;F%`II+L#):N:L8'"")#I1]0R6PL/&'M=HA_\5,XZ!)7F+=*]B*-;-*#6'#\U-_$5L5A-8@W9AA#-X34+L?,8WBIJ2[D M-?DP4=Z61%(!*"?ZUJ/'H;T:^9!NHNI:_7>TG6U8.]`Q7N#R$I#2X%4STC=AA'5(Z0:#OI#@ZE>/AW#9B.T)U2>=Q(IXK%ERE M2`X*@ZP%DPAB6D^BK5WT1S.-&P_.(N>;R]?OM8A2E0+1SIW75?Q\%YA"W#-. MW'\K2$G*%B#'0'(*D*LX$6^!,ZWAAPQGR`6YIQL*$LLA?T1WU:CON>5$YW@+V=6-"*_4=+M1H3U!L7FXM#<=! M@?19<5AB=1()4^ZY_1(W71D+C9N2;L4S=[ZFM,8K],5J90#K9744_\#:,PT. M\Q'*3\YT)_3#9_:2@H6]F6@^U*C%EI78/K]B#W!JG%1Z/0R5X)H4VGHJ9`AK MN3P<@Z!IDY!I+8?F2#9K+!<+ZG@,TV'\C`VD=O0R=Q1'P6A?1RFY90%'-BLS M@@U'\/J#U6;B0`4=TI)MGM//JB+VD<*) M.C7$KI=W(&/F'D-Z5J(M4@H2`5S/)S4Z/,J*6'Y"^5^:D+,UC<\G),0@\:4N M'.WT'2]PX>7_90F^G1)NRC'.+8K,C M$=FK.`N]CF:S>3P:C9WDXE$\G$_BD]FL+ZL3:P@<3XZEP[!,-IF=PK+FK24I MUU4;7_\*@RE=N);3*64<7822P::S$TY',EEC*M["O`EF5DR/1_2&ORSC>1J? MC@#GVJL.-7<&O!V?QL/9B7<`N]#/UGB"2Q*1O2ILT9M\21,S=MS+)MVSV1N;9O_ID.$'UD9>YZK!-!TJ'KEKB8"S#;A MGT^!)9R<3DEY)F/^B^A@A&QE$H^&IX?T*UQ;N(*GIW/Z=1H?`TTZ&>EOL]$\ MGDU'AW8(Z[&!%\:#L0XSF(_II^%@R)\#`NH,; MC_ZSM5%K#I*]\3FDHF%"KSI'XT>NW8'0BA&:#T$C\2^Y=GRE)^NZD_#VTJ7( MX>_>4,;Z2/X=R[^3'96"`+<`T4Z`WXU/V[\, M-'^D90-?D-:@!DTO;)TU<:LZEF[&NSF2Q`F2Q.D\GDRQA=[!?'0:'\]GAV$D M\?HH=UH>[T.4?`&UK^"WV-G0SUSE5_$]O\&@N,8NMW=8" M:R%Q?1&R4W*;M:OD`>]2\`)2KZ0?-;KEDK4SJ3YRQ6:T:X[TN)3"\%?42"5Z M+\VA_C&CPN^B4UZ13@D?4?71WNV^QNU>JN/J_0V]78M%MF^2[RN0JG[9(4%6 M:P]X@3XU>XYQ]%YK]EV0?,^)P7L;^$DW[PYC_[=).A=%LOH3V^)$/2C7P=XLO0S$I06 M@>WV+]%]!NO8<\4=Q)2:70)*BU?7@<#`]MOO3$"3=P3(/IU^,]T@;T:2#2-) MV7-ESIT@HYTWUC]A][,02*]MMCATRB!VSOL?FU=1[5QGCV6="5 MN#2U+&,0/^`PPA>A.^DO@P_]J.J-?Z9PZR6C3[#-"J_9P6/Z#9CM-UO&RXZR MY]DNVT_)Y+<<'G;O1Q9T6P>A/MZ+29>.7%_9W[,7^O MU$]EJ%$O4P#-#"[+Q>4YWAY2.7HO#>5#FS*`9U@6IGODUB#YT1HDI>=D'XU_ MS46PWE`1+*=2UQDJUS%6\L9#P/9A[2_GG`S1V96:33]X9M.^^1T[:=\KHV'/ M3.[-[OO8I:NM*CTM#LP!]I93=U9JLCQ$H?I@:^I\P$CZND%Z\U9Z]<#Q8P@F M1D'#7W\G@=+PXWO')MBN&_1!?,D=6`\'P^&_/+8BLR%GB@Y.=Z\3$F$]M/=% MYYS/,9:KL.UZ:^2W9G-=`A%:Z?PT]-='UO+Q<]D9?10:9S0+_?5M\@4/8I]) M18J]V':V`_K)*GGHH)X<Y1>BK[_5;EP;Y[9/9P MYIB&=Y'SYWJ3=B]_[UTC<0V%5HN3*4!B`WZE#O-PW$N]=,]S%_63:.LSVD$2 M?=?1;M`$7$3[(&),Q3PEV.'2Q;$S!O&9J=.(HI"8_EB2]'$I'B,+ MWR[;"Q+]*T>^%_^7=K<\+ZD1GT3RPR1G&!!"A]4'HYYS0U!)5NH!RDF'T5DK M!?0JJ0(7I$U%@)P+L[0J5A#(?62'V>(NFP,*BV]3`$-78[()2E\;#NF81B], M7%^/&OV[2P>63T`#3S!15+D2S:-Z<4=S4ZR,/@!" MQ=P;9K6#VY^$,/0U5A;X8&.J.^"@:7=HVBZ*\Q)5GR,,[R*=%VIG6T0"DF;< M3RC99`U&FKKH%#\R;*^#[4F,V_N4G91IIB@"G<-/-]8PV8>;OYP[ MY)&M."X."I?'V#?)$;-^_?9'K@]$O!GA'>!3>Y<#G)Z=)HR!?/D?62"6!=BY MMB>6/GT*Q3C;5.;DIMW[M!A$XY/PPXMT:>S-DPZH$`C[F9K[2IGNK7.$S9C= MUX%Q4$U8)BU,B7L)U"XK:*]>]ZCBUM62O.$NBS;18H-A=W$M=?)"JTLP]>PG MFYT5L6.#62':J!S5\LJT]HK>:I-PT")]D_I3=%6Q?L(8EUP#,916V+5SGYM$ M5I=A[#Q\&J-S"W;Z6G8Y:]2KTO,.C=-ZAU-4=_IHY,T7T3>2T!K^QG/Z]*S` MI;_3GG=:+'?GG71D%T\H;*IBP?K5](O:I`9PT?P')3L'>SRZKTKI>YE2R+_ M:,>^OYMFL^[)T+>UT<'#JH#X4_WW5%'`'1&BAU8BR#Y[Y&])GLO!`@8 MIF<_>^H/B*C[SX91R('I'@M0>%RHT\M(#H!?BK'D`P MA5+&V/98_^";=Z/W6'L,9V.RRN6R]A=`^FAPO\8:,RV/7>M`ES?MZ<%]NL*L ME!'M-9_YC:YW!&!RU(9)OVW]%Z3Z3QC[%1=MT&@"YRSZAWME&E!%%U(>K(4? M`7$B.HG_^9_^:3P<=^K9NRY8=27N8ANSZ`ITC5^@O`=_ZF">&WI6#)/V`C[[44RO>\"M!A]6X& MHU?VF;)^_IP_:K&B,RG7X]^L_UP`=!9#K_!M[5?T?\DU.?I@W*/R?0A6K_D' M+$JMIDZ'4)8DJ=16+QC_SZWDCVDMG43#*^DQ6>T@\SN5NLR>TNWT=\X"=/X=]HK:,:ZK_=Y_?I#8(A2)_ M.@C[35TWO_W?4$L!`A0#%`````@`O(%M1XE:)#R\`0``)A@``!,````````` M`````(`!`````%M#;VYT96YT7U1Y<&5S72YX;6Q02P$"%`,4````"`"\@6U' M2'4%[L4````K`@``"P``````````````@`'M`0``7W)E;',O+G)E;'-02P$" M%`,4````"`"\@6U'Q,LD0Y0!```\%P``&@``````````````@`';`@``>&PO M7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"%`,4````"`"\@6U'I>*]*=@" M``"!"@``$```````````````@`&G!```9&]C4')O<',O87!P+GAM;%!+`0(4 M`Q0````(`+R!;4>]$[,2/@$``&D#```1``````````````"``:T'``!D;V-0 M97)PC$`8``)PG```3```` M``````````"``1H)``!X;"]T:&5M92]T:&5M93$N>&UL4$L!`A0#%`````@` MO(%M1[R01Z]2`@``>@H```T``````````````(`!6P\``'AL+W-T>6QE&PO=V]R:V)O;VLN>&UL4$L!`A0#%`````@`O(%M1Z4[V4!/`@``]`<` M`!@``````````````(`!P!4``'AL+W=OY*NF%>@0``,X5```8``````````````"``448``!X M;"]W;W)K&PO=V]R:W-H965T&UL4$L!`A0#%`````@`O(%M1_&8Y`XH!@``H!X``!@``````````````(`! M91\``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@` MO(%M1]4=+36F`0``L0,``!@``````````````(`!"BT``'AL+W=O&PO=V]R M:W-H965T&UL4$L!`A0#%`````@`O(%M1[U"-92F`0``L0,` M`!D``````````````(`!ES(``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`O(%M1Z)QVBRD`0``L0,``!D````````````` M`(`!)S@``'AL+W=O&PO=V]R:W-H965T M&UL4$L!`A0# M%`````@`O(%M1W$2O@NA`0``L0,``!D``````````````(`!MST``'AL+W=O M&PO=V]R:W-H965TI"Q+2=@(``+D)```9``````````````"``6I! M``!X;"]W;W)K&UL4$L!`A0#%`````@`O(%M1P0G M1>FD`0``L0,``!D``````````````(`!%T0``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`O(%M1Y`HC56F`0``L0,``!D` M`````````````(`!PDD``'AL+W=O&PO M=V]R:W-H965T&UL4$L!`A0#%`````@`O(%M1Z@D=&PO=V]R:W-H965T&UL4$L!`A0#%``` M``@`O(%M1\."%.>Y`@````L``!D``````````````(`!*UL``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`O(%M1UB`6&/I M`0``3`4``!D``````````````(`!TV(``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`O(%M1\BZ=(:G`@``E0D``!D````` M`````````(`!/FP``'AL+W=OO?4$``#)&P``&0``````````````@`$<;P``>&PO=V]R M:W-H965T&UL M4$L!`A0#%`````@`O(%M1VN,2L.+`@```0D``!D``````````````(`!3'8` M`'AL+W=O0``>&PO XML 14 R33.htm IDEA: XBRL DOCUMENT v3.3.0.814

Debt (Details Textual)
1 Months Ended 2 Months Ended 3 Months Ended 6 Months Ended 9 Months Ended

May. 08, 2015

USD ($)

Jul. 31, 2015

USD ($)

May. 31, 2015

USD ($)

shares

Mar. 31, 2015

USD ($)

$ / shares

shares

Sep. 30, 2015

USD ($)

Jun. 30, 2015

USD ($)

Mar. 31, 2015

USD ($)

$ / shares

shares

Sep. 30, 2014

USD ($)

Mar. 31, 2015

USD ($)

$ / shares

shares

Sep. 30, 2015

USD ($)

Sep. 30, 2014

USD ($)

Debt Instrument [Line Items]

Proceeds from Notes Payable $ 1,741,667 $ 0

Debt Conversion, Converted Instrument, Amount 300,000 0

Fair Value Adjustment of Warrants $ 700,000 $ 0 $ (4,400) 647,342 (4,400)

Interest Expense, Debt $ 1,500,000 1,500,000

Amortization of Financing Costs 71,421

Common Stock Percent 8.00% 8.00% 8.00%

Common Stock [Member]

Debt Instrument [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares 225,011 225,011 225,011

IPO [Member]

Debt Instrument [Line Items]

Debt Conversion, Converted Instrument, Amount 2,100,000 $ 0

Debt Conversion, Converted Instrument, Shares Issued | shares 1,875,000

IPO [Member] | Common Stock [Member]

Debt Instrument [Line Items]

Debt Conversion, Converted Instrument, Shares Issued | shares 350,000

2014 Convertible Notes

Debt Instrument [Line Items]

Debt Instrument, Interest Rate, Stated Percentage 8.00% 8.00%

Proceeds from Other Short-term Debt $ 1,500,000

2015 Convertible Notes

Debt Instrument [Line Items]

Debt Instrument, Interest Rate, Stated Percentage 8.00% 8.00% 0.00% 8.00% 8.00%

Proceeds from Other Short-term Debt $ 1,000,000 $ 1,500,000 $ 150,000

Convertible Notes Payable $ 1,001,250 1,001,250

2015 Convertible Notes | Common Stock [Member]

Debt Instrument [Line Items]

Debt Instrument, Convertible, Conversion Price | $ / shares $ 1.00 $ 1.00 $ 1.00

2015 Convertible Notes | Pre IPO

Debt Instrument [Line Items]

Debt Instrument, Convertible, Conversion Ratio 1.25

2015 Convertible Notes | Post IPO

Debt Instrument [Line Items]

Debt Instrument, Convertible, Conversion Ratio 1.00

Short-term Demand Notes

Debt Instrument [Line Items]

Proceeds from Notes Payable $ 2,300,000 $ 800,000

Debt Conversion, Converted Instrument, Amount $ 300,000

Debt Instrument, Interest Rate, Stated Percentage 8.00% 8.00%

X

- Definition
Price at which the warrants are exercisable into common stock presented as a percentage of the IPO price.
+ References
No definition available.
+ Details

Name: opgn_CommonStockPercent

Namespace Prefix: opgn_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount of noncash expense included in interest expense to issue debt and obtain financing associated with the related debt instruments. Alternate captions include noncash interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.8)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 8

-Article 9

+ Details

Name: us-gaap_AmortizationOfFinancingCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i)(2))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.16)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.16(a))

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20, 22

-Article 5

+ Details

Name: us-gaap_ConvertibleNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

+ Details

Name: us-gaap_DebtConversionConvertedInstrumentAmount1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name: us-gaap_DebtConversionConvertedInstrumentSharesIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The price per share of the conversion feature embedded in the debt instrument.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 20

-Section 50

-Paragraph 5

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6928298&loc=SL6031898-161870

+ Details

Name: us-gaap_DebtInstrumentConvertibleConversionPrice1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Conversion Rate

-URI http://asc.fasb.org/extlink&oid=6509012

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(5))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

+ Details

Name: us-gaap_DebtInstrumentConvertibleConversionRatio1

Namespace Prefix: us-gaap_

Data Type: xbrli:pureItemType

Balance Type: na

Period Type: duration

X

- Definition
Contractual interest rate for funds borrowed, under the debt agreement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentInterestRateStatedPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of expense (income) related to adjustment to fair value of warrant liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 480

-SubTopic 10

-Section 25

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=6939902&loc=d3e20148-110875

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_FairValueAdjustmentOfWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense for debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.8)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_InterestExpenseDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from a borrowing supported by a written promise to pay an obligation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_ProceedsFromNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from a borrowing not otherwise defined in the taxonomy having initial term of repayment within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_ProceedsFromOtherShortTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=opgn_ConvertibleNotes2014Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=opgn_ConvertibleNotes2015Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=opgn_BeforeClosingIpoMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=opgn_AfterClosingIpoMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShortTermDebtTypeAxis=us-gaap_LoansPayableMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 15 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 16 R25.htm IDEA: XBRL DOCUMENT v3.3.0.814

Summary of significant accounting policies (Details Textual) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Dec. 31, 2014

Jun. 30, 2015

May. 08, 2015

Significant Accounting Policies [Line Items]

Allowance for Doubtful Accounts Receivable $ 79,697 $ 79,697 $ 79,697

Inventory Valuation Reserves $ 778,944 $ 778,944 867,816

Operating Loss Carryforwards 76,267,809

Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 5,700,000 6,100,000 5,700,000 6,100,000

Cash, FDIC Insured Amount $ 250,000 $ 250,000

Product Warranty Accrual 2,750 2,750 2,750

Goodwill $ 291,747 $ 291,747 $ 0

Developed Technology Rights [Member]

Significant Accounting Policies [Line Items]

Finite-Lived Intangible Asset, Useful Life 7 years

Customer Relationships [Member]

Significant Accounting Policies [Line Items]

Finite-Lived Intangible Asset, Useful Life 7 years

Trademarks [Member]

Significant Accounting Policies [Line Items]

Finite-Lived Intangible Asset, Useful Life 10 years

Common Stock [Member]

Significant Accounting Policies [Line Items]

Convertible Preferred Stock, Shares Issued upon Conversion 7,374,852 7,374,852

Series A Convertible Redeemable Preferred Stock

Significant Accounting Policies [Line Items]

Temporary Equity Redemption Request Of Minimum Percentage Of Holders Of Outstanding Preferred Stock Required 70.00%

Temporary Equity, Shares Outstanding 0 0 3,999,864

Accounts Receivable | Customer One

Significant Accounting Policies [Line Items]

Concentration Risk, Percentage 12.00% 79.00%

Accounts Receivable | Customer Two

Significant Accounting Policies [Line Items]

Concentration Risk, Percentage 11.00% 15.00%

Maximum

Significant Accounting Policies [Line Items]

Accounts Receivable Period Due 45 days

Minimum

Significant Accounting Policies [Line Items]

Accounts Receivable Period Due 30 days

X

- Definition
Represents period by which accounts receivable are due.
+ References
No definition available.
+ Details

Name: opgn_AccountsReceivablePeriodDue

Namespace Prefix: opgn_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: opgn_SignificantAccountingPoliciesLineItems

Namespace Prefix: opgn_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the request of minimum percentage of holders' of outstanding preferred stock required for redemption.
+ References
No definition available.
+ Details

Name: opgn_TemporaryEquityRedemptionRequestOfMinimumPercentageOfHoldersOfOutstandingPreferredStockRequired

Namespace Prefix: opgn_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
For an unclassified balance sheet, a valuation allowance for receivables due a company that are expected to be uncollectible.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=49124121&loc=d3e5074-111524

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AllowanceForDoubtfulAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Antidilution

-URI http://asc.fasb.org/extlink&oid=6505113

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Diluted Earnings Per Share

-URI http://asc.fasb.org/extlink&oid=6510752

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Contingent Stock Agreement

-URI http://asc.fasb.org/extlink&oid=6508534

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.
+ References
No definition available.
+ Details

Name: us-gaap_CashFDICInsuredAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 18

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6351-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13531-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6404-108592

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13537-108611

+ Details

Name: us-gaap_ConcentrationRiskPercentage1

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares issued for each share of convertible preferred stock that is converted.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of valuation reserve for inventory.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 5.BB)

-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SX 210.12-09)

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=51655945&loc=d3e3927-108312

+ Details

Name: us-gaap_InventoryValuationReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 3

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

+ Details

Name: us-gaap_OperatingLossCarryforwards

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-Subparagraph ((c)(5))

-URI http://asc.fasb.org/extlink&oid=51674963&loc=d3e12565-110249

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.15(5))

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

+ Details

Name: us-gaap_ProductWarrantyAccrual

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.27(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 28

-Subparagraph b

-Article 5

+ Details

Name: us-gaap_TemporaryEquitySharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MajorCustomersAxis=opgn_CustomerOneMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MajorCustomersAxis=opgn_CustomerTwoMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 17 R37.htm IDEA: XBRL DOCUMENT v3.3.0.814

License agreements, research collaborations and development agreements (Details Textual) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended

Sep. 30, 2013

Sep. 30, 2015

Sep. 30, 2014

Jun. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

License Agreements Research Collaborations And Development Agreements [Line Items]

Future Minimum Royalty Payments Due $ 20,000 $ 20,000

License Upfront Payment Received $ 250,000

Royalty (Income) Expense 7,484 $ 23,810 (13,769) $ 73,142

Licenses Revenue 27,780 $ 172,220 $ 208,340 $ 1,133,340

Life Technologies [Member]

License Agreements Research Collaborations And Development Agreements [Line Items]

Royalty (Income) Expense $ 150,570

X

- Definition
Represents future minimum royalty fees.
+ References
No definition available.
+ Details

Name: opgn_FutureMinimumRoyaltyPaymentsDue

Namespace Prefix: opgn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: opgn_LicenseAgreementsResearchCollaborationsAndDevelopmentAgreementsLineItems

Namespace Prefix: opgn_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the upfront payment received.
+ References
No definition available.
+ Details

Name: opgn_LicenseUpfrontPaymentReceived

Namespace Prefix: opgn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of income or expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.
+ References
No definition available.
+ Details

Name: opgn_RoyaltyIncomeExpense

Namespace Prefix: opgn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(e))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_LicensesRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=opgn_LifeTechnologiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 18 R9.htm IDEA: XBRL DOCUMENT v3.3.0.814

Business Combination
9 Months Ended

Sep. 30, 2015

Business Combinations [Abstract]

Business Combination

Note 4 – Business Combination

On July 14, 2015, the Company completed the Merger by acquiring 100% of the capital stock of AdvanDx in the Merger in a taxable transaction. AdvanDx researches, develops and markets advanced in vitro diagnostic kits for the diagnosis and prevention of infectious diseases, and sells its products principally to hospitals and clinical laboratories in the United States and Europe. The Company acquired AdvanDx principally to exploit AdvanDx’s diagnostic capabilities with respect to MDROs and leverage AdvanDx’s relationships with hospitals and clinical laboratories to accelerate the sales of OpGen’s products and services.

Pursuant to an Agreement and Plan of Merger (the “Merger Agreement”), Velox Acquisition Corp. merged with and into AdvanDx, Inc. with AdvanDx, Inc. surviving as a wholly owned subsidiary of the Company in accordance with the General Corporation Law of the State of Delaware. Under the terms of the Merger Agreement, the merger consideration consisted of an aggregate 681,818 shares of the Company's common stock with a value of $2.6 million (the “Merger Consideration”), which Merger Consideration was distributed in accordance with the liquidation preferences set forth in the AdvanDx, Inc. Restated Certificate of Incorporation, as amended.

The Company accounted for its acquisition of AdvanDx by recording all tangible and intangible assets acquired and liabilities assumed at their estimated fair values on the acquisition date, with the remaining unallocated purchase price recorded as goodwill. The fair value assigned to identifiable intangible assets acquired was determined using an income approach for trade names and customer relationships, and a cost approach for technology. The fair values are based on the Company’s estimates and may be adjusted from time to time, but no later than July 13, 2016, as better information becomes available. The Company received stepped-up bases in the acquired assets and liabilities and therefore did not recognize any deferred income tax assets and liabilities. The following represents the preliminary allocation of the purchase price:

Total purchase price - fair value of common stock issued

$

2,584,090

Fair value of tangible assets acquired:

Cash

1,367,211

Receivables

557,112

Inventory

1,073,855

Property and equipment

250,636

Other assets

359,587

Fair value of identifiable intangible assets acquired:

Customer relationships

1,094,000

Developed technology

458,000

Trademarks and tradenames

461,000

Fair value of goodwill

291,747

Fair value of liabilities assumed

3,329,058

$

2,584,090

The total consideration paid in the acquisition exceeded the estimated fair value of the tangible and identifiable intangible assets acquired and liabilities assumed, resulting in approximately $0.3 million of goodwill. Goodwill, primarily related to expected synergies gained from combining operations, sales growth from future product offerings and customers, together with certain intangible assets that do not qualify for separate recognition, including assembled workforce, is tax deductible in all relevant taxing jurisdictions. The Company expensed acquisition-related costs of approximately $0.5 million related to the Merger in 2015. AdvanDx recognized approximately $0.8 million of revenue and $0.8 million of net losses from the acquisition date to September 30, 2015, which results are included in the Company’s 2015 interim condensed consolidated financial statements.

The following unaudited pro forma financial information summarizes the results of operations for the periods indicated as if the Merger had been completed as of January 1, 2014. Pro forma information primarily reflects adjustments relating to (i) elimination of the interest on AdvanDx’s outstanding debt, and (ii) the amortization of intangibles acquired. The pro forma amounts do not purport to be indicative of the results that would have actually been obtained if the acquisition occurred as of January 1, 2014 or that may be obtained in the future:

Unaudited pro forma results

Nine months ended

Three months ended

September 30,

September 30,

September 30,

September 30,

2015

2014

2015

2014

Revenues

$

3,902,337

$

6,631,510

$

1,126,530

$

1,955,894

Net loss

$

(15,623,109)

$

(11,784,997)

$

(4,650,817)

$

(4,517,541)

Net loss per share

$

(2.29)

$

(11.72)

$

(0.38)

$

(4.49)

X

- Definition
The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1500-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1524-128463

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4922-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4934-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4926-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

+ Details

Name: us-gaap_BusinessCombinationDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_BusinessCombinationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 19 R29.htm IDEA: XBRL DOCUMENT v3.3.0.814

Merck GHI Financing (Details Textual) - USD ($)
9 Months Ended

Jul. 14, 2015

Sep. 30, 2015

Sep. 30, 2014

Common Stock and Note Purchase Agreement [Line Items]

Proceeds from Issuance of Common Stock $ 4,958,335 $ 0

Merck GHI Financing Agreement [Member]

Common Stock and Note Purchase Agreement [Line Items]

Sale of Stock, Number of Shares Issued in Transaction 1,136,364

Shares Issued, Price Per Share $ 4.40

Proceeds from Issuance of Common Stock $ 5,000,000

Debt Instrument, Interest Rate, Stated Percentage 8.00%

Debt Instrument, Face Amount $ 1,000,000

Fees Related to Common Stock and Debt Transaction 50,000

Payments of Debt Issuance Costs 8,000

Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs $ 42,000

X

- References
No definition available.
+ Details

Name: opgn_CommonStockAndNotePurchaseAgreementLineItems

Namespace Prefix: opgn_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of fees related to common stock and debt transaction.
+ References
No definition available.
+ Details

Name: opgn_FeesRelatedToCommonStockAndDebtTransaction

Namespace Prefix: opgn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Face (par) amount of debt instrument at time of issuance.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 55

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=34725769&loc=d3e28878-108400

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

+ Details

Name: us-gaap_DebtInstrumentFaceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Contractual interest rate for funds borrowed, under the debt agreement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentInterestRateStatedPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3291-108585

+ Details

Name: us-gaap_PaymentsOfDebtIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Per share or per unit amount of equity securities issued.
+ References
No definition available.
+ Details

Name: us-gaap_SharesIssuedPricePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Details

Name: opgn_AgreementAxis=opgn_MerckGhiFinancingAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 20 R28.htm IDEA: XBRL DOCUMENT v3.3.0.814

Business Combination (Details Textual) - USD ($)
3 Months Ended 9 Months Ended

Jul. 14, 2015

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Dec. 31, 2014

Business Acquisition [Line Items]

Business Acquisition, Percentage of Voting Interests Acquired 100.00%

Goodwill $ 291,747 $ 291,747 $ 0

Payments of Merger Related Costs, Financing Activities 500,000

Revenues, Total 980,786 $ 834,824 1,828,133 $ 3,004,246

Net Income (Loss) Attributable to Parent (4,670,582) $ (1,608,833) (12,624,339) $ (4,265,887)

AdvanDx [Member]

Business Acquisition [Line Items]

Goodwill $ 291,747 291,747

Revenues, Total 800,000

Net Income (Loss) Attributable to Parent $ 800,000

AdvanDx [Member] | Equity Issued in Business Combination [Member]

Business Acquisition [Line Items]

Stock Issued During Period Shares for Meger 681,818

Shareholders' Equity, Fair Value Disclosure $ 2,600,000

X

- Definition
Number of shares issued during the period for merger of entity.
+ References
No definition available.
+ Details

Name: opgn_StockIssuedDuringPeriodSharesForMeger

Namespace Prefix: opgn_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_BusinessAcquisitionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of voting equity interests acquired at the acquisition date in the business combination.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1392-128463

+ Details

Name: us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow for financing costs associated with business combinations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3291-108585

+ Details

Name: us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Fair value amount of financial instruments classified in shareholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_ShareholdersEquityFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=opgn_AdvandxMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareholdersEquityClassAxis=us-gaap_EquityIssuedInBusinessCombinationMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

ZIP 21 0001144204-15-065342-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-15-065342-xbrl.zip M4$L#!!0````(`(R!;4?^UZ>;,=```(M6"0`1`!P`;W!G;BTR,#$U,#DS,"YX M;6Q55`D``SA21E8X4D96=7@+``$$)0X```0Y`0``[%UM4]T]E9?.O:E))YDD/?=.;6VE""@)TQ@\@-/Q;NU_7PD;6V"0!`8;TM2= MFIMK7L[1HT?G2$#[P\78^-@ M]-Q M+`%U]%^2A@]\0)V\XM(/):#Q.Y9Q: M$9:!W_/GZ=W52#X$RVOO3Z'G'I/_'V&U_>@XF+Y@K5_C>'I\=(3_`_GD34=$ MKF1"W);%;9[K_UC=1B235QP&X0N^4X)'Y/(3%IG>3JXZ[NH!^F;M:'%Q=>O& MJW_"Y%Y@FN91 M)/T!QQ(80[!Z;!:&F&=ESRVOD@>5[(,.1*0I3L`Z[_ MAJ*X^)'%M8+6^)9K1\7/))?((R#[2.3:Q0_@"T6WQ].PY'Y\I>"!631^L:SI MZIEG*WI*^G-YH:#I[QZ#-7]>452>Q2&#+/CJ`1ZMH]$G0O_C*"'V'7H>)>#R)U,/<+:Y+?7$#U_/B"C>9R.WX\!!(YB.4DK\7*JV>0'[LQO/E;ZM?78?\ M_NRB<)2HC3+-3"$_N_S;P1<)CUO9A`8P/AWE'TY%'>5D9328HM`-G+P&>#2' M,3:MZ$M*9@FD[UE?2U]%-<>A'C+'4%H+=Y:/T"I1PM.?EA@NW\T$5J6`5?L( MK%H'6+4U8$^B&U^"CQ#T"="%YXF7R$!L2%:O7UYI@G(*-9:UGH]EI42\_EM4Z8UFE&-LPL/(:6,GH.;!R#6`EHPU@]0_DUO4NN77]`[GU MZL"V[-;U1Z#T"="L6]?'0&G#K9M+RD&*41@BYSX.[!_? MT.0)A;.(!.SN8^PBL+#XS+.BZ.8YN>'DW8UV#'[>&:(7HM1*WO*"@Q5YGWJN M[<:+1HR<%*G/!\L0Y#&C2>DMPB!].BH4N\;AJ$C?;GNKE4T>N-)_KK3GI8K# MLH\4"-=!C*);:TZPR?#D-0CC!Q1.SM%3_#"?HIYSI+@YZ64F(+OC1)<#T<7! MJ\?+VYL,;69/D>NX5CB_MSST,9/26U8@[(\JG0K'%5/E+)A,`K_<(WW] M]PPW']\U#7S\GU'/:<-NUMKRY$`9*+01>%S%R1Y/G#?+=]XO?9MFT.DL6%[]>^G[P9I'K%S/?N?(R;[E#'CF] M<(L;/G\(+3^RDEE[=#JGK_2;E"5('7PA^^O'>73+J5A'=A5\$W5$NV]_(Z96 M1)F.F[8_8NH8W6'@[,":#T.H0FMG#Z[$+`Q[[\^.(]?A>*3H:%=987#%B&I?1JVBL_RL;"\`PTZBZ-LIDJ\E@VVC`O,I4V M//"B#[S()TO+=9*E:3HU;5Z4-"5LH%&':90U+TI+FP1T@9*!%WW@12-E693V M9B_4LFF@47=IM/ME-!SXT`\^-)%=7,P'(*\+9PR\Z`4O4@["_04IT[N=)\K14M M'#C3%<[LIBYCL>$X1<]!B,Z\('+]E\MI()0U_$M1AY%HG#"H&,%R]GPX^G;9 MY)6P_N0Y1N%`^OJD+P1PX'PG.+_AYFODR_U27.]$)ERGZ;Z;&4IA@>.AE$EW M2IETIF1S`R:NQW3I6;)'2^8BX4[9374/M+< MI7364`;!7OU'9^H8Y6S'#9Y@G7A>$),FWTQ)0O4PY2@%Y=>P(0,GNLF)SIN5 M]8'8AY_!PVLPB[`AOG"?8X3\6\_*L(C\][4UZ7F">K85B?MA-7U?]J.E7)R2 MT]!#Y^^Y\[M\Y+DT43U")+W@!$LBZ0/!-)GBOT\QZ)DI[*5O!Q.T6@1?R'GN?M.1V:CT)D&8FCT8(O1Q@'W/&KM4+[QD22(^'/K+XEYPI4LKC%S$ M?N#(GCBRFTA]L9]9FK@0/=X$"/ MII4#9;I!F=U5\=5*/^K[D3-I>I3#TM87"!3*9PPDZ!P)\DZC>B6A''?:"^,. M:?H=YT[-%6I["5$#9SK'F?PBM;U,*'-P-MWN_):FFT"B=I;7*9%7@>47)3^5 M?/:PK_W/^8KC)@I[VS$&4H=*!)2D6MXG-YCFF?GL\37?G$P MB?LVB;O=YM2J8$"C#K&@%PM[\8HUE5'LGJ3(68^!,9SB3+0R^VT2^P6WL MVVUT>:>G).`[D*9KI.E4I+?DA*)M!S,\N;]#-G+?\M3!=MC&`(3)0=,[-_IQ M.C]%OOTZL<)E?<)9%`<3%-[XF>>^6?\*PO1:S[<7>1BLJ5>&9;/KLR)L%TXS MWQ>#M6R?^`\_@X'X'2'^JB\&XN?S?ZCS9(/%_W#$W[?%KYF;U-KW"EHE_F#Q MNT/\?5O\KA%?'TJ\?+3<];J'/G:1]SF4>/DPN>O]H-F0N][+W/6NDFLH\?)A MW&3'-O5**#:XR9Z[R7[0;'"3O7237257=@[V=3+U@CE"R=&OS2+5)S^MT.G_ M+F.N&:MJ+&6-'V96#'LT4*9#E.F:E2G>GALHTR'*='AC:[`RW:1,M\O5I;\CRXM?+WT_>$MFC!??C2WJ[^;IB<>#ZRGU&#\A^]0,O>'%1-"SM M.$N[8L!ZMI#;1=AR*('1W1RL6H'+MDI@%,>ZB6=`H>U:WJV%W\OE33W'/,2Z M*K*XL%L:=MJ=F#I\P)A?E[8K:I2]SSI(Y$9D> MO;K3@79"M&-`-U".0;FAS*%8F<-?DBK9PT\#53I`E:X=>BK[`&SHHNCD-D3/ M*`R76ZB%<:3$E'\,\I0W:9T44`K++TNG&7;V"9/Z-!0+/D1],2-R`)9('=5[FYDO3JU3+!3"LE8'-VC)-`X'B]N=9![?![823%($HX=+3EYAYY+YT@'B7H7 M)&+I/(*#+T`:__W34?Y-::O([R?X1X=X%^BRK*5A>RLU-Q+R^4NU*LG M63WX\G=8))=Z*2WY:V)?[]!+DBGHQ^381V6AVL&7F]O?OEZ/+J_/%K*+7KLI M]@R1>BD>B?Z\_PW-*\O5LUZP],6TY+,9]D]T9]3EEW'P99P6(V&]>+/9%ZZ' MPC-\Z24(JS?://AR/[$\_(K1'9H&(4G`&Y'-#\N?TQADI-!*D)@9?N9^/GD* MO.IF0DHZ^WHA*O.N@@Y>[[TD#B2ZF<4DE$J>R4I.OMLH%4L$!R-B`9,;E[YT MY"#;Q2A$GP\NKR^PY9)5:.J2DB$!0WBJ:GE)GFL4+WMT4]$R:&1*4>*4*2TQ M:BI6$6*:BLC,ZX^YS.WT*YM@`G:_2C(P=5!/ M08ZQ+4.,[1.`#J"BJ]0H9MG5>O9>9MM[K`!4#$T7U*&6)RH#AVWR34F&<"M' MA&UB.$/.E6L]N9X;NZ@Z>!RO($/\3]:I%TO<0K4R]-C^P32AINHU-$O-R1W" M#FZ&*B/&]@9`-0RMP'AEI=75J0PJMKV'T`2T6:BF$\>\EZG$-N^RJ4E*@4I, M&T\-B.O`MRMV'&0;=[S*`I"R5(7":FI4@A%DFW-55U2SHD*+Z^*8<,RW9N)9 MJ6'F;:>HU+)VLRVVK*F*"0%/Z!:F!;(-LX;]J"I1MH5O5,ZLJ1M;WA6R(G3S MY+DOB[W,.C1E6V0(=$-5Z)D;1W`#FI:AR#;0V/$"Q=Q"4PIU8@PD$YJ: M!BDOP9?>A+YED++]Q-C4=%W&TZ]MU$V8FCF2*PXG9T(/3$7)N-Q-676T*0.+ M[4'&AH0=B%Q)&\K)X%7E-DBQ'QL6BM:OL:G>\_WB$'H4EB0-:?RZQSJBL#`=LW=7;AT!(:;&_8S@K$ M3?+S":-P2\C6./+M*NMC;<-%OD?NL>]ZGP_B<(8.1D=YJ-EH'HWX+`B7X+@ZCZN2"-X]`4**LFM;XM%KN5@N2XX/P>A6^NO;J_.G!LMV;H,CEDRA:ZE6H,V#B[&KH)H5E)M[/` M\Q8WDNE+;165C2^`F0/ZN8Y&8'W>.;V]=WV9N1PU3F:AOB%"7KX M;P\EF<>^@STY-GO_D_Q>'36V$]`!?D*CC6Q]W7;03D;G<%9'NF;0L^CFVYG: MAY:[D^./3*#39^6V4*W]5C(ZD[-<@YJV2=I&6LG\V$SUWF([0:@K0%9TVF(P MI#>A*@-RCE.4=%61I9JJC;CFV!L>)JJ8D&6IM M=D*3JD#UM7 MTC2%NK:583L;15>TS#'LC+1ZRC"`XIP4)LJHL((ZE08#`R3.5A/MXD3'PFHP M+Y6OSG^3[2#P;`=FIG4;$NNJQ$B7X6TO`4U6H59!I\INBH$7)^:F&)HA@3IN MZ@]$2I,@Y^0-M^8%7<](]!;/+4DB#)4'(F1RWA&<;BBIG8KLEHK?5 MD8$SYQ"$(IN*44/#](C$+0H3_+=F?,X[4=G1E,8R0?60=O8S-E4Z9/1S<8K2[\"%LN`Y)S4%HSLL=AF@M7\X$# M$F?E`W5-;25>+0(+H,8Y::W)FJET/F`MTCN<)1)^0%:[ M'K$6Z5#.>8;LB=).1JP%>A/PS@B:F;7EGD+6`MT%.`L_'<\@Y%W$K$5`YZP# M)=G4U-T$K460Y9Q-U[!)H',B6XU:BZ#+=J6JJN(5:OM1:Q%D.9Y6-S6C5CB` M'QP6T8ZW1--4:*J@X:BU2`>S7>T8J(;44MA:!#:V?Y15`-N-6XL@R/9MNPI< M"Z#)*4%05TMVG%@`04[I`2A#>MM^JZBU"$J\L@-XQMQTT%H$)+;GH&-H306M M1;3B'+D`ABJ#)J/6(AW(]@2J)*N*5&31MHY:BP#&=@2*:DJ:LK>HM0BZM,,H M+2DE:YBP1B?CUB*=9/#;N-_`M4A'IW?4N!: M`,M\-87R$+!T2-.^UURC>9G+,J=F`)\>ZI-).-R.O MCC(LR-@>;0PTR3#H,Z:UE1$H&,@IV##&[D16(#T]WUH;%C3%57E8)F;EQC1ZJ3FU'C@6$>^1NTTB-4C MO"-\NJ%(>IE-VW6#!$8%I^`$MM*&9AA*F6'<5XM87<1Q@HJ.31.]<;5E@_"S M(4D`/D>+?U_Z246JUC2J/0MZ3DZSF3O[UYCNN4I]:;'#52>6UEX2ZA-."0WBM'53XC2L M@HH[:C*K(WGQ3;+'O\L&YTH,5N]$3BV/,3`DCEG(J="4SHQ>X)3ZP#X&J.HV M.I.*QU;T>AL&9*+CG,Z_1^136VO;A_5X6U1#2++#9_BWY<7`KS&2.+5!Q@!( M.E#IQ?1V&NZDO:P.Y$P2H"FIP&RMN=B,)MG]#T'R2=,0E=;OK=&5G+I6IDSO M[HMKTG@;6-W#*8UH9H)]]=M0TJN+D'T;PXQ32!$;;U/7N:P3U&\GK67U(F-S386O\9&R(DNPF!"OLUK^3:Z>&8E-]6ZY/1?\2OR52;P2]*]3\R8F^?TSH*JQ2+]MUDG)=M.:!@& M2`^:-J#ACEK,Z%E>K1:\G(1D-=ETBXN80M<-J=%WW,UAH-'U-LHD;ZDA"VOA MBB^BNI6OS=;?RZB!)"?$H$JZI&DB*\2U%@UJSD*8$U309)D]$^FRQG& MS?,Y>JHQG^'4A8%Z]DQ<5ES&8M`72XJUU>A]7F%,69;2(]H""C2D,`M/MM,U M)%57J^O+F8AF)*C@3IK+Z#Q.!1M("CAIL*W6 M;AJ`]/M'M4)0G!HX8QG/'F2FX:3$-Z$K"WA>8303>\S&5*T0,V;ARSEH)6G0 M8,(K$C-.=]610SX_A_RH7BD8P"EY`W`/R/3AN6*Y6VG'ZGZVIS0DA2[4(*:; MH&MD8<99$JMBSG%UC+_P^U:+;T;FR5%#68ZCE!2H:_0WYZJHTT)36&S@Q,XU M8.AZ8RU)_&YR/LAQXUF(HLO%MR"@HHT MW`!&-W`JT6RA^\;R+5EPWTP3K[A>L'U]1Z'MUBE(`'BU:8!2L(CD:-&P]BSD MV=Y0JJ][VF.MU!L#_]_>GS:WK23YXO#[B9CO@.N9OL>*@-3<%[N[(V3+]E&/ M;>E*.GW^\[PY`0)%$6T08&/1TI_^RQ-IX?8G2\;.!E[[#.#6FI+C('F"NP;<).R M?44+7KK]N);Q;[FE;&$FW$:CDIGHVZG>%>@V<$.FZ9W^LBT&LHPO*\I2,$5P MO7&\M#=G?F#+C5,?D;':JRSL;MJ)*@3@=G;(*W!OFIU&H]WIOG#,13'%2WBI M:WG7"6S+;=D;;G.A7`62`[IQT-*1W=8>2]E$+!'H%6`Z*XX4-AZ]%LQ=UX7_ M(Q\`%L'*#+;Z!/3T'0NG^-"[YQF;PU5O#I>8LM-N`>+TDF&O$5?_#5X5_>8[ M+"SDT5Q_UD;WCT9+T@Y_#SCME]=7&3J34>0ZKA4^(S[&(@SYYG")]2-:6TU! M[(LHR+!!'KK(V#P^B#D7"5[+/7?>3WP=N2WD18Y$W7`N*-2`Q:=1^:(!ED?J M=1+:$]BW7(>NS>!J9/,6Y.?L\\+T_MY9.0PH&O;+ET$1ELPZU"]Q!TB^^R^7 M[T(P'*X'(O`&Q=H3'"-.-K<@9(URHWZ[WQET,UW4E@UBOXOR#RW-L[#9A6A+ M$4QG@4_F>EY9#5?SH--J=7>PD(L%@]]-*`%S%DK/VN[_T>QP)IP[#Y;O/,$6 M6>?!AR1R?19%E"@243LWI/Z/;["%^_'%"T:6]RNSO'ARZ?O!`^TQ/B>^\]7+ M/$4T&KJVPOCY#NB-D&VP)_SPK/\RQ];6,KPE7".]QNHEDN%$$3"4$,!,R9N8 MCTM?&^U:7-Q&E/;%S.9J&6TVV[UV+P=AM2Z#ULN\T#AT\!Q=XG>B>'8;2]RQ M0HXLD4]IM(C]!7NJP^!8>TV3WSG3.UPN8L-\'&847_I1'"9()[R4\1Y"*]F% M`2EL4PG#6>F2[XM5J_S?O'`M(KYH!_SYXO(C7)N$S%G(H>(=8VL%)EBKF^MY M4_2V_)#./2]XQ,7P.0@O@F04CQ-O5:[#TC$NC_STASV]K^QZ;\\8W?F?N=&^ M6"^A^X]OKN].DVE&3BS_?G[+UVKTW_SMNMVX$#9NR8O+':#UM.X`!S#`3G># M`::1)7XZ^GQC/7Z#E1#"$J2.<,ELYKF,9T8AX%'XL$$?K]8*M"Z8^DXS.J^C(."RYBY&, MZ8R+\+\2AE"3PF<"=\*&\5KWL"/XE1?E7HVUIV9IQ;O=<#VT[QWQ+H-;-DNR M6YWFF[\USOK"=]HQ#]8["E/@:1=N9'L!>NW+],(?ZOI+?P8C^(JHE&V=3>J" M#\_JSU]=%B*,Y3-=7L"SY8Y$8]6!6@$1.Z$^-^H5_D2S.>@W6\.J#+YPZIHO MGKH5&*&'P(36BYFPW/=Y9?E=Y&ZL@)Z#34>WV:_*T'H`"F\#P^DR?+?L3*[8>;EEF&9^ M_G)W90U7;\[KW8R>M1Q>?FV!ZF[]T1KPV2^+Y`R0WZ*3D4ZCVQCV5GBW?-#K M'H0L\#%ST]W2$F!V0/NJXL8ZNZP,VRLVL?L8J8[ MVDSO@/3ECEF>ZEU,]+J;V-)(7J>%5YG;UKF+-7Y=^K$.*,6/4_?#AC7RC!0; M2B'K1\-*4U:]\%NZ!]!2AE?HI7CGY>P1?!*M[`X-*8 MS%[=M0RF93ZZU,+HD@YIN<[P*Q>6*XM5G:H&XG132V4(F;R#!>X@\J@M%M!\ M?C%^J;,HFQQ0P)LE;N#*S.+Y,2]/S)`E!2AW7,4L6CSD!99(96N3Q;+^H)>3 MJXTZU34W>#Z3W]D5S^T'-@Y"]A%VDH@F>+>L M.A_#).V=4YU5G%J'!2\=2[)2ZM#O!HK-(KM M8*A:*Z!,^\U.2\LT6?;NN<@D=R+$(.=,53R*[.3D&-G6)Z'X!HR@UM< M6)1Z\++5EZ-[C?`<)IKK"*`OI"C/H$WZ.JVN'V@MPS-%6>OG1&VC[D[Z4EF5 M05MB04`K#WBZHK9EY7`WUG"%NZ\%]0\7;`KNZJ*ZM%7*?1D4*LZ?JM/:=.QS M"D3--R)7.@Y5(V#6K@OWBFI_FC.1F[X$]6U'=2"M93"IQ(MACAD>FM?!Q$B^##$(J M:_(91?Y^Z;P9K&W.>JNXLXJG2?Q)`C=?Q>>F*51L[O' MX&X2)!%8]L\N;(N9C^C..N7X^;LU+WX2!*IV%1&O`*5-9&:100/`ELJ,=SZ#'KB.>*EB?]9J>K'>9I[]I\&,M6 M[7)CT&MT6GHSP*V&L88N6P&T.FQUVJ4-8QDW5BC[]K"1Z5>Y9!S+!(J?B,X) M]5IBLZH?6*\W&.J:9*UQE#GX)>Q=`7XZW]UW;X-?0T17H)]2-V#P9/JO./IE MK%_1\&NN>_!6@^>7P`_",?O`?+:5=EP!>MKL]5KZX5WA6U\VN&6\7-O`E#JR M=61T!93I[MBVC@@N-S6;LTV".X&4CER?[YI3G"3_C:@L=LH#+3PZ;YPU-+G?LASGY85(.X*0:>>Q7/?*AXU.SG=$_QKPJ[T\ MIN,*,EY,]>YG?8WSW)U0O;"F>.?SW%Y-\2I:URHR7+.(UQA#*<->X+VV\V"M>QGV)G8Q.]SF&HEQ MK48C;]"6O/M%PUS$U>8:OD;)PUQM;W-#7,,Q:+:Z[6%?!Z58\-JM1[=PGM
8Y&7C1`0FFY=58TJ^ M%N_=>"O=7@&WVFSW^JU,7=7BE[]\G(LWTNT5Z*MY@*KU1OAI/&8V;*X_/=D3 M3)S$.NR`C&6<7WZ@TBB'ADT;9ZS!_]8*1/%A M=]!NKRQS6=*I8MLQ+V'V^B"@&X_V*KRW?%$/"@YC%'C"6X/)`8F]\OOI^]\YHXN<[=\HBXSM[-&Z"J>6;_`O30&R,L?'F_]['[XW_5,%R?__\L?F-8GGOO__4- MAI'=\3.]#U_W9WC?:[U[)/\8`^_EBW,/I(NQL-%H&J>&/NLT>KQ3D3*J`E&K M:/F_UG3V_K^:O<;[>0*J/&Q]L%4G;9\9;SN1!J]7@WZO/S?&5>^\??$>S::'=/`Q6\:]"30 M$U/LS`NWQ1,&`\)'W+NV86G^P%O\21O#-Q;>LS`SB&!L4+^NBR/>QR$4_@&_J'7L:<9:.?(F"7`_HCABYF/&A6\4OR=L^J$C\4Q'MUXPEGC MPWBS'*/?LE^!2G]P'_!9,,?KCS'+(2%)\].C3P'?(Z>S8,A(!?)UPD(&5@>A M3'`@.6G`0Q'+?S[3)LFX@TO$]YD13YCE_"NQ0GA29`CY_&*Y>)H8C9+PWC2^ M`0$>C,Y4$C0+0;K=F>49`>S%25>NN)=N_3V`+WW\,HHL>Y)$+(ZC,WUDL#0C M(`XHTA[LHDS,F#^Q[I%K%\R?6N&/L\-2;H>ID[E"OC"H7)M",NNM[,N$]/(;/K571'H:]R'[E M+!#8W'^"')*28&%LP5M#-_K!YRWQQ7=8;\_EB?\((N(EH)"X)HN9/?%!O.^? M#;XQ%ZO.9]SX`JFH!._#X#&>9']"8897_F#/!HPK"GR?>=DK0#!C'"#*$!EW M;*H#7\+E\;-:.^IY%JQ[4#`2],.P.=Z',9;X1`:L'.YA6;;-9I2F(STOZ0-3/\S3/_$U^`G M+1VKY.C!7-4V^):HJ.$^ZD=X/@(2OP0<=Q>DW'])W*%=U;A#!.+VSAB<=4%. MF\TST"FO%M;8++30$NYYL]MX;_"3/UN4WB$7*BP57D`'01>$7INH#GA.O2`C'M&"N\AAI M.<(.G[P)U-(A0S6J?"!P?94[`U]&8YZMB3]Y+M?'FG/BHVN-7=E@TTU^W$@D MN)\9MRZ>B./_$*")J9L$VF/!3Y@5*C9V."[73Q@YV/23:43`1W<,GA$P#A12 M)%W"U.AFMV_XU''B.XSO$S7;#,8!'#47G+!X$@;)_03VZ>1$>?"N!W#SP#5+ M;9J5`C/DWD!6Q,D,#%\8\;`*!E&X+8>GO-NY\-U]^O_N3B^_7WQ"77C:0+4$ MGOB\1!I-4%2[7DS<'HH'?;BZN?AT<_KAZN[NZANJ[2>#)/F](7[Y^NGS7>;[ MKY??/YW^^NGRRZ^HUYM=L)Z_7U[<_8HC05.J\\7X"+2,0M>,0$>=1JCGQ05B M[$U@CGS3W=5UT0!N^)O4#V]T4[["1!MDX__Z!D>6&@!ND/F?CF3$]?G%Q>7W M+RDG<(KDEX()^)6@5]LJ#NYH`_:*P3]97S=G)/[8M^V"N*_ ME[+\E]S;?S%_H??_4CP+C;-!-A`_=3T/S0]0%B%\]REN-L#LH/5Z*XS0V`UA MGRZBB&B$N"8N>6#MXH'!ZQP"IQ2#FC#/,4;/%+("BP9>%EJV$".I]#U82MC6 MN6P,%HC9"097X1E@2V#HCPRWD"R.\5JP9;@70HL_XS`C%$"PB#I\J,PAHQ>+ MZ"AG2,3@9V?G'&DMY`AG!=EJ"QP,JFHC:IXYC>BL\$",;463$W/]%?=G3]QV=GF6;=8>^]&>[?.F@NW23ZC,U;*-N0N.,;" M7-_E6XEDY+DV[CC@^?X]G5%?7E^9N-UPW,A.(HQOC9,03\2-$?."1]I:U-J^ MUO:UMJ^U?1WB>JGR[ITU-M#=NA\><4<<4\9A('BVRG-V@BE<$83/Y)CC\7+GJ>/PEZK[R M!X2'GS/L&]^L9V.P*,,7/0.P_IBLJG)F^3&A&W,?@?'<23`@SG+%L^$J,%KF MH-LP&XW<8L!JBL@TF,6/*C$?C+),Q@88;8,*M`I7@64X+(:;A(G&KV>BEXOQ MR'L>4/J+_,[R]5R0PN>"WQ/C==)UDCX3'B;R37'9>B''BQEX8,B/,^-JS%.9 M`\R]N4=$TE1-E#V.9G^!C18C([/XAV>0"=\7(E MD@JMXD\/PI\9U&61"Y##)XV2';5K3`,/BL-'['Z"MX/OBRV=(I5@!#J5IW7! M9S7UC*,5BHPL/A^HM#&,G4X)Q;CWX_%3'C^.!9>QS=M*&I@QP$>H:,3,52;: MFE".EQL:P0,+3RW9=\0(>* MN%\J;_IFN]\!]9@[7^'5J7DM=9S9GP=O>2]%=0VWN_%\"LE^?$K0E^@]XA(H M542;9K/=,]N]SCHB:KSE52[H\R?E&\[N(N+!?)?ZHLY9I\!"$\TGP@DI.4B_ M@+#%+O^OEUJM3W>5]UZQ-7/`>7M%VM9T.?"E3.FACM&*)I4D'.BGI]Z)RZ8/1MOH9(+.1+R4D!^)GC;(P@3 M/-^($LP^P!(+E"/,9M,3Y^1Y$#S%8Q;5<#"#D4NT,/>B1P:;+GR@QVK:SXW` M)Y%)XB+_>YQ@=<3"7'.>6M?+:E$:/0@_3X'4:"`:QU[PR&VXIY)=D3C*\.,9 MXS)1,9/!KR;->]83)1UP*&T["-&5P'I$3$9)<(/BAG8R12?#%LF4:GA!@FD@ MO&"$4>X'I><[";P>BUM"((Q4AC.%_05566(FB)Q!^LUAGH5U=Q&S0GLBOJ(L M>/+70`M@K4&DY1S2&)3_!+,1$5,P5=%@P`A^(VWHDMG,<[D;'+L>[O>P!DA, M3#"B.@*-K2HYDB+&M%^$%U"06"L1]41AR@.Z223?4Z!`RKA''4]$:=:?\3$@ M-3YWK/642WP#+]7D?-`J3T4Z9F$RK!.00,BW43U?VKN4IZ$0CW`B;'1^97D! MK\'!HB_,Z93IKGA1Z%`F3@0NOC7E^P-1."4_%M^KI\K2$IQB%1(*!#BQ('58 MIQ!-2$ATL1DQ;77(C%@4-_8$,H((3<=9KK!^.<$#E MSI>!E);S3[5][A2I=M`2.&M4`6#L"M0&6``R5?#,2/MBJT<6%!8`L18903*A M:@\>)IXP5R&[3SQA285WD*U=3)O-TO42=P:UGXBVD'&Y_?31I%1'.?!TA*J6 M%P,?&9,,;WN>LP#@(O!"3W47O7@,`P_A/NFWL]LS*F$-J5CSG,K9 MX*=4M1C7O)C38[RV]\OY^;4IJE%Y1+60F>7,B+`6(RK8X*F3@?_/Q,^%1.0K MB@6%C*DF;2)/4YBT9_`ST+>#VR_`2B$6H=%NBA`)E@9C*3#6L;J>1"[`VV"^ MN%4N7>0"D_%]GT%2 MC-O3YI_/#<(<$`\)9N"E<=.>>NHF8B)@#:62--W?>)L-7XM*F1#7`/=XTFM/ M-*\`W6(NP>/^JJQ3E#)3-%WS>E') MIEZSE`;P_!G?8/C@*!NPFX\GD1"/!>]`0>&BL$(`%@PDI!";8@:6ZXB-#,^2 MSA#!W2IP+P,;6*J&C9L)8$Z$Y=0HT'P\\_(\LCQ29-&$L3@5&HYL05%G#!QC M/TEU#K=L;9FPH>##R6L@1U531IJC/J]_4)NLH4Q>8VM6Y8GB!84G`P;\/8DV#4Q"(L1I M:P>N4\0*TS4[\]PIMKT1;HK:]W`EP,L*\9Q/;.;;J``KY)%Z3(6(AZANYMK[JVJOYU:;U.4WTHM;M41 M97MU1"_?777KW=4^=U=B:@TYM\>VC=*!J\!+!*&4N&<%T$T_=Z@^MJ[F_/OMY^O;K[)O,%,U2U)ZM=/=W>?;DYOK\\_7G[_\DZX M>N\-E7#H^AZZ4/_'101NC',HZ6[/G@H,A91OD<;T^Z^7=Y_H\9_2AW_^>G5^ M)\?T\>KKU%CAD_D-6JR/50&'IX ML5`D\NB4]ET.F!@KC`P.%A3X\I0?,5'H.'8N\`Q[!&P0A.D8I,DQYHSM5^B= M(HP*`V;3N;>*9UD8`+QG^3?A/L>"\>(Q>J(R!^;?ING#C-MOA?)J+H`\1FKK M?6*HEATQDO!;X#/N/,;\J`S,+UB47R**UL;`6;ER):\5(47OI=@:L%A.!';#/7A.8C$2BH*)0B\V(OG?"'I' M]^N4&_>(>R-"2L.41-`\RI?"Z_GQ$2]>Y:DG3/CZ`_5E\:?:.OSF^_1X1F*PR,>W.&&UN'*7[63("P/+`@*]U:O= M\GVZY;\)?%@Y8\=FE"YE+!<-S8+(A-R?XSDLA91Y5#V-LJ*M47$R@K_[P5*6 M\9AVFE?!PX(60=MKGANZ?5,5]UCDG8HP:1JQ$Y6OZ/C1P?F"^_B;')&B$2\Z MH$[#L/-#$@D=D>Z^1LL]4)%CL1EDE*FS#L^-(@ZHR>.7&+O$$`VA/P!'%@=SPK311^X78,S2P5/;<>*EX24.1X'Y'YBF%(S0+XULM`HFY8$I M\TYA5A[AU0]Z0/(3&5FEWN#T/4^[Q*,B8\RL.%'99FF2IL-&L`EQ%%JQ];1L MOB4X13HD19DI,BY`A.'=ZO0()@W>]._T"\E0VE0B#SS*?\`L`%B[IQX%D?D0 M3$T&,AD(11?C"1?!,\J(MTTG0(Z+R<@R*HT0TVI&C\8B9@W97*#*:B,U@T->">9(-DXDQ8G%BFTY3&MC0!YRY/!":7(Y<3D"[&GXIP=(]%NZ^E MOPO;4\WU)7KY2<2@5OK[5/HX?VG&`4MG\MA4?58IO,*\;)"VK@KE(HK?3-S[ MB?S3H(;)ZI%![>0J"U5O#*PX6$"(Q\#GDRTM!DSA]*O[]$!]WE&]#W%3-]^ MOKC\>(+/3G#K0#NA\@LL6P5UK_,2$331-DNF#MHPG&`*QO7,^,AUK1L1_#BE4JI=`0+&9@)CEKIS0>(GYH.Y M,@QERK(BS(;&$<`N$:V<,``R@GIF%"P)VG0Z"<_J!F:6:>W:N1K&DHNE.SD< M0\=Z%C%AA-*-Y8&_C+0BD?E)T2VOF`&TG6,J?Y?!0.*C2M(=I2X3I?(:?D(' MY[3AL^,@G"O*`IMSC[X3^$GNE!6*%K69PA([)V'FPCVGS,/FQ_83-Z+XJ@PK M%DJ,BCBDW51F6):%OLT(EHS(I[\<*S:-&*52)+[L``?C$SGV%)^86-2\#BO% MTO3=QPGS>?@]>X0+G)N",>6,3AE:'#;&Q-M2O:TRG]4?FKUA?]Z`*.E;FH$] MEX.,^>/13#;86^%\;7"V7%*-_7E12DB^C8-3*,H\./T8I,M,E;O""%PG(9\\ M9"+[DI6,+=/,(B?\B=A?[AN:N3?@PB8TD`)V@,Z-BV;_`#C9'V;I-'?`RNXF MK#R6&-A:^XO\IN12GJ>]..S5;M3[D'WN0PPY=>[QG?*7J@TRS-&81GX'Q=$= MT?93H0^>Z".NUX/=4J3Z]LY(X4(,8H/D1=W^\^OKU_/H6:*%]VRQB[XVK M?WRZ^?SUZO=WQH,;H?N=17M=/!2!NCEWP6K(UT4<"24[%'9M2YZ8<>LG?]G@C\;L%"6+O?.#Q]":B<57178` M/W"5P6A!U%N;\D;MAU(FP<:H%I%:1!1OY#Y/DY!F+2%K0`;7=J86D8V52-Y# MXP09S=0MJBS#7J9F<$M?BTPM,IN)3*<6F=H0U8;HL$G/Q`'FM=>NU,>AL:F6 MD%I"JB8A+SG83LF1N[T\0[9-'FFKC5:IF-=O/@Q*5>//7B M>?7%TVQWS5YKF^.@GW7Q5,2/J50.O6RC>S8[6JRX"%6. M7S_)IK35[IF-3KM>@/4"K!B_?I(%V!RVS79O4"_`0W.G*A46NL,2MMHE+T\I M(5P8U@M[;`=:_,6BL\F1^W[B^1NRL<)[Y:UYNX7N-YO=KMD9O)KVKU=NO7+K ME;O%RFWWAF:_TZK7[59>6UJBON0]&7YL4`RJ5?8NQ9]X`<+'FJ!EKU"OJY53 M%A)]O"TB,@3L<-#5*%S7:]7U?GOGX7T2&;]/L"W/%^8CK,XW:S;#"O;;YPC[ M$R$,#`(0QMGL-P7-+AZ!)>K)E,J3?[AQ_B[5\8?CL?^_Q+5_?+Z\_95^O/Y^ M3G_#?7A,[22VA")?\>9%($2>-0I"BY"'@"D/KLVB,\4!WK(^?!#0\#KTNT2W M=P5F4%9$'K&S3*G@/_W^P!QV.MG7X!A*?:B^GO5AA:?OR\+=YBNUGCG.P3YT1,F_$HYFU>E@\?ZZ3R M-JW2`SQ7LB'-!,$A1J@S^/EC,E-]OSW"4$=\+&X#N<5$[)9"@RIL&P>A<]%D M/C#175F]5.$M4C]!U;J#8\*,$4G+LVR.HSNSPCC3@T4]1+9@^3W[A>C"]\B\ M!XF$S%'O-$IYSSYXX^+G(JZ>["S.>X5,+=?'B[/C!4/M.RS,/"+[/K2_XA>T MZY4&UVN9_6YC7E_L`UOO&`SL4L,Y!R0&+IT;HI!?A1=N-`M@J5V-OX)B_HH- M:,ZI-<7+0<9:AVY\7]W8'X[E3T4*EREH8M!E,0C9F>PWP'4AE;QA MV8/+'L4NRDU9@QBI#(R2@=#!,>'D\^ZSO!6:&]K)%$PAX=;F+-8[ MDW"<5FX;>2,98VH]$]#O2.LMA="3-W.-ID3C&0[-/V&>(QLB.P35RBR.?@]& MDW>HM4(WXHC$J\8`C^2=/=$PN1&!&L*3L($GX?J/O>`Q(E1[FW<8PQ%PV.*8 MOY$:FN&SY@8NQL7A^M.N6S@2&$+F?=J[7&P6B9V,4P@XL/.@[PA3R_!@&CQN M)0E4\Q'I\T&)P5M`$%0CKLNQ0-P7/7L0`U?@_RHZ^"QC#TQMODD4[.#>!Z'# MOEZ<0,XY]$I4UX(BMO*7\5!PM6-3D5:#D208<#4;G-E9R?C^KNCI'GZBG\_<@9C?, M88QB.=>A:%1'%UY&4;)U;X%V^]#-[6%9O'02,_T'9W)&#>KH?6PVK_H;3,_C M?2O%?H$BLN>@AM>9+1,MLKI'+4Z#5J?Q5L=TQU9JXCTN+EM'-#/U&6^Z3;UR M2+6G/2N%TD9U*_5N=ZYYI?$V`OV-:L+HG9R8/"PJ+J*WE`RA;_3-=K]C#KI9 MU&R-B>`%@!7A'%I$95&8^/+Z2B.F?U(>Q'E]-K+C570=NH'JO@WS:&:]E(P/ MLG"]H&<`2R9D%'.1[IT-7\@>%[+]JO3>L&\"+"9J$,!#'-3+`6Y)1(.-Q`>C MC#<\H)<&?E$4+':0'ZEC*K@JEB MZLILF\/AT!ST.HM6YB+6@QY+8MQ(H++B,:&ELZ1I1\&18!9K&DMX,/BQ7-63 MC?C\2;Y/&_U:U$;)Z)\4+@O`%0QC"Z0?O<&8VG_)YB?3N=YC&6VUGH4@=MD> M^-WNV!4^/EM@7A)&'1UU&*(:GI`U<9\3QQ3892!J([K*^DNCZA8%WG"=! M6WO$>=?ZAK??N>'[*V3SRR-6G=J%WJ\+35,H]\@XA\?F+^O=A50H()*]HT`Q MN%,K=+UGWND#CSQ(U8G]-AW5\\-Y<O$[L.Q[RQH.!3?V"G/?<'((*X$_1MX5!H6/OQKP1%PZ3FI'(>(_J:82=C&Q+Q+&0%!$U0J-0\/#,P9,; M0,%;%+'M"K]!:"L/K\+@#FSI2>R90:"`1(*KV MJJ[P!["&CLCQ/Y<=MEQ8*R0Z:6,?G-MHXO*S3)2#"?P/R0;*NT@JHFVF%!"E M"Z0?+4]`\4E\^>C"E,K1F7%;^"+A<^=>)P]'23O5XK1'4I)-+6G6BJ0):/SD M?)[>I*J4KR+X=Q1]L&>9Q``7[0/L^%#58R\8I%_D"'Q(7'0YE?V0>EVWAW,Z M/AN[GUMUD7JKL*"I,9"K&NR=;\-:Q]V!L&&TN4T;[V5:!6);8PM[-\(/)F]` MC`<:XF%&'(I$`%RTZE>5&(A)?=FC"7@R?(!M"9HFI%9T1H3=[8B"^RI^D^$C MN@$^MY%9*U8O_@J1LG()+)-_U.O64H]IK14RYP5EY^5PI*I MO`M%8>-G'X$>R!"PN&*B!%+F.U%I;:'6#R@L=Q**'8!SY\'R+YX,Q[7N_0"W M`TKL=FO^=TGSQJ0:\?/,M:E39H&HHUQ+OWFUS)?,I_DRF9V*XBO[HSD%="L5 MD&S!)]P8XRT&Z`V*`)]:'KHBH.#=Z.2(_->;HFT9:>IE3,+?,_X>23`9_)1E M&L=,GDVK`CS'I\8/QYW;;NVH1O$J25AN[.F4P)*:_#A6Q8IHJ15%@>V2CT3^ M[1K,,3")3(0R^4\BR9I#=LZ"D%Q9N3`H_I'+4(--%#F#\E$6D&!-Y8/J-53Y M-42G;[2_+BA<^WE73P$SM'631CG$NL'#@1&#+T4<@SDB6(UKB._(II8#KWFP M8'^#1Y"UM3FTE3).2)T6';)D#E..<]%DMO?KLD(D,./F0NLBG0^L8-[!%M&4 MRIXI&11\6IM'LB(Z2D;HHM(@L4C)"C&K&H:GWSEUP;6-P8>E(N=%;C*-F+*R MU?6ISDJ_0J[:$Q<>P]45[O`2II]7NI3=\TV]-!]#UV3 M#`%L#+RC?:[K/P3>`QAD_H.(Q;"G' MXK7H6*'$\+-?4`5X:)LRGA^_9I8(11"U`RZ0OQ]SAFP9!X\F&WUENLM&;",CHN/!.\X$@4 M(O,*6U/6"#LBNG^/&TS32")99_/!L^P?I[J;]'ZPV7:<+(& M#$P^Z7*U.:44QX#\:1I?1%>-IX/XE//98]2>>*08LR[F1J3@WP`%]AX[DZ=74];:\ M;"N@;;2Z M2E$H)W_GM8Y8Z"?[SJ%7-1[+>GM:(*>T[K/Z!-/G4"1IF4?99^J8/^BDG(ZQ M"B\4RL-%$"B04S.57)G!;CR[S'.T'\`M`R91"IWT?M1OGCM.2_]H*,?BWFSA MKS5[+1ZGF0/I>RJ*QQVV)Z/31AZ,V+^+;6P*X<%K MJ'EF3UKUS"WMA:Q!@,>H*F3M2I?->4?RT%_I#E&:C4]024$4'1"6787L5#F# MXX)2#/E5(Q8_8O!O[/J6;V,N$>PI8Q''R);=4)2"9T?#>&./<4N!NU^T+700MYHJ-#3">M'`%"59%Q)^RHY> M@L>0M\2M$2]I(I[01*%-.S/.-4.,$:='RDC+H?!0*,5GV-+,X@>',.S$9BD) MKA)L#5)`"Q7,L0<6$*6>%JZ:+2N(%D7O<%2JZ$:MA0U+X[DCCTL'8Z.T&4`> MQ&X*IH#-4AY=CX,(T$N3<`9B4Y0F>\@>W!$YHW>H9&`O-795JK,;O[B(]0PKV30Q6[P]&VS)P$#%8Q[]2 M^M76ZAY69\P/-_UR*_RZ^0H_P2P8R(BAQI9Z@;-%[O&$`N4`$S*546<0$H_N M-VVS$V#Q#S]X!(U[KVTJQ0Q0TJN'98`>>P#7'KQZ3+L[>$$^IC69JZ(=,SP6 M\0@Z!D%'.-"+%T2\&NC[U5>3>QV@=GF0`":]7.C0GME"7,_&,,-<##K)*N"4 M_[(<&-V6:.;&?!L(H\P.4@9S1NS>I=`X0:&2`6\U6JUL110"^E`NJN:WI8ZA M*#&UP#R%/C_T@:7@3I,I78@>2$S80>@]9,I?S[THP#"66B=SPZ17D\921;6X M\_5]+*.FK'/A.T3B9)T7=]\*2(#VH"4??>G3\#R5X?HQX)6OS>&@APL8U)(X M$%!HLPX/Y84BBKUGA\U*5H"5QHQ4@G/1H+[Z'\?$R3-@BUN M?BO\R0JQ3B"Z9B%MK%^^(^[7.^)][HB_@JI#CY['L(]M3_P!]G@VJ?.41@[8 M.9TE`@J,XF.H]=$&T*69Q!*)28*W2G0"X4<],@Q;HPN$^&'@$/@)^?7R1&`> MTT2'&Z@CR54FY3.O!2:P59A%E`V^#^6^L$H`X%MN[B^C2X['WZ>.ZR5H*DV# M_@()84)/KBF&8LN[J2">+A9$3?!F7L)==@12LWGA%5BT61"+XBTY_,PK0:F* MM!.1\"'*R>=$7,2I:<=`W\!.U9Y8D<*.C;2SGSBD;<2SN)2'H4R9I[T0&R/_ M.\$9I4]UQZ8!L5:?@1LRUT M/.>%7(EV*NT9(:!['0=B/2,ICM],0C@B)J MJ>D=#DI#^PK:+E"*)ES.J[=5Y(KK-$L>LQ;/J$GY1F5NH\J-)9SU%T?5,.7' MD]O]RI+0.VLN4QASQ,C()<4K>CT$SPE'*@ZA:!+KNVNZ,[_@C9B<8 M['DOX+VXLA$RS'4,3^'@TBSL\UN4ZA--\8CE$.E&_"VBB:%K(-7R*G6E^(PL+ MZUSENU[#G@?^Y/#\XA#XY3O;0;VSW2_FDTV)G6D6\RPSK<>VU[WTC6_6LX86 M^%D=*:22;4CX_LCX$,`_%`_[?'[[P93@HO>)ZU`$#"U".(^;)4L#>?4&(N(A M!A13N34SA"0/DJCP7CU""'K:`W;SJ/L4D5_44:[K.T!\^'RJTL+EJ+AE46,4 MST.?S4!W+A8'B`B*KI68N'B6+0#X7!OA0D&28\3B`@$G/%(X[\D!!I8?X$ M1\71+,&B)"$5W]S#I7(60,\GZ&;QTQ@3\_,DG`+JF@G=&G_1`9# MJ\[!V5%`!GQL:EQXE$O[7_>!+>WCQ6MW\/%X],WCTH0O\G?+3_#8E\>U!]RL MD6]O.0(9TB6_<>K&W&&V^'.R-_8S'@?M%["2#D^J#"8.H>7>D.RD21GV_K,I M`[V8,@\L7Z0M^!1PR`9>L5!T8%=O,BM$"NC#\^0>;M)5(FBZ.47'E0A.>0K` M082(/3?!* MAXU=37^32H)%5>X1K!QTJ_%^CD)3_=A\#VHVNPG)J/$T9X11*7FJ.V2F,B4Y MNE/EPTH(,5+-BFA0L[`^9YCA*:O9<0L@]0`H%%+IF,LCTF;&BQ!89I@+R(_! M/+`M4JG/$XEZ7Q$C`6)U+>V.B^\415G\X0Z?7:'P5PS+Y$9$8^`3F"NU M1.=?C^!C$]P2B:TV)'/IF"BDJ<;%C58O^S[,R8DBWLA*Y8ACQ0ZI^G3_(;E6 MF.G`HSRX+G=L8OJK3$QM26I+4F!)0)MX%/*8-R3:3!?8%)(*BD_G`,0WB\P;+EKIHR0ZR9\9O*F=:7F%J.\UH0BZ=6`CI?;2&1%H? M+*&92(#![#?Y'JU-5,A/T"*>D8TQ0IZH1L$UJ@@QJ373+!;I@.HU>A,M?O;U M]?+SE4QP"1DX'YYVN4SQ_E[P"E&MK?5]S.$Q;QI^-P5H#1#LXAX%K[&Y2UV[.;6Z M7*(NTQ.>]74F1YH$$1NKOBOR&EP%^F(2^P/>FI8+N%;#BEZ+5"<".):'W!8J M8LNFU1NJW&>QG$5G6QE8T]\'/ZAT?43)$(4D&OZ%EI=3,'97XF!GU[9>S)%] M819`=*WXI7#Z%(8\9EF(+''+5BI/'"^EU3&!VMD"L/T4+#>;+(CA[+6Q8>CP(Y(%V?SU",5B^0%!L+;$3J98OH4RX!/ MA4<]O\UXWRF\=,0\Q#`1'4*=3/NE*%U"(LT9-VT\E*EJF-5),QCHD225,ED?045/:,O6L[-2)-6N@#N<$>],CZ?R1]A=1,D95S3"M]YA;P)N) MYC]OC+AP1(6UD9PCZ2L#1UXL6(*YRD]6)3`5:2F^!^AY;"I%?[` MM%D.:H?['F9/_,`+[CFFAVKH(7'2L.V/R)`CB``%QR,!@MP02[;&"19@/;#R M&S$VLV6:9JE/SV9MEIZ@F7L\5?'G$Q]7SA]'3\`$%8&=H'5QQP`?%9:)0V1T MF%)T&=L-[62*#II-7SBN2"]9T)14[]Q.I7;HS*7X`;S9Z"7M).33$)R*=*S8 M@F8K!?G>+L8J7[ZG$L\1IQ7/%-VSU.YYZ7C$GA3CG8DOCQH(+48DHS MTO"T,#DUDR^4!?M)W\?A,W&_C/$`32YX"G#*A49'<-!5B7+I9L\(>#FPBAI&.;(K^.2O=9!O?D3/&;%J?UI,`V.*1H MIH+_G[#6(CS&X''(\VQ>ANYUZBM*"UDIW`ZL'9G-PN!)0LN56D7>&K;,1B-K M6X_-ETTW,_F5G]OF'#+)>N"'Y`:SR[!C3-8BD!'686'H5%[6SO,<-1XMO;+C M@,*:!):$6,;HMX@J1KS3\J)`O06?2]%8Z8%@?RKR0S+.AT`-2B.^9B%`B2FQ M?!8E[6B6<`0>["/9'K3BHL$U1]P\EH#.Q@&9?$3G2B)48-7VQPPH029TNQI?RC/2CSR2?8?,>$'M1*=9QYE>]N[5L18^8Q+NC%:>CM(Z=L,H M/G5]4_R%^:H\I4"4^O+H=%%B`YX"PD95>+A::(:>*['-WQV\[MYCZ$7SA9>2 M@"4P+"Q5XJGCVOG7RR_?W_&GOS?FF[#]?GEQ]RO>T/C3PK%P92U&\^'JYN+3 MS>F'J[N[JV_OC/\:LE$/#`>L;.PZY3KO#7'%UT^?[PI_U_J^O;.2.%"#&*#6 M%W=_O/KZ]?SZ%FA!4'YK%K'WQM4_/MU\_GKU^SL#CX4)+E]/Y5O@JD)0ZFXL+?Q1C[#:"(+.Q?WW2[ M?UHE;/EMW))=G#"M!T)[<_>D/TYP3XZ2Q=[YP6-HS<3BJR([@!^XRF"T(.JM M37FCPA<:^E7#K$6D%A'%FT)\M%I"BDD7>Y/:SM1V9CLEDO?0.$%&,W6+*LNP MEZD9W([6(E.+S&8BTZE%IC9$M2$Z;-(S<8!Y[;4K]7%H;*HEI):0JDG(R\V, MQ\;Q-DSZ_:L>BHN+)MSX[^W8`*A\15SX?K\XN+R^Q<9,^_*$[O7YTQC M8];TAGVSLY6#7Z^9ZG"C7C/[7#.=AMGO#`].2%YOR53$?QG3?RKBO_P>A#]. MJ9`TP#3"UY*FK7ERE`IX=Q*R9V[L3A/OD$6;:^)6JV4VVLV#$Y=Z\=2+Y]47 M3[/=-7NM;8Z#?M;%4Q$_IE)QF,^NSYN?8OIV'7O91O=L=K18<1&J'+]^DDUI MJ]TS&YUVO0#K!5@Q?OTD"[`Y;)OMWJ!>@(?F3E4J+'07Q)97N^3E*:4V*"6$ M`,?A58=AVQRY[R>>OR$;*[Q7WIJW6^A^L]GMFIW!JVG_>N76*[=>N5NLW'9O M:/8[K7K=;N6UI97A2]Z3X:LTM7SZU:7SU6EN_<^]A"S_%B# M4\3Z>I=%+ZE);QU#3?IF^(/?@Y@9;>/4N$VF4P2"QP[3*7\S"+2"PS2=!P1* MN!E#\D@D1TMHX35EH+5^(*P2D".!$V2I#B,(%(#&B[XY-.ZN@_."JX4P47C/ M0][4"I%8F!\QG7[$/%O4-2GQK<1Q)8ITI'VQU2-3Y&Z8CYD5? M/IJB!0#I"UZ=>C+PUQ#F-!ICF$00V>Y;@;A(;$2&<.$2ZNHM>/`Z"V"=( M=`44/WHV?CN[/3.^$+J2OE:]1*C@7XY/[\V15SHRD M`.,ALS@:>^#_,_%YKQ\U'?(5Q8+B.UEIXUR0#2^H8Q9'C5,PZ&W>+ZNC4-N! M-6/78T[Z2I@O#EU>NL@)N/O(FK(4S(BHY`!'A<^1;>`D^'UQE[![%Q0'%PD- M.M\W/B.$W^UI\\_GR"U3M3R9N;X`R$Z[L"&NT=C#IDM2TG3$_[?9;O#%V,FS2%K"Z2G!8!_O%U!`4@W5[(I M0J)J#+@=J"`7A14"L&`@`DM0,L/U%"(E`O@+G2+O)=0IQ+/DX%1RV./$0\&( M;.`,"C0?S[P\9SMH*:'!?N'8Q,%"\,.04`]3G,DE:\LTL+^WA-?4-5"F[Q]] MGZX\7?^@-EE#F0>$3+Q/;VC.$UBB33.,6T.U*K#@M"^+,M%7,[!Y MM'H1=.UQ$J#Q"QY]T5*`6@##=]AH*1E%KN-:"`[UGD2;!B:&K/! M-T%=7'BO5([+RJ%F15,-^0C=W5RQMG;B]U9%U.O]SG[W.^!G,!B?P6,7]O.A ML7$5XR2`Z_F?;Q%?E?=`)Y_L(RQV?P(N%'C[%\Q'2#C>O"02W4CRC__]\N+J M]UMXM@C"WMVNGN[M/-Z>WU^W MUU_/8>I^/W7R[M/]'@]=OGUZOQ. MCDE$)Q4=L`D#GVT*:,A"U)NEJ#0U70\$EGXLTMR?F!]0D[80< M!$8+(_2[N2?.Y':-:VI+]JEV4L92&\ M]CW+OPEW'I9+;0BUIESS;[L3#R17.-=ZBU_-!3"@MCEHMD(V@4&A;\FAM2WZ M%OC,8*T**WDO;EX!:'VH/!AN<3!-.^Z+1 M(%/FW>SJNW\_C2%915JQG'`'R;@'7T8LQ@`;9U-S3[$UR/]&+99T3TLY5H^X M6T$9H[;9H'F4=X/7\_;UL.ICQ%=,[$G:YDZTD0O0^6$4[A\G,>Q03-Z!.[># MELCPENP1A="\.+;J2^-/M!GYS:?6JZ1/'MV(=_US3`%D/F8HA+P+H(PCM!KO M_UO]#=85'&OM)VX`]-_I*=*/SH;V^,6U`_T3Z+V*.-"_\<;#LE7QP1TPK=&& ME<=!J2EJ\:Y>[FT1(YW"L3PBG48HT2KHS5"GUH^TN[/6&F'&=^T44N/-V34? M"QVTJ8H9+/(C18@QVR09HP/3SVAW$_#&_P5C6P59C`-:?6.-IV7Q3 M-RFX+!V2HHPW%G"PZP>\6YV\B$93Z1=II_%\NRD/UJYH.\.'8&HRD.DX5'0Q MG@[%"<7;>;38IM,3QQVC"1,17>P5I&:TMEVU[=I;\"?3^:EPY1X:9U?&@SQ/ M;4Z6A"*P&9?+(P+8,T"VS]):YNC=0E"]V582*=,134"_G.)N!0&.Y&%S(!N# MI?RM8TR9&!,_HTY;H66ZDA6=/J*A`.EV[^B"?AZD@0X6/4R/N2]E)Z8%$N M!7B[$84S)N[]Q'L&XP&SX\PKE2!T[UT,A^=M`"8TB#P&\+LI7,*;2N;G.GLZ MB4>+]B*Q0"<7$S!XN"QKR]TXX1LKS"@@0X9*387O`AL>1H%[($;K2#EF#B8A M&??HY?JTC\/C$OO9>/OYXO+C"3X[":F=W=3E6Z!RN\AU&_-=Y.8XXE,;3=Q0 MX<;$H?ZA(F`)Y/)XH[ZAT7:EJOF\J[IKPI."B&]2\4%Z-JD-I,*%H1O]>`U# MD-5-Q>_9(*I8;:51$25\+@4'MGH,5AIF@1\8)P]>_59^@'<+?%-K7GADLT[: M^*MP$;-"3'.1P1ML!<4[#=-ELFDV&(./7`.YV(PXYAEPRJ6U?(-E8C*6NG-! MOAZF\;@R`F**AL8>)K%2,ZJ8=+]J.LR#=V=&P9*@'9.3\&1<8&:9R[&=5?]T M;%#BXSO=[.,=ZSE2[A1!SOFWZ-'`=Z#.V6%HH4CGEE1C(,T%VZ89/HL/]N= MN!&%]F1$JU!BU'99Q+E@"F;6,QWY!R-8,B(-&EMW"S;!;AC/VQ-?B#+&]$1J M-&VN)U9XSVVLEG6)W<9YY#=[S@>*7)<[.I8[F>KUOZ)(L=A76/(I<&6DIRAO(-B:>6$ZA*/.XZ&.0+C/9 MOAPTUH/K).2IJE[.($IE3I/1;&4H_Q.QO]PW-'-OP(6-L`%%[`"=&Q?-_@%P MLC_,TFGN@)7=35A9!W#J`,Z>]@Y:"]M#X^`^>68L8EK=][?ZN41:J7?=][?N M^UN9-BYU&ZR=DOX3-76M^_[6(K*"-W7?WPTDI&ZW6-N9NHEKW?>W%IG]B$S= M][.K%4_?]_;G\F$K% M8>J^OWMNHUEQ$:H@-7DUT^R`.N^OP?J3E4J+%3W_:V[A];= M0P^M>VC=][=>N?7*?7W>UGU_C[_O[\YPL18W%'Z%>EVMG+*0Z..%_L\0L,-! M5Z-P7:]5USN;G8?W263\/L%V*U^8CT@XWZS9#"O8;Y\C[#N#R"V(I!=GL]\4 MD+=X!):H)U,J3_[AQOF[5"<7CM[]_Q+7_O'Y\O97^O'Z^SG]#??A,;63V!*X M>L6;%^$&>=8H""T""P*F/+@VB\X4!Q!!!+\50.(Z4+C$0G<%S$]61!ZQ8TBI M>#W]_L`<=CK9U^`82GW+H-[BU%@#>[@.ZIT00/!A'$R+#JFJ]$X]$* M0\N/CZ[9VD'H_TH/\%S)AE2IA/87H;/&S^J2F>I&[!&^-<(_<7O!K0OBG!0: M'V$'.,::B^;E@8F>K^JE"DZ0>JJII@@\"\/4,&J^P\+, M([+O0ULE?D$;6&GLN);9[S;F]<6K0,<=EOVIFA*MBC&Z!"?/#:>B%2`H!UA> M,8>"1+#/F6Q/<$P&ZKJ02MZ=Z,%EC\()=E/6("HE`SUI(%AK3'C=O"DD[WOD MAG8R!>U,.-JB1SCC&C;6&QEP9$RNKGG?"=6C>Z0UDD&POYNYKC*B3P6'")\P MSY%]2AT"QV061^$&/YV,,-&XRF"%Y@>F9! M1)!(A@?3X''%33"&CTB?;[@.O`4$077=N1P+Y&_1X@-11P7BJJ*#SS*VIM/F MFT3!#NY]$#ILXL,)Y)Q#0ZG0TXO8RE_&$=3YG>-,AQ7%+!CA16K@MNQPGT6` ME*"IA-V.!CZ.%BQJ,G0H>9(!-2KBNOJC1D4L`>$/M.4]+6:M_PYFH#VZGG=H M7%W=/2]/+84\+%OTPH.5B'ZT5`[?6'C/0C,/4.BPL8MM+D5K,7R)'WC!/3=;$KB8 M=_G#$.+$G8E8)IIUTA0.1_0&0V=YD3>[T',6G1^5[WPI6\,M>YH3B!8UJD-/?GQOW3-V M9FIC5.T;%+].BA@"7B+V;Q7T/*&HL9EL>N?2UD/YE\O\6G'"8`"- M[:DKPO-^G-^51I.D9`,_>"='I(L/;BN@Z=>V;L:7A?[;P9HQ25**CL^W=+C\ MHDB*_2P)0;]%J&Y* MW[0XK2<0=@SMTJVN+UJMPUX9VU;]$]9:!*J1;.>9<0Y/E6UH*-GSOHW%`YP@>RQ8>C.OM M1<&#?23;@U8-J(WE,=C)AHIPX;*OO'H7'W M\(]V05%%$TMTN[]EE#=TCNIEC=DR48&I>Z[5C[?X([C]6K,PW$6(][C@.O!^ MH/!HGY$+P%N3TN:!7A>YZ5$!.M;2P^YFAD-]EM]&X*E_#V##UCN!;03YS^(B M[F"7VYO-Z)OM?L<<=+/MF#0FPF8-]@N<0XNH+-+9E]=7&C']D_)Z9QVZ[:[\ M*KH.7,##*")&AYH)4KH'C9QWUHLTK;%N=[!25V;;'`Z'YJ#76;0R%[$>]%@2HPN& MRHIG8RR=)4T["HX$LUC36)/`HV[,9TU7H6@MAE>[!;=,>N.+H$F0I";#@I?%%L7TG9 M,TK:8#>'W6:P_R*2!J(K*2T:";P>?(15)PP'GB]2`2U='4^2.M3*8`!*S*&Q M1F8CB;:D[,G%RS->W"^,(09\G;GM)V% M%?R>6P7F>3RWS^5-9L?N$QZ%A&D35:H>X@>*U(Q5!KLIT\&*`KR"$B<2WM\W MIA:S4=:"X'L64$RNJ0@@H]4;QX_4#Y@?Z$PI!,\S\::)%[LSCYTR3Z2%I,1& MW&.+V,S""#G<(3K*BRZ.0.1[=/%@4.C?NC%O=(S#I&:/,KM#]8S%3K&V)6+O M2(K($4'=6/#P3.:C*T^;'G(/A(R;0H!Q/X'Y(-E'=Q MJ$F[+2D@2A=(=U*FX.*3^/+1A2F5HS/CMO!%PO7,O4YFYY)VJL6IB@0JL?&G4B_2%+_D+CHR2O[(?6Z;@_G M='PV4V]NU47JK<*"IL9`KFJP=[X-:QV=9&'#:(^7-C;/M&)W??#^/9Z'8!J> M.W7IB%:F*,2AR$3'1:M^555O%7B)252V"9_-,QWE*/::T5,N<%9>7(5]\O&L9Z;A'8JYR; M1!Z@.I173U&J+X+5`:M.K%'*,)!?I187QH=)"/R<7MP[L>#MT@DV\9DPMQ:G M/[-9'>'YDBP)D=I6)61D'6=%EC8,Z>QB8K/U M[OT`MP-*['9K_G=)\\:D&O'SS+5!53T7B3IE60B_>;7,UPD[+_!'NB)T7']R1/[K3=&VC#3U,B;A[QE_CR28#'[*,HUC M)B_G5`&>XU/CA^/.;;=VV%/,:D67+R)U'ER_LKS#"Y&[U/L3`H_I'+JH5-%#F#\E$6D&!-Y8/J-53Y-42' M4+2_+D`9^7E73P$SM'631CG$NL'#@1&#+T4<@SDB6(UKB._(II8#KWFP8'^# M)XBUM3FTE3).2)T6';)D#E..<]%D\R[79(4HNL#-A591EP^LX/'[%M&4RIXI M&11\6IM'LB(K2D;HHM(@,>?="K&&&H:GWSEUP;6-P8>ERJ%%;C*-F&JPU?6I MSDJ_0J[:$Y<]"'6%.[R$Z>>5+B6Y?%,OS<=0]3%C?0E/5,^=P`8^3[J(TC/8 MM\V3^;'X@1\R9!L_-GW;.I'#DT`)V5MD*?7\2:K,5P'6LDS*BL9X>$'[)$,` M&P/O:)_K^@^!]\!%30PA^VY^J/NVJ+BAX"^H)-9U[P MS(3=[W'[9QI)),O^/GB6_>/TUD:@JLB8!@[S M%#@3VF:X3!M.UKR`029-J[:.E$<7N7%^$ZE5,*9>`-[P@"-%`\SWFC*YC_3T MF?$9S!>:$ M#K95;YHK1\H5=Q]PSKF`T&K)G$LO6%&FS#`5GL@L(0,\`<$$,1"YJ>AV4(WA M3!QWD^^5UFR+XE[Y.\<=0M`=V<(;?9[Q6,*QT0(YI76?U2>8W(8B2+N+I@IR:J>3*-&OCV66>H_T`3A,PB1+\$4B#%%"9#ES,_* M(%[(?'8L:-8*H+7"Y[P3(T_.U1(7:&;X!)590UML88!5W$NEQCLNZ*Z07S5B M\2-&T,:N;_DV)N3`QBP6P8!L"0=M]2E!E[Y;,%JN@6CK+Q$V:&QT^+,^Q0KB MC?L7S+>X^8:[0BH0T2TZ[/@\?I)D/8G]'DV.4.4$^8$?))09UHL5LP-?G8NU M"R`)GF(,XXT]QA4Z;B'1!-!IUFJJT![($EPYCM"!82K_:`=W#ZHSY":%?;K58-U\M)I@%`QDQU-A2+W"VR*V8 M4*`<-TGF`^H,0N+12Z;=<`(L_N$'CZ!Q[[6]GY@!RAS583_&>$I4[^,J1(I^ M_(<5F6.&9PL>@44@3B?'1N5`2:!HOU]]-;G7`6J7[^5ATLMMEM`S6]C)H#', M;E&LM*(TY;\L+46W)9JY,=^MP2BS@Y0QEQ&[=RF^3,T?R("W&JU6MJP((;TH MH5/SVU+'4)0K6F">0I^?G,!2<*?)E"Y$#R0F^##T'C*EE.=>%&"T2:V3N6'2 MJTECJ0+-%'R$4K>%[Q")XVE>*'PKRLO;@Y9\]*5/P_-4FNC'@%=1-H>#'BY@ M4$LBJJ[Z:S@\XA9R]-H1I;?2N0%Y*:IL>'[4I&@)7VW$2"4\&PEN=_]=H[C6 MF]D];F:_@I9"9YQ'B0^-BZOX]@&V9S9IXI1&WC%A.DL$\#5%H%!AH_JF2S.) M%1*:`F^51>K"!7ID&!A&[P4A^<"6^PFYY#+F/@]MH5>=U[':*I/RF=?"4K<+ MF$64#;Z%%&A5\@"<[Y:YJXO>-![_GCJNEZ"5,PWZ"R0$]NI83[2N&(K=ZJ:" M>+I8$#7!FWD)][81P\OFA4=@C&9!+(J7Y/`SKP1_0*1=B(0'44X])^(B$DS. M/GVCD/5$\F"DG:[$(>T`GL6E/(*D8),70B3D?R=4F_2I[O@TA;,14:F#E\CC M7ES<6Y;+I4!C6YZ=\-0$4=?#8V.C(@T_8K:%/N.\D"O13J4](^1T"J@O81X3 M2]=3YL>BE0'7O'5/"M>$";_`3W@"$KJ\>(E^YAE';\FQ;G9.Z#*X;L'JX:OC MK?MP@JLPAZ&SZ:+!`Q<6VFYD">A*]L2#>2+@J.D=CDU"6P+R]"E%$2[GU7A3I7(J,IL09ET,*:D92+:)1?N"?PE#'S.4G`-1`E\,: M2[PF4T;KX?$8[R(XG7S+$(O0^EW;G?'->L3L!.,T[P7*$UL1PBW8B_15`I=`VDFCN9/\28+$<$4HL+]!"C3&+1C5&+FZ=Z M+H,(1/J]1O7H74F\]Z\[E'6"*;<@_31-L9#`S^MA=E/U>;KZM/ M5XUOUK.&Z_99!>S/4Q[<4FT9!HD^!/`/19L^G]]^,"4,Y'WB.A1?XLCW<]!. MLGJ-%Q@@=AG"%#&58#)#S/\@B0KOU>-OH$H]8#>/:4\1G$0=E+J^`\2'SZQH MORP$>FB?Y&#NX68_LFP!E>;:X(%T3E0:^*)+4,EV3]*#%LDPX10"`9&8*T,` MC!,:MXN43G!4''<0E'X24GW(/5PJ9P%4<8*>$#_K,#%)32).X`(@C#E^;*?J M2D*7MCBDT[4"$IP=56O/QZ;&A0>EM$5U']C2OL"\O`0?CP?+/.I+$!A_M_P$ M#U5YU'C`+0^YWY8C,/Q<"H`CRION@XK-X'5H@4T(?GR3WE`OK*T'`!PXY_CAAE/>.TJ:5#02JHPF)"JXI"N586":" M8)ZAY49:`07&0X)D!%9J))%NN!K+K!YYTD'[)11.*@.#,=T'HFP!5K2?4XW- M$WDD@5>*-A>9#`!85.4><,I!MQKOYR@TU8_-]Z!FLRY:1HVG&1F,JIU3W2'3 M=2G3SYTJ-U.B7)%J5D2#FH7U.<,T1UEPC5ZZU`.@4$BE8Z:,2$H9+P()F7F@ MO?DADP>V12KU>2)1[RMB))2GKJ7=(DBWNQ7)4IC40FI^G2+ M(+E6F$?``S&X+G=L8OJK3$QM26I+4F!)0)MX%)68-R3:3!?8%)(*"B'GH*$U MG"!+3[=)3[9'JCU5FM,_LCQZ1C1AF"))NIV**WA2&M?P*EQ6U)A*#D>]1T48 M588)_:Y`K67%1>K&XQ+2&[=F]@Q%M*H##%K*JQ=Y7N='VGJVQIB>H["L<49P M7NIU6Z_;^77[]\1[WF#94ILZ'SVX('P^,WY3&@GFELGW:'V+0W[(%?%\9PSC\30P"M]1681)S:1FL4BV4Z_1NSKS MXZFOEY^O9/I(R,#Y\+3+90+U]X)7B(+BM#0K#QG,J0EP@XFV%#@7\K29$;Z9 MX?&*ATZ'5N$*J@O[20E$\BB6!];@D7%@1%`PLR"R/!%3Q1TRKGJ+EU==IACH MVMQ-TD09(\(`J"S*(K])G7I+ MO,Y$R4?92JS''TD$RI)K+CE9520D;T2%NY[+(6/3"+DI<%6`8!?W*'B-S5WJ MVLVIU>42=9D>PJRO,SD8(HC86'7(D-?@*M`7D]@?6`X.C0NX5LB)7HM4)P+; MU!+MZ!8H8M$?+U29Q6(Y.SP**`-K^OO@!Y4,CT`.HDQ#@VC04F<*QNY*J.;L MVM9+);(OS&)(-.@1W-E<.I(%8EG(R>#:I<=1'<,FV2IIWAZD_10L-YS2CVH"GC M*/=5/2&%[]4[(XJD9E[*L2.'LM;%AZ/`CD@79[/`(Q6+Y.G[PML1.IEB^A3+ M@$^%1SV_S7B'(+QTQ#R$V8C$>LLTRHG2)222B''3QD.9JI!7'09S4>(*G!:F M2$^G0Y)4PF3Q`1TUI7V*5XB;_(!_7/271Z;UFS=[[TW[SMYR@I\"M\6;@K<:;,M=-P1+9\;)#J-=:[6?S-TRX$V"55>IEWEN)VX,.O[;Q%2S96K[JP62 MZ[$8W5(EN:HNZ#S])BO,O(I*XEG8]%@0UE_2O`H)Z(7]:2@53@!J((8:AY&D M)%,!RJ.!N:$@'F M[8%A/PW:/S*5VXHK0(2;%96\;3,G3+96%^3<\L6=7BHK\W6VXOO298V?U`DA M`=#A@_7NI@@!!-Y$>"\+TH/P'O@8\>X#(S[>-!XO7O-+E`[KX]?+-W=WA&?"@WOI/#-[X@=><"_!`](>!.>J:R#N/-0= M%#5#+CF\*#>0D\OWC*@."/A02@$3B&P^[NC=4!F\]#[0.I\OSGFC]P=>Y__Q M$^BV\`>EI2CP=MYF6P;61$4XI>["EM@60BFI1=9GQ0<>1C(A]X>J(I#A[,@# M5EGNI[*9,:O8E?MOG$+RE^?[*(KR87X4+COM*&FB/FD/`@OA#-0KL(02.V5_ M"?*@T[-YCF.#/S!W?@/' M7/KTP>S>?_?5M1&/2_$QNA'(F!]3Y0J/.?>=BU2QIE>7X_=W:K^_;+^_"7Z_ MF-O4&!.FJ0`^M3/S.X>#FMYSY'N$=3)]*]TT^FKVA7$`W]3>H0KTYF:?HZUR MS#1IA&86G9^+F@'2QIJ=/H/Q/UN>PNI1:/0$]4`GA9;'`="*VO_Q?8BHX19H M%GQ4VFN>SXR/8C`R2IJ.6(=XDR8"0\W6LS*?H1HAO%D2/<5$4>;STU'&L@V( MM2QU+4I;+OB`V1GD^D+)CUO7;9K/36L8Z+#W#@XH3(\^ZM8"'%M4`7?IB"R4P M(;)"_$RR2BNM7$EIF(U&3E(4;%E&11SGAOK@=7S^C+-M&ESMYW;?J5(M-N;9 M\SX5"N(YOLQF=.Y$3993D&T%C\N/11GM?HHATW4L//G*,^/6Y;@?3+\295S# M!L_&%`KZ1V0@TJ(L'3K&>.X5$G[]?79S'8O2N,0YT\PJG0@FU9W?OEJX+^:"1-MF'1P7I[WK<"$]2W4*F')VDSM M-;PUHYR9TLEM#,QVI[%C"]`TF^WV_'NT4_07Z'ES!\:^;_8'.V=*OV6V6HM9 M\A*OP11A/'Q4P`]_-:S]X[0[%1MVFEC8``,B>Q;F3`A6$U,1;41J&3^"?N5^ M-88=0/,$H><\N@Z;WV+P`-Q7A"*^T[81)BA2^\QXJU5:S%VC%5J1HU< M=#[/*&/ADSKZ#26KX298G6X_IPLB9E`XNE[2@@EC]#O\7Z=8%6 M\PFVM_$SAFS*B:1UZTC:2C6Y6:4WA=.&QJFA3YMVL&DPFD+C+=:JV6Y""$92ADV^9W:P%A6/,$*FJ^ M6FH$IF4."K8;'(['Y'VOLL`^N$7D0!]YU"M";<43,[B)]'TQ>`_%\^1WV8.G MPN>:6(9@^>H4C/B1YOR7;0=[9WE>(+0)\N/,N!(;*=H/W8<$YQ,&-F,[@#-M M]L^:V7$(F!J3'V<^R08HY6X[%KR4W"=LZ1+1:>?H68(DD53HB'YL2@4BF-%[ M9IQ3SFJ^IE6_QA2)@?#S(Z(HXR-D19?)3TBC2)U8J+D7#E'Y;&^=#8L9\):O MS$?".9W@P;LC?$4IO3/+Y5G(ULP%`3DQ-6'!2",E%2IY$=G.*B8#_"U7?A9- M)8@QCZV@ZD$7A'@.LL3'JZ8"L?4$,!9JGUSZM1M2D.$4_7*>"2U2-+4SA^SB M+E5M=5HMLYM?J(N@]L8RH[-L8>G`[KF;&0.%D$#>?0&MJY"P"9E,:^=7E#&E MKR-TR6`DY\:UPD&ZY=H0M]H9I"2>/2]VX=V"G[C,*C!`VOB5.AM]L]WO@"') M1=B+`4`W15>J79:]#)`7)A0O()G"'=&)HQ1A!=DG&S<5*H03T7DC1=C#Y5BJ M^+7-5K]('13CSX(W4;+#T"MP&"0(HZS>B-PG&4CCA1R4_":TKP3?!H6,S$GS M;TP.."[2W91&'4-*5*J1'46=O\39A"=4\)J MP=9EW#6F\DX+O!ERH;!:@G:2/Z<^G"]ZSDE9N;)B-ML]L]WKK*4A0&2_@;KZ M87SY];+4<2A')-N,N6RWI'N66Q7*AXT8,RC`T3UY_78W1XE!6!)1MSIF;I7) M6F.=MQJ-7*<,606&W^&OW+4U1&](5)8W*3XP_^W:LWR56T[W\&^6QDXRWG5! MW0$'NZ(FCP9S16T^PC%R%#X=RAO>C$M;+O:8!;7]=&@TK`0+)MK<@P:0R6,GBP!8,'93`8^Y(L8.]RAE)6 MV4*64XYPF)C$BRV95FTY#VX$%]9GCOM9[WD0HIQ0SN6`9X0H MTJ+N*F_?%$()NUM^@(+GBT*.3S110@@+#Q.<#S2NDAJM<29H!XM!H<'KH:XR2D!7(O/$V! M%#"U'*9EV2C%AP2K1E-M$D#UFN]Q# MXR?19MJI%UUWV`BHT@VQUS@]4/54^#/.;MM:5?N`)=O>(G1L7 M=]@1I71:E(-WW9-]9170&5ID/X@)JPE^>]L\*7NGU>YVY\^3J-_*V]:)R-]3 M.6ESM&@MS/1PJ/"#,IIP(!;^O$;-Z.-4Y\L@-YXGB71$V8;1$(#ZO$:,PZ!8 MLN,O3X=#Q"A0R82GSQLAIM'QM'^L*4AMGZRD[X')NAWA#\A=3N(K`@BS' MN5'2(U)TE$7"E,P+J[)<<`_(2^S:U*<3K`YR,"U('+MAA.UMR=+2,>/8C>#: M/"PF7)Y%QNQQ!YB+!>YI\:.*09YDKVYU$8:5#B)$BULT0?+L!:'`.-EE+X-L MG.%/"OY+D^A%W;$X>SPKY0Y'5)DRQ^4'?FB7.)"YQC)R@7"!63[?10CB!-TI MM(_LES3OK9\9MW,R*M8=F5'F%$ZX$K=%2VB--8.+3&`O"@^,GZY1"K!L4D&5 ML[RI381]5FELF%DE'L//WJ*)R670NL<,*[@CVT5JE0"?&;\&CPCI:\XO!LPY M(W&F52$"57"50"!9\,;$)\PY;0&>1]RWRJ=2FB5W=T);E='LGH%-D]*?V\T=LW#0,#O=%[&P5*60&0BER/(&$"(0K0>?BD:# MYB/M[ZO2,%PZ4!G3KC=Z]ZI+W*8$YRIN9/A]!MY8--JR7G/WZ?^[.SW_>OGE M^SO^]/<&?77Y_>(3IH("P]X;OU]>W/V*-S3^M'`LL;TX]77[^>7]_"2*C<>!:Q]\;5/S[=?/YZ]?L[`^$,X8DKLWH7 MCB>4@_GUT^677S&KM35[TGYWY.\:"PS)`\ZFN__]"J/SL6.*EV6K2`9'A+J0 M^&H`-5Z0``S*=0\A?E`B&N60)N0HP]7=W=7W]3HC.;L"7,?74>(\I%2_S@!__`4 M5P9[YP>/H353*VOG''DY!UHM4"6P[F'\L'@[<^RX0Q\JY0GW!;22970*TH_* M.]":MC?,GW:)B!*&6@]6G[@R-,$KTR:4SMW5=:'&V;L2W+.*VYK\`K'&?="H+:3@=:F?NH[CL274EZWI*C[9!>3^]Q94TNEX,9G7YQ<7E]^_G-[P MEW=E0>J&I)=`:H%<=X=F;S`XN&FMI;B68HW6IMEMU4)2S2VIO\P]=ONIKMLGZ"0/=J3HNCVSU>X=W`37\ES+ M<^%&NF5V1.G@(ZN;Q'NB6-+(2X]GJO7WMS+SP8K+@G[9\BA[F\Z M7;/7?#6K7R^)>DE4;DD,!\-Z/53.;=COAO^`=PBOJ1K;H`F<(!GA^ZO#D6W. MZ4H*@6[(IPIMMK9F5M%>3,NFKI=2O93JI;3]4DI+!NJ5-.>?I/C#QOP])>>; M9[.^$8KWO7&@-<`'G3J?UPM#-NK9##/IY0(35WS]]/FN\/?RDN]S:WWA4(3F MF;N@JLG[^9D]JJ35/1!W8.GK>^!(JZVGLW?GV//=]:N-["[W.<>&GRH?>$?55S4QYKE'#5:YJ#Y@Z/FFJQKL5Z_V+=-H>-]L'-\C&_8S;:K8.;[^.W[$><4'UXWMZ. MLT(S_'&FF9W=:K>1957"$5\2R.+^?Z M\)S,72>*[E@"CCM1M*K,*P2RT`&9Z\55+ZYZ<96VN#04\GIES7DPN:SLEV<2 MI\V&]->7!>).#UZ8;OU::>2+R3R.7A`722@;NJW3S"#;PT!V4)EK?&;9_TK< ML.S>R&:OUS#;@VS;@24=L2WCD:$BQ):3#RRT[E7+;D:MC%GI36I;9_G1J;;9 M6FLWT7]F8CE%0^2M):GIT=AR0]Z:66N_7?:8VV>B$#WMEGVGS?$$>TH'L>7M M;9:'G8'9Z@S7FN5,.ZVX0&"KU8"N;@+\_J:P06&5Z5NC.^@WRIR;;_)"*QTH M+>[*N+LU!-+?R[?16=P7'(?R<>*RL?&)]PU]8,85[\S+=<&"X5/G^$P_%>RW M-*'F5>$#ZE=KX8.I/=;'3U>F,0Z#J7%EQP$N6V!A&_L2!DO]*K##F[1WGW7&Q_$NEM]7JFHUFKIV8FDUL3ACXONBG MC-V6>6-'V7(/6S/#940L7`@>;HSUFH;#1K&B+&+PDY,G;=&S%W2GWCTGVAAK M,/O=O#Y>+.BNC]9"=D46AI9_299H9/D_&+:H7-PZ$8E2CT3OW_:L*.+MIF&M M,6H<>M8S2/.[L?O$G/6-7MWJS5-YPW2OPQ][PEZ#*`1P711'ZD7D6<"'&S;^ZYOK1O,/^"].TUW0&/[1;M#? M;PS7`4&S0&J=/]J=WIN_Y51V6O4<8P$R%S8N9_EXD\F_,$$R0"Z-4HO"R[8` M=<.]&C6@;KA7-YIZ,7%UP[V74E\WW*L;[KT^1$&M!U]?$]3]R8ZH/UG=<._5 M::L%NFZX5PTS7''4ZVH`3!P>Z',5R3V$2ORZX5XMQ;44OP@6I6ZX5TD;??SX M$8<'?5Q%<@^JOKYNN%?+7-U=K"2&'.K^IFZX5R^) M>DEDV%(WW*NBVW!\X`^'YT'67<(J7)]>Y2YA=<.]>BG52ZENN+=K_Z1NN/?S MI<[7#?>V=LRKU):F[JNU@K:ZX5Z%LMDK+3-UP[V#(:Y2&;`'T7ZM;KCWL\UX MW7!OYZ'7*B'ZUPWWZLYDNTI(J1+*>-UP[R#(K<5Z,[&N&^Y5TX@??\+TX:$2 M5Y'<@THPK5)#LKKAWD&06\MWW7#ON"S[$2=4'YZW5S<3*XDAQ[(?JAONU6ND M7B-UP[U#]"R.+^?Z\)S,NB=8A1-%J\J\NN%>O;CJQ54WW*N&![.GAGM'`>Z_ M*XS^?#,`<2=SBA_\2>#1;X[LWW]#'8'HCM]N+]X8#K-=D.@(F?2W)A@AL$$I MP>N-H]31=[31=W*C'RP=_:`!J_Q5QY[A_!\R5>;<=R[21!GQA&^4$9M$^-)+ MWPZF[#:&U^(57X70G#^Y48X!P^73UVL.FL,*<4"<,P(#SC.GC"_A0;>QE`>= M3KO5JY(4W((B`B4$//@F([(O(K^YE/QNK]_L=*NS@'>P"+JMI1QH#QOM"M&_ MDR707LJ!?J?1;E6(!66O@,Y2ZEO=UHN)_Y!$KL^B""X=N3Y=6=#!9W/SV^U6 MM;%.!)[).V.`=7)&LWG6\,VV-7.U+L%CX]QYL/R+)^SCIHT,/EFP[WBBW0EH<%`?U.#M3%T? M"CN'ZU.D1>OGL/`W7FB+]FXN#@(>^N""&-+(Z!O#<:U['W8&KFW\P+9KV)DT MIB:A]+W+'SD+X06^[%KE^F/J-I=$ULJ0;,P8/_DQO+G3%\\C0DP/=;(]=P8!T#-]$2707S&MXN; M*SX"CXDNU$6/"YE'.B":N#/QD'7(I9:/L(O$=E^,=_RCLW7@^-4,K'KF'8JO MG.^\56NUVI@>J9JY3D+LVD@"8?G&^7W(>,-)?#!0E?XOKP:B%XI@%NS!G_ M+?-5REUP(1[\F_! MSX%A,?%\^L3;"8^1Y=8]W'2/+RI59?<&F(`_R`BCUK-48\XO4:ZI,,V,Z$!? M=M_YUEFV[;PQ=<&[A7V)472=\6B1,H]#=Y0@IQ=,O^>" M<#K\%C`*8Q8R'WM$1RQ&TP%7":6]0!:QJSDZQ\9';'$Z=FTA+NB+*X$R25"G M5-1;J[0]MR;&64]\G")T!=`EL#2%I/DKX#N%#"6$-(OG@;?BWU/76J&CU,+<_^($7W#_GA\Z[W_*.HH)C19V`)8NEQ_ALC&"(#@H.LAU; MS2/R"[5(AW]-`[2"X0?@L,2DS"WI:[?)U^[1DAVQ.";7%5O)S&7-.DQF-7?E^J=`(;N=EQR=_'C11$*:=[4,9^C84 MW;@F'=17(2DWFA)PKQ<\]ZQ2X($!KD M;*M8^E6(LNY>@TR_3@=8]?P**<4]`=>L@*E)S_AT7)J=-7#=3V;0:^&4]EKS M9XYW`>Z@/-:+HH! MO*LM:+7)K5*Q;S7HK:3:JZ(X[U+MR>T"1Z1M-K8$H-Z/*OQH19/:'E:;W"KI MN9+0U?<$PF6V>WVSU=QA5T3:;]_^7Z/?-@?='>*S')Z$ M5UC_[=?_N\:TXS!^IG01]J_$W3$0]>&9RBJ2>T3*<,\'P]V&V6O7S8`/0Q7N MUQ6\PJP[W;6^.^0_;^ M]M>XKTK^8=MLMX9FHSNH5TGE]&CM(;Z^*+PNZ-:+)>"X^XM5E7E5A.RJXN*J M5(NQLK!#Z<$*^KD<6I9B!VMPF85T'`_B<4PHDEFH\9GE.AGL68$TS)[`L7!$ M\X@B?&()T9H%05X3.G@!(K*)O0<2#]O7$!XW(@`_T9N]YW(QQAMG[:R@28QQ M+:A]9GP1?YF(N#FU0M=[YGE@'"B9/6&?!`3S??99>(^$W%N$A4QXPC8U1T%: ML(B*)X^9HL7!?1@\QA-^W3B)DY#)!@PF'M(;;I_`X6S[8VF=E6)-A.1>\\(CL+[G:4@X4R2>U($K[(]O92 MG\6&%T2(3LT!L@O0R)%UMVP64YLIH]V0G6@X\CY?SARBFPL:4]JF"*4;[T6) MA@'C^O$=+C>HLM!IX"K(]2W?=JFCC.AD5?/^;OD)(I0W2;P[9\:U&ID^'MU*C#U&W6H(8IZ$5*00`X6P M9MZZ)X9`/M5 M-BZ2QB$UOEPWIZR%>Q(T#% M$"?4>H@8&(QB;@D%@S,M%6P["<-%O#5HNN#9`J,_?1)7&]Q:O@X"?/5=QCWA MP6O;*_[T50CQB\:2`8Q/&_4]O;.2.%"/&)0.(;]P/&N'J\#`Q>P47\'>^<%C M:,W*"6!L%YWJ:QO*=F]^1_F;U*F91F7I!U(%Z4>QR+?8;$MQV)SP:H:UBZ9Y MLU#W]AQYN2BTVK#T8)W`^$'8NW/L^`Z:-67)%!331&ME1_V(:ADXUTW8PQ!W)PMYZY>*!1SV%ASZ%G7H*#WT*ZU5X\%/X M\Z["VN$Y&.+*KCZJ%&TKUNCQ$%I/XA$06D_B$1!:3^(1$'KHE4:[JSDK\H5N M>"YHW9&KXN1N(_?K5@D=9RWEL-$RV^T:;:/BY-:"O9E@]\Q>NVEVFS668,7) MK05[,\%NFLU6S^RV:\&N.+FU8&\JV,-NUQP,MPDI'ZU@5V2SM3M8AZ+-UG=1 M`_=:@E#%NO,JDEL!#5<-,@NTV=MFU^RUVF:S,3PYN(FMY;B68R7'3;,_Z)C# M8;^6XXJ36\OQ$CGNF+UNPQPT:S&N.KFU&"\5XVZS;W8[S5J,J[=-VMT..1\?N:^GV79(9I%F:YVU7F^K5$MP+<$OEN!F\ZS?JD7X",G] M:42X<=8>U!)\A.3^-!+<.>O4;D25$&MW`E*[_)7R`\TVH5V-@M!A(:%0R<(; MY.L[!,IZ;]`UIY[U'"3QN['[Q)SW*]&LU/-#]9>C1J;_&:9_2N;_Y<])='IO M6;-W'Y+(]5D4?23<4L*0NW`C&[9U2@8".,7RX8>._OKEN-/^`_V(-UEW0&/[1;M#? M;PS7@4FR[-AU_FAW>V_^EI.2%"TL-E2W2#Y'1FXV3?Z%:=SBG!JE0J&5#=*; MXB"&;!:RB)`#";\P%'B!X3,"L`9V!CAPEH3VQ(HT()]9Z-JOA).W>+T=/3+> M"AR\5/'KP'?BBG[I,'<''8C:KC,K85S+U6#0(C!.<[C5=C"=(GQHC+K(C:*D M[G)3G:8-E4QRJDQ7ACVW/WSMM@M57!X5"?#7[6U>7Q2J2.XRL"%=7^V-'14Y MV]R>'W4#QNT/A1KJO:;9[?;/5;![AXN0>D0;SX8[C;,7KMWD0+'XA\Z@T(9JXL]H!K#BY5=)\!^4`-LW&L&/""PYNRG].9;C?<.`%>V!>,&.. M$3-[X@=>(5.%^'<-.=_":BK"*\EUA1;A?K_`NM!PVM<(? M$9V,Q/C1MZ:OER531;-917*/2!ONUS'L])JU6UCIR.!KU(7;22K M3>X1J;T]GP@/FV:_4_=NJI[:JPN%7U\4JDANE51=->BMY*%'%<6Y(IKM-1TZ MS[5&KN?&+HS/BJ)D6F/(;`2=TIP]&5'@N6-O&MQ'%CYABS,#!H!HVQ MZUN^[5J>X:9S:L"F:&J%[K\9![`-691X<82;)ZR5XCEB^``.8`O\#YP('N"X MMH6/M^`#![?]QL)[%AH3RS%&C/F(WSGSF+@&'O=WRT\0%K=I&B`?G3/C6HU, M'\\L='$\WC,,9>PQ&S-T'63&E$!V>=X:4!@'QEOWQ!!PNSK*KHMXL2R*#?CJ MW'FP_(LGKH$&K6;_/8PEB:/8\G$5&@X;Q28=>KYUX6EXNS4-PMC]MWIDFC&< MY@J?&7<$]BL)@'L2')T3@#*.$=ET!@_!,8Z89);[P.0()9/CB14;CT'B.<`V M^!D62V)Y0#HQ,!C%%JQ*1S+82A>G$=AV$H:+>&O0=,&SIQ8^2WN23T\:)W$2 MOA+L<`&L[SKB?7P@Q)I-YT]?!4N\:"P9E.)4JSZ]LY(X4(\8E(Y;O'`\:^^1 M'B>@HD[Q%>R='SR&UJP&[@_0#J8+THUCD6WAX4APV M)[R:L92B:=XLOK(]1UXN"JTV+#U8)S!^$/;N'#N^@V9-63(%Q32)TL_,=[:* M.=8R<$@R<#<)62T$.XN?58D/19;A1<&R*A&WJY6^YW6\2:A&7^;-IK[,6W.\ MN&6SF$U'+$R9TFZ8]9S73WG]9S7P7H4'/X4_[RJL'9Z#(:[LE/=*T;9BC1X/H?4D'@&A]20>`:'U M)!X!H8>>WKZ[0HZ9O7;3[#9K`*N*DUL+]F:"W32;K9[9;=>"77%R:\'>5+"'W:XY&&X34CY: MP:[(9FMWM<1%FZWO+#:\(*K1!"M.;@4T7#7(+-!F;YM=L]=JF\W&\.3@)K:6 MXUJ.E1PWS?Z@8PZ'_5J.*TYN+<=+Y+AC]KH-<]"LQ;CJY-9BO%2,N\V^V>TT M:S&NWC9I=SO(9=LD1%DPHHD5LGKG?'SDOIYFVR&919JM==9ZO:U2+<&U!+]8 M@IO-LWZK%N$C)/>G$>'&67M02_`1DOO32'#GK%.[$35,HO=2F,0-(0[704AD M(6:`6O?L:OR/`$'I+@7R'+\*X=DR0(GGT97?Z/_1[!0!)`[>&(GO\BMG2 M&`ZS71#8"'GPM^9R2E8/11(4S.[]=[,[?W*C/S[!Q_B9O_72EU=]#*8C M`>"G/X2&,@D\D*6(W_C1L^"9\*`H,F_-]?_KP^ M[?GIO[:>"7_P:LQA#F\0AI`Y'P/@\&>.J^C?G\.('CC8_,8`F;V&1L9OMQ7ID?FOZPQT@SG.T=1<3M,@1Y,<5'ZPWUE\Z=O!E'W% MZ,A.1]S:;,29D2U2&9J$WS`[N/?=?\,"T)K2GU,C>KE0SWWG:]JVX)QW+?AH M11/X`5?"@^41$N:\:BF!_O9B^E$)M7O]5K-`%>V&Q#5TL-`I0MGQ57T5XK_X MUG]@'PAXO'OO%^KB$AC66*,PXP^6^*HK!'>#N&$)G3]S9CE3H<,6J'W;(5=D/B3MCJ.K1 M?J=:M.^$G?TE_C>PL],=[(:;!?25SDOQ*JW+\TXXN,3;1P[VFN5R<(ZJO)+\ M(KJY[H;:)3L%M!+#9K^CJ3,YEETJ&C>Y@-RI<^V:7+,0C M^)VP;LMM0DDTK;&1BF0P3&S"-X]@])?[].UAH]5N%UCX)8,H;]P=;=R=W+B7 MN\^]7KO9;2[?PI4_[OX:_%[NI\(&JM=MO]:XE_%[N2/8'':[@V%G9^/>.)B4 M&_URM^NTV>VUVN!\K3?^M>)'VU*Q9`X&R[V=TV:S/^@,AVNNUIU0L<8*&"SW M.$X[O6YCT*P"$,B0/ MKI0?X;`"?ZW8_S<6VC^^3-PTWGP?,H;[56X@T=537\T;Q4%[=>2^V6S#;EO3 M!IL0,<<`[<+KT+79-0OINV7'-"^F,F?Z_X`=_A_T5IW8%CC(9QU-6R\I7&+[T],+_?ABU:CS9%ZP$8AV%(<) MC@#>R\ZIY]).IVZ)9X!4-?-4+1ID9D?WF;%(G-;A,N]B&XC MW;2M/_#%IV?$(3'?=%:U%QJ7>QR#!0=K]B6["\X=AW2QY5U;+NBA MC];,C2U/.VWN/<'.BD$(JUJV>G3]64)/X8T!^>SC M$].'4)_#B!GX;.SZ:'N)\TI]`]7SRYK]3-N\KY??/YVJ^I(F]LK36N_E,P."=1JA4LAEA310"+0]J51\]E?ZFY[_I%3`JP4T"0,B66=0C4'[Y M]=/G7-O`!NJE.=B(S$W41P'5%DXXB6T76BM*0*/!+_]*`M[E%K9(J*&PARIV6L43`19'&S!_X[S* MW4K:Q>7M]=?S_\6T59\5RUBMZ6I-5VNZ`]=TK:RF$^HMH#R,>&+YJS0<;_2, M02SFTDV.&S([]IZQ"32VGI:?E`I]C_VN:[U8Z\5:+]9ZL;)ZL9W5BXD_[P/" MX/C.UG/C&+X&A><'0B\:CA5;!GMRHS@R<;L;LG$`2C)D>%1.^V;?P'/T^-F( M`W@3I>'09CMX!!V+9^&$XNCS/@P>XPEJ4U"ZD4WAZ#%H MYP#VRM9LYKEP+3S;MJ*),?:"1]#AP3\914BCLQTJX.KMM?<<:4G6%;7/*JYB M42(%S:6GY=&(D!B(8*S'5@*0$!`#.PE)E$96Y!9$S)(J\&*3J!-#ZJR8Z0&G M!8R)DA&*,LKWN#B"6,@DOM9B%DYA85,4"A9*&(!S`Z\U/%KYP&J^K''M\#C8 M,UXZ-9@%WX9L%H18XH0X&6[@8(P*'BR?2LDR8IF+0)>CM6AL>#GFVKMCU\;HMA&,\W$R^:)LI(P8](AJANL+<1/H`#!<\03NPT>K MF-S9SN@X\$#AX!!CGL4_`V9@QC2.HBA("'>$ M.K/XRAZTFOWW:TC#!LL$+U&]-HUVPS0PWD]/O&"V^+9)WW9>)])X`&%G?A]" M#DW4<'DWBE*/'[1Z6MGK@KZZ_'[QZ7O.L2/?==%8,IYV>G3S],Y*XD`]8H!. MM^CO^O'JZ]?SZUL8B0VB;,TB\/6O_O'IYO/7J]_?&0]NY,(35SO6B\93-_BJ M,G$_>R,^/)-+"29=FGZTXGIVJTM;W6_H"&BK)_$(:*LGL6YY6D_RD7A$:L>8 M4@U;QWI2#WI2Z]593V0]D?5$5FHB:Z?H8(C;U6H5(4AY\BI&;#1G3T84>*YS M..L90^OU)+_9UX260_TF$TQGY2D_FO5D_SR3W:HG^^>9[/9/.]F'W@MD*Q\- MP1#I3)R2AUB*B;B%&!PM$G(5R96S+1039>`5:*5-N'%D362WYDQ1C]FFV1ST MS69K>'""4J^+>EW4ZZ)>%X>V+CJ'O"Y.#TX^ZN50+X=Z.?QT?57*2MY5F;J\ M[*I.=Z[3G>MSK*H1][.?.M?IS@=+6YU/<`2TU9-X!+35DUAG]M23?"0>D:R$ MUR$I-9.T3'0QQ=;;S&MG.G7J2CWR2ZXSGGWO" MZZSGGVS"Z\SG[9VS:B1S;.2OU9G/=>I.G>&Y,G6GWQF:W6;_X*2D7A3UHMCA MHAB8C<[@X*2D7A357A0'G>39-#N]N@R@XN362Z+.>_YY\I[+PKVF!R_&T"\Y M"WE9\K26<5M(X&'@YF^`%9_!!Y<]NR*$^N:(X+/0G5JAZSUCM\_(C6)$4K<7 M[>U-T5L04<*G@<^>91>'<>(['&[\M[/;,^,N)*#Q9^-[$+/H?0;=7<'*<]!W M!J1-L5>M#DB.(.?8XJ%@P+R9HFBV\S;Q+6J'RIP3V7F'[G6P982=`J'#=SH. M^EQWGA5M'BHVOP$I1\E'BVE M15#]0#Z]A7FN:H8@+E](*O`'>_G&H@$"#`17$K5-"2*VD(F/C/JIJ%:EU.P$ M%W7\?&9\!MIX?X:(-QZ5W15H?@K7K9-O3L#''67XJJ\VV?]T\CP*7)R%+5A&_`G/0`"Z._"+UMD%.)*]GX82+>0WIU=7)-0Z M!@?V`/HO2(#\(*+R#5!FR&^#P9""J6L;01+;`2Z3QXGKR7FW8+ZH\0SI'5*( M?#1O:3@Q:$`5Y\MV>Z_^@UA2:G(&(XQ6!:&$3^*L(X!S'5A7`#1;:+K!= M*+Z1A9TOQ",\%ZYW+#%`-@89$&TR\%?LL`QWG!O7]!,N#]Z#_H1D0ZADWO?# M\P);R6?Z>EBU8`!0L4ZQ7X]X<`0&%MD)"^$W8E.,/3_$Q',&F0MZ!%'/6FAH/>1H_1;B_=Z,)<^J9/.B9_$@1 MN91DUZ\G]*`G]$8[9:FG\J"G,NUD]K/.X^N5->S'K[U@D1VZ=%CTT\[QSU*K MA+`<:6E:77]ZW#TYP(_2)[MNK73,DYU%)?P'H1+6\WV\\QT'*3,^45)(/=W' M;KT;9JW0CR3:W*FCS0=#6XE5+C\-Z05E+(=&>SVO->FU2!\,;;5(UR)=S^M/ M3WHMTI6FK1;I6J2K$@.H!H;"1F&!B[2T4!0VJE*E;>)_1XL24$5RMUD+1X:* ML9&.JV$O*DYN+=";"72_9;;;V^"#UE)=2W4U2"^0ZEZG;[8[V^`;0[/6[)P[@W.=Z?$])C$_BL9-WQ?U:8 M50+=#+%G=.`6VPI#MQBWQ0_\TQQVRSP3DBJP8P.0.\,)<$D&L3&Q'IB!WXQ7 M\6@9N$T!DVJ`N'U*^'>8@)4SN$3*?P8)]]?AT0803K6$'Y*$'Z<>%^(:$4*D M%_CWIY[[@`P@_NCHH[,PF+$P?N8@BO]*W!EA)>(GUX\M_YX`W@1?WZ;WW0>! M\^AZWHFY)E>-QPDCP#1X58@0AVS*$11'S'!AU"ZLKC/C>\"AX[0'\A]I5(]6 MA*LMN/?=?Q,"($&EQ1.$D<,1IZ!I"HMQ$78:78\%+/5RW<.P;V&"O@LY2.)W8_>).>]7PKBIYX?J+T>-3/\S3/^4 MNXJ__#F)3N\M:_8.ZS*H&N,">.8%M*[OV%/\P0OL'W_[S__XS_\PC+_,77Q. M#/PFS-:5?R-7XP=F M%8%^G3_:P^:;O^4D+$7&BQ$=CXL9GWTC)V4F_\(DY,RQ\::J`EN(!SD#SJ,: MRHGKQ&6A%=J39P7>6(2[6::+@9A6#XRRJJDC=?O<%;0=,NY`MIR1=&F-LW48M-7P=T=`6SV)1T!; M/8D_5R%I[1$=L4>4(C&EO:8;9CVI!SVI]>JL)[*>R'HB*S61M5-T,,35H#FK MUO-/C9/S,P!A4K)_GLG>INK@M:T5Y'<'4`][+:&H[OO&HXRD2":3;,YZ)O-UO#@!*5>%_6Z MJ-=%O2X.;5WLO>:OS'51EP16G-QZ.=3+H7H5LB]/I4UK8E=F]9?TQO?93-VS M+N;JUNG.=;IS?8Y5->)^]E/G.MWY8&FK\PF.@+9Z$H^`MGH2Z\R>>I*/Q"-2 M7=K3\]]FG>U\V'-:+\YZ(NN)K">R4A-9^T0'0UR=[;Q&MG/=T_O8)[G.>/ZY M)[S.>O[))KS.?-[>.:M&,L=&_EJ=^5RG[M09GJO;Z72&9K?9/S@IJ1=%O2AV MN"@&9J,S.#@IJ1=%M1?%02=Y-LU.KRX#J#BY]9*H\Y[KO.?T`\W#84";KXE6 MOA#M_&N*H[WH(;_YP2ABX0..XM*?)3'\'/@VW&7%;N"_!!&]]=,BHL.L(>AY M/#$L(TJF4RM\1O1^>V+Y]]A]PB^`]J?0E-'>&OM<@JRGS1X6=WEX7?#SZK;3 MVG.6_K!1O2S]*A^Z%S5NK\]@#V3R5H7F/UB>Y=MU=O[QS&B]-.N)K">RGLAZ M(FMC6>FC[-?F0^WC_B3+5M5>U--XR-/X*<+]O1M-F%//Y$'/Y$>*R*4DNWX] MH0<]H3?,]JPHSVO->FU2!\,;;5(UR)=S^M/ M3WHMTI6FK1;I6J2K$@.H1D7H1F&!"Q:Z#U;L/C#CT0I#RX]5J=(V\;^CK7FL M(KG;K(4CJ_'=2,?51;P5)[<6Z,T$NM\RV^UMT,YJJ:ZENAJD%TAUK],WVYUM M4!MKL?ZYQ+H:9!:(\-M^F925Q;X%[[B,H@26W1HP0"]E8V\>\OF5Q[-%#]B*[O>6RVQR"K[=9P_5?# M7!O)/U9!@WT/8F;T#>&%=<'+0\;`.,X-F"O&IN1#P20]L#!&`"UC)B<2'@L3 M2.Y-!E%,O7N?B&B[ZH^^\CEK7I-]@_Q01YX13:P07AB,4VE0Z]>@!6R\ M=7W;2QR"[)L$8'O%/2Z:?P1HP9)*2]DQ/CD85*&.DE<5`\2W*C\TN.<[^8OT2X\'^9V\WP MI=HWV_V..>BVLM.4\L,.IE,8/(G^(B)1*UO^,Q>Q0:O9?Q\9E]=7&BW#DS-@ MJ(MX@\&R6TSZ<>$Z$IOF M<#@T![W.HI6X<%4`81(E!)5*&Z$__[O,L8%I;V1'-8-7TR)HY02GFBY M+R[F"5=#FH$.IC`C`2@!'Y1-=&9<^L9G-@H3U`NH;TU]N6,*2^ESUVETS<:P MM_'<(- MS25]#]PJ&MJ9<1ZG2ZS=-`M8-K&`8V!Y8N`5C*E4=K6W5@UH\&)P-L!K,3-K MIGQ/8N4@=4_B.,WK1O:NBH2BC9O`V@>/5?I("T4+!1XOH-,'[G+9#%.]_,`_ MM9-IXO',+R`17"[?@2THV"7+"&%#7_8*&60X^R)PPG]QMV/PZ MB/2"%(R>:>@?`BMT<"P7+@P^#D(P'7>K:.;;0>;;1,7,>L;H@1$\X"MA)P'S M!W^1DPJ/P!='_&FX`JR9B_J!.]-9)Y1[T[!49C`29*?&-_42W_!<<',=BD;0 MP[6?4I>74Y&_-.,22QHBOL6`F2E5&<2/05;8^0',4H&:)2'X$1':<]=FJV9" M2"F-'AC@QA[\!FQ[P.T&4@QS,;7B&"^*)T`?J!_:&1#SE9#[9.:BTW2/Q:'1 M:39R2R&CP-!\2O.X8M>"4C,*`XN>C=L6&.ZIXWH)S06MGZA6B)4D-*<0UU>& M0IZ,*+$GP@:2_H.+W-`(9FI5HDZ$U8_KP^16><'>F]^,_^^?6K.9Y]I:I(H" M#*A93=P4.VSL^LSA2\CU049!Z>0NI+UTJ6L^\%EV/N7P:9^`KANS@!E:.`U_ M0`WMPM=VD(#/.0)5Y.`DP<]X!VI#OM?GZP7L21Q:?F11!`+4]0=V[_H^!F6R MNZ!6(^N>32UTT>#V$0-[$(Q`'*R8:PP>]EO#FS+1AH3L7PG#\9EH1339@/GQ MF!65K$C[C9QI$[J(Q$#S[K3AY^*57`I2Y9^GXI$83[R)K1_`G)EGV;2O*]+L+,#J:G0E@+;JX5'1UGYS2I]78@S2W:Y/CW0D_\%1R'RQ"28W?OO[F0@CQ_T?$V=EW/?N5$S M<*T\EV^)%[LSCUV-KX7C<$U3O,Z)'1>O\^RX"H^=/J(C=S6F"PJ.G(;:D1/X M+RQWYM3ZRY]+)2Y_QO11Z70QQ%O2`G0B[33WR0I*>E&LX,I(9\;E]\]O_M9, M16+YR)=)1LJN[PF.\FI\J:F._=+<7#[][>+I7TY!?HXOV"B^<"/;"_"HW%@#CW_+M MHXA?\_Y&S<[>8.Q MG,%+HDD0QJ>PUYWN-JR2#;3O(-[?;9B-_%E#>L"JPM5=VKV$C+PU9`TV9X=_ M_Y[X=,#:I>WYWQ./PO_=[%9`/,\J_8PD.^RIZWDX5[N*8:85H*<^;F M!\3I&PM!>K[\>JD=QG9/0&;$3B??YBT?U([TH';)QQ*-1M-L=7-LHT-P;14? M9V"DJE;M0E.9!VK4+D6GQ"#!9HJPQ03=&J+TJL2+L1O"-CW[2T[P0\NE2)V2 M_71B2UT$K;-VL=:`[7*0W',ECPK+$O%F3=/KYHWT'9%=3%NI@VXL&G0PS@S* M-";,HV"[Y?,8[;-,K_!X$![FR+`G+AN##08=1O&=8#R&G4YHBJTVY2=2JL<, M:,)`E@QYH_6QYK-H\-6@WS`4O\@7H"?'V.DRE(].'UGNH5B105O+PUB0.Q.I M?$TNL!FZ8/]/)WM`%@A!R3'])6M_.G_,(NE.PY=C>S`7G>SVN[PBGBV7,;;%,PQKR# M1(&FV6T4:,6=IARZ<:0=@$C5F>4),DJ>T<@3&J&D5)@_I/&(F"_L.G!C&2_> MC,J`>W9CMSA;0^PJC1D0X).Q$W%EH4Q=-*H[U?)&7LVC(""3,*\2:!XG*&IB M;]7DF3#=6B>_-BF%N<3K$G7PI[1ZNA_*ZS+O?K]:&]2$#S?8Y$B+W,< M.U0"C9N_AV M7%(R_<4+(KQ4?*314VZ]@^?HF&(S8F.T3?AKY#ZM]238&:JT_P4$\LR`P`># M,R)**>J'),']/GOT5$A/Y5>I^*HL-X!WG/`M!F=7$LZ`$ M*QBK/*7%?ZW$B_GQ\+)YH8R'(O^">4)",AZ&NB=KI2-0/ET^KZ/LY-/F M6:N[2/*7)NH2[3O.0]?4@\S12NMM;-!3$=^0TE']O-3!#V_=#+/S*3>%_`U\ M4?TS=T>%Z+;&&`$J7&[5\M?J9#,MV4R?1[X%P:VHX_`#D'2F,YJ&\D?T0YEQ'S06'8N_6O,K#BAA#3X'TPTX-E3^/"1.P9K;:6:"0O=Y/48*;-4 MJ@LF[(0)A9IZ3K1L@2^ZX$6AQ/S[!)24]('`#2$0ML$'Z*UD^Q5^HY=6. MA?$67Y1$Z.2-&%BV$U+Y2[G`30\/\V;&BOG,P;WO_IOQ#1#/5A)C&6.*U`,5 M-*=E?056X,SX;1;X^FN!0=\L_5@J9%.8*N1=XEO3`.[^-ULQYOD`V7Y<6G+( M0._=U#V!,Y%Q%2`S[:Y!46B8/0._DC^(H''4MY=)#,L2)_.6&B)A+Z; M0G8XTKR`_079X0^.XO++/_I-L]-J9LGG&=)>%"PE/LE.=*UC*TGH0H=-Q7AH MHD4M@[..TF%/++3=B*XI_0"AU8*M1[.YUM8#=&NSV?B3[J#SK$=4@OHHR9=V MTZO(8P@Q&51MH_3+1RK'-O`W;K:V#Y\H9, MJK0N*W?/,U9`SF"Y0+;:2P1R&4'XRC21_*.,B:2L798.W]467U<32W2H%B>$ M%\%0_0'V.'-Q,@*7Q`6?Z-;"%/Y%V>/#U1GS[9PRVHSB4I=N*MXO$(5F8S^K M5E[[B6_."G1O4Y-R25HG-]CF&H9"FYR"EY9B'C)#+%(NG4V42[.UPCSDR=JC M>2B1RE7.3$F"MIY.75"'\I*%M,2)P5D<;*E2;YC(A8NNQDOH*?;,7D+/"J>E ME:-GT3B7FX@K41.(WYY/<6-78!5:J55H#`KJ:)I+`!MIJ,W&,J5=,(9,N9,^ M4Y:U^-QPSQ"+^SO/)8AY`E;@9I`D7)BP96 MX%'A8N(1OQLW^I&NKO5*ULYMVI,C&B-S'_+"-O?X#\\?F&]/<#M,UOIC`MOF M*0NO_,Q]WZQ_!J'\;1Y>LM,=&ML0)PKK=?C=K.PM>EA_2N0]/%B`%MRI=[],3@D8R!Y4F[AJ2F,B[&G\2 M(<%K]*?`9^>F8$F`8$%59ZN]=!>!>KS;SQFD4H:Z3_J7..FMSDKZ>WF#?##T MKU'5V^H>\?ROL4EK]:HR__P8FSETS0=$^L&GP$Z0'B,VA5LL\.7!H%:OV>WH MM*TUC%('OVQVEH1^+R%\>1>IT>\W7I3X;7BI_";27^UK-;NMU M5T"6_IVL@.5=7EJM3J]"&KST!;#\O&TX&%9H\7^:SKS@F3&*V5]1!IY.]/FC M%3K%$:SV\D8I5;/3+Z%T><>2US/JQ=&1%Q"ZXARNV6^UVLU7);6T.5WNJ`T: MG>Z+YY1&Q8^F+A(,#O+N/OS(ZCM[+&P757Q&3K`67[Q@9'F_,LN+)Y>^'SS0 MRS\GOO/5LW6Z;YA'47PKC)_O-.2U#\_Z+P5,6>.$KMEL]]J]3LJ;]:B[.#KK`'[U>HWV0!.< M'9"Y,2>CC=[Q.T-(3^:3#]>P')5[9MVS?_6FOQOG^DN_)Z94/8<7*5U>1R>;FDNP`NX MNSQPR?7'L#,`=Z(\WLX15QKW>&)(>H@OK=);';7GV4[_9:W?U(Z(5XWTY?65U M=NUT^FO0U^X..YM31Z?Q))H2'%;<(O*^ULK5N'L,[B9!$L&C/[OCF#'_VK,R MNAL_?[>F12(^6(,VV##0*=JJT:XU9Q(H-8W6?[001.K#LWR8N#`J$%F5_K!= M=M\56%[<\!"L\[R)6S/;K[/.7F+0S>9UOHP5&7FY"9ZQ_)M';3:)B'QUQ^R. MV1,_$)[:MG\\HU5=WE(^+39;73[4G:*1CZ?YL/KP_A%=]:3N.X#E=%M<:S6 M79'[U^NU]`2?I6\O9[!+3EFZRR.LC:U'BF+_B'D^GX/P(DA&\3CQYE,)UC]V M[RX/A/:'O6$NRK#Z[1DIUQ;XN>]@8IA4.N?W(:,U_@($Y6ZG1E`N&4&YJW=B M3<%*/\LRSXH"\QPH#NBJ85])8*>.1(.E.CVLX75YWP)>P@<3=8]H%3I:!J.L M68'38AE$6KH+#3=EU7@_?XGZL?G^A".J*$$QL?@-4Q$) MZ8-W$DFE2!;&E=[MK]GNF>WU.IWEVSR5W9NQ<]99V)MQ'^WR%L`>G^%4JXE! M!LS/:U9^J.Y6`+ED@(NMG<)8WG((Y5L!:G2=0BB3P.:E$[_,R*,HR9R%+NBK M&?8SX8DLI<,E+\*7I@5A8?.3TV=FA=CTBN-N4@7J&.CAZ`D"NR1%7]`:FOX2 MR98XZ+V!B78$=`CQP"(<5LX?!',U/)?YLL=65KQ_B02\YW&6OU=LV)F6M#ZO MX4X!QA1`P@ZA(HK@;4/N^BNH#&G*31P+5]$['-%@?D`<'T4`2-#?HSC/)D*? M#;'6'<,"*?"$%N%%X_7ZYZ;Q73HR%1:&`KB(QUF@+/ M'5=5]<8._L;E@L4E(?K&H)1ZR.Z*6I=\.>2ZXUZCC&2>?1L5+.'M>/QC>=<6 MN!DKZ=XNX+*?P]WNBC*>7F-U\"D"`&%!=/-CBCR..TXJ>JK`EI7%ON\K'PP#8J"W&3CH9>X MPO^9^"3%O[LH_05U5>M4>VVU^G)\6"-JV1ITM87R$J(6A7($_PHF7.GC[+![ M:Y49+WC-RZOQBM(O=C5#O26!2BKBZ[^\B"^39['S(L4RF+*JQGDWE8V7/@&$ MNC'[BN!1H`@L_QY+F,]I3\0+#)"?0>`\PO9MV?%:CJ#E@=/FL-OM][1S\DU' M4CXEBT+`O>79H(WR:-B"RRM2.(?-?D>+3V_^XH5,69Y1V5C]SJ^!?X_>U[H8 M);GWKP0C[CA6"Y]Q/`-PN??0Q"GB^#1WSSXWUM>R9$1 MW/S;MA[/DD.?_HHSM`X8[^XF@T*UZ_+>M6"_P5YCXC<#YXE%I?2?[#?KTY/R M3D]6]BXP-C^,:3:,4T,3`]DT,16$BA['_(PM'ZXX:"IL!;#M^/I3<_`0GCRK MFN,?,CR:4NW.6G,='T!!89LOAX/\BMY2"*[_Q7(Q4RH:)>&]B0TCGCT4=MY\ MC'/4-!BX>C;A22*483_MD,A1'?]N^=1RHDUM4%KPOQ2+1W1P+28WAOMY9#YD M/GO$$X+%'6,D+'PF.F^XV.LRFB'2I009Q=![$BN(2P+%#R/$CP:LU+.53XI?_!2QJ*7D&-OR,>SFY7`,2)P-&HMAJ3-!'M74 MN4A7.`8&%YELD#!AEB.F/G?>D.$>'2SQ-8)=RBP;N4;H_K\',/T^3G\46?8D M0YS=HAU"-->`08!Y$Y8UETD>0*;GCMAS M(+Z@&+XOWL(A0?'@YLPX5ZS`;E7ZXP5E0G(Y@V!P%\Q'^(;W?-KYBPC&6JX( MN";3Z8IC=,*U8@PP@7C$P]NN$=PI(;Z.K,@EF&9?@SY6YT5%,JTXGN-G1(), M<*WLW@@YMO3$JC0R^(J"@UQEYJO+[3-QN-'"9JZ:<"[4[3'/1:^7.7 M:,:7GY?'4SW,XZVYP9;G'+TVZ6M3\E&T--G,QE=L(N_FU95-``NPOA'_=\:S M`80*`PL!VYHD%"9,72#4S(,5ND$2J68O_('<8(J'C$HT4H8;U,@@ M5V&B3T%$C)R)*3QB, MD')>*TKH&AW,[(*N43S/2H)G@R`^@!AR#TD[Z4J;2$4&[W#WS^/+'A%T14%G;BTQE#\#F)(("*Z^9ZTOT293*XS M/2;>`=%:N&1=G34WI]MW756MI-3 MW-%M>5Y`"0N%WV?@C86;\`JORRMTI&WNB38YEGU[2=HC_G`W<4/'.)]R1Q;% M%.N)*"/F4DK[+_,+CA+-WBRYXHW(?4R7C(7'OK07GJ59:[[HF99VM\AU'\T* M^*(.7F?&YTQO.-5R0+5"Q=;B?\(.6M,@5%DPFE3#6OLGK#W5]6$)[1/K@55L MK:^W0JJ;++-=4#O[\N:8VS]J!RE"V;M,&ZE'7..B6*X^>%Q_&_16R<>%@KN%8B(:@1 MM/?ACR@+*;7TQ/_#,P><+4Y/ZP_?_.VZV?C?E-IU1KLS"@5X&G-4[>0S]WMT M@A>_;06Q`[!!U_VJT"HA@,DN+.2Z&R60.>6]G8-LS!8`2/<'70:PQ(, MW`LI6*))!LO]G!+&7D+6]2+N+T\E>FD:=4D$+&/^\GRCUQ][=IEOU^9FL`(M M;GFWA%+%_+6KT%Q&_/+&JG?>`JR"CV\[SVAE;E2"RM!E>.RUL MJS*.CT$4P[N!\6G"XP6;A?`.,K7PM\;E2[)&V)GATN!W-HM1O=3K>"I*UA`X?+/9!AH]WO=BI,VK)96^Z:])KM M#F;CED):ND9WLK16=)P<=)LZ8NJ>![YL"I8[*,U.L]%K;#'PO_R?T]//01!3 MUN&MB-K"2TY/)5V>Z_]X-X9+,)[]%3X83_15&&!L=1+'LW=__O/CX^/9TRCT MSH+P_L^M1J/]9_SYSWCA&W%]_#R#ZV72RYN_T_P?VD4 M_W]02P,$%`````@`C(%M1Q+L_*9@#```M+\``!4`'`!O<&=N+3(P,34P.3,P M7V-A;"YX;6Q55`D``SA21E8X4D96=7@+``$$)0X```0Y`0``[5U;;RHY$GY? M:?\#FWDF)"H24$U#(V5EIM1J9;@/>-#9K-R3,:O_[VNYNPL5M MNZ&!:I*G$'#95?65R^5+V9]_?1U&M0GF@C#ZY>CT^.2HAFG`0D+[7XZ^/]W5 M?SFJ_?JW/__I\U_J]=I73#%',0YKW6GM!L7HB:/@663TM=/CT^/SFOIP5G]@ MD_JGD].?:O\\^?'BY.>+T]-_U?Y[^>U_M=O.4ZU>>WEY.0YE#;&NX3A@PUJ] MKMJ)"'WN(H%KDC$JOAP-XGATT6BH\J]='ATSWF]\.CDY:V0%CY*2%Z^"+)1^ M.V^$PSP$-4)%3&BP1N5JL9$=WI^?M[0O\JB@EP(37_/`A1K53GY MJN664/_5LV)U]57]]%/][/3X581'4@>UVF?.(OR(>S7-P$4\'>$O1X(,1Y%B M7'\WX+CWY8B-^E2K^>3\[$31_W#-:(BIP*'$%A$0H77%8J4T)T!QK$XJJG: MOS\V9T+(6C!5"+PV?*AJ2SVUPVI$F@8>8QJ+5:XV4M4EMBTL:MN(!YM=L M..)X(*G(!-\SL:8LA1O9A;372`SN(O92@DQS597`>6<\'"(^;?4ZI$])CP2( MQI=!P,8TEEZB+1D("'9S[5O-SCB^P3$B45F,SVHK@?\;W(V=;"6%2FCM:BP( MQ4)(N^\2JON"LW$CS79X\87)1CKC+$!1,([TC_>2CP4.\6N,9<<*,QY5K25T M0>W09=,1"Q::B]10POBB1M+6]'C10Z*K!XVQJ/<1&C64IAHXBD7VC=9=_>0T M'3M^2+_^734NO9GZ<_N?,9F@2#'5QIRPL$D#CN6XKB2'/U^WK5 M9#K>K:@/.%;\M3F;$(G=U?2[!*5)4Z].^Y=!3"8DEAU4(B6_&,OOWER^1?A- M*YY3QYS17?)%S2`>9#S(CPL6MQHWI"4:0CDD55N=2'O+Z'N<#3?!+V6+E:N& ML<"JGZO_4'148SS$7,:9,LQ\P:0_B.7G/9J.U`(;IF.\S1+FRP$`MARC-T`] M+R=@Y&ZP#-`"DOIX.:QH!&AX.60$G^DPU$NH'[D!XNSG_AF^#_!@+^'.5>: M4-;ZA%YO7T=J,+Z2T],>B:W(.R@/&'2'Y&:\SR#@K6=E#XP&:B!+V+9@;"Q] ML+@:I35C^2,$+)?CCB9-IU+B$0=8QBC=R`:N'_G!HNTGOAG^G^;@KP/"OTDG M,BQE7$_^"P"_0/>.$%^0VPSU7X%"K9W5FT*$T$N)!3`W5_".P#_("LP*,%O!+V!'?3[&X3U!71)IE63+[S-MS?U6 MU#P*5?V^#*>0:LPF=0[3I+(ISB.6`^2XF$M9H7U'1K$B>][*#P38.P/$\172 M*^]#-=UQ+?;D$1PLP'D"YZ`*8D$OBVFGOW&ILAOV8D/45/A@T30)FX,DB+6Y M.T3XWU$TQI?AO\ MUM?J":1B9.QY)Y6G/POBB.>L5`!`+Z=#+)N!56K`.[5M--4'8IY8RKW4BQ0V MGK8C=8J*AJICC%01"^1%*CE8"RBB!/=XL;_UP!SMW!&*:+"%`<.[8@"6L\4! MPUL-@/<.I4P!QJ%0#K`IQ%B=1V[UY"QWR&@G9L&SS8>X:0$80#F=8\5UN&6' M/(08N6_S=-5*"R`[3?(%5D?4US(%=X7OS#[<"MG*M&3U3+#Z)M>&Y:#*8]*- M\`.+]6IV-G>6JFKULI+73!CGH.55?7#&49YJ`$]!YN73HJ0[:I[>8Y'DX$S` M+?)6@@4/#Z`=4&N4I>VDUG?[BGE`A'&[L'@5!P=G<16X#Q*!Z+F9OVE2J0L4 MMI=/C5B_)B\H%?;7HP6*[ M*NIV#@KE..SYYJ_1B,0HNEXG%>!%C;=M?<:?FU2/PJ(XNC;JJF%JDP7P!NB,?^GT MB1C@\"MC87$D;=150](FB_=BP`X&KE+NAMC#>+:0J'DYD<.J/@7,YE9T!RR2 MBA572)#`8GZ%:_K(U"T<(*X#5753'6RE938R6A(!\C.6`SSD7Q6VM(\QG(%!L+0KJ""^- MI0$@MM&`9A0*\'S[*Y<H5%"V9!(8\``";+-K22RY;#^E;@R=G&ND==QE7I M:0?S"0EF#.5M7ED(`*O-:L]3!M9TUE`)[&S29$Z>*"U[S[K2R``:/`E,X@ M`.1!0>W62FVH5*0;&9=$3*>5N5:,C4KX@'*J- M^%A)//'8M7%25@E`IS"`?6,'1Y$Z/$C#;X@_XSEQ;;-\"U&5@+/)`3B3Y+U< M2>V-XR81"HAL4\-[$G-9]X\X4J>%\A++UJFD2N@6D0MP%DGQ&\2!WQSNCD4+ M7@`.)2(-,1ZJHU.+6:DW1)V[IZ%]$\))"PV[]0^*>0CKC_.^CF`N/C6VAP.6 MB_=CSBM?7T_8>Z;>VPN M#@NG7$B,O`/&)B?Y2KVU,)9^U7ICD0=M-5#S$`3P1'I.P&LG9J;"U0#)Q#G@ MJ?+2[>5N9/((8*&S),025PBI/",#+A//QK!LE8^E*0624`/`27TX$ MZX;*15@IU%S"`+[;9?FV,>^^YB*L%H`.8=PWN^P-P"<\'#&.^#19L[E&G$_5 M#M]0Q<.7<CO5B@2T_3U^/8K\2H7!-U<*VJ'2`W>:CNN.,XO`6<2K':3$GFYS9DL!Z MLL"'N%+(^@CD/;'?P5ZTX4S+'B^M,W#SB`/6I^0/'#9#&>R1'E&Q7_((;/8X MB(Q*YF,4(6'%H?W>N]);`G->:VTQTH<8_!ZPVG;#`#K]EHS1XU19J9H$'-J5 M*GJR*)"4?'L8?F=9L1^U_F'#)"@6\&;FU84=/S?<1/Z0-?QAQ69K@46FB<$X?,+!@+*(]4T!ZFZ:_;#&(OZ\58]H:.S#[C;1GOL9E_U=(\!8^$(BV][B6Y'#MX)5 MF.$>V3F5.=7:_F$?T4KPH\GL5%`KRZ7[4`U@Z-2^4@5I_U"F,BAU>6=$YY M\&#D\`TX"29AUB/G;[$<>"26^(6C"(.?.1 MO,0!'.1E^=QO!S+48\#>N>QFLJK`9Y<"=`"XV5/`H%%9Y!IP;-;F>(1(F-Y` MEKVMZ3M(>5%7!3,O82"=DJ[JHZF&O`*/W`LKU<=CJ,4ZA`<$A_?PZ1WCDC6: M].5@^L01%2C0NJ>A_B]%8O9X6J:3MKHH5?Y0+$-VQWQ4TZQVK"3O@,CLOS\W ME!!=)+!6]O\!4$L#!!0````(`(R!;4>Z0VJ&6#D``*NL`P`5`!P`;W!G;BTR M,#$U,#DS,%]D968N>&UL550)``,X4D96.%)&5G5X"P`!!"4.```$.0$``.U] M;5/CR++F]XW8_\#V_=S3&#"&B3-[PT#3AU@:I-4Y4I[YLLT`ZI2/OF4ZB4S*_-O__YS&AZ]TR0-XNBW#YU? MCC\C'CQ^_^-!#5O3PRS">'GW\R-X3!M'W5R^E1R!8E/[V89)E;[]^ M^L2>__F:A+_$R?C3R?'QZ:?%@Q_*)W_]F09K3_\X73S;^?2_O]X_#R=TZGT, MHC3SHN&J%>N&UZYS>7GYJ?@K/)H&OZ9%^_MXZ&6%JI1R'0F?8/_W=7WZF_E(N>,;/EJ^I=M#]5/[Q`ZCKZ.AO21S2)SHZ*F3]-9N]T=\^ MI,'T+608B]]-$CKZ[4/\-HX*1HXO3X_9J_[M)A[F4QIE_.KD-XQ\&,%6Z,B#Y??#///#A M@W$4C&#D MPN0Q',8YS![1^!%4-PSHXL5*X6OV9D#^6R](_N&%.?U*O31/2F7IBBMO;%FZ M3BOQ.KMG7W<$-^O4!!J:0,=/U*>P)W@-*7S[L`?*`OCQ$9K0)&%S0#S\7A=0 MTWX-8+JAKUE-<7E-C,QQ0S:C]L<)+4?B$TVIEPPGUW$8>J_Q:HFXH>\TC-^* M?!S["V M9+,;"A]ED&E/ZLH.=B"E]K>JVX\!F:_R-(AHF@*?KT%4#$A=GI( MVUJ539=CC1X,R/F5)L/O7R;!+;P"OLUH7%-*9?NEC#"M+<2<_UCM=GG(#*+L MDQ],/\V?^>2%X0?<;@&WZ*VM2/`S.Q/$T4>?CKP\S`P*R.G; MH+CQU`LB.]+.NVXM;-'/QRF=OM+$I*3K_;85VXH< MQ5G?Z+>TZ'`I&(S8(`K81'4/W:V]"&8#"F=5?_$J)E$CZTYA=X)WA?%P[04A M,X[%"1=*`2.EPU_&\?LGGP8`IW/&?F!3X=G'X\[<_O5O\"NR>'OEI8"&WL&9 M.EWT#ELS&A;O)*HFY&REH!V+_<)V\?HB%X^3TS5Q5XSVDW7!850MNIX/L%I3 M^2B)I_H*G+\XUI,_3RE;Z=COV`(4)[!+^NT#+.OE`/YU"%M1&(^?PV(3#1\! M';,?5G\/XY3ZOWW(DIRV(V_DI:^%)O+TX]CSWAB#W4\TS-+%;XK%N$+E_-=D M:<2Y#KTTA4,FV_#U?P:\(:AL0WHG%Q9IEY1TCFTRP]N?MEW-A##X/'1WR<,U($F\\`YV M;S__%YU)B=AXEG0Z^\D$#P>?BO/=[NY>H%O%CHX]0KK[IO=-Z?G:[NU6VX\T M"6(X@_@W,,4JU+[V+.GMJ_ZW8/")N-@-$7T0R6=BW8;>6$#`VC/D?-\4OR4^ M7^&7NU'X=9XPY_YMD`Z]\#^IE\@'O^AQTCG9-QZD4`0GRN-=KL.W04B3:Y!H M'"?R57CM2=*Q>:*WN`9OHQ"PT-D-"R^)QP+3GF?3US@4Z'_M&=(YVS?-;\LO MT'G+(W;-'6@\G<91<59YGG@)30=YQ@+IF*CR[:BD(>GLW1Y)$Y2`LI8G[KI[ MIW(B+;<3M_`[E>UTZWEBU19BE\*(G![\!TG'YBS#]7P@Z^D_LO+L6GO/+%I]]-R40V4JFTYZ<.+3W MJ"D1+&;:R*RX:5I\;N5%F/2)#BF(#9/V`\WFN&5?G:09.7'HVVE*H!*0%6]/ M<][N8)&-H.\9B"GAJ?H8.7'H[&S*RQ8`.QZ>YD3`'N?-"_S//]^*^T'S"ZEK M,"7\:+0F5D,"+=&FB\N.I\C0[D-WUT'L1@-:FO"V$-CQ(+7YLN(W.$C,V%7C M(L0<%M;B6IU\RI,U(Z<.(\YJ[PN52.PXD)HS=C,_[@U&\"_L>J[C-)-9"+G/ MDU.'L6BU.1)#L.-':K-CF&N2W@?OU+^+,B\:LU-ZB?7SSV&8,]?DESCV?P0A MSW/>M"O2N]@G3IO!D_NI=L^W!H\5``CL3=K\K(LMT+LS`T9EI_,01T/E5H+[ M/#G=)T+$$`3D.+-@E$(J-W;D%(%AKZ;]J)!9H&]GYH7[P'L-0M`<9:D%MB_# M:QCX=+L@IPAL?K6,L;60"9AU9H"H"*]OK!4W(F<(=@BU"%%RRD,H/@"MGMHG/T[`5?.S!T/<4;UES7.TZ1[N:\T"=$(2')FH[CVWH+,"^^I ME]+!:QB,RRQJ:K[D#4D7@9FW$7,:N`0<.K-W5.)]ZGUS\H:DB^M`4(-#-2X! MA\[,(K6V(9S%NKNOFT)[T+7"0U/F$+P0E8 M([4T`4$.G,0/)"IV]QXB4S;4>!H`4YQV4<:4J@#)Z` M/&>&D@U9%U&P_2FSM?:S+`E>\XPMW"]Q6:1"GU9U7^0(5<@N)@!EW MUV-\/RB%>?0"_RZ:;Y]E7@-^"])#8%]IQ),,D(`N=_$FPV$^S0O'U':AHKMH M&$^+:F+:G_ M2K:SF8'CPN;LU2;9SH7DM"P#Y'?;?#;.JM.;49 MH5S76W,F3/C-D?HO;\VF"??4>?UG"5UUO36GAU?Y^11[X>?3.J6$3P^O[//I MWE1]KLD48F]-D0Q`)WW^YJ/D#.=.6[R(<1$@<[`\>R%-YX*R7'GIEX3MQ23+ M$;\_5MV`=$J,PYBN!/7)4J/WX\O2X4#K[#;GW7N.$/3U[ILE[,%S* MP5&ZO`'I(C`4:"A=`X4Q%X=`Z==Q&)8"L#.(0N'X]!?9JF]H7`F'P;%L(&?0UJH-_+[TSC) M@G\5OY>:79IW2S"DE:VUO+=&B\\OP0`MIF>S@Z)1K^0"P9S;8$PT!VO.NR%< M"`L!V?:G+<&M^B,7'9PNJFUN#>#$YO\H=KN/23R27BVJ/$7.,>1\K/4I;DF/ MS;&,7Q/S(X>"K2+"$TTI:(,5[KJ!C5T8%\4UYJ)+ M=Z^2=N02P9Y'SH-H;ZM"A:["`8T`9LAF9W\*2F80L^"=JAE4M"27"'*^-.%0 M!Q>V>@G/-`Q9GHO(_^HEWVD%L=2?=A3MB6=SKZ=^C0Q82O!P$K+ID5&Q%+HNRBC"?Q&PIZH"0!$X+;3Y(%/ MHAP:MDH,"^G4)X6-)P$.`I=32Z8XB+"57[CU@J2(]._[?^3EN!J,?O>2Q(ND M6T=I.X"*8+?8BCP-?-B*-`CQ-EGF`"*"?4DK"A78L-5GD.50NZ*C.*'RQ'-: M[>&,L^_3:@V'.X5S2B0H`7`0W"/HN7J*$&&K:[#`\VT#GAK MSY'."8(30KLI=!L/MN(-JQP;ZXDU;H+WP*>1+P]O4K0%R`CL)ZTHU,2(K7## MVLCKOWM!6*;4KES'FJ?(N_+28*C[3:I[(ET,3B5S7ZTN8FP%(A9Y1QEU4T1+&^[YO@;008BL4\3L-QA.0KO\.L,?T(6<*&HP*`)4[E?H\ M-^L0E+/O6Z*_PM+7\[R>+[( M,_W(7'?PAWK5*W8J!VQR$1RNZQG]=Z\?;"4S..@U\L%+6I%S#/4O:\;8*M#( M*V2XOPQ_[:63VS#^L9=7WKON"B0TO?-^;G.$U[WSWM6X'+T2^Z]+[YLW8<]M MAHVWN?1^KDYFP`5S8)?>SZT:*PQ<>C\7%^/EHSFP2^_G)_MRZ;TF4V@OO3_3 MA%55J)F46-**=,\0;-H$GXM@#E2AP78O/G]-`S_PDAF[\Z.Y:(G:D'.;EVLBS#.Z`4V3IH MC5O5PNC,I7GW.%`N@\MG``D&@Y7FUR1P.*^#0985X(%FS#3QF,3,+>=?S;[! MV?$N6L;:]@'E>U$AJBP)GG;/=$B'@89.L*5> M*-R^#Z`94(,ZFISS-.G]^9@6J0%;7H9%[!#SEDZ9F*H9GM^`7"`PB.Z88HDF ML.5M8!?&(I;[\?^L"@:UGQX2K M%8(M`03H(:$P`=W0\M\*\FOO+) MV"V]3H`\`CR2EHB60P87WH+TIFNIFLK?ZHZ#&EV#PA#8 M:NR-D-JJP):K8QO5PJ8H+JJ@W99T,"2%ML0^%RNZ_!VM'%G67/^@+`3;A%TX MC%LK"5M*$0&F,H64Q:"2FB\`Y2'P(QN)*FF$'%N:$@:LR)$),^8MZ*F2+U,6 M[BYN1&-.&E'&'Q1*%6#+:P+[Y;DU;2XV*`<09[/'T(LRV"&Q\NYO4_G5 M6?U.0'<(=ICVQT%=C6#+J=).0];6"](Y0;!%M3]\3&@)83X7'J;;(/*BH<6M M2,T7@/(0)`@ULA5IA!Q;%A@`-:343]EJ>I>F.2"B@U$ED8UL75*UA349@?O" M)'V"Y4A/$=@2QO#%7K_%!FMI^0L*?VPV(%0=@F81&$Y=C1(][9C+*B,HG28: MPK`D)EGP&M*'."M,>@N??9&58O&DJ`Z"J:Y)!\/U&'M#Q*R>L.5UJ0(K,,R] M")HS2;4)Z6"X'+S;N6(;OSP'C.'9H)B%!F^EZ,O!]_DG388!OUI&W2X`%-YC MAXVO6TL?`I*=V3IYT],=8\D+'_/7,!@.1K!N@5)J;A"X?;C%A#9P$XIF,&KKYT[]NZ9JVX` M@VHL-"/I-@40![UEKZ<'`9G8K(N:>K%F`@)EX35.&_SB36A)D.3'F77Q,RQ# M0SAM?/XYG'C1F#YY&1U$A3LF\MD_S.#^[H54'A9?IQMRWD7@%J]G*:R/3T"T M,WL@7]9'V(/$_F;8A\I7J=D-C'@$A_MZ1-?')R#:72H\+H(^3%U),H,9J;BL M49OAC?:D@S0!:VUJN<`$G#J+?7S.W][*9)E>N,C#>A>-XF1:I@A6.WDT>P#X M>SN"RK MP,(:TQN:>4&8OD!_.VQ5(ZYT@2_\NU+MC'"/`@*]Y@@"-DTZ(YLE0SHC-3 M##LR5LZ'\JEP^V'`9C,ZQO(<*,*#K+S"NIBL7('R\Q(U(9V>U?A3[8E0I'H= MHC;A("N_8)@N7'.B.=Y44Z*[4@C/DSC)7F@R9>+KG*IYSP-$F_$`MG>'8DC8 M:A]LB:H^F?%;D,X%CKE1HGQ-MJJ`L%4&,,H7KLG1)''*Z=%=XY$V:]L/`R@,$5'UJ1)!P99+G]VF9O>C MO/#1@U5>X\/B/$_.3S!$PS3YH(1HL*7#-UM;9(E2UX+E+\[X4FMW1RF:L2%@<%1>U-`,7>.T`LLT0 M^5T%+XBA84NXOB&I\K/D/D].3I&8J-4$\)F3P,*60]T88[@F4//4*:=.=R$I MJ[R$6E:TM6VW.!5*97SZ/;#Y/S8:MH$[66O+@]J-JL`L:7N-L`:KJ7/)GVJ M1;!)NFQ!PJNO,-5\_Q+&KU[X=^J%V>0NBN+WXCQSFT?^?3@4+G:UVI/S#H*4 M%J*O99V^RM,@HFE:N;2I6/X$+4`_-J.=+:]U4E#8\DKSA"W+-*C# M6I1MR?D)COL]4DKT6>2`,Y?L>4_XQ+4@VB)6N1@V,,,(%L.^_^Y%_L^[2+'H M;3X'8B)(#*#YF7#6.CX><^F2S6?2K41**1*H2EJ13@]!.LYF]Y&5L##G06Z= MS;R'(?E":]ZV,6%.5*Q)FJ@)`$20KK`9:7),UI,2+TI<+`H8;"=H>9YX1=8> MO;3B[3LEG0L,29%JD6D*M;FTQ3;H?LR3X<1+Z6,2#"D\_0T>LC($>"\BG8`.FW"%[&E?=+$J`D86PKB]$5,/&[9,O]5P]YRI92%U.1?<117?J]Z7 MINP&%+&WYJ7Z.+'E\[5<6?=D;XU0FN`P)N5=I>VX]8:TW(PI-JF\)N3<:MR5 M];VI&),\?:[K(X;=3,H]##4Q3!PX5!@%:?!L6X,J,P2L]`HK?J-^`-[>G1E; M`!7PV-E1KNOG?#KUDAF`#,91,`J&'HRSX9`--&:,C,-@R))]EUFOZZ6[%AFD M92^ZE^2RKM&:G#2Y!=I$8%'&:LV6(*A-UPFUL2LY2>FDZ:^NFBELO2(K:<5^IQ^J.%2&4C2P39@;!4IY^ MFM*,+2OW@?<:A$5YM+F,_B!ZHJSZ85E'[2&.DL7_7GEI(+5W6'D/.7%GO#AV`PM!DN3$\"A1#34,MR,Q'W(5G&X32:E&K']`$CCQE=8A34*^/&YEQRMD( MP&72/)_F&)Q]Z] M<`WYJARYS&VDVP3L%'1\B^)79M=DIZ7B MPX,_Q]$06GESQ>B;@PR^CIRC;1PR]"J8*'<>O6-_&"C6"Z.Z.P2+ MD:4LR%V;*U`S^Y!1ZOG#3$,IR*Q#AI+QGEL->C65/KF[%3:A`0N9,<<88;B, M,^:90VM[F2=64)[FUIX#1`ANL$H^$SX['`Q8+2?MEX=K+QSF8?'C4QR&MW'R MPTO\W>SH^.\F79PV9.I%:O)J'*R_#W()EL(TW6(Z=/&D;O4V:SHJZ8W MH/7[0+,(KL_L:`#I.QD,Z1694:PI4@'0XEJOENW!Y/M@(CJL*79W(U9#K\@B MYPPC+=-IW47#!+JC-[3\=WI9&)>[]"'^F659:OW8X M,5=>2KI6:Q[^"`7Z#G'*3`9@VSR(F;WI>R$T!6S@069\+Z13V@$K3P$*JU9` M_8)-ZWJ5*+\J.#)3>B/UXS*;-^$!K6'\J_5K:'.9X(C M.3)S^%?0G18'U><`"8)4@+H<;$N.S))[#;MPV#PDY38\2+]?S:YH-)S`/E>5 MN4/5%/`Z+V%E8%G7@XG,W+DM]$)D=<8(15/`BZ.0HQXQNJ3R0"*S"%HF%==N MPS:[JIV),ZO8?(IB%A(:%!83Y0(I:D).,%BD]+XU/I-R9')S$(8/=/8"[ZR_ MCBY:`4R;#A^'2^@Z0@&1SLIX;@G,Q*T_R:Y:`4P<92"55&@RN`E-P*"[1&8V M&$2_0AJ@4K4N=IR94+YZ?\3)=9YF\90FJI#A[8]3.5T$Q1@&=>WZGLGNV#Y=@"P+XS$E@ M"1AS9LDPQAC2Q=$8=ART^&)&=EXM#0(W#M.US M==+[X)W5\,J\:,Q6Z#*5S]6L/-"R%5^QX-7L"=1Q"$M@(]2"0>`PX;L4Q`H" MLW$H)^`&O9&>75N9]H+:B,Y&(T.L!L'H<)A#'L'HP+5XNQ\FRL7>F:WI)?%\ MRL)+4N5:O_DH`$-@R&W\X?()YH,4Q,<[,S[=&MD#U.@%U.`\K[B!];\V8@'Q MSNQ7$@`U9_::/9$+JYZ`&GG#ZU)8>R2(X0M&@[L,\BY'`ZXUWMVP4*WMI\ZL M9S)*IEWI%2X"-(%2VT2?,IUT+KX!>9Z:VA4/Z MB9;7SM-)\*:F5M(*8"+P5QBD58E50&D#TYL@3&([)+M,.7'#S>"D:D).3QT& MJ9BXUJT$)V#$7(C0"YV^Q8F7S$H;(?-W3=_*M`K_S&F:#4;S>V@@&`O]],9T M,/I['(("TYM9K7=0FL<$;9?-(-+Z/T_3:2Y+9 MJ,S!)?LRQ8T`Y/[NM77A"3AT9M#J`T0_"/,,3G_/+,U9D9'M\\]AF/O4OP7U M,)]^GA63S&#TV4LB`)?"JE$,TOZ4*4FV73+1/ZC.H=_#U&[*G"8$@\B9V8O5 M&[J]N;N^BXH\?LI!P7V>=$\KGCW^@:=N;Z"6@S@' M-<,M&`[.`M2^Q+'_(PAE'^[B$=([W?\9=AV,@`UW>=R%IO1O*1WEX7TPDB:U MUF@.RMG_`X\^4`'#NRI2^$P3P*1Q1Z--6EWS]Z/N->H/4CG,EW-"@E5M0`EKO;`NS M$((@S-I\:N)"EDWX,8F'E/HI^#3RGV#7L`HPD\[1ZN;D]'0?EU]]:.:2%.M]QO"-6;4>\V0X\5)818*A,)#>5/^@#@37(EI]UBVQ8TMN M7-D_CK;'3+,F9W+IS>[V.2/=LG]AN M`U*>"]IZS`(3V7TX`I-BI:5[C8`$00MR[N[&[[I(JE`$SM/DM&=S/9.&($CU M*1[M7`0'$7PPB9/LA293AE*C\A'W>7)ZX3Q!MY(M@8--C`=9H,&6I$I/MJ`% M.;,:(E(CY$"L>TVRJH"0Q1P8I0M9](%!WM"&']S'7I0^>C.M:G[;#P,V!!X3 MZ0?#YTH$!5F@P?HTKUBTMA\&3,XSB35 MAZA-.`B#!`S2A6O!,L>;:KEJ$!H@*FVT M.'8E%2!CGGI]"KJU*>@N)4;@J#-!P1H@;.5\G_/7-/`#+YD]>\O`<]615M0& MM&+SL[%ZK)5CPN8IKPA9ED1[26`7Z@V9@.ISD[(Q.;.;L4S_Q"NG1<"E)CYL M]7QW0"JN;89%=FV4^!6L>E=T%"?T.HS3(!K?O2D**_*?!I$11/GJ?CB<=4\& MR[H7NS_*:*)+`/=A[5H-#C.0&J`K MB0<6X,%6J]<`24C7K/9L*0N&.X8L;`5B;'D:;8K6/6C]3LCII<,Z%BU9K@,16_W> MZKPSR"8L&TXE\%1S!MYN2,XZ"*Q*+>=A$2QLU7S7858"?U;3SQ.[NZV:CK7Z M(&<8;K.W_E*5"+%5[IV?\^=)W0=)45]R<4US58'AV@M#ZE_-YL^E\PL'4#=SV]>`Q6VHKN; M<9OJLY"@!>F>.2Q`U.:[E.'!5D37W?7S`ST5<6":J[)KJH9?N_"O>?6IVR#RHF&1C2R5KH*R9@`4W54, M+=+4H+"5M=78JA?9I5H>:,H^0`7[.Y760&BNIJWPTLTR)&-N]1!%OFX_2;HN MJR4V($&*0UYTUGK&E'L@'6;G_CBAA3LY9>540163ZS@$*N*R7&[:C_P;^D[# M^*VP1BZ?;I-L13`T6DIT+TFW8K1_TG-757;I_5>6B%E[D)QU;'XYW)0L%G3. MG^)X4`\A=\L3#0OCL)=DLTH$=WHUJ_Y%$12AWPDYLUJ,LEYI&0ZE(H=G/7S( MLKY4A52&)VT_3,[LKHC:H0UU:5"3606(+/>+`=)PQ1K89,]"!ACA_F%$7^AP M$L5A/`ZH.&!$\C3IG2,(#1!]!YS=I0P&NIPN9:;/)UCIHYSVF8%U7,[RZL1D MZL:@(C0Y7_37+UU79N8VS_*$SG,Q/\4S+V35C6;E$3X79K57-(-=@$-7G_6#I;X*;*>HF:/\ M]@;HHVS^^BQI,`QV$&\)V9X+BHY0EKK!NXF=T]**(Y M&+;KN*C83B-6K]U]IO`!'"8\)M`]]5+J%V7@I19LO8:P.4%0RIPKHWY-9CX[0Y.70Y]&A9N"#Q*98;KMO=FS,ZMQ M$`8N-Q=:YU,EPH/,#FV`(URG;X-DX4T\SN:,>K9/41/`B>9:<]O948X1F26; M)ZSR`Q0W(F<]J\'QVI.EG`1]XJJPD!FN+5"':PXUSZ%J*G5FH7YB\JKB'Q;/ MD#.KGKV=3I8;H)"5,2^D4]_67ST%AR<_EBJF:9<$#;975EE?` MF[-I;[6F*G&D(B#Z-LJ6[X!YS>;7*S5DFJ)99>PTHJ)#L(B6F-3'_+7G`#Z: MXA2&.>4/'`YZ9";1YN!7V"+_,?0BK?I+-EX'>L61"HW#MF`^L:8%9,;<`QE= MN`X2SH<96C-T&72Q-+C?LSHRJ]4>D".X&=^8VQH8D1G; MGVD(?8Y!\J]>\ITR@Z8NL:JF@!=!RHG&G.K!PV:K[X=%Y]3G;QS%@=SU.B!G M%PARI=FU!-;1!')3O\-`8>P6_]XE@H#CO;#X7]BV:75O8&IPH:7PK)K$EC(C.[&",-E M/#'/'%H[]CQ/K_*TM?8<($(0/"/Y3/CL<#`@LS&W+#)IU8-@BQ4!#F1FXX9! M")>'&(0@WG)PT",S$Q^"F[A[C&.#PV%[A][A0@O(C-4',KIP[<:<#S/5YLV9 M]?SS]"V,9Y06B^>@$$NY;1"V`:0(-G7VI@K!CEVN#FSV]55]PD+@;\!/^O3\ MK49M1TX[@(H@Z?JNF==0";8T*@MPBCUH]3&8+Q'><;6X!=T&+\^CXHY%Y?*^ M&0YWB2-4:%O#65D;TNTYS`XE&^?KRM<$(M"_PX2SU4H-R@2SFP^#)@XQHE6\](A4 M(.#58?+9JIQ:TY^H">F>X[AZ+-*]#E.;<`1\(:G4TYHO7`N7.>*4"YFYM+`W M=`K3>+5PGGP1$ST/8B.(8Y)_#9RE3`Y'H'UW,8;Y:QKX@9?,GKUB!=#)J"9J M`Q#Q5/G8212!7!.""`)W04TK(=E`'HPJ]1C4]E1E8]*]L%K?0#^X0$Z+@$M- M?`)2G=D]=D`JKD71(KNJ5?+$F5UD\$X3%O1:5A#6LV8+VY#N)8*"V;H?')]0 M!3@!?RC*^NRBWE;7:D0HOI6XKFH$X\-9J%';LD^]4ZM[91NUNKIZ;%8!"EAS M9@0RP!JNM=4F?8"%P"XN^%L[AM!XP`4\-;#T"GI:5``0+W_9#(-B?(U!=!%W`B3GS MS?*=P@F-]QCI6;U`H%Z`1/J2:;4JND"OYLKM--2;L?J8G!(HY*O.\'@=&9^VM75]6X'@F'[^"2?!(*6/23"4WN+?G11`PS[$(ML=O:;5*1C5SFR* M9C_?#?S%'V]@];GU@N0?7B@M-[EC28`.!#G$]FENUE2I8(0["[%KJX1!GJ69 M%_E!-"XWTQ;'\-:[0*5_G;B;*4TP#O%>=Q7!+*]QKZ+"TD$VHX4RG`]*U6AX'Q0"HHPG!,&C@!Q$X/LOXS,B?#\>T ME.LNNHZC/_*HB"_Y/6"1","!%S[FKV$P'(Q&-.%_Z*W[)#T,^8SM#`!#RA&, M";?5<>8X"M,-C.?B=ZK="*\-#/L_AQ5-#%[`KS._`KMD`Z/SG28L!J'\J=BD M+*\^3>,\RCH2NG6[``46]!YH65!8[]UXN&]#I.,VGRL1;=@J(.WNC37C^"@=3`DB[;23SFR7`""-=7 MMV]OBX'.ACSGWH,;%$%Z>E*1Y M8Z0-2;>'X4:-U0E"1P,"NIV9>.=K7_`:TD?HEB;)/*-1=8.T/I1EMH7ZO8%: M#CX4JK%:!*/%F0V5:S=9QFO1(1RELX"FUUX84O]JMACZ\P=ELT?+GD%=!Q\7 M941%@A&%RY"Y%H2PFD$72&2GG$;]@6H.WN+50C&"--<-[*"";>OGGV]!4E8V M\K**'.7$*-J8REN!Z`=[C-6&+V#.H.F2"?^JQO>ZB:^2M_N1#N&WWIAGJS+_ M$E#,@1LWS6M+,(P:6#OKGUL;'$M!Z(-U?^IA%Q#6P'PI((Q_U"FRH'Z+X&5< MT[DHG+EECZ37.VPC0UO5"$:#NY2E@2E-0Q&L0E=O8 MLMRCBSJ/"VDJ:KK7J.`H:T;.>^[N?2SOW7,D3*]FE?_3+\&HUQ7`MCD%2RLM MJND0?#B-,!Y"J40.7D6&)4$+4`G"K!-UZ.0/#2E<9/4/>;*R'Q.JSOBJ;`N( M<>1/DC*B3R(''++JB-;IQ)$UPS:O%FHGBO*7^.]>Y/^4)TY:>PCD0[`KU?P\ M.,<1#AAD)1$YV!;QWQE-:)J5^^5!4IRF8#$H=\MI&HPC::*2=AV3^VE$_@#^QS?O9#*(W;L MOAATC<`!9WLLV1_!(LTB*UYI%'*>),ST53P)O5!`#BUW-I8%KP>](PAR/8`1 M+=4OLBJ9)H'?1>_P?)S,=C20E^\#S2)P>N__R-U0*+;ZGB:A/B;Q&TVR&2LS MELW7G[>Y`7,78U?X?E`]`N_^_H]EA8*Q52^UM@`5U[]=["R*%X.R$00O[/]H M%FD66_G6AIB_Q+'_(PA#+O8'FMFS-NB^F?2.$<1>[-CD4$\YYLK7"BS09C^H M-(NG-"ERYS/'V21X$P9O67\Q*!#!+9&=C!*.G7U'ZK5>P=\TY5NW@M*`_!W9-#&)M"Y9JK;6QQ9,Y!O"2>3Z=>\MWJ;+GU,E`4 M(I?2/HY"@4JQU5]>Z$JRU5L\`@#VV`VTC@);6663\U[E-SLZB%9^`^I%Y*=Q MZ2O<4HJY2M#XQAP__-[2FT"=B#PG+L?84AGR.M<.XZ\[AQ.`[:YHN-,`;)N? M6IL`;&&IVF88_PK`7H^3M.GALQV`?5X_`%OH?W-NV[45L6O5[64@`+O7)E!7 MG&3W8.G*+O-)+6?-%H#:@112C484J;/GM)%$3C=)'P]\I+@V&SV9W;%>DAC;TW-Q`T\$NC MDQU:-UZ@FQPD.A`;1\]A]@:7-HX+F]$`S6T/B=$]L'"UYQ7W)_`+G?I3W M>7!".SA@D!D4BKWO)`Y!BK2\"%TD6U4L$C,R`L"P3.\_+ MM2VZC?\19$(T724R6<3PU M;8/J#N&SPAX-)3%DM,%L[L*L+)&TJ*[C;9Q\I6/QMEFK,0!!\"77):\N/FRW M/^L$/9]?X'3$:'U=ZRBPW5Z`0`(+JM5Y>M=13F+L69H4'7 M<;WNHSV_1'1%K2XA'"CF+H39,@$M]]HW0@(9UR)G@-,'Z+\ MRI5U[S%,TL/O7R;!M=;LBGRM5L1A5NG=`B1\A")0(S^_9#`,;FL;NA5=T,13R_R39V8[YD%2=" M3N5E4[0.%P MWR8>MQS]ZT'!YG_UV$1:K)O+(ZW9#>B4-[A-G= M0FW8R+RT56F+0J:+<%35>8O7!A`Z-%V8)5:.$9D/EE_:K*(+F3%1U180.[1_ M&&55$RLR1^L-?DUW,8\V24[[J@ MD;E#4K)'+X#]^K7W%F1>6/'VZ[+=IEM0E,.X"*/#H;T:Y+Y;K@/C;Y^8 M+*PH>Z'"_P)02P,$%`````@`C(%M1U%?N-Q/5P``:KX$`!4`'`!O<&=N+3(P M,34P.3,P7VQA8BYX;6Q55`D``SA21E8X4D96=7@+``$$)0X```0Y`0``[;UM M<^0XDB;X_-?3@]7>OOWL+\#_>G'TJGLY^_.'U7\!O/_ST\P__]//K MU_\+_+_G'_\_\/[S'3@#S\_/WR6(0TTX?!<7>W!VAK^3I?GO]U$%`>I87OWK M-X]U??CY^^]Q^Z_W9?9=43Y\_^,//[SYOFGX#6WY\]BOBSBJR5!I^P6D+?!/ M9TVS,_RKL]<_GKUY_=W7*OD&C0$`_U(6&;R%.T`Z\'/]TS_?0X?\&3A+[S%7WC]7_$7_L1^?1W=P^P;@%M^N;V2"O2V MQXL1?8]ZZ:J?-[!,B^1]/JW#0VKW/?]<1V4]H^\\OWQ5UE$WJ-T_ILL>? MX+1Q[NBX%GMK/:C":&;XYVO4AU[OX-<:Y@E,FOYA:H5= M)YO5YCHQ# MG=8O5_FN*/?$N)_?5WA9JAM&I/N$_;];T#;2-_+WNEK"JCB6,;22G8YJOT_1 MO4V?T)J'*/'2#O.S+Y^_^6\-&4!T@!("CA+\UM#^KW^AWQ\(=5[VIR`JXZ:' MZ)\:J5B+[^,"+?ZR+^_?QK6HW@QH#&&7A,^C]$$&D"BAT@C9#U0% MP@6"8AEE5\C=^OI_PQ"!M80D)8`-0T!#Y+1%@&A'.JUW9`[ MQ%;C>M`F7MP-UCNIBX'_'H9/P8_CF!\A#N+:,]N>>5RB54@SQ8.V7N9ZV%_I MI-.&:)^2X-/'0.9_=+3'@*`8ZK40<8Z^F^!O?\BB!PD2!FV<(F#8O^',MW\' MN('?^1X=2WZ>%0.YUOQ>',L2?S"MXBC[GS`JU4HO;^YTUA6]%C8$M"F@;0%N M'(CZZX:>1X;9N*_K`GY(,UA>H(\^%*7:`1RT].#^#?LJ]3C/!:(+@K(WRG]_EE?U\(@\]D&+1Q.O'#_@VGG/T=T`9^YWIT+/E95@SD MRON\8K\OT0)WV<=1HA/&AQ"A%&7XT,RY!YN.+:[#VD>Y7&* M0%M4J>8NUH[Q.MH.3]XM8]>A*\>'U\I6_O[LL]E&:*]`PUM@Y(D9[K+MGI0T#P(9\O(?X MT`VV!VMQG>;P"OW3Z&:>:^S/:O`]5E@.W`R0=@%`1#[<4A,B&6MW$#FO*EA7 M!K[,L*%S:`@]%8[D20.M&S*[HT^PO"_:,,>Y_?4/VW$(#"&KFG_7<&6GUL:H M%=I[`J_8[W%,;$!SNQ`6F/7];_H=!85M"5[&(:X$BT/_+JH>S_,$_^?]?QS3 MIRA#G:K.ZXNH+%_2_.%O4794;0`,Z=U[@89R"(Z'3_8R-?1&V./;&Q:&/$,?%$77G%L80=0WMT3_!FEEUE:N@)'/O,:BE M$!P'UAQT[3<`4;2N1!`V<:I0)2=4#FO_VF.",<&],`:8.UVYRI_0UXOR!75% MH1O]9LYU8=#+(4S:/S/$!P!T\QY+X3R[JS7WV'%J1Q5#Z5+=QF`Z5"\Y1MVI MTTT)#U&:O/]Z@'D%T0JYK1]AV=M7*+3,B-JY\IG)-`0.HP*,C'A%A!`,MKA^ M]72><)"2542Z@D@7![8!MD#D4*&LX>A2SPKD1]\'FJ>AE3 MDWG0+*44(NIH\PT@!`1T+4DX2]]$J8@XL!,G"#?/!&>BVIB"S)V^7,(=1`J; M;'?HOVA_=E%4M>HN2-+>N8;(^BU$OK!VH&D(2$N_BF#=^:N;+4BKZHBSP(!8 M+H!+#5`B9PA]`]BXW-HD<)?F:0VOTR>87.4U&O04[;KH"O;^:YP=<8SB+T61 M/*?96.CQ=%8>MDC6THJ;DH;%&>$!.B;,:0.O6CZ@8?2M[XW6`G*W8D;,-PUB M\9D*8'%C-`>][A360!$]*I@"0,V?UMK'H:(J.O@A2DOPA(^,\0'Y M@[*[+A50IUB^%8;;CWU"$FG/%R3MG:N2K-]#7/3/"[JF?H%LU_N\;1+,D8`2 M-D.,&V#&I4L7%WO8!D\9Q'](*3PX:+*^B_X(;@FX*+>``JLU4R#Z'@;C[PY` MUVETGV9IG4*+&"(5D7,8*248(HEK'%Y(D94D3>>SCLB_+NC1-%0'4RBYORR_ MB5[PC:3Y-?F0P-L%N=!SZ2TR:QG(U8-]_P^TI7_@JT$CN_=6(<8=X-_O#UGQ M`N$MS$C:8$$C%=@WH'6N!B;R"&^2&9':/*61FSJ'/8CO1WBI&D2S([!O,_^\2Q#PQ#&:BBX MOR%F_=';?2>U;6,A#3;=__,A20JT$CNQU6(<8=X#\5-33?]8ZV M=@[U\3X/<4):"9O=(&*#S`3X_%B4]5D-RSW(B2S!;'P5H!FB78L8A\_`HPQ6 M3.OPG57U2UE4RJ?@$@+WS\%E/1<@@QMVAIVT1?_!K?TBWEB"F[)(CG$-*DS@ M'^EJS`COV0T`X_+IY"'%H>\PJN#V/DL?R$F`P;Y41^CAL:1&$O$%&B$`A`)P M)($X._8"L8/_?50?2[+-PS$"69$_T`4B9@)G1."B8^E?A@0Y4J M5F0!O!G5NM#L%"5N_?(9ED]IW"Z#(SJA(W!;ETO5<^$BN6T+FL9` M>=2R-OCG2%"QQBOU/&$I#(G=7J+KYP\/)2FOUVS\07(D,>[U(V3/R0'6&C`B M(R+)$X@/#=*:NDBCX9;>X^[F2\UYJSARYD M+(CC!PLAPCES4.%%B"_1@L7[+LPH4M6`-I2]F#(&5+$="R6<=8I8U_KM%_K*T1B@AELT__&QW&6H:D7A6_D,8!Q#%G^SON:*890<0=U7TKVP(#T" M`$4(XF*;H(LBRZB;A?5`LP&2-':[^9'U6-S\\^T"V/-,ZKCZQM#-CL>TX^)N M!T9ECC8PDDU/W!,T0L0DTKP"Z/_8QJ?E>%)42_A0G:^A&I^&OM0]F$S5;8$?&O=I-A/=3/F9AV&&H+:[RAN"F+ MIS2!R;N7+Q5.0[-%V_@(+WKG<9T^T2<<9!4\HM^Q/Z(MKL%^8K<#IL?-W]Y\W;S3S_\1(X^ M?GK[9O/ZG_ZY:9D2^>DM>U=O&]<9^8P0#O?WL`1O?M@`#!+2ZA+&[+>OR6]_ MVJ"=:'6`V+3#[,6_ULEP.W9N(@>M2SVKZNV.O';X7&1)FT;Q$B*#%J=D;43_ MSB"I&YLGR"]'!N\?HY=DO6&8P]:#_LX:!5%C*G*M0A@"S'$#NIRC/-,-:-EN M",!YSG[MPBHC'XDH&(.(9!'(W.UQ/1!BRE)`X3920) M*2$=93=1BKQK%D6D,`52"O=),J1]%Z[OVY8`-\47[ZRQYP094R3`Y0_.D`2Q M2@*G63+4&!)R9)@`R.DY$,T'>*U^?CIHY^-4IM?/L<,5EJ3Q%6[RK=LS5=/S M$JT,V7JO8XVN2N;UT?'QBXC0E?1VD.D_=1B:NB5ERW+^$NC5-U9BD]L8>+>P.) MQ,-"2@0:*O"*1RLC]%Q]8I)DO!@);>5?Q\Q1)X8)V$'.971J$?_^B/:'R&&B M9[,*S1EK["$2=:3'8OQIU^C/?WKS]J_-C8!;+]3$PS.2AX;%5()4D$KU*E&J MNMNH6AF@Q%A:-9I<'CO\_5C1,+.[XA9B25-2>;9;\>X*P]L_@ZNU=3[GXDN$*Y=%7GF4NAJ(IBW8_8J1 M>=YASQ"J1M(<\)I5!:)"1E"395W#.53]WI-ZJL[REAX`>]Y'RYD2_R4C,5.[9(V"8PF*Y07B$(&HS7<3, MUCV0J#8@P9E>R@KK-HWZ#L"SL<2KYJF$ M&5@=%]3&:=RBZI%MLQ2:-]K:3S%MH<_CQ:A9LV:/[W.S8-;MIL,IR>6$%DFH MZKE+15!`9;2$M@HG+F-+*H@$?42KWR5\@EEQP$Z/'NH:.@\1)6HYQ&`2VIZ] MA&DI0M"$6;(D'85_G3!"EQ@^8@PM;VX9692J\_9QEKD[)E+Z=L-&9-&[7Y0( M=%1!N5P&(@FNEO#@SK_Z&().XU.I$>=9A>BK35OU::C"4)U6!F.U6?6MZAR5 MD8HB4Y=4(8EW5>F#RTA-QI#E3D6N\KC$.:0O(?WO5=Z42K^%,4R?-)4!S,B= M*XVA5$/(-63@54/X+0[0:6A!1[RT(KVEU9]L]D[==@'JD8:Q"?6F,ER*.+,#U2"V4;%$J=#)Y7YE&H&>T/$EQ MYTZ5?H$Y+*,,'Y1@GCQ1 MC\:_YA@B;:@X5C!S^/8$9AD.CA(@W+03(43G+2,D^V@D'W!$H9T;Z.2A?PT@,YL1I/3G`U(\>@I/*YAAET@0A2"O^Z(;VU'].+E3-E3U4*G0QAAAUH M8*15!+_A!D)WS&Y$U63^U4%]:3BN$\%<@TZ3)N#[3Q.0:?4D@'M/>7C#3?1" MBBJ543(M.J?/(("MBT0RVP@=1KX!A(%?O9HL9"O-@;;SKU%V2#0/TY'#T+.6 ME6B-Y*K4G^=)?[LU4N3>5/^L6(>AF7:C8:ZSF"_@B,FUY_`8@ON[STO<%0:F M&0&<[Q;F5??:F!Y<9#K!O5N`"5IB9!LFJXC#F*2RJ*J;LE`GZ.FU#_PKHGP.H66O2V0/YLW]E&)E\(21(-O,^%[8FCP^KJFNU<@FT`2Q-HCR& M:T^;G^E650C9GZ.H%ZR5()A2SL9PTR\!2JRY?*G:U`J\Z$H%ML$E9*_XD=0S M4RB2!0\/+UC-Y5/44>2(01=Z0\C!;Y2!Y_*0 MSV*Z?>AKJ9SBH]])FGDJ):L5-FDNXQ,K43V"]N5*4WNN7;3\L&A34_M7_644 M8]D"U/Z<_"=(,V?3Y)Q7+$N)TK>7D7APZ:6]'XM%I$U9IM@-:%K[/1:RD(`E MD$E)2_]ZI,..Z*B;`,D#[LJQ0>*[U8L0V\,NYO,/F0)'@0 M8:P`@W?WCBJ9=KTQ*(.RU`=" MH>%IAN8$',&)*F3H$,[2'W?FY4.4EB0`NZNMLMW]&I5EE"O#G35TSHV!3HXA MI MKH*"BLI]L)Y2AM&%KVE.USZ.P&MI`WLYHD8.I$[WQRK-857A:(-[I$%AU/0Q M`)@0J6>*+H>N?)&W)V5T:ZS?DBIHW#OJAF6'">QEM2V?@=W10G5==\-Z?TDNC:0:SSU MM;*N^STA7[^NNY$N3943_[V1A.E5'7T-8:MHA(\85&G'J,*DJHV!T9(I(-JZ5RJHCU@A_HX%:U.8^\L:SF&4\/1O,RA MAY*-IK':AA+<-+49`;+B@2U9ED4:`RO.*#D]_4`/;]:[WK#^0"C7&_8C8WF] MT7[@U*\WYH_4\'ICUP[-"5QO3%0AP^N-6?KC(S:W'[)WF6)I\D1UQ6%`ZS$6 M5RZ/(@9W&'?;DOEU9J=(-!Q*U*'YB3C6@D\>:&B'.X>:Q+&((DPH?I.+, M`$CUX7;'/896[1GUM.ZWB@;RC/B`A(8N!0T5WD'Q#_=]KH/SI4HYJ>+>`_X< MDMO1M@$IBNI?U8R!*>P-[5#I\$RT?(AR5NH3K:A5D;%\G6B_BJQ"U51^W>X^ M-!><)(T:V>D:^,,+\7=_IKK0N`AGKAQ?XN9VG,F)",\;:T#+'73LU_>##:_1 M70R2?Z5?5$6$0]SE]>-$C,=E6L5941U+>`>_UN\R];*^_*=.RZ2,C]8JUJ7[ M%/@-?PR0KYVRJ;$?O!.W.@K=6M0`:17+]YZAO[&A(K$TY-,V$GJ&@>PN#"0W MWW(,-_+,EC!^H6Y%9@\!OS\Y#-/WG]06Q50/S/8M=DI@8@.*PT-.-/N'MV]^ M('J-?R/=-K4O8S\5-TO,`S,J+AR[%VINL+CH;-04/WZ)JP M)GK?,-^`3U0#6I(+N0:L:P:=V="SLP^S128J8!!Q'8S&P MZP[0+3Q0+Z$"]2..K]D5Y9X5-4%\HS3'%QAU`5BY>GR_L=!@?N?/VBYMG1J[ MNXYI\N.%D5ZR7'J&?E:?Q*LG->B]VBY0ZWBC2HSHWA&RDJ#OZA1[]'-1OE!= M/`E?9PQM*F]&#K6%_!7B"6T/]%ZRU=7W7V$9I]5H@D9[%O[\#[UT:KS1?01C MP/L5H.7AY\!A<4DA:XD5B-X=%IS4SRN]_YKJ&-A+>X=6?7YMCY#EB%-2+N<'R6&0)LFG-`!$WX1&FI6*40EKQ#?5;NK);*;??[B[AO>HJ5FSJ(9Y(Z.W( M?K*)C4?HPHU\!PMIN]P&\Z,];R+ML-N0H'%4B!%`*DBX0_%[I$4QVL.^_QJ3 ME]:W:&:V.7E3F2?X/SAT_BG*H#I+@!T;Y^BWE'((,TJ.M:)A`#`'C#KZKA8Y M2N0?')N57VV9+$6+2$V,`6S$+B.\W49R8[_3O[9-0>]0$Z=#U_&[>Z$W-VC] M*Y)ANER%EMJQ\?,RWUS*\2?NHZI(>8"1[,\^7U7.E!=?`KQ*N#363+B4:B<9 M"O(/V#'WK[)3H#SZY'\2CF><,'$5M=]%58K6;5:U!,?&LW`@15C>!!YNSY@L MY1.>^G(UU0D]VHV!C@-H2#T_)5E.U)2]I-Q'>?1`@C+^_*=__O'U/_T5;<50 MM>OYFW7(^LE]+$B?CO`;B-FNZ2U94<-B3' MDAT=X@M'O,#21Y.J+*P^\C_RZ)`E?Q2AX=:[^Y`5SY^06.B?74*Y/!EY?=5% M?AD$@<]G[<4+G#D:HY#%/#>`<>5R.V(;/O84LA>-&<3SQQ5&YO/Q<,C(XA5E M(.D$1GN^G(U4VANIL9>1/_M7]:54:,S37$Y_7)J40XJFE#S]1I[*$1=ZS>,C MCAQ[=ZP_%?7_A+I%TYR%!Q-A+)UH"@@IX&E!0PSNCS6.*``OD*[&?K5]LI!< M"C1R>M-DOP`'E@\D08MV61P?'M$&D8Y'AO=*06P/[8`K*NP4U+I33'+W2&LN M7Q+WB>Y:::;';MI49ZWF+)PKIH5TPDI$KIXI+:#$[-AF0].W;OC$BUY+/\Z0 MDB^6S$J(AYN,T1:K0UV5 M1-M6Y.$3L2!WFC!6&8%[MU36B\6&[W'5M:95,*9'/MQ#I.C&VJ'!>2S*^@Z6>]PEDP5KO+U[0R/I MMV!D<+LSY,+O24CA)K#%2C7Z@GG1#[TOT_(IVNO7*3F)9S/3Z[W&V&P`;AW0 M*J6;"+7ID##,,R$F\/H#2O,_O/X0RR##@ZX&1R>5':^.[WF`V+9I9T.Y\_6Y9A@E9&*0_POT]+!5(TM!YNC"2RS%^ M;\2GA6(4X#=*X]EU7$P>_PIB!+'QRS`C?+E3ENLBRHTU9*RQ<[48[;%86@XU M"@S_1AWO+0U['&]`L.(?\G*@#'&N0\F,5U9-7L,FP988/O3Y,2)!?6:),99@ MZO8=UMP1&`^L.^?R!XY&V0'*U7%*#:,L.4N/2#L.;3WD^Q=PS!-8/I]^, M'[7P^8,*9`+.HBPK6/UXDCV&/+4L\AS&Y">2=.?J9NL[5\XB.M1["[:@`KE; M^(17:^2$YH7^O\DII"D#YPNDL61#Y-.'F07_,'-#SR!?P&_LO\$<1,Z7\L!E MT?:_OMKA<;CF3@&C.UW[4)0P?<@O<*!]COJ#K$05Q4V&+?)C1@N%F:O?#)[. M-7*._$/X,EZ@809X;B1`E><7K/JN.23^E7DVX(?ZO1#:W:G\EPIN=^^K.MWC MG#`*/1XV=*Z<0D^'\/I"?;RV2;AKHJDHL&GB7U/&<3*$OPHDKLLTMU4VKO&7 M<$$.=4B6DLI3N6:9#)*2S6UST+0/)D3+8$[&2Q\;3(C#:X\H@RQ"'H?\;'>< M@=??@!@0N[\,,9%(.(Q`1-R;AW#N0XRG1[@:L9P;A\;L9JL][^7:N#=47/\$ MLW2S#>1,5]G+\0RM_N$L3+U@(&&,4I+\A"4JV[5144R'U>U.32C=[\1 M-)1+V.$@.OK.N5\=CJ,-URN=)?13(_2N%3KM:/WKDA52A5V=/4R]9Y4T/J`Q MI`\ECZ3VE$&50#)0S9LMZLDDB#0[19D`27?ZACS#!*+>;>M'6+*#W.J65&8@ MI>!U:YXAO7-],Y5+J%^!Z0@*"65S*5&!CC9H,*?DUV+G`@HW!`HW!$A.!5S&<-XJOR?-OD$!)3<2)FN&A&C0L`2BJ)G'2< M@DJ5EXM=T.NQR\-I_*B]*"TB&.0D'HZEI;T7CU58TW!7_PG2!/'N285R4U9),>X9CK]HG6=-70>$N6IY1#76=H>,()FN0U816Q%;"1C M:UL`=_Q&8!.3WADCS>'2L3]$:8E]GFUYF5:'HHJR[>ZZR!^N<57`\ZJ"-@<_ MT]BY7W*F22T8\)8-*$K0,,(GEIC5&>$%*+-PM7&%L=B!#,N?$?DCPL"_SLY! MNK#XS8:Y.PW_I2B2YS3+D*-[A78V^0-^A$)[./Q9NUA.X.59AW9(R`F4?ULP6S-&,U7/5PN7N1C0 MOOR(>A@7#SG)HFWNO1O0>LC.H)='1"NA`1Q1N&HZ1\"R(_*O>\;($Q-16,'. M94:*J(3O<%6,BV)_@'E%[@5H?7CB),1H!X`<_AN<`UR_PD[AYB&3Q129Q:?, MB,O9/2DHPO/9`,J).=:,%R#,@M70Y8KMA0Y] M:%:3=/U&*1F-6;A?S,RE$\PU(\6GF=RU(R-G11G"4:"%)$U#NI*TQ::P&$T" MYHP()#XU']X*1DC,[0Y'!E1?.(8A-9[#.?>RY\9CE-_>!2RSE:"TC7:0ZO:KB7NIBFU`$!BI?)&E28&!#J MH)$ES)LYNB23YB$>^39Z_HC6I!+949RKAM241QU$5G2[NX45+)^4^6$L^?B+ M7#:44Q'.C#B`E@4Y'6^8;+#G@A?HAI'OD[IY,F-!]SU!*T;I_\!A$FZE@='V MH/6@H;\6Y>]7.?&%*GN]5%'[TT:E3`H=Q'0X<2>C#%7QK,3#C<^03`?:/"`= MTR-/JEFFL/.@3Q_0UJEZA`F.);/7)Q6U/WU2RJ30IX8.$,)0U:AKJY!DM;M@1;4!# MQLJ&4$K_"#2>J[%JAQ83Y;',/'L%2EZ'JJ"G(_1?=GXHB4'Y^4W[0IM0^0>< MV?1HJ]$KYL;IHT6:B)"&EN*8F2+'K[YUI7[5=#X>+2KE&.*,A5AW[8+)*6DT M(R,O^TRGPWO&4FU*20U=*%E+I8DD%7E+@TDJ:30WAKE+_::2O(49OG2ZBI(BB.55#B)S MKFVW_4-:"@QQGZ%$A8O$CJ%:3^4N:.RZ%(E+;V3(8O2=?4P(OJ7L5VB'-V*M5#;]:;E1!24T7A)XK MR_Y(%#V8>/Q)`IV*INA+%IG#RX.NT!0.'^DP)]O\%L;'$D?WD4IJ5NICS,J? M1IE+*U>R#4MS`AHVN!!FRPC0LGJA/8E98`3XIS%=$GHN"TJ61O=IEM8XLFS? MC$U4@QV7OSX'$8[!96-UC[\9D%I;*H-4TR=I@@?EO^YF3-;9+WEQCR]`,9RO M\L.QQB_3T=2CR<:''%8&8M'/^3,BRXZ:RM!P7U)9FPW@OP?(!T'_B^$:I'5' M\_-QOX_*%VRSXD?T!XACFCB#%&?(@*6[E.1F`]?P"8W`FS^`)5M!LZ76;C6U M]N8.G>>)6BC4X%.1EWVS+GFEL,(W?#M0L\9'L7WYR'G[&\[*8>^"Y^?_-<1J MP-'X%$NAQH-JO7MI__EO*2S10#^^$(.KN1`S9>!/*722J9;XEB"8"S&["9/B MU6*V/("1MS1B/[479)9\_$'34$Z%3>8`&LREVJ1IE"+5?@Y/RS&Y5KQZ6^D[ M)^F@7"M>THT<_V"G1+]!$UP7=CYTK7MYY_@.8\UQ$X]R\1B%NWE:4M?6\.CTX!B0 MXY2*>-:OM7$Z2BI_B_:H#*HEF!)LV('=Z[5#>>R64B-I6,_]JXH!D*1KF`Y% M?M7AQTGJ\&-0ZO#C!'7X,5AUD$O#>AZF.OQHKPZC*/*K#F\FJ<.;H-3AS01U M>!.L.LBE83T/4QW>V*O#*(I.\\+;])9GL4^=]$6W]LYGA4OND`XH%P;P M05P2S9?#ZK1ST<^=LJ*:GGTNJ:S:(]`3U5CS,\#5X.=.& M_11R`]&_!^$K&O;5[\GAK$ZZU.Q1A`Y54@%/O[?3OZ;UHV`#JKX1J&X'UP/4 MJKP07I:WV`M\+XC;[B7&3;40[SJ<+S/DT`'`^:)R3CX MCKA8S#291&8L;)?"-^H264B2'J.]S;+?.QFCKANWA8VZRJ9OVKS\8;Q377DD MWU8(VPW.D\.B17"0!>$=Y$O^Y0?G,\1% MM\`Y*$^DU/)"NC*T)XLJBL,\6/BAE2[-5=?&?18KKG]B2G;\2"R46'QA)(7< M4^/#Z'BNM:=_O59^YEMZ4,5F/)C@]I$1'9UUOV=5'Z.OZ?ZXU\[\H)WSN1_V M::AL7!"_ICC"M?G_W\@[F\>,^*G_7.%-Z4A_IMG72C"3<[D@` MI@$M23`>F>DLC>3J5]!*DG#0!U@C1VJ`O&*S2=)SWN5)/DZW3) M)(V,E,+S:9`J_@G&SF,ISX88PVCXD1KMPI!BMAB$^(84I.C+6NJYS$ MN6HH>C_$5=,4=&T#<6[G">%?`700&FJ`&7Z\>L)WZ)OV3G!'%8`GPLM@X(3@ MUB%[O<,9,7!XQZ?#(ZYPA^S=7)[*/ZYZ,ACC*ER_5IP3+;)D$^+R-/3O17EQ M1`[0'I:Z@D5CC3V/1=F8.0:^@$CWU/IQ*)&(8'1M,^!@%$`PR@8)4AP6#*2 MI21G92S?O5S@=+ZZ)[I**O?E(I4RJ)*PTR/%^Q=`*,)Y_&HP*T+12-,I<8@M M. M\P+C,`1TRQ*PVINL,#K'M0=MS!?TJB]2UBLM*4D1'_'C"W)$Z'!8;N$!\2`9 M3O'KO;R-Z:_H\.`R%'00R%TI2/&P/#^F\2-I7W"C-[A6!7&4@_OVYA4FWWG> M*BRE7+V=Q;*:Y2N:X3)]2A.8)[=1#6]@B0^KHP?5CL2,W'.<@U0J[=.6AA)@ MT@WHB$-8X.8@W,,YY8]Z/B#Y@-@NP/-)P#Y1D"+ MW9+CQ"UZ&3="^-%:V8W0H1LA^!435+3F4@3VS8`U;]Z;03O@#](U4QIN%-@R M.%LO5F3M$/ MAL9I^<]ZM5DKC*+6E'&FBWT4FZOFC4'W7?Q;]F7\3]Z]'YX2-9_W>-K^OP?6 MT?+A8&0'6ZF2#29:#?9L,`_=8*+?/M*/_?E/;][^%?^LVDN5[+-@5Y3<&A78 M6K*6=54M,>N:UC56GN95]%6.>I)EI+R(]3HRSB2054$BH8TI8LD%D*'AF01I M4`REE9ZTI!P=3D/2G:XHO$CPG&89/EZA,>[!G:Z8P=U,L?58GZ&F8BCQ#OI@##.'\5\;I"V6M'7=K)$!K6M4\IC<#B%NW8RRV)QZ0+"QQM[07E8I]5 M88#71?YP5L-R#PCN.^*`0@(5,S&&(>4T.,QM!;.HALE-5-8O=V645\ARXS2S M!DNNGM1]%BR]-.+.@)``0@-XHJ!69--Y$M)H64V2?]S9K=Q67()!H]GJJ`"F MVW7?*`'O,K(>B*PU1Q^NYEGX#)-AZC`E0Y85SSAH\4-17A;'^WIWS,3C!(4J MFC)PGZ[!5#+A[*LA)%H[0%B@.H3%2`4A$Y!Y12 M@B&@VL8`MP:]YOX!I9^,(:!,9\*A9Y;7:9)FQSI]@I]Q$0522^_]US@[)C#! M[TTNBOWA2&_+MKOW48F+#%7(MI+0\O,]7L95CMLR_-W[=0N-B^#V<7Q!QQ@T MG.G[)HXW/J!JN.,UFKX3V0#Z!?]*L"B`!-=Q>?2X/3RESRTJU+N+YME)=S1' MNZ?R,LU9>#EF-91N]':AH]V`EIH[>PT'X;;S.'8>:S^)O@[YK_(:(KS4^!7& MYYH<+)@\P+%AXOE*0"/A*%IY7#;T[#$.91'4]LE^1M5W".;3.2/PZ3I%'"MX M_E!"4O:IPKXV$OSQHLA0UPJZL:O.\^02/L&L.!#5:5LKKA269>\VH&JY41GB MFG$&76/0\`9]YN2I#L>>)PGA%F,-^/0BGU;!CC]5,;L%6>U+)Z5`9C<,R^A2 M4`$7[@&WTCQ3'D7:8.2"W,J(U M@.L"+#.JOF-4U[-T2QKX16[:9-GENIC[3T4-*]3B)TV:.06%XWQSJKZ/W$FT MCPM(:US_]*<@4M#9B$$Z+QEU6[Q$6?UR M$[U0=9(_=="2N06X7@JA6#*A:)\S,AK0$/E^]V`O$+O"DLFV@]#[ M.F((MYX66&%MOC?_Y8#ZG-?L"_1B7/Z@6T/DQ<>62B#S^!A!@W[0D`3@RQG+ M,G#+CDRD`Q.I9)2^%<`(9&,^D0G"EG5O_F+MWOPE&/?F+W;NS5\"=6_D8I!. MGX![\Q<[]V8403-@S9:+JSPN]O#]UP/6)!F@Q]NZA;*DOX*Q8TLZ;0=8PZ6Q M^Y9V.(8+\(QRC!O,XA975.VE+/A["I.WD%)WXEIXLB#T.H3ZWGC2Y M8G3UY)D-#,8F+[]L&84)9-5MDCF2O=]$KB9SS+,X$3W5O@:;`]T9&]YW$&T@ MX`5BCSYW==!40I*U=KOIE?9Y"!S:$+"6X.IF&\*YC7'W;U#?49\];\G4".EM MRDS@,2?%U@ZYD:90E31VG%9+TF/AL`"W"PVGIIV_*:HZ`)PJT=%/B*6'AH]* M7MTC$QA5,#FO*EA;E/12D7NL[:642I7=@WM#1"@!)0TGM8?-S,G+?IE.F\/C M+-R1\^[(\>Y%6X%<3N+^@$O>>^&D"S<%7-M-6+7'=1,A'(`9S8*O!PK<[4WW MJN(6'[7K7M(8\O#\/$$MG_9U`D>^X1[9`,+!/Q:MYU+],L%X(IWGI/R57+;4 MV_(6WY\T*6.[1VP749;!Y-T+:U>QA@;9*Z=S]I7G4(:`)^EH(0! M\;+B0BKNJP3NTCBMOPU5]2S.AB=BU<(/P,RZT1I.&>D+>?M_"^/B(4__0=ZFI@5J5Z']KXD"K_=-C\E&O13N``DP`OJ M]'ET:(5$3_)Q=6AZ)V.WZWZ>W*`)^13MX66QCU(A^IO7RE4^Y]X@KS-J0V2S MW2>SK+19`.A>$S."E5T=,'XO![4:HR(*XH)0BE[I%6$P0-9/B,DUH5]0]>_` MJUO4*?:DXQ-4G1]KZ#SF2!V70Y$FE1!L`"9I'CEM`*+R#S"CR9$G3-7.C,OJ M$C0Y2#\=".N7-)K,BMI#-0D3F<3'SRRA3#3(:L0(/8>?+2@$N%Y)WO:AS'Z/R=X@75U,-TY.ZWWWJI1%.^2@)@5U+ M%)A*31$KRB!]U[)OA<*5@)Y(K(=_C3+%G;#KM0)=0*=%LLWXM4&AXB68AW<2 M9#(B`JP-SN$UQ_#7(55-7@XVUL=#EICQM6]GL>LF:J(C]+QS'Y%$LW7O7B<$ M!5JS"5)OWM6SX[8678S3IHSKBSQ9CRT#+[7HC"0;JT5'".6WGNLFS#'TBA80 M,/P0"CM\CA7;LP6GRY<<.UB6,&&I5>P>!YD0>WB[82"1^&B#$C6I<7J^3%"7 MM^83)K[3L)LM/\6!M5=.8XV]EOJ57C'U*_J&<[$D'VY5(5N_%TG-':G&(O6; MN<^KU.^E\)X:_03PWX.Q)F/#*B1(DH[I"6SMVS2&O7<.\A4MK@)LY4![-N MF\4DA1%-U,9^XPO`7\I MBVJ5&WK5UTY'CY5CMH(*L^]MJ+)6(,W9@V'\&_35$U9?/?P6TUQ3[`6DM-(W M+:.R_`IQ!AN8G"._+'J`[[_",DXK>(/<#^6#6)>]"$_)%QWC*5)FC_0#=2* M-F3D6R=G)<;&:TT[P'VO.3$X?167@FYI)=8@[@34E"88Z%++5J0\T]UCE(_: MJ36TU[H+IZ/4]J.[@JZS'!)<+UAQL1KU0^X1G+`9F`CJQ:S#+$3_$8S&WV"% MG!FO1F/8A3^0T1!&UY_1H%WYSV$TQD'MSFBH$.TYT3OG!RF474\:1JKVOC06 MN=@Y0O^*8#I11FG4I;/D$'A1]?CA\NH":FS8,V>S"53?]26#$YD^U` M!$'@OKP7418?,RIZD64?BA([N"9F#7%7'E;(]7* M&:ON+3S0H_)JN[N(#FD=922]TO8^2Q](9\;,CCFIVU793!H1KPT5]C09'4V@ M!3A*/QH\0ZZ;5JH:M`,F)AG7*:H;1J1%FQ&S_+)(CG'- M;DU>SN.X/$:"HO`/S24$[I_IRWHNZ"EMV-Q[O0#6="75I#KRN8[*6N\](W@%=5=83)ET.1=U7851>24[BYOZZ<)+-P M2-9Q`2T;^E!]TSQ'I:S`$?$"'3/_B)TQZ\)=Z-PI=X?UJQR7_,V1SW"=/N$P MDQK-)^XX36#Z[N5C]/>B),$!FOQ@UIR<8]Q>5O'HJ>%PEF$6H./1YK(-)/W8 MQ(D=0GG6K+K,M7E?=\K$]`]WMPFKXC7OM0+%MHP\Y."TE%3,QWE? M7-C?P%K[A_.T"1;S=$Z?72_^!RY97J&=LJ;&K93"IQ\QZ+O*5R!-`6OK'VR: M"5`L]_+1=[FDUQ!-;5/G"&->N6R/M/:P-(_U65Q^::NNV!MNZ!\OBA$7UU/- M<+N-K#S/$_P??`C^%&7XB$7CY:F(O,182B48"[0D&V3R#ZY],"Z;?D+&@BY- M9L-AP8%]@2PA/6_<[CZD>93':?Y`RLTK8*4FUFF4W1SOLS3>[G:P''\>M0!/MS9OIOSC6,6F\9DQ!"D%;IJ#N.-)8UU2 MRA4<"%NTR%*^'H/55AN.AF&CQRDY)^\/!^,**%NP77]4:[2G9 M\%),EV'/]58MY&@PPTF`-3,`UT$'IM$7VGHD.=PJ)W\_5C6):[DKSI,DQ4J+ M=#5*L1[3.!?.Q<'_CV_]M5OI66S=;[7GC8*P%>_8X>C.CB'`',E:2GEN`.\L M;T##.)@M^P+H$+;TBT%CKAM]@V#T&%6POWSUK\2WZ+^XPA_I,$V&H'2C)_/T MX$9/EW_<;VSX"<[CEWZ8!&\]Y;WI)@+L^LK]6JOB2 MB?S"R)!C(+=%VIQ^[FH>PFVC`,`\"P!&27;L9G^&YW7W7-P]%LDA+XF7BY,F="E$W1@9M'95;<&ME$$KCM00T63=O/U51>V[<>FMQ M;N$!=8;LVV$G6<(D4_CQU'OW[9>;0;"G&C;XF[/?QF=<]_K,A/?#S(2H^;[( MZ?X`QGC"'\9.:M?XB.,=^<(CM$)>3OHE=A?2?LOKOGWE0;M!3A'](]ZI-Z8! M*WQ$4LOA`7M^3.-'^KNV0"^H\%P#W.JI?=&D1?=N=5;2[?T"PGFJ[?1_017ES`;O= M^09QOW5/`PQY>'D58"K?Z(,`/O2?(]_P9X>!U!BRGLNQ5P`3)M(=6D>.VK2% M;14TSM&HZK]PP8C:G@T/I`.(CS.>BR&Z#"?"'9JXW%H7Q[*$RO2Y8XV=XV>T MQT/@<(V0E:+--N"NJ%=[FEYCWKK+=:.^DUZ"F/Z=SQKG'^]RM`R!KH.*.X1_ M@LB>(Q<-7A=55Z+UKN`\D,`Y;4CRJ#@`[5I&^@P1@X@7.N;V5XR!?U6<".NAGL["M.^R)+K0 ML!&"0$I^6!P$!!`.9MO]6-M]_]4_E)%@&N`XQ'V4P>V.;I--@R*E).ZQ+^^] M`!_4E)2EI^E`C$(BG8)(,Q$"C(QFP1V0WAVK-(?(Q,?_<4PK$MNE>8KRY.M5KG$$Q'9N%_R1?HH//U"3RZ_X9"N`VP/EZ/;6,?70 MNERO]GL9IXF4FG-0RH+\HI<@._P9\RMXHC4\N)]14J]B&*H;;FL)S$9@ MAI?1"V&72*$)Z"695M1EG]]\VFM=4"!K;F_'1 MR25,(-P3G^305L7I\MKQ48=__M.;MW\%D#`'KW#MC3BMO_6OHZ;85`0)&P`S M'%U3%'FV9Q&<[BFJ*X_KH/?ZT,M*ANOBMBHY*%1%I/XLJ"0;AU>7)Z.2LI+4 M\_#K\!44VIY%.$$3JY6@*KQN0./^%92B_\(KJ*9M4]K"047V&LVT5M^F"0%9 M8_]*H@61\'S+#$$>U*`+XC=1`+ZU/^CW^BS'2^\YBD]_S[;C^"5)0"`7(2*% MMPP?[H#]/BIQ(=:JB9LFKT_P!5::'>O1M"W&E,X!KY=%2-_"*+H(>/;*BO@? MC,ZGY;<7J7U:A<,K^(P)X`SG8V"B)90>O$ISD!19%I64@+0,P*TRA.50L:PP MZ4[)?H4XB1A,SI%_'3W`WJW;MDMC8:Y[4QDZ5\G)D@]AW3`"C)-X8\NQ"TR) MEQ^$B`V"F`I%JN6T:0"J/4\9AAJ_A":X#QV^*/;W:1ZU0:4TOO069A$^*]7D M%K=AXBV8V$A":50Q1[WIO3%B#%3YP=WH]"PYN0"+@'9I]N"4Q4S;(M-ADH(B M+_K.-]MA&AQK&-"Z3T1@((_@(7(T[::/D7T;R(G'%+FV]2-R"%(F$-.K`!8\ M8\P).0/L`.?P-`2/-'ZV7<)'U)_T"=+N?2A*M!SG-!%)_,*9.;3TDI\R:A3: M$@AHM[+=W45?;W`6>/2'NB[3^V-- M1)!-_AG8L0F(FPFHN\_ZMWU>+(5PW.;/3+@L./Z$OEZ4+[^6:0TOBV=5;/=8 M8P_EQD=Z+%8;9XT`:766H&9^+S\MNUW<5XAY%2.$!?!@2(X2L4:Z&B).$XOA M"*&;LGA*$YB\>_E2X2AUW,$*NT;G2&6?:`:T(D>_.*+?L1/V(E=MI.@90PZSB09*>,-.N:>\Y$M/RSDL=.!'Y9C M,RQI.RQ1R]F_:B^C)B-YRQ;3$8=/H(Z'0T;R(D<9[OZ'K'B^RI&KM*<+NGZS M;\S!_<,G8]F$-T\<)55[3`LXXD!V_PN)F*15C+SD8TFSAV.!R=O%M&/E7VTM MH2H\YIJ"4^]K]X^E![SZ$0VIAU\SGQ"J_+=E-LLB*8,@@!4513X9VL+W,HW?D0B!8#1UA8$XE#!+]PCIY0N(,@)=EM:7 MI%Q#@CQ&%:1I4OSK]AS\"R>:L\'O-14PX/E&X MWQ1%(S"[-DCUIB8+P9_@I3`K.70=4N8WDWDQ6!W@KYWJ2'"15VQ MHANJU]!3&89@\LPD-]Q)]3*I4FZ@9==49Y$\A?:]IS!'@,G6PG;Z9WAA)&<3 M39U]29+BWY!\^/15.MK@?(0/8NECF=4@)*VKS11QL] M0*A]ICB>*EZ7<8`]NT^II".E$)"8>U@^T-:H/\CL^LYE;`73GL\[`:/N%I.; MZ(7%*N(-2?GRX>]K$+B;L8!PY+RZ+^HWXR&#?I?,";. M\G"EF#7%7ATDZKHUBQA5QFU)"H_<9_!O47:$YU65/N2VCI(5XQ`<)KN1,'.< MF+/?,&V6,&3%&[X;0#B#AG5PA]'SAH6FR^W?*N&WI5%:@BXMZBCL/.'S/.&SD"*)]NB7 MM,FD4*3%/AI"5,ER(VB6[:;['N`_""B[=A-'WM;S:8+95S=-PU!R!3L=T@\] M@U6C/Z5X["(Z)!'C_7,X9FL]534(H%E%3T_3W+%*!%P5`DEKZVQP7__C6#^CD<6-_ECF3:Z::YHXG5Z>J)DCJ4YJVA*_!D#"(4IGQD[Z M^=,V>?)1=67X:`\8`6'8=.(/9/_,AUDK_\D:0XT"KVH2C;3W-`UCF^W&D27D MOG?2IH\?-T>VKOWD'\>RJ491(^ZI&C)!X=:T7!)M.TU3=5/BI*#URPV"2G2C3T?=/VI2IQM61:6NZ@/Z%.[%I][*'_>IY,#V8/9L1;]J2(8%-PS^6 M3=1J]IHVTE"M3]-F]EQ7D@[4QXZ7??BDK>3H2'K:Y9+/_W',H='0TDS`]$+C MCV7]Y#KJ;%,[HJ#!V[M?BB)Y3K-L5+I/L%[O"M?\RZ=B\2S&Z,\>W?[*;\8*;Y'^^BUU:K%S*1TU1Z1O#TLJ:\JHL]B^K#3^\> MT\/8S8:K#[L-VG8QDD:Y5&:Z>:#Y..A]W8^]\S:R[2"4#@;!*&K>QRCB8H)]:O$55DR`CXAX))E$-?4??.[-SO;E MG%0M3].N?8*N8K3(ET[:CM&QXN)U$U5I MP",HA1K*9ZM6.!J-,@"O,(MOPU4PG:A8E`S]*6PU&P6DC;(IT.A.Y;AGHP9> MY6AKYVHTWF?%D^.@2IDI1GR('NUP^ZC#T.;EZWJ'=UIE0I_U536^][A`>ZNT M_A_'*",YNI*4=,R\0L/\CWBLW;#`"*FJ.G09(3O^]-``?P%TG]@`^A'`O@+: MSX18\V$I7,FK02P+JCEU(AY*2&I?2C*XCS5R7"=BT$.A3D3S=^^IV.4#VJ\3 M(1_-)2;RLMA'J7#1*W2O:>9I,MM>*J:3M@EF0OL#.SZE8Z,Z8U(_PC+^_9?' MM$M`VWQ(7=A%3^=VV@WD&.*`D(!?_NV*3SO<82.,HC"F\],#B]WDS$#/!4G* M2E)TG^?)IZ*&-RR+:_O%ZV$-DB&2['BX196E?$(*\E,GM(>^*;/YPP@?H"P8OFT[XI^#R[A?7U71GF%-A0C\4F-W#8`.D=35:%1(]GO%+EE)Y;$&PI@,JGH'1,T:`EKNP/]^U&!* MY$4,-/-A"ZP*QM\]%$_?)S#%F/H)_P-#Z2<.2NA7_W[)#`EW':9R,?0DSD!D MT'OA*09KWK_?#<)9,)V+!D!V$S'#%;A.8YASS@8RBQ5$0CU>%!GJ2%'2!V3$ M,)+G!62CW+;6^JO+\7?K1BPX+D.8,M:=0XM=#LH<]+F#\[Q]846`S9&$@>M5 M,-1;JM#MF1.U_:#:42'\M1LN:F M/X`SI2GS-%SF[2=IW5,$Q76=/8O@SA`4%WOF1P@!W/I-G4W;\X/%$X$8?%.H M,3\!@I("\T%@D)=O.@@Q%T#8K!5\:'20,%->?)2`@VA+")*TBK.B.J)_XKJ* MPC%"CD>B+5T5-=Q]GR9,`;2M%DK0/$,-;\HBAC"I/B!AFJWE=B=VI4*[4,GM M^D0^;M5Q@IPC&4D)"X!Y=`<+VUW_A.^<*6L%&"N?6KF`V%@S8UQG)T5\`LU4IWNW8ND%KAVOV#. MPOF>P4*ZT:=[M*KC_0O058`/9D]A.Y_#?<6TR72'5U9GD=17O,I'WME(;\6M M.3A'J[EL0[`V%4II8=(T!Z,I&OS?F$^K,/T'6R3[Z2P4@<%R5J[/NB6 M]%D\MMY!P+<,P(09C/K@,%D_Y#/FG_B2S<[OUP@?`]85M8PR$"A)W")!W7O! MCI#]0GNJT;1GRY[/C9.=''B/E!\Q#/!FB.Z"VA.*YT8J6D(;),<2Q[WA+50) M#T59XY\.L$R+Q/=&R0![/54P!IZ[I9J^OU:LQ4T#YXMMVS,A.I:5-_">D$#: M0UHN/I0B!/TI'J[68_/K&GZLR(`6A6T[3V#L^BG#)&L1##CE/:88C5G)D+"P M.L##.&1'P>!PCX-M><_+-7BPIR)ROYM123#J>HR=_YS7=9G>'VN2$J4NP$U4 MFESVS9;.\.'K3"$A%?)5`G=IG-:25[Q.MV9:W`G[,4/0N=.=JSPN(7*!+B'] M[U6^10Y=A#V[B^B0(L-DH$LV3)SKEI6$8DE+2@1>->3?XB.ME@-@+-97LAI! M1JMBLV2]>,1A&Q66KVCE:\J4Y`F?,FX#Z M.A740:1$>A^5.>IH=0-+<@;T+JK26*'!]JQ"2!&AD]8V4T3#!R!&])IE`PBO MX#)&V$K>)([`NW50X9;^570J?"W2(!E@U^'U9IJG-;Q.G_!%05,'BCC07RJX M.V;X=$YUM6E$[OY:TTPJX4J3D)T1.M`1TDQ^&T!I`2;V#U2;B1/N,*UG+01` M5N]>/D9_+TIRR2IYBC^)2T#P')/1"J45OHPG+)J;=\\/_F?,JSEL-9/J" M=X+2;G:=_!3M]8'FD[AYV,M,D5G6&AD^]G`=M M]"9.M,6Z'I*Q&ZGE=)L^/-9ZVZ>E]/!63">+O*9:1P(H34"FTG".Q,=B%A/D M#G&C-2.U:%-2.4>:6@9IW=9>\X``9C`E0W`9SX=#8!7[0PD?85XAHTNSFGZ" M]79W%WU5`4M%Y1Y82AE&'H!UK?N9=VEI^&('$.5&`L``00E#@``!#D!``#M?5MSXSBRYOM&['^H[?-<799M^3(QLR=\*=9`!*9 MB?3AE:99F,1_^V7TZ\$O'VCL)T$8/__ME^^/-Q_/?OGP[__]O_Z7 MO_ZWCQ\_?*$Q3;VWCY<>[GWF'K^[]FJ_X?1KZ-?SS^P?QQ]_):\?CP\ M&(T__.^#X[\?5@U_J5K^ MY6<6;K3^<;1J._KTO[[>/?@O=.Y]#.,L]V+_O1<;AM=O='Y^_JG\+33-PK]D M9?^[Q/?RDE3*>7T0MF#_^[AJ]I']Z./H\./1Z->?6?`+T.##A[^F243OZ>Q# M.8&_Y&\+^K=?LG"^B-C$RY^]I'3VMU^2Q7-3GK7SZP<;_?WZZG#_UIS*C_B?WFD[SS)YA;R]E]I:G_^Y>7 M\":,@0L@9,HI<7I8F,>-%Z;_\**"?J5>5J24@XKH51+#HLI#^.<4NM`TI<%#GOB_*^=H,)*%>5_3IUPM564C&U1B\WY)H@#V MF\__+$`^K^DL]$/U%"0]+7%'&]):S.=>^C:9/83/<0C2Y@%PWT^*DL73)`H9 MDU=_JT78<#@K!;I,5O6WLO?"P`$,#;O? M5R_VGBLJ3$'ZLVN:>V&4/=*?>>%%&MNL_E![6T_+#UM:4.O1]CU_71XT&[2; M_4&7]+*N>SDAX&P%07VA.9!+36+C\3JE[J@%>4<=STU7:#5&Z.)>9SA+9?^N M3C/==23OW/'LU'*HZ+W/&ZKIIMIT7$NW5\/I\KITJZX[3 M[=W<<-8&(W5ULC[D\&#LS_HA[ M*X6Q,FWU:_O@]I67O=Q$R0\+/*T-96'FD_39B\-_Z=F7-QMW?,-J=:?:XRW$ MTKVC*WVSB899FPML%AE0M?SQ'7QZ8U*P@BA(:[":%ANOD6^B])K`UZ+$W_A` MQ/PU2:J"S7Y"9!^X>,J8IRI?#02[!(W*X8EV7W+X3A;=J2Y)4?J/,NK_^IR\ M?@IH^`EF?\S^P6`5=12`BAG'])QG8$1P^7X\<\+7%?@P'(;T%FO"6JZH+.>[/6M7! MPF?H,6*&5F?1/7T.V1$4Y]^\N>APY34EHP.$'-S@R2X7A4#X[!NC9]\5P$^] MZ!;4SY__@[Y)^;?5EHQ&?64@#PF?@R>(.;A"_PC#*G90UH2,^\>N[?GSF73: M`R9-:1HFH+\'UZ`%*+BUT9:<]I=M.T#X_#M#S+\+P!$P+#>1]RS@VT8;4FS'PO^@_JI?*E)FI.1H?]8Y\4C.">?X"8E]4A?1-& M-+T"&,])*E=,-EJ2D5.+31NU9!>'@'DNK#2ZS'M,/18V__`V?THB`=LVVI`1 MQJN<@F&["`2LGQJ+OG-I\XB#BZC\NU.X[FOQX#).UT)S8B]N38:@K;O`=S+DN$_/S-: M-G;\4NN)7,-^%"5L+IED6>ET(X='#992=W!D2TVK'P!RNKSTB<[WOVF`L[2, M7FGZE&3T;L^K2?^AI(,5MCF#;\7\B::36:653[V*,:N(/+-%V')DI##G(U0K: MG)'."A+T`!!.S<4Z).8O#"F@?B\,\2-W!ZME=S),,]=8-?*.Y'@\=K5Z^#,S M6T_:8P!0I_XT$W;P5YHAU'ZO/5D:!P>K3_96Q>0(,QJ''!^=N%J;6A/56:!F M`P%D%+>\!GSB+]HF\/N]HN[H2T`( M]X\CK#*58U;MBFS]WBV$&8,<'/*BN6B:@W.__HFN6"LO!TMR=C<:B%'.V(0JN\9G3&(0#):,A!F: MX"]F(W[UHG>P6N8ZG?Y`-:>1UNT$PP"BI<>8&`2#Q9FOG=]+PF7WU*=``!:B MH=HQM/H#U9Q&:[<3#`.(EMYX8A",V_@5*)JD!C<041>@38\U1CDJ2P]&,7#\ M@;U!\-)@FB9!X>>_>2E[@?ZFW`*D_8!*/587-:!9>G&*00!NYPM0CI@:-&%Q M4(LD\Z+)["Z)G^_"5QI<9!DUT1F:#$>`(OT5E^:(+;V'Q2!%7Y(D^!%&$9R8 MM\"X^)F%>E;0M_^OW%J,QX);NM/G[.WDIR%<6R]PMXW,6$)_WH.'-\,M;[.L M4&NHC<>$E8DB^*[IT=4*MJV'P1AVI'L*&EP!V/WD.0X9)/U#3-D7R.742=U. M2C3AV7I[C$$:RKCO2Z_,W#I?T#@K.34IP94;KP_4AN.ZS$^JWEW,1P.2]MA, MTABPK5?-&&0(4"9S^NC]-+D<\[L`<7IL&Y&CLO7V&0/+/WMI#,3)IC0MEX`^ MYQ4]@50]MHYH@;/U>!J#''RC/VJ42I,8_NG3FN]`7S!,AP)B]OARTPRM0'0L MF%3W%*^NK,OFY-'(,E-LS0,H%\F<&[I@<.LT4J\9#P9/^NTV9A?E MF_^OE+W%EII?-,<@([>)%17\%%E?C-`-*!YEO53N)"G:Q8W)(0IFF^_@FPCP M)/5N$8)=NB-TPJXW&I)#%%93`6/X7.0@&%#`1X5NF>I5FY];[Q:76223AKD9OXK9,65.FZR(;4F2#+M>WJ(#"T&F\5>]@ ML!65D">Y%SE>T\D"KO]OS&E>EF$$5:1\Z"_?JF7=R!$*(Z>V)J[$,J3X@>OE MA"[X>X:)FS=(<@1"JNVD;/"")M`*GIIYJH!UW=FB#N18Q0ZE1$[E1+! MPRB((^FEC6QEUIUZ;Z5W7=NTO=F!'*,XI!6,DUNV.8@$G.ZE!>SS?!$E;Y0N M$[/MDDH6F*WJ2XY1G/.-^*\'3B`*O7S8`Q*?%H8B(.Q#CE$<^4V7O@24@.6] MMJ,MG[&I^.4DO'$4G'%_%78!&@%W^VBP2^+G1YK.ZW(LXRZG.3D] MP\;@QM88(3P!QWMIC!,<8%I^$V5?,D81*LQ!,4(>P6-@X%1H$,]-/^!T=D$I>`E2_2 MMIJ2$Q0A[0IFB36#'2P"OO8P6NXB",(*QM0+@]MX>=61^>3X/<@I"BM>(Q[+ M(`E8W4OSW87O%_.B=#B7`8,L16!*7VB3[ECUF0D M.%Q[+!U-L`K$II?O4>]I[H4Q#5;)Y&H$6956%TN*NC,Y16$T;"0;FN@$TM!+ MF^$NG8QT0'**XM+8B-L"-(+$+^8)OIU;B%0:<8M@77**PAK.'#MEWE M[,PNWVK_,UM\^L,!?!2>$C6+5$O1%/.`ROQRH$_3Y"9)Y]YM/&-_Z8J0X4A` M213VTJ;2TPAN9Z5\][*?K\N8?J4>*SM?>A;=[>CKZ5R'F1\E;$8Z.[JL&SD\ M/G"U$M?SJEY.+FD<3.)[R@(R0,\H*Y%KU=DV'`I@H[!DJ5G#7XO-\`YH%U\3 MH':I$U'A>YP\930M$X_=QHLB9X5X8A]Z:6_U77P.>(+BX5MK&;1.DWX?&KN& MA:4-T=W!P2]3ULCY6^](CD^<'1[ONNSJ#=X#R%?("C[P2B==1.5RZ#JJ-&\]D`.%-$)#4Y<,1Q+94AP<5>M0/-[D!&.C,<2?FDR MN(['4LT1MPH5/V^%LN"?M!^0!\6M6,H]F>5#BFM(14KN$B_6YOEN8R`(CFNQ M.:-%8(94=H0]6:)I69G86]!48U%SVI,3'!7#&BUF(1Y;-4DPL)E9>,(@]-*W M!X_Y3[3,'Z(^0,^^*F-R2+;JDKC5R-Z1L>O$9/:8PC;F^0R56CE3=B:CI'@^^YXU?>K85 M>[BD%Y`(Q87+?!=7@K)5H,3M\N6C5&[ATG[D$$<92"4+C3A?QV:KA@D.;]4R MBT@R7R1QF7!(TV/%ZP?T09%4I8772@S+5C$4IVS?@J=]'?J1?G+;1PGKR7E;XHXN(M\X49NU)^+.)B\; M0!M2P1+.2T7%UB[H`;1%$7%DOH]+`=DJ6>)TT^8A9/],J=K1K>Q+3@Y1V-RD M;-3G/`>;K9HF=K?SB^#5BX.?M[%BV]YN!YA0Y"/2)#YGM^8CLE5W!$&40FWW MNEM5UE2&*/`Z`650W+/,-V45)ELU1IQR>YHF/J5!=@,$J\5C,+^OA-V27F1T MBL(PJN(>G^=*8+9*CZ!ANF;E$5$7H`I.G[ MC4%Y\:)I\12%_F0&\X4&(FVLU:!D=(;3]R&5`5NX;94E020ETR+U7[R,3M/0 MI]#Z>\S-+-O-A\CHO(?*0I>TL%7SQ*Z$U<])!M2+?3J9L5EGWV.8(1?DES3) M>'>&EB.2PQ$*MUP#F6D+VE95%`3"\8T*=YFFXP&-4%B!]B48:\BVBIXX?\!6 MHUP:/H>`AOVT*ODRDBBLRK[D$(?!J9GFJ@G/5MT37-:GY2E:GJXR&9!W!`JA M"*QO)@`ZV&Q51\$2H'6&UW(R4$/54L]5+;*H^Q##ZA$%11E@4E1 MMRM0JX?\-$-GJWX)EC7\K6"^D174:KNZC6O!#IH/*%3#`/5Z;(0T1VJKL@D: M(_3[JJA%MVE:H[E]@4X]-E5JPK-5`L6YWO^>M^'&\VFEU"K4?5X7CLE7HQ#FOWXFS]*^Q'6Z=Y,/PJB<>@IR.>V@,:(92(!LH;8:U30Q4'X5# MJM$X0),>WO5;0!6POXU5$%'YHV7&U4'4/QJ-[?E\E"6CA$X<94^8*`H?GXJ4 M/*^,)KA!)%:UFHGQ<.3T>FW$/<$]2HYM"'E6VZ9D/!RAN"%F"^IZR>BE4GD'"8!QR>.C4E"'G M+G^#;@#04N955&+R6Y+^?AN75[G,7#C$O8%B[HL>-!4)%2Q+^5E1"<)-&(?9 M"PV^)$E@+@CBWD`QIR\J6@F""I:E5*ZH!($?Z\1K!C1PKQ,T9>UZ_I9RM2*N MR=VF#!!2V]16%EF\MBD<65!5I&QHFY)D1>V5H>+>BY]5^C_#>3%7,FVC'W? MX0B?<9RY6S(.8=`9OX)ZK,7!>CN@`HK0.%T.[LY]0.:BJR3V@59I2?S[,/O] M\NV2QOX+:)4JYXRJ*]#*J?G>PCFI!W$(!7EVD:YPJATWBJY`)"S!;1K,U!4$ M'L8AE.U9KI+LGOHT?-4J_B#J0@[19!K68!Z?\7)L`S+_<%:'1M$F22^@D'N[ MG_7M?Q/=0,K\;(+4JN8DZ06D06'S4')/D^G;R&P5^7%\]_K/)+TJLCR9TU25 M7GJW,5#"Z>79PN(6@;)5Y<ZL:"AL0E4M:V`?H@N+*+>(8G[\*.+:J_-B- MT5C-=!*+U2Y^0T"%XE:M(#O'T"R`8JLH3SOE2L&GQQ^)'I_6#0$!`E M>!3(WW&S2[%&H47CT<@I#N-,(Q%H)$UB*C@N]6-'HAY3+Z#,@Y@I#Y;MID`% M%`:@Q@SDRP,?IJW"/TZ9?6/EP#$8!6CGU.!NX;`Q1CN(LD$2U(:'C.%(Y,RM MK;$QVXVE1XS><=$A6SF'7FF4+&CP2/V7.(F2Y[?[\/DE5Y\SBIY`(Q1VRD:L MY4N)%N)A%#E:NE[*`GV`)'L)%VJ)D/0"VJ`P5UJ4!B5:QP607*9>.#WO1^J% M77W"&*7CBD>BTG,[8815T87K0OBX3-*%'!TASWZSQ10.3Y7P')JE;Y59CCE0YN4<[^D_"YKED]GRO0"@86%DWC.=S/Z>1##Y;#*;%'D&NUS` M*+7A96&]P_3]S>>V,'3\67(T1KY!J`5J+R2R57<)0[##110E/UC.OILDO4Z* MIWQ61+NK4A;WK34`.3ISGPBBN6PU`>NX[E)'<<'OZT91V$#8#:B#/"1<2Q34 M$!V71;*<$.(?7E146`T2@NQT`LH@]Z!H,5\%T''1(TOF[9N M15>@$O+(<2TQT(,YB%)'DP5E6UW\?)=DV967IF^S)/WAI8%L'Q!W`LKT^?*B M"W`0Y8TN@"Y!&!5Y^$H?J%^D80[T^?S3CXJ`!E75X?FBJ'@WF7WVTA@HDJW* MORA3XUL9'^B-_)VQGH)ICQ:#**YTY64O-]>W5[=Q5L"$E;+$;4_&"!(36M`X MQ=@<%U>RP^MIF@2%GR^+D[X!E5*6J$K,;'X',CX>PE53!FX0-9>$P<;U0D+? M%ZM2$JPH@?S&:3H:T'(@%]%FR`=1D8GE9/P11K)M8M6$G+HMM6.)WYMP!E%/ M2>P`_)[161'=A3.9"5*G.U!T"#=.?:@=%%_:2S++RR(#0L!M*ID_A7$YGL-R M*IS9Z"2ME'4C)R?GKA;:@_]"@X*5[EO-\,+_9Q%F83G#R[?:_T0Y+YL.14Y. M400GJ5G#7WG-\`XA+R8'KR+*4=`#2((B^J@9*_EB(84ZA)2:/(!^Z0U5QR\J M^P*94$0@2;FHSW@.-I257BZ"5R\.?LJ3%FPT`C`HTOEH4IT7:K(+QVV!ELZ6 MYUJ1-%N9[_KGR2F.%XW=;M-;>"VE\\0F#)5G"NX*%)B85\:`25H6:@22,?86@BTA<<8_8"JQG`TZ'OJ)W"U_1?<2@-@!-QQO74( M[W)_#B[BX`Y^'$:E2P-^5\SAAU631C4&5"9&YND8MX8 M^`7;"%Z]B#VTWY/T[GX8^(3BD7K7DMB]_(MH.Z`4KU;)5:1,+JJ6[_&/>UL) M@L\#SU"D*AS`>I!2V%+BVZ&MBG5PX)Z6P?I[P!44"0;Z+_=;)+65['=HDCY- MDP5-\[=IQ#Q:U;FY8#F(]B3YPN\#VU"D5^C_2E"0V%:>Y*&MC(V#5"G MV[:[E#EY`D2>L,X_#,1'X1C?BXQQ?'-[(C".).5[D&Y.3I1]R#;GLT!X5`[^ M/DNVD+RV,K"CE>LE`=ZSRW4IS3L?`R*C$Q,-'F?EW[R9XN_[6?`&M0^01=>K5WR&(K>_W0)!9.@SU)*GP)6('* M2^=20M?DL)5Q/T]R+ZK)Y5Z>;EPET#+.X`X&UZXD"@,OI\&E%[&$.0\O%(@P M+3GR0O/0!W@.WG.LJR1,9C?`M-@/O6B:+`-)U38JG>YD*].1"W3*QQL;#%[1MO#8&8HS5,XG/F\%8-P^ MF+##U/T6'1L=H3`>"_C)9[XA.DLO-3#HZ^NELE8R=3;R=XW4;=ZDYCOX)H(A MO+;8ROX%NNTD+>$&9?S_*B>/A+V:(Y!S%)Y+`2OY?#>!-J"W$=R,A$<#U/:\[P&9T"1]%WFQ\01 MP-Z>\]N8!A0ROH7W+H2_@I)#E1Y+8]_@[.=V)S@B]]J(@1C7D(*J:]4V&ZB! M&KW)"$>$D)$H:.,:4A1Q#;2!]B?I!23JGQJ@Q#.DF-D=L$JE3]`#2(/+/MN( MU74L.`)*.V*SGJXGZP9$ZI^BIP;47:"EXQ1TH\'DH#L=.S.`.LU!AV*YJ5DC M,*8VPCL$+ZC-''0X#.B-6"F/1.%"'8*3M.L<=*C>BG*YJ,]X#K8AN%2[R7.& MP[S2[5:PA7>@2>^F:7*3I'/O-IZQOS3CNZ5OCOZ2N-N658#7H#Q;">)$H^:TL,'_2`7+@RS-]H?AO#/9&R>D\-A65C M#*`>BC-H/R+#@3X@_Z^$AMMUFBZ]+/2;G4O!. M$S5>2X88;,(PI:G/>/<,9/Q'PJIWKDK`K/,[&%KUU`,"(U`<-6JFZUOR=%%; M>BY@]^Y01KY5F^)UD;(*KC0-DZ"*A;M)TJ_T67RGT.H,X%&<(:8L-T5HZPF` MTVW")._7R1E6;X_64M[$82MJWRGWIMX;BWO-)K.O-'U>I@UE&6Q@+UIF(8F? M+_P\?%4E\C(-7;5!8:P;45]>\XNT/I^);)PJH)H$9E\C=E\B8.6\'\ M3KFGZ\+?]%6?G*.PVS?E(P>,K1A]9+:_];7W.LS\*,D*ZN>H6T]=[LQ6]0/(3K4<,1LX[-(#X]:[+>!?[?7L11Q\2W(Z+5+_QASA-0U\G3XVP#Y#%J9G+KCS(40[!S3U- M$Y_2(+L!"C*@+$'[9%8CH,S,K>H+9')J*[,J#)IHA^#NOJ9/^6T,M]:"46?E MD+WWGQCHKS&Z$>6`.\U+0EV=B MZ?;5Y% MM3`@72%I,RQ0U[VMT984M2=$!Z[ZO3CRUI[)K]1C;LF2!DMGG@LO'L=3JN/. MDW4CA\?._'KK>2UKDFW4(EN2/)BP.F9%RD+W2BF.T]5_V4OK3.76L_8-(!0* MKYZ:F?Q5;)D00WA(6WN4L/[GWT.:`D->WNY8?6/%LRV]`8!@*#R(EB5`(68: M)!G"2/6R.\C1=%GI6D&BG??$EZ MD<,QBOC=!OQ4"(8(JR5W:DY3QXEZ>$@/&\G"X9H^*,)\.Y6%#:R6'*&H MD2PF#(E2X4UG8P&K)'8I(%EJH:[+8C4Z^`ZQ#$9V\7UW7'N4L^7/=2^^5 ME[T`7O87B_)^]:*-%:\5#Z\]!M`.1511!P+!ESQ#RO0[$9W,"N>D!$(G9KBQ MLQ((ZWG)A;64SN]Q\I31M`R3*T]@%BL7^]#+TTE29_M30#95X_(`^N<$JVP4!9&J"#,$.MX5.:6_CMB>' M)RBRJFGPC,]L":HAF,U^\]+4DSPMX+8#^"@<-Q+>$G)03$\HU?['=#HCFOQ M<\`1%+DR]WF8=$?'(;Q]L$B=*R_RBZC\YWT213=)^L-+9=F<.O\V&;L-I.Y> M!#L7>1EA!U2R@G=?_RW,7W:HDVV2)[O?,H14]'XKQS)TG;;^'G`%A2JX)_'3 M]\Y:HJPE0^>BRN:5>VG>2YD7$*J,I--2:&Q^#[;!H6WQ^Y-Y#`9+MOB`%:#C-*67B$-;G4\T#R/*J?'_I9$ M[:-DC"-KW)#6P0YY6S_$.J^D/Z;/[`%0+^4?E_Y_>((KQ+)/4J]!65NOSZH+ MP.>X+O)[\4H_P(?9@[N`TCFCPU42P^4[#^&?TQ6"\E6,^^1OF_/93"LQ]981 M"W$PR5]H:N;2;CDR.3IPYO5^SP!3SOVRJD*@GR5NIQ>`0:$O6N&)P)>H0C\H MSW,);@E5U^N\W0?(@N(847).X3SFXQJ"X[B.3.DUWFU,CG`D>U1P2A!&)H`S M!%]Q=3Y?;.Z&2L^QI!>0!L7^+F*:8`6K`%ER*6-P/-0IH^,5YK8G1SA>TC3< ML268AN!B?:3S19)ZZ5L535'/CB5AM*07T!)%P+J$;WQ&*S$-(2_<%DA07R=I ME<.H5&,ULL1IC@`D0Q$9V%8,Y/B&D"V.93*I[MH9P)BDX7,(8-A/J\1&(XDP M*/O"D8C"UFDL!IK(AI`93I0$3V!^D5HOC$8"$O;SJ&B$3H%5F,`Z_K8P+-$-A!-`6 M!HNHAY%&;M-B'[Z&`8T#EC%3*\^H3G=R=-1/U4(?G.-L#7[#\53`I'X] M4;%^-Y==3^0=@4+]U#AT8#FN_Z:W=;R+\SW]9T&S?#+[&L;AO)C72PC_O:IM M-IG5CM+-/93U%A1GWL=G@>+]UU:Z(8JMBG/MK.&FTKCR\;(\SUX4B4+%S`;20%#%$`=_[92S=M`$MM7=6,F25_5OW'#(;B(QQI#=L:3/3@RD0E#8F MU+U$*S&L[@.1REFL0TXTXHOX'.SVQ@(@<*S(^43G[4B,`,*Z]GQ,0/':[0HG%DV&+@! MJ;-,F0[4WN(I"X/02]]J-655MQI1'R`HPA6KOMG(\0PAQJ5>,!CD?S*K%7I3 M7W24GSG*:Z[.,V)L?'*.Q)+;@GP64K7`3#87L[G2CM#NLV9(PC M77DSM@K@#")THYNLP\='*!)%FNI.:DR.HS8P90X>XZBYH\$T/K?3;=H_EX.HA6Z-\#_3&. M$A$*5@G6KP".@+']>LC%+V*C6,'B3D`9A)X`Y1)6`1*PNE]&JGL*]`C]G`9\ MN/R?*@_J-L.2$R11L`K^\Z6F/7)!9,>^;%Y=.!+O-'(^"'H`3?IHWY:B$7"X M7W%9];>KI<=F&>L@8;&H"SDZ0V%VD3*-SV+QZ"G)ZB M"/=I(`AF$`6"T2^;W":5;N.<`K=R]OZPRG.A]4)3?Q!R=([06J+1 M+_-=?6LL,7ZHS M0VL,6[K?4&)42`;_;(.+BTGRQIJD_0^?'[)U\E067KB,I7RE1=%-+A\ M6[;+E@TULL8U'9D<8[0T:LF1%>0"Z>J73?*]T'/PGT66,PJNZ:)7:YW3#^C3 MUQU&`Y>`[STS66Z%#ZHOHX(>9'R,(JRJR2X@0R3@X>T@[V6LH!*GAW MU"\#Y.J2]?GG@L:LHHWTRL%I3<;COEXWA6@$G.V7X?%B#I>F\%\E'R:SFS#V M8K],BI5)3WA9-Z`.0B.S%J_5L`1,[Y\14G%3*K,5M;Q15F,`W?J\WQM@%,C& MONR0P@6GBHZZIK/0 M#U?)+EQDN=B=$].3-;)=R#N2XZWJG/N$])Z,GBEREUY&`Q:&!N?^4N+AIO=< M%32[?'MO`W>#TBG!"DT9E-9I]PT@%`J52H>=_.W5,BF&D)^CPJ3.R['1#N"C M4+@L\U.@HNTB'T;VCJ84>R=('$PC+]9Z9][%YX`9*$*-.!(BV'\Z(\(0DHW< MQJ!^T'4\YQW[$B./?&.2]`+2H%`F][)-*>E@*7,)1A%1[C[2?D`>%/=%)0>- M&%_'-H3<)O?`$Z`GB[Z\IJ\T2A;E@%>8C0RT1>@"'E+5%I7F)%*\[C>#W]H,#O5'$4.]% M5;5%KB&DF;F(RL%IP"?* M83;JSNST9QB*VO?!3G^&0CG186?G=OHSH1K3+SM]1QE4SG%DU[#+;X%0J2DQ M!+N^G;0KQ^YV]S@\]6:PK:-PN.]%Y=D%[C@Y MNEVV*Y65[:"U7Y(B\^+@)ISEE,9L[O(< MZ;(^9'R*(LTCCP.;O-*$,J3LZ*TK>)VC,![L90,6P1]$?G6;A;_&)RA\`B)^ MZ7!W&XWC?.J"K?J:SF&;JK_UEV_3HO:`$<6=7$-XA<[!/0)EGP4I7A1\].)^Q#QNCV!QJ@\.*(N,.Y)YA!752T\#FE5&*EV6T$:%!5S%1N+?RFI%3MU&6(AK+.%&?^2"RG6-__W.*1&??R]7>$KD&D6>] M,3'6"8++%)`71?Z2I.&_WE^/V)13T;?(\3D*[Y`MB;(LKW*R#2)7O"W:O'IA MQ/:-FR3]PH)]]R#%VY\DXQ$.A:L7PLRGWB!RW._K3>881RF,;N7-A!:#R&'? MF)R5D3,K5U-V&T]I&B;!ES3).E$]Q5\#7J"P$"#=!U6$&T1"_N;:/Y<\OU%6 MJ8(&%Z\T]9[IYY\T]<.,EKEL.XEP-YX%\*X?4:K="KUM@@ZB;H'=K6*+:.4O MK^&`7-?ZV-MNKYP)\!!'A&Z/3@)-H@ZB2D-;RDV*/,N].`CCY^IVT:'H[WP+ M^/"G[:(IV091BJ(Q;:K7KN^Q;EE9#O#QQ8NY6T(74FTX!>`:CE!?G,+>B)J# MJ,S1'`:CO"7GJX!'C4=5R"QE(&!5W^Q=O!)9%?5%:B$ M(P2S4YG3HT('M5`<)3>KZJU=%RE@JU9#913_1G^4OY(G9-(9@(R1U-KH=J\R MH(5`>O;E+1-$A%2AS'&PJLE9@;EEI?K^LXC+J+7?0A:P%.:A%TV+IRCT)S.8 M+G];:3TF.<61JK@;N;%$'H$H]3(!=K56*AJ4=K400+P_@*W0C!H"4>J7*^B]]'3VF%P$05C! MF7HAVW2]19A[4>T@9W]ZL4^5!3U;#`O4_0.8[MI32"!_^_*^R'2F:9'Z+T"6 MS5/\^V*UJ-CRXCP!DNI,#<<$6@WXCF:)/(*$B_WR5TS3Q*EJUN4"JBN.F\M&9B$R'PUH^0<( M1&Q,&(&0]R.2YWV37\&7W1<;C0?T_`.8.UN01B!JCC/8?/ZY"-.JXI27UR9? M[=TB75W>"_`.V(Z@30`!PUV;NQGB)S51GK:)4DOW/:4^8^7`CXS+]IE@ETO\")8)UJ@QY4%<:E*4,S%&$46[R0,*P^[R&4'^3*[IU&0D5Y1R`0BAVW[2+506FINB`B M,ZM6/SB@4-R>=)BHPWXN/$L%`O=OUH*6<6D9C+,D"H,R_]?J M\I&MUPO\]B(.RG>FS(:8TA?H%;[2.^;*<6#QNHT!`EU/5,.V)>A!CDZ$=QI^6INWK_1$.3_9)[D5.6L>??DUFYV3\D M4?#YIQ\5+`?3-04D?E@].Z"+B):,B8.+>9+FX;\\P>MJ&\.2,Q0Q+T8J46N\ M`B.$<4A:3E/'FT!%BM6!9%>@&HU*D)2Q-)>GYG`%XF1LU&HC3L*COX3&5,VV MPM%J/'*&I'Z+CEQ80"H0"6-#F/LSJ[R53--D%LINVK56Y`1)Z)S)%K`S?P$# MC8U>[AFX=F4M'5@ZAA-A'X(CGL:(MW(P`D8;V\3@/D?) M8O[NMI3>$B3]R#D*_5#.0]$=0H5+P'MC.YI[WG^A,1`H8F=1,`_CD!$G#U^I MFON*GN0^Q"?]UD`DDP-C4YEX"'F@$8SX#VJ]>^CNMT4IF2Q5V(N`$K#)RR(#C2C+KI+Y4QA77'I_ MD;>LZZY*_Z@_".C*O3T>3%$*A,3<#.E<2':H97(3(*.#WNX(`C""H!5S MNUX5JW4G]Z1R6@-!<$6O&%WPMG$(&&MNF'/.V&])G&RB7(JPQF5>V9>,1OV[ MU6NB$HB`N2'.^:Y]&[_2*N5P!?XU+>YK99`"!1NWY9,3>FSTS)<\K>=>W)]Y3B6FF/ MI?V`3"CT\E:LUT`H$`1]`QXB01#2JLG1#N1!H<>U$@`%.@'SS6UWSK6[W59W^<(OM_W%@@%0@'N9V/N?B44$$8$M"7=*8RMVQ@AY` M&!2U.5IJ!!)L`J;WT)+WC>9:E_B-=F1TB.(FUV[;WT5DJU2]^[5\3P-*Y]Y. M8OWK\#4,:!S(PSD5?8%8*&QSK=BOB;)UD79,JE]=XB]>O3!B\!^36A+@ER0" M@-FEEX6^[FZ@'HF,<;AW[>T7NIAM%4EWOZ-\]M(8R):M*N65(%G,0Q@5.3?[ MLF9/6&?]5QBU,-JJ%NY>:_B-LLH$-+AX!8(]TW75#`:]5O177T::#0AD[;^B MV0:ZK=K;[B6JF1YZ@N,YGIE'81>!K;+8[MDHNCC?P)4Y?(ZO"L`2^V^/J1=G MGK^,E"C_%U5,6]O@@$R3&5R_IBR*`GZ1YVGX5.35F3LMV=+`5-')/(")**Q@ M9M[,_5/(5OUN]V+.H=N*"M+W+L)>Y&2,XD9M^*!%@<=6E>UM[7R3W[^ M@N6A'D*FI&44'9PU>?W`RB[?ZK]1)0#5'H0@C]5_B)$J>0YH),[Y*6I-3'%E\183? M9),2R!`R*ETO9[I,NF"6B*PABDOROK8AI""FXY5N7^K-.=G!ZC>/RM MR]8F0E%'ZC:C=S=WE#M)VCRKXP,)>Z+#=0#;;6)Q@>3<%'F1TJ]A',Z+^7WR MYD7YV[)F6'8M3B2EZ`9*D5-?=0?>N<4HCB499D ME*0*%+0$4CA5]3L7`BEN6WF@:@L;1TF`*R][N8F2'TX2_Z\G4IN'QJLW63?M$G':G5U=GNW4`3E#BE M;RR+H^;V+.I#3G`E-51NSU(@0S!9XRC1)JY]KP%80@E);_1 MG%T.IVG"'FP%EV_?,QKX M1&9+$OAR8Q&ZK:H*SF-^F[U0.$5Q.[/(3Z'`;($>3O&#]TCW[#&YIWX2^V%$ M-Q`_)IKDU=AVNO@<.441&M.Y&'9&.PRU%_J3S?44Q9'7F3"(`GT3-W\9P!5)U,_`[D#(79?,_B(:&%K6(4/EILS9J4R?TO#G%XG M/V3RL=L85@R*S!-[%@X1(6P5J<`@&=VDNSQ#8=7=L[BH26*KU`4&P0$:IA0V MSFM:_5VCVI6W"',OTKC"ZP]"SE&$8^Q]!S*BSW#J9NP"O_#]I"B#!UGHKB)8 M2Z<[.4=QIAFR6%=.!'A;%\U`%!6["WIU8(?2$AK2?F1T@$(/[D@L=I"VKK6! M6B#*V]_[UIME5*K4Z`T`A$,1>]*1B(@AMR[?@5I65COFU'LK,_*D7M#LB*D/ M`(1#8>+M^)39A6RKS@=.51=PIP4@"+VG,*J4N3C87#BUWYE*D<'00&P45KWN MY,N8&$.J-+)-CZTWST:"M=67C'!4`.](`0U2.%M>(X2.5F\]TSZ`[5#RC\LIDPJ08$ MGJ`PR[N2,#WZ8"C#(\B.)5HXH`"D>?@4T6])7AJ+5_$W9;[]5M4L!##5_-':A'=Z6>AL#,;UH6CQ% MH3^9`2(@J*%*Q!T#KCU_8#U;0A)KY7B:-.W,2`B$QNPXL;C;V*"30"![:+O^#`>O#[?"SS_]%U:_X1X6R"0N'91Q MP/YB;J17+Z+RYT@FPY"3,8H0%3,[M#E"0<[`'EJ;^2BGH+$EP7;HE\KWKSD, MK#,4)APS(3%'*!"2'M9=YV._@,TV3=]@#RV?YAE+QU9_,D);?M18++C0!/)@ M;/-=E#('TTSS/X14H(@"'8K&(2CIYT2IM^FT\ M2])YQ3"-9/9Z(P#Q>JAI&($32$8/\VCHX3B@'/KN@XS/TJR(J4:&T';H8'4*$RP%B3(#BD$ M4M=#T^O2HE0F'0I"5G8L`Q6\8`@NB_Q;DO\'5>TUND,`Z5"8:NV(@$B\3&@A M$*,>!C"7+C#FLZ#!=<%<%-5MKDHT\AZW+<_/K#<$.<%QG'4I1F:T$(A1#Q-J M,+]&%9F1`9AEC`:S.P+)BK+@UIR]Y!U)Q$AW"'*&XTUJEV)D1@N!&+6I,+B7 M0F23]-F+5ZE.'90:JW__O19:6&8+G=9`3F9+AGK1>YDT#>W-ROAD=.BL>EDK M`.\2_PA"<1G)`RUM?XJ,CE!8TBS*`'^KZ(9PENJU[<:\[&5CN0OAI`4M[@UH M\-6+O:IN=\:>#AG6-!16RV4?*"=ZZ65A-IDM4U6P/7_)-,D&83P&G!4C=^8L MF(07LV"6ZZ1X@CDE1?XE80_HX>2C::RSO/4'`:A./2,->2.R=9G!MK3LMO7! MO2RZAV(^]]*WR>PA?([#6>BS=WIKJDUA7_)9LA('Y_SN+'32_PL[D='IV-EB ME-%6:R%J#0`04=SX54P0K#H#C/T^Z"Z++(QIEETE\R(```1`!P`;W!G;BTR,#$U,#DS,"YXL`YCIMV M=Y-K=I$V23=`4@>)>[O`X;"0)=KF52*]))7$>[C_?C.49$N61$NRFU5W]=+* MULQP9CYR.!S2S)OOGP*?/%"IF."GO>'!88]0[@J/\=EI[^/XLO]MCWS_W5=_ M>O/G?I^\IYQ*1U./3);DW-'.6#KN)Y7PD^'!\."8X,-1_X-XZ+\\'+XF_SI\ M=7+XSGWL1WESFG@$.W(&=4? MG("JA>/2T]Y.JHB2&-7QC']0^'_:-APN**D&NYS-JHJ'LP$P^#^"6R M'6VPA5)"EROCB]\BXZLLHT=9,0^\*""G3^Z\F![?%-C#^`-5NI@E>E=@#7>8 MJXIYS"MD&699%'.+&>!%`3D`H)<+J@JA,6\*;%%Z(4L:@3<%K7AT(:F+8[VT M?QT/'.E*X5/0P-5]^K3P'>YH(9>7\'GE$,%Y&!0+\;0ZJ("88F\Z% M&V)4.>/>!==,+Z]`E@Q,"SW"P"U6BE6K2;L>G3+.C'[#PR%$P(0]_0BB2"2+ MI(2]&6Q*^.I/F^)#1;T1_\X\`W(*I!E>#!`M6TO[ZEZ/C?RB">7TW(O(@W8=!X,CE:'K/9IQ-(3^`Q8!K M5KJ,SVXAR+B,QG!5I+4#]^TF<+%4C%UJ+9SWG_TF'RGXX?TAOJH./,!!(A4/S*CL)P$P440AY0"@E28CHD M\C,)E1"C[ZA':>!,?`HYZ@.5FL'CK:13*B5FP<+]%$\FE;"]ZA4%Y"J MZN4Y*.ZRV-/EK^WN?Y7K_BE!)O:= ME*]37QN!':#7FP"E1)FEBIL6UF%3L(QTL>AQ-I,TFGOOP&1'NO-WPO>=B5@7 MT\[I`_7%PNQGK*B3E>9N0NP8YRH#<7/$64GX.Y%QBP!XNDG3![QUHRF>KC/D M.L,=];'F=>M(O1Q+6-([KO%BA'+I6SM\N5I"+(] M*"H>=;C4K&.DD;$1V+&I6M/HX&FP>LM$ORU$=ICRA8RM*[D.L6:[3^=4.\Q7 M8_JDP^2<1@UZ.XZY@DB5G2GR(FZ#Q(UTD#;-1V)'UDE($A8[L/E22XV,)&ZB M@W5'6#-CMA&G'>1S4R.$AMLAVC)#'54ODG23U#X.@12F\PV9[D"D MBY\5CXP405KPO1VMPN,D'02[E"BS!9%M5'9X&APWZ6:U'4#+QL>*Q'8(\Q6. MZA!VXZ_1&:(B,*N3V^',U3VLYXLZ)#__B:/BW85]BK3WB(*?QNSC--(?NNO@ M/W@5QAV=$G/'Q`G^?/^TIUBP\/%N"O/='#+'TQ[>TM%/[N3X&8P^>`K\A`1; ML-QV8?K?II_BAA,1\8T%]CLP0(A88$9+U2!1OD<&>S0,$*EK6!;$=IH%@Z&N M6BLTG#-CNZZHM M6F_0*6G8-%K(.*"^5LDW_;6H6O9;;K.Q*53`%C_WUR(:*5)T2U`53=)\R8>= M=2FZ>:B2,FG&U:?^6DPC=7*7%%519<5DGG;M)OD+C*KHL.:*'OMK`8VTV+P5 MJ8H."0\^[-S^YH5)E11(F,Q3`Q7RER^9R8;3&9ZVKA:Y?"DS7!B^CC%L#K_> M68V*P3.E@MY+\_8KJ*JJE)9RL1;20$/K1615>DK"@P\-8H;]JJQ*#MGDVA6G MXEN^ZFDB^(?&RMCO1VL^\QI9Y3$UOI70*&2_+.QLHO`:1.BO45IJKO4[@>\8 MGUUI&N"JJD>!TMA6',[4SD>+I'@7 M2[MXHM)EBGXI'MIJ15FT-">;C7IO'<74:+H^?9F$VO9,#/6T+3'9N"K5;[#+ M4.\\1'-NC;KW_#2<^HQ5T+:)H=>,FZ;4;S_K M5-6S+)4-E1:P:AQQ>D.#"96KR&CNI#[Q1.`P_KPF%>BT1?OQHVB=]BF=2K0? M4UR.0ZB(#EM$X7X4:MPUP/P[E4Y><2UPXUUP,VW`0C]E;./I/MJ@T,UMW=V" M:JY)I58P8^()OL!DD]&Q/0I![2;T-8,ERFB:F1JS+F)>=Z/=G2S5G MK47>T5]"BNNZ&\99$`:0*+BX\3L#T3]$!W)&TQ11RU/AB$IWC>^N8^OLRXXQMZ)I>/KY:VSC/RRE\)N:2:R8UUWJ^;V4?!Q,96" MZY@CBC?K";&%Z[TM>E?OKZ_;W%]?;^FO,=!7W(5$_.)I@2YI\^Y#L;XEQKVE M4R'I.XA%./"/3,^_K&V#JNK;?)(LH;.2/RX$CR86_*.,(_C_S/>%^55# MM$_5%I\T5K]L2?LHQG,1*NA=EPPB'>5X`U%K^KU=O1*;8,9D4I5]9[L<_AR5T/_XH2I`11R0AYH_N=WB[7)'&F=_;H2"]59;NE M<3GDMZ_A[-F<$J=%UQWX`N:3'RCD5!`QN'@P35V&W+OVW=9T]>JJEB50W@,, MDR?(&EMC4UZE6EMM4?W8K,`G7]ZNVH;VI6NM5'VO7PIY@Z7:MLSXV_4L6QCF;^:!E;^8$+(I0[7.E*):G;E1 M]1LZ[#5\S7R&OZ6!=V$`,3K>Q#(W56,2/6>+?:P#JM9Y:@[(9S#]&9P>UQVI M-Z;NG`M?S)9_#)<7&OX9'1XW.Y:.!^LL^>EWWK,+S"T+[TFY^^R)/?_9!D^? M>"S`/Q8:;2FEXWQ6L6WJGYNIJ`WSTZ9&UKPU=4W7BK$U4^UV%;=G/&=132-9 MU*XDM.@\33UMRS9,*)Z1-W_D82RR$C$Y3/WMB!9GN76,^#R;B2WJ%ONSI/DH M:4^!N9:RS0UNVQ9R/95K_C!B4W12^&UQA*AO2FF< MV[*\+-,.+7HSB'[I9XS[/U!+`0(>`Q0````(`(R!;4?^UZ>;,=```(M6"0`1 M`!@```````$```"D@0````!O<&=N+3(P,34P.3,P+GAM;%54!0`#.%)&5G5X M"P`!!"4.```$.0$``%!+`0(>`Q0````(`(R!;4<2[/RF8`P``+2_```5`!@` M``````$```"D@7S0``!O<&=N+3(P,34P.3,P7V-A;"YX;6Q55`4``SA21E9U M>`L``00E#@``!#D!``!02P$"'@,4````"`",@6U'ND-JAE@Y``"KK`,`%0`8 M```````!````I($KW0``;W!G;BTR,#$U,#DS,%]D968N>&UL550%``,X4D96 M=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`C(%M1U%?N-Q/5P``:KX$`!4` M&````````0```*2!TA8!`&]P9VXM,C`Q-3`Y,S!?;&%B+GAM;%54!0`#.%)& M5G5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`(R!;4=OYIVSF4```$="!``5 M`!@```````$```"D@7!N`0!O<&=N+3(P,34P.3,P7W!R92YX;6Q55`4``SA2 M1E9U>`L``00E#@``!#D!``!02P$"'@,4````"`",@6U'0TYYHX$-``#WB``` M$0`8```````!````I(%8KP$`;W!G;BTR,#$U,#DS,"YX`L``00E#@``!#D!``!02P4&``````8`!@`:`@``)+T!```` ` end XML 22 R30.htm IDEA: XBRL DOCUMENT v3.3.0.814

Fair value measurements (Details) - USD ($)

Sep. 30, 2015

Dec. 31, 2014

Fair value measurements on recurring basis

Cash and cash equivalents $ 11,187,129 $ 749,517

Level 1

Fair value measurements on recurring basis

Cash and cash equivalents 11,187,129 748,048

Level 2

Fair value measurements on recurring basis

Cash and cash equivalents 0 1,469

Level 3

Fair value measurements on recurring basis

Cash and cash equivalents $ 0 $ 0

X

- Definition
Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

+ Details

Name: us-gaap_CashAndCashEquivalentsFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 23 R31.htm IDEA: XBRL DOCUMENT v3.3.0.814

Fair value measurements (Details 1) - Warrant
9 Months Ended

Sep. 30, 2015

USD ($)

Changes in the fair value of Level 3 liabilities measured at fair value on recurring basis

Balance at the begining of the period $ 0

Established in 2015 72,333

Change in Fair Value 647,342

Reclassifed to Equity (719,675)

Balance at the end of the period $ 0

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 24 R8.htm IDEA: XBRL DOCUMENT v3.3.0.814

Summary of significant accounting policies
9 Months Ended

Sep. 30, 2015

Accounting Policies [Abstract]

Summary of significant accounting policies

Note 3 - Summary of significant accounting policies

Basis of presentation and consolidation

The accompanying interim condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission, or SEC, for interim financial information. Accordingly, they do not include all the information and footnotes required by U.S. Generally Accepted Accounting Principles, or GAAP, for complete financial statements. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited financial statements and accompanying notes for the year ended December 31, 2014 previously filed with the SEC. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual financial statements included in the Company’s registration statement on Form S-1/A and, in the opinion of management, reflect all the adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company’s financial position as of September 30, 2015 and the results of operations and cash flows for the three and nine months ended September 30, 2015 and 2014. The interim condensed consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. The December 31, 2014 balance sheet included herein was derived from the audited financial statements, but may not include all disclosures including notes required by GAAP for complete financial statements.

The accompanying unaudited interim condensed consolidated financial statements include the accounts of the OpGen and its wholly owned and controlled subsidiaries; all intercompany transactions and balances have been eliminated. The Company operates in one business segment. Certain prior period information has been reclassified to conform to the current period presentation.

Foreign Currency

AdvanDx A/S is located in Copenhagen, Denmark and uses the Danish Krone as its functional currency. As a result, all assets and liabilities are translated into U.S. dollars based on exchange rates at the end of the reporting period. Income and expense items are translated at the average exchange rates prevailing during the reporting period. Translation adjustments are reported in other comprehensive loss, a component of stockholder's equity. Foreign currency translation adjustments are the sole component of accumulated other comprehensive loss at September 30, 2015.

Foreign currency transaction gains and losses, excluding gains and losses on intercompany balances where there is no current intent to settle such amounts in the foreseeable future, are included in the determination of net loss.

Unless otherwise noted, all references to “$” or “dollar” refer to the United States dollar.

Use of estimates

In preparing financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In the accompanying consolidated financial statements, estimates are used for, but not limited to, share-based compensation, allowances for doubtful accounts and inventory obsolescence, valuation of derivative financial instruments, beneficial conversion features of convertible debt, deferred tax assets and liabilities and related valuation allowance, and depreciation and amortization and estimated useful lives of long-lived assets, and the recoverability of long-lived assets. Actual results could differ from those estimates.

Fair value of financial instruments

All current assets and liabilities are carried at cost, which approximates fair value, because of the short-term maturities of those instrument s. The carrying value of the Company’s debt is reflective of fair value based on instruments with similar terms available to the Company.

Cash and cash equivalents

The Company considers all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company has cash and cash equivalents deposited in financial institutions in which the balances occasionally exceed the federal government agency (FDIC) insured limits of $250,000. The Company has not experienced any losses in such accounts and management believes it is not exposed to any significant credit risk.

Accounts receivable

The Company’s accounts receivable result from revenues earned but not collected from customers. Credit is extended based on an evaluation of a customer’s financial condition and, generally, collateral is not required. Accounts receivable are due within 30 to 45 days and are stated at amounts due from customers. The Company evaluates if an allowance is necessary by considering a number of factors, including the length of time accounts receivable are past due, the Company’s previous loss history and the customer’s current ability to pay its obligation. If amounts become uncollectible, they are charged to operations when that determination is made. The allowance for doubtful accounts was $79,697 as of September 30, 2015 and December 31, 2014, respectively.

At September 30, 2015, the Company had accounts receivable from two customers which individually represented 12% and 11% of total accounts receivable. At December 31, 2014, the Company had accounts receivable from two customers which individually represented 79%, and 15% of total accounts receivable.

Inventories

Inventories are valued using the first-in, first-out method and stated at the lower of cost or market and consist of the following:

September 30,

December 31,

2015

2014

Raw materials and supplies

$

697,414

$

40,749

Work-in process

222,031

135,625

Finished goods

236,043

193,368

Total

$

1,155,488

$

369,742

Inventories include the Argus Whole Genome Mapping Systems, reagents and supplies used for Argus consumable kits, reagents and components for QuickFISH and PNAFISH kit products, and reagents and supplies used for the Company’s laboratory services. Inventory reserves for obsolescence and expirations were $778,944 and $867,816 at September 30, 2015 and December 31, 2014, respectively.

Product warranty

A warranty reserve is established upon the sale of any Argus System or Whole Genome Mapping product that is covered by warranty based on the estimated cost of replacement parts during the warranty period. Warranty periods are twelve months. The reserve is adjusted during the warranty period to reflect the remaining estimated costs under the warranty. The reserve for warranties was $2,750 as of September 30, 2015 and December 31, 2014, respectively.

Impairment of property and equipment

Property and equipment is reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. Recoverability measurement and estimating of undiscounted cash flows is done at the lowest possible level for which we can identify assets. If such assets are considered to be impaired, impairment is recognized as the amount by which the carrying amount of assets exceeds the fair value of the assets. During the three and nine months ended September 30, 2015 and 2014, the Company determined that its property and equipment was not impaired.

Intangible assets and goodwill

Intangible assets were acquired as part of the Merger, and consist of definite-lived intangible assets and goodwill.

Definite-lived intangible assets

Definite-lived intangible assets include trademarks, developed technology and customer relationships, and are amortized over their useful lives of 10, 7 and 7 years, respectively. Definite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. If any indicators were present, the Company would test for recoverability by comparing the carrying amount of the asset to the net undiscounted cash flows expected to be generated from the asset. If those net undiscounted cash flows do not exceed the carrying amount (i.e., the asset is not recoverable), the Company would perform the next step, which is to determine the fair value of the asset and record an impairment loss, if any. During the three and nine months ended September 30, 2015 and 2014, the Company determined that its definite-lived intangible assets were not impaired.

Goodwill

Goodwill represents the excess of the purchase price for AdvanDx over the fair values of the acquired tangible or intangible assets and assumed liabilities. Goodwill is tax deductible in all relevant jurisdictions. As a result of the Merger, the Company recognized goodwill of approximately $292,000.

The Company will conduct an impairment test of goodwill on an annual basis as of October 1 of each year, and will also conduct tests if events occur or circumstances change that would, more likely than not, reduce the Company’s fair value below its net equity value.

Redeemable convertible preferred stock

All shares of Series A redeemable convertible preferred stock, or Series A Preferred Stock (including those shares issued in connection with the conversion of the 2014 and 2015 convertible debt (see Note 6)), were converted into 7,374,852 shares of common stock in connection with the Company’s IPO (see Note 7).

Prior to the IPO, the carrying value of the Series A Preferred Stock was increased by the accretion of related discounts, issuance costs and accrued but unpaid dividends so that the carrying amount would equal the redemption amount at the dates the stock becomes redeemable. At December 31, 2014, the Company had 3,999,864 shares of Series A Preferred Stock, outstanding. The Series A Preferred Stock was redeemable at the option of the holders of 70% of the outstanding shares of Series A Preferred Stock, subject to certain additional requirements. The Company’s redeemable convertible preferred stock was classified as temporary equity due to redemption provisions outside of the Company’s control.

Revenue recognition

The Company recognizes revenue primarily from sales of its products and services when the following criteria are met: persuasive evidence of an arrangement exists; delivery has occurred; the selling price is fixed or determinable; and collectability is reasonably assured. At times, the Company sells products and services, or performs software development, under multiple-element arrangements with separate units of accounting; in these situations, total consideration is allocated to the identified units of accounting based on their relative selling prices and revenue is then recognized for each unit based on its specific characteristics.

Amounts billed to customers for shipping and handling are included in revenue when the related product or service revenue is recognized. Shipping and handling costs are included in cost of sales.

Revenue from sales of the Argus System

When an Argus System is sold without the Genome Builder software, total arrangement consideration is recognized as revenue when the system is delivered to the customer. Ancillary performance obligations, including installation, limited customer training and limited consumables, are considered inconsequential and are combined with the Argus System as one unit of accounting.

When an Argus System is sold with the Genome Builder software in a multiple-element arrangement, total arrangement consideration is allocated to the Argus System and to the Genome Builder software based on their relative selling prices. Selling prices are determined based on sales of similar systems to similar customers and, where no sales have occurred, on management’s best estimate of the expected selling price relative to similar products. Revenue related to the Argus System is recognized when it is delivered to the customer; revenue for the Genome Builder software is recognized when it is delivered to the customer.

Revenue from sales of AdvanDx diagnostic products

Revenue from sales of AdvanDx diagnostic products typically is recognized when the product is delivered to the customer.

Revenue from sales of Genome Builder Software and consumables (on a stand-alone basis)

Revenue is recognized for Genome Builder Software and for consumables, when sold on a standalone basis, upon delivery to the customer.

Revenue from extended warranty service contracts

The Company recognizes revenue associated with extended warranty service contracts over the service period in proportion to the costs expected to be incurred over that same period.

Revenue from providing laboratory services

The Company recognizes revenue associated with laboratory services contracts when the service has been performed and reports are made available to the customer.

Revenue from funded software development arrangements

The Company’s funded software development arrangements generally consist of multiple-elements. Total arrangement consideration is allocated to the identified units of accounting based on their relative selling prices and revenue is then recognized for each unit based on its specific characteristics. When funded software development arrangements include substantive research and development milestones, revenue is recognized for each such milestone when the milestone is achieved and is due and collectible. Milestones are considered substantive if all of the following conditions are met: (1) the milestone is nonrefundable; (2) achievement of the milestone was not reasonably assured at the inception of the arrangement; (3) substantive effort is involved to achieve the milestone; and (4) the amount of the milestone appears reasonable in relation to the effort expended, the other milestones in the arrangement and the related risk associated with achievement of the milestone.

Share-based compensation

Share-based payments are recognized at fair value. The fair value of share-based payments to employees and directors is estimated, on the date of grant, using the Black-Scholes model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option. For all time-vesting awards granted, expense is amortized using the straight-line attribution method. Share-based compensation expense recognized is based on the value of the portion of stock-based awards that is ultimately expected to vest during the period.

Option valuation models, including the Black-Scholes model, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award.

Income taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the expected future tax consequences attributable to temporary differences between financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred income tax assets to the amount expected to be realized. The Company’s tax provision for the three and nine months ended September 30, 2015 resulted from the deductibility of goodwill for tax purposes.

Tax benefits are initially recognized in the financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions are initially, and subsequently, measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement with the tax authority, assuming full knowledge of the position and all relevant facts.

The Company had federal net operating loss, or NOL, carryforwards of $76,267,809 at December 31, 2014. Despite the NOL carryforwards, which begin to expire in 2022, the Company may have future tax liability due to alternative minimum tax or state tax requirements. Also, use of the NOL carryforwards may be subject to an annual limitation as provided by Section 382 of the Internal Revenue Code of 1986, as amended, or the Code. There can be no assurance that the NOL carryforwards will ever be fully utilized.

Loss per share

Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of shares of common stock outstanding during the period.

For periods of net income, and when the effects are not anti-dilutive, diluted earnings per share is computed by dividing net income available to common shareholders by the weighted-average number of shares outstanding plus the impact of all potential dilutive common shares, consisting primarily of common stock options and stock purchase warrants using the treasury stock method, and convertible preferred stock and convertible debt using the if-converted method.

For periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all dilutive potential common shares is anti-dilutive. The number of anti-dilutive shares, consisting of (i) common stock options, (ii) restricted stock units (in 2014), (iii) stock purchase warrants, and (iv) prior to the IPO, convertible preferred stock and convertible debt, exercisable or exchangeable into common stock which have been excluded from the computation of diluted loss per share, was 5.7 million and 6.1 million for the nine and three months ended September 30, 2015 and 2014, respectively. The Company’s convertible preferred stock, prior to its conversion, contained non-forfeitable rights to dividends, and therefore was considered to be a participating security; the calculation of basic and diluted income (loss) per share excludes net income (but not net loss) attributable to the convertible preferred stock from the numerator and excludes the impact of those shares from the denominator in periods prior to the IPO.

Recent accounting pronouncements

In May 2014, the Financial Accounting Standards Board, or FASB, issued guidance for revenue recognition for contracts, superseding the previous revenue recognition requirements, along with most existing industry-specific guidance. The guidance requires an entity to review contracts in five steps: 1) identify the contract, 2) identify performance obligations, 3) determine the transaction price, 4) allocate the transaction price, and 5) recognize revenue. The new standard will result in enhanced disclosures regarding the nature, amount, timing and uncertainty of revenue arising from contracts with customers. The standard is effective for the Company’s reporting year beginning January 1, 2018 and early adoption is permitted starting January 1, 2017. The Company is currently evaluating the impact, if any, that this new accounting pronouncement will have on its financial statements.

In August 2014, the FASB issued guidance requiring management to evaluate on a regular basis whether any conditions or events have arisen that could raise substantial doubt about the entity’s ability to continue as a going concern. The guidance 1) provides a definition for the term “substantial doubt,” 2) requires an evaluation every reporting period, interim periods included, 3) provides principles for considering the mitigating effect of management’s plans to alleviate the substantial doubt, 4) requires certain disclosures if the substantial doubt is alleviated as a result of management’s plans, 5) requires an express statement, as well as other disclosures, if the substantial doubt is not alleviated, and 6) requires an assessment period of one year from the date the financial statements are issued. The standard is effective for the Company’s reporting year beginning January 1, 2017 and early adoption is permitted. The Company is currently evaluating the impact, if any, that this new accounting pronouncement will have on its financial statements.

In April 2015, the FASB issued accounting guidance requiring that debt issuance costs related to a recognized liability be presented on the balance sheet as a direct reduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected. The standard is effective for reporting periods beginning after December 15, 2015. The Company is currently evaluating the impact, if any, that this new accounting pronouncement will have on its financial statements.

In July 2015, the FASB issued accounting guidance for inventory. Under the guidance, an entity should measure inventory within the scope of this guidance at the lower of cost and net realizable value, except when inventory is measured using LIFO or the retail inventory method. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. In addition, the FASB has amended some of the other inventory guidance to more clearly articulate the requirements for the measurement and disclosure of inventory. The standard is effective for reporting periods beginning after December 15, 2016. The amendments in this pronouncement should be applied prospectively, with earlier application permitted. The Company is currently evaluating the impact, if any, that this new accounting pronouncement will have on its financial statements.

In September 2015, the FASB issued accounting guidance to simplify the accounting for measurement period adjustments resulting from business combinations. Under the guidance, an acquirer will be required to recognize adjustments to provisional amounts identified during the measurement period in the reporting period in which the adjustments are determined. The guidance requires an entity to present separately on the face of the income statement or disclose in the notes to the financial statements the portion of the amount recorded in current-period earnings by line item that would have been recorded in previous reporting periods if the adjustment had been recognized as of the acquisition date. The standard is effective for reporting periods beginning after December 15, 2015. The amendments in this pronouncement should be applied prospectively, with earlier application permitted. The Company is currently evaluating the impact, if any, that this new accounting pronouncement will have on its financial statements.

The Company has evaluated all other issued and unadopted Accounting Standards Updates and believes the adoption of these standards will not have a material impact on its results of operations, financial position, or cash flows.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for all significant accounting policies of the reporting entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18861-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18726-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18743-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18854-107790

+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 25 R32.htm IDEA: XBRL DOCUMENT v3.3.0.814

Series A redeemable convertible preferred stock (Details Textual) - USD ($)
1 Months Ended 9 Months Ended

May. 08, 2015

Apr. 30, 2014

Feb. 28, 2014

Dec. 31, 2013

Sep. 30, 2015

Dec. 31, 2014

Class of Stock [Line Items]

Debt Conversion, Original Debt, Amount $ 2,100,000

Conversion of Stock, Shares Issued 7,374,852

Series A Preferred Stock

Class of Stock [Line Items]

Temporary Equity, Shares Issued 594,904 1,405,096 1,999,864

Temporary Equity, Par or Stated Value Per Share $ 1.00

Debt Conversion, Original Debt, Amount $ 1,999,864

Proceeds from Issuance of Convertible Preferred Stock $ 594,904 $ 1,405,096

Temporary Equity, Shares Outstanding 3,999,864

Temporary Equity Shares Outstanding Convertible Into Common Stock Number 3,999,864

Preferred Stock, Dividend Rate, Percentage 8.00%

Temporary Equity Liquidation And Redemption Preference Multiple Of Purchase Price 2

Conversion of Stock, Shares Issued 1

Temporary Equity Redemption Request Of Minimum Percentage Of Holders Of Outstanding Preferred Stock Required 70.00%

Temporary Equity Redemption Number Of Installments 3

Debt Conversion, Converted Instrument, Shares Issued 7,374,852

X

- Definition
Represents liquidation and redemption preference expressed as a multiple of the purchase price of convertible preferred stock.
+ References
No definition available.
+ Details

Name: opgn_TemporaryEquityLiquidationAndRedemptionPreferenceMultipleOfPurchasePrice

Namespace Prefix: opgn_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the number of installments in which the convertible preferred stock will be redeemed.
+ References
No definition available.
+ Details

Name: opgn_TemporaryEquityRedemptionNumberOfInstallments

Namespace Prefix: opgn_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the request of minimum percentage of holders' of outstanding preferred stock required for redemption.
+ References
No definition available.
+ Details

Name: opgn_TemporaryEquityRedemptionRequestOfMinimumPercentageOfHoldersOfOutstandingPreferredStockRequired

Namespace Prefix: opgn_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the number of shares of common stock into which the outstanding preferred stock can be converted.
+ References
No definition available.
+ Details

Name: opgn_TemporaryEquitySharesOutstandingConvertibleIntoCommonStockNumber

Namespace Prefix: opgn_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfStockLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name: us-gaap_ConversionOfStockSharesIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name: us-gaap_DebtConversionConvertedInstrumentSharesIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

+ Details

Name: us-gaap_DebtConversionOriginalDebtAmount1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The percentage rate used to calculate dividend payments on preferred stock.
+ References
No definition available.
+ Details

Name: us-gaap_PreferredStockDividendRatePercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (27)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 480

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=27011957&loc=d3e177068-122764

+ Details

Name: us-gaap_TemporaryEquityParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.27(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 28

-Subparagraph b

-Article 5

+ Details

Name: us-gaap_TemporaryEquitySharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.27(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 28

-Subparagraph b

-Article 5

+ Details

Name: us-gaap_TemporaryEquitySharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 26 R2.htm IDEA: XBRL DOCUMENT v3.3.0.814

Condensed Consolidated Balance Sheets - USD ($)

Sep. 30, 2015

Dec. 31, 2014

Current assets

Cash and cash equivalents $ 11,187,129 $ 749,517

Accounts receivable, net 553,938 503,983

Inventory, net 1,155,488 369,742

Prepaid expenses and other current assets 538,312 90,233

Total current assets 13,434,867 1,713,475

Property and equipment, net 1,021,971 587,956

Deferred IPO issuance costs 0 296,041

Intangible assets, net 1,955,769 0

Goodwill 291,747 0

Other noncurrent assets 293,135 57,459

Total assets 16,997,489 2,654,931

Current liabilities

Accounts payable 1,274,657 1,160,081

Accrued compensation and benefits 840,637 423,099

Accrued liabilities 1,232,328 993,657

Deferred revenue 158,860 339,171

Short-term notes payable 1,250 1,505,000

Current maturities of long-term capital lease obligations 227,049 100,499

Short-term convertible notes, net of discounts 0 1,500,000

Total current liabilities 3,734,781 6,021,507

Note payable 1,000,000 0

Long-term capital lease obligations and other noncurrent liabilities 317,854 134,149

Total liabilities $ 5,052,635 6,155,656

Commitments and contingencies (Note 10)

Redeemable convertible preferred stock

Redeemable convertible preferred stock $ 0 4,564,899

Stockholders' equity (deficit)

Common stock, $.01 par value; 200,000,000 shares authorized; 12,539,704 and 493,178 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively 125,397 4,932

Additional paid-in capital 121,216,140 88,701,737

Accumulated other comprehensive loss (49) 0

Accumulated deficit (109,396,634) (96,772,293)

Total stockholders' equity (deficit) 11,944,854 (8,065,624)

Total liabilities, redeemable preferred stock and stockholders' equity (deficit) 16,997,489 2,654,931

Series A Convertible Redeemable Preferred Stock

Redeemable convertible preferred stock

Redeemable convertible preferred stock $ 0 $ 4,564,899

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3-4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph a(1)

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e681-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14A

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669686-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of capital lease obligation due within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 30

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6455398&loc=d3e45280-112737

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6455314&loc=d3e45023-112735

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_CapitalLeaseObligationsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid more than one year (or one operating cycle, if longer) after the balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 30

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6455398&loc=d3e45280-112737

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6455314&loc=d3e45023-112735

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CapitalLeaseObligationsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.(a),19)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.17)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_ConvertibleNotesPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.8)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 340

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=27011391&loc=d3e105025-122735

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section A

+ Details

Name: us-gaap_DeferredOfferingCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_EmployeeRelatedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=51655945&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LongTermNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_NotesPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TemporaryEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.
+ References
No definition available.
+ Details

Name: us-gaap_TemporaryEquityCarryingAmountAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 27 R6.htm IDEA: XBRL DOCUMENT v3.3.0.814

Organization
9 Months Ended

Sep. 30, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization

Note 1 - Organization

OpGen, Inc. (“OpGen”) was incorporated in Delaware in 2001. On July 14, 2015, OpGen completed the strategic acquisition (the “Merger”) of AdvanDx, Inc. and its wholly owned subsidiary AdvanDx A/S (collectively, “AdvanDx”) (see Note 4). Pursuant to the terms of a merger agreement, Velox Acquisition Corp. (OpGen’s wholly owned subsidiary formed for the express purpose of enacting the Merger) merged with and into AdvanDx, Inc. with AdvanDx, Inc. surviving as OpGen’s wholly owned subsidiary (see Note 4). OpGen, AdvanDx, Inc. and AdvanDx A/S are collectively referred to hereinafter as the “Company.” The Company’s headquarters are in Gaithersburg, Maryland, and its principal operations are in Gaithersburg, Maryland and Woburn, Massachusetts. The Company also has operations in Copenhagen, Denmark.

OpGen is an early-stage company using rapid molecular testing and bioinformatics to help guide antibiotic therapy and to assist healthcare providers to combat multi-drug resistant infections, or MDROs. OpGen’s lead products are its QuickFISH® and PNAFISH products, which are advanced in vitro diagnostic kits for the diagnosis and prevention of infectious diseases, the Acuitas® MDRO Gene Test, a CLIA lab-based test that provides a profile of MDRO resistant genes from patients screened for colonization or infection and the Acuitas Lighthouse to aid in the interpretation of MDRO diagnostic test results. The company develops, markets and sells its products principally for use in hospitals and clinical laboratories in the United States and internationally.

The Company’s operations are subject to certain risks and uncertainties. The risks include rapid technology changes, the need to manage growth, the need to retain key personnel, the need to protect intellectual property and the need to raise additional capital financing on terms acceptable to the Company. The Company’s success depends, in part, on its ability to develop and commercialize its proprietary technology as well as raise additional capital.

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=35735333&loc=d3e288-107754

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 272

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 28 R35.htm IDEA: XBRL DOCUMENT v3.3.0.814

Stockholders' equity (deficit) (Details Textual) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended

Jul. 14, 2015

May. 08, 2015

Jul. 31, 2015

Oct. 24, 2014

Mar. 31, 2014

Sep. 30, 2015

Jun. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Mar. 31, 2015

Dec. 31, 2014

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Allocated Share-based Compensation Expense $ 261,540 $ 24,977 $ 1,172,231 $ 80,457

Debt Conversion, Converted Instrument, Amount 300,000 0

Stock Purchase Warrants Issued Upon Conversion Over Allotment Option 422,500

Proceeds from Issuance of Warrants $ 4,225

Proceeds From Issuance Of Units Under Initial Public Offering Gross 17,100,000

Proceeds From Issuance Of Units Under Initial Public Offering Net $ 12,100,000

Stock Issued During Period, Value, Acquisitions $ 2,584,090 0

Merck Global Health Innovation Fund LLC [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock Issued During Period, Shares, New Issues 1,136,364

Over-Allotment Option [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights 3,272,500

Class of Warrant or Right, Exercise Price of Warrants or Rights $ 6.60

Expiration Date of Warrants Issued May 08, 2020

Demand Notes Payable [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Debt Conversion, Converted Instrument, Amount $ 2,100,000

2015 Plan

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized 1,355,000 1,355,000

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant 528,890 528,890

Share-based Compensation Arrangement by Share-based Payment Award, Common stock Pecentage 4.00%

Stock Purchase Warrants Issued 3,457,750

Stock options

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Allocated Share-based Compensation Expense $ 261,540 $ 24,977 $ 1,172,231 $ 80,457

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 1,660,387

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price $ 2.87

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value $ 3.16

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number 1,948,249 1,948,249

Restricted stock units

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 130,640

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period 130,640

Warrant

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Class of Warrant or Right, Outstanding 3,716,355 3,716,355 33,594

Common Stock [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock and Warrants Issued in Conjunction with Initial Public Offering 2,850,000

Offering Price Per Unit $ 6.00

Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs $ 2,900,000

Convertible Preferred Stock, Shares Issued upon Conversion 7,374,852 7,374,852

Class of Warrant or Right, Number of Securities Called by Warrants or Rights 225,011

Proceeds From Issuance Of Units Under Initial Public Offering Gross $ 17,100,000

Proceeds From Issuance Of Units Under Initial Public Offering Net $ 12,100,000

Common Stock [Member] | Merck Global Health Innovation Fund LLC [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock Issued During Period, Value, Acquisitions $ 5,000,000

Common Stock [Member] | Over-Allotment Option [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights 185,250

X

- Definition
Represents expiration date of warrants issued during the period.
+ References
No definition available.
+ Details

Name: opgn_ExpirationDateOfWarrantsIssued

Namespace Prefix: opgn_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from entity's issuance of units under initial public offering.
+ References
No definition available.
+ Details

Name: opgn_ProceedsFromIssuanceOfUnitsUnderInitialPublicOfferingGross

Namespace Prefix: opgn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The net cash inflow associated with the amount received from entity's issuance of units under initial public offering.
+ References
No definition available.
+ Details

Name: opgn_ProceedsFromIssuanceOfUnitsUnderInitialPublicOfferingNet

Namespace Prefix: opgn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Percentage represents the amount by which the authorized share based awards under the 2015 Plan may be increased presented as a percentage of common shares outstanding.
+ References
No definition available.
+ Details

Name: opgn_SharebasedCompensationArrangementBySharebasedPaymentAwardCommonStockPecentage

Namespace Prefix: opgn_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Units of stock and warrants issued in conjunction with initial public offering.
+ References
No definition available.
+ Details

Name: opgn_StockAndWarrantsIssuedInConjunctionWithInitialPublicOffering

Namespace Prefix: opgn_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of stock purchase warrants issued during the reporting period.
+ References
No definition available.
+ Details

Name: opgn_StockPurchaseWarrantsIssued

Namespace Prefix: opgn_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Stock purchase warrants issued during the reporting period upon conversion over allotment option.
+ References
No definition available.
+ Details

Name: opgn_StockPurchaseWarrantsIssuedUponConversionOverAllotmentOption

Namespace Prefix: opgn_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i)(4))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i)(2))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of warrants or rights outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_ClassOfWarrantOrRightOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares issued for each share of convertible preferred stock that is converted.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

+ Details

Name: us-gaap_DebtConversionConvertedInstrumentAmount1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_ProceedsFromIssuanceOfWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)(3)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (d)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Per share or per unit amount of equity securities issued.
+ References
No definition available.
+ Details

Name: us-gaap_SharesIssuedPricePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of stock issued pursuant to acquisitions during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueAcquisitions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=opgn_MerckGlobalHealthInnovationFundLlcMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=opgn_DemandNotesPayableMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=opgn_TwoThousandFifteenPlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 29 R22.htm IDEA: XBRL DOCUMENT v3.3.0.814

Stockholders' equity (deficit) (Tables)
9 Months Ended

Sep. 30, 2015

Stockholders' Equity Note [Abstract]

Schedule of allocation of share-based compensation expense

The allocation of share-based compensation expense by operating expenses is as follows:

Three months ended September 30,

2015

2014

Research and development

$

59,688

$

1,528

General and administrative

156,236

22,460

Sales and marketing

45,616

989

$

261,540

$

24,977

Nine months ended September 30,

2015

2014

Research and development

$

161,819

$

3,903

General and administrative

443,267

74,032

Sales and marketing

567,145

2,522

$

1,172,231

$

80,457

X

- Definition
Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

+ Details

Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityNoteAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 30 R36.htm IDEA: XBRL DOCUMENT v3.3.0.814

Commitments and contingencies (Details Textual) - USD ($)
9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Operating Leased Assets [Line Items]

Operating Leases, Rent Expense, Net $ 447,007 $ 341,862

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingLeasedAssetsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6453985&loc=d3e41499-112717

+ Details

Name: us-gaap_OperatingLeasesRentExpenseNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 31 R24.htm IDEA: XBRL DOCUMENT v3.3.0.814

Summary of significant accounting policies (Details) - USD ($)

Sep. 30, 2015

Dec. 31, 2014

Inventories

Raw materials and supplies $ 697,414 $ 40,749

Work-in process 222,031 135,625

Finished goods 236,043 193,368

Total $ 1,155,488 $ 369,742

X

- References
No definition available.
+ Details

Name: opgn_InventoriesAbstract

Namespace Prefix: opgn_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 5.BB)

-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section BB

+ Details

Name: us-gaap_InventoryFinishedGoodsNetOfReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=51655945&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a)(4),(5))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 5.BB)

-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section BB

+ Details

Name: us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 5.BB)

-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section BB

+ Details

Name: us-gaap_InventoryWorkInProcessNetOfReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 32 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 33 R7.htm IDEA: XBRL DOCUMENT v3.3.0.814

Liquidity and management's plans
9 Months Ended

Sep. 30, 2015

Liquidation Basis Of Accounting Abstract [Abstract]

Liquidity and management’s plans

Note 2 – Liquidity and management’s plans

The accompanying consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Since inception, the Company has incurred, and continues to incur, significant losses from operations. The Company has funded its operations primarily through external investor financing arrangements. The Company raised significant funds in 2015, including:

·

$0.8 million in short-term notes (in the first quarter of 2015, $0.3 million of demand notes held by an entity controlled by our chief executive officer were settled as partial payment for a 2015 convertible note, and in the second quarter of 2015, $0.2 million of notes from a related party were repaid in cash),

·

$1.5 million through the issuance of convertible notes,

·

$12.1 million in net proceeds from its initial public offering, or IPO, as discussed further below, and

·

$6.0 million in net proceeds from the issuances of common stock and promissory note to Merck Global Health Innovations Fund, LLC (“Merck GHI”).

On May 8, 2015, OpGen completed its IPO pursuant to which it offered and sold 2,850,000 units, each consisting of one share of common stock and a detachable stock purchase warrant to purchase an additional share of common stock, at an initial offering price of $6.00 per unit. Of the total gross proceeds of $17.1 million, approximately $2.1 million was satisfied by exchanging outstanding demand notes. After considering the demand notes, underwriting discounts and commissions and offering expenses, the total net cash proceeds were $12.1 million. On the IPO closing date, the underwriters exercised their over-allotment option to acquire an additional 422,500 stock purchase warrants. In connection with the IPO, all of OpGen’s outstanding Series A Preferred Stock, 2014 convertible notes and 2015 convertible notes were converted into 7,374,852 shares of common stock.

In July 2015, the Company raised $6.0 million by issuing 1,136,364 shares of common stock (with a value of $5.0 million at $4.40 per share) and a $1.0 million promissory note to Merck GHI (see Note 5).

The Company’s current operating assumptions, which include management’s best estimate of future revenue and operating expenses, indicate that current cash on hand will be sufficient to fund operations through at least the end of the first quarter of 2016. In the event the Company is unable to successfully raise additional capital in 2016, the Company will not have sufficient cash flows and liquidity to finance its business operations as currently contemplated. Accordingly, in such circumstances the Company would be compelled to reduce general and administrative expenses and delay research and development projects, including the purchase of scientific equipment and supplies, until it is able to obtain sufficient financing, or pursue other strategic alternatives which may include licensing and/or partnering arrangements or mergers and acquisitions. The financial statements do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.

X

- References
No definition available.
+ Details

Name: opgn_LiquidationBasisOfAccountingAbstractAbstract

Namespace Prefix: opgn_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 40

-Section 50

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=51888302&loc=SL51888449-203568

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 40

-Section 50

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=51888302&loc=SL51888443-203568

+ Details

Name: us-gaap_SubstantialDoubtAboutGoingConcernTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 34 R3.htm IDEA: XBRL DOCUMENT v3.3.0.814

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)

Sep. 30, 2015

Dec. 31, 2014

Common stock, par value (in dollars per share) $ 0.01 $ 0.01

Common stock, shares authorized 200,000,000 200,000,000

Common stock, shares issued 12,539,704 493,178

Common stock, shares outstanding 12,539,704 493,178

Series A Convertible Redeemable Preferred Stock

Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01

Preferred stock, shares authorized 6,000,000 6,000,000

Preferred stock, shares issued 0 3,999,864

Preferred stock, shares outstanding 0 3,999,864

Preferred stock, liquidation preference $ 0 $ 7,999,728

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_TemporaryEquityLiquidationPreference

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (27)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 480

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=27011957&loc=d3e177068-122764

+ Details

Name: us-gaap_TemporaryEquityParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.27(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 28

-Subparagraph b

-Article 5

+ Details

Name: us-gaap_TemporaryEquitySharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.27(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 28

-Subparagraph b

-Article 5

+ Details

Name: us-gaap_TemporaryEquitySharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.27(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 28

-Subparagraph b

-Article 5

+ Details

Name: us-gaap_TemporaryEquitySharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 35 R17.htm IDEA: XBRL DOCUMENT v3.3.0.814

Related party transactions
9 Months Ended

Sep. 30, 2015

Related Party Transactions [Abstract]

Related party transactions

Note 12 - Related party transactions

In March 2014, the Company entered into a supply agreement with Fluidigm Corporation, or Fluidigm, under which Fluidigm supplies the Company with its microfluidic test platform for use in manufacturing the Acuitas MDRO Gene Test. The Company’s CEO and Chairman of the Board of Directors of the Company, is a director of Fluidigm.

On July 12, 2015, the Company entered into a letter agreement, or the Agreement, with Fluidigm to expand the companies' existing relationship to include collaborating on the development of test kits and custom analytic instruments for identification, screening and surveillance testing of MDROs. The Agreement also expands the existing Supply Agreement between the Company and Fluidigm, and provides for expansion of the gene targets and organisms to be tested on the Company's existing CLIA lab-based tests, the Acuitas MDRO Gene Test and the Acuitas Resistome Test, using Fluidigm technologies and products. Additionally, Fluidigm has agreed not to develop or directly collaborate with any third party to develop an FDA approved or CE marked diagnostic tests for the purpose of detecting resistome genes for identified MDROs if the Company meets certain minimum purchase commitments and other requirements. The initial term of the Agreement is five years. Both parties have the ability to extend the term for an additional five years. Under the expanded Supply Agreement, the term is extended until March 17, 2018, and the Company has the right to extend the term of the Supply Agreement for up to two additional three-year terms.

X

- References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph b

-Article 3A

+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 R1.htm IDEA: XBRL DOCUMENT v3.3.0.814

Document And Entity Information - shares
9 Months Ended

Sep. 30, 2015

Oct. 30, 2015

Document Information [Line Items]

Entity Registrant Name OPGEN INC

Entity Central Index Key 0001293818

Document Type 10-Q

Document Period End Date Sep. 30, 2015

Amendment Flag false

Current Fiscal Year End Date --12-31

Entity Filer Category Smaller Reporting Company

Trading Symbol OPGN

Entity Common Stock, Shares Outstanding 12,539,704

Document Fiscal Period Focus Q3

Document Fiscal Year Focus 2015

X

- Definition
If the value is true, then the document is an amendment to previously-filed/accepted document.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: dei_DocumentInformationLineItems

Namespace Prefix: dei_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

XML 37 R18.htm IDEA: XBRL DOCUMENT v3.3.0.814

Summary of significant accounting policies (Policies)
9 Months Ended

Sep. 30, 2015

Accounting Policies [Abstract]

Basis of presentation

Basis of presentation and consolidation

The accompanying interim condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission, or SEC, for interim financial information. Accordingly, they do not include all the information and footnotes required by U.S. Generally Accepted Accounting Principles, or GAAP, for complete financial statements. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited financial statements and accompanying notes for the year ended December 31, 2014 previously filed with the SEC. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual financial statements included in the Company’s registration statement on Form S-1/A and, in the opinion of management, reflect all the adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company’s financial position as of September 30, 2015 and the results of operations and cash flows for the three and nine months ended September 30, 2015 and 2014. The interim condensed consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. The December 31, 2014 balance sheet included herein was derived from the audited financial statements, but may not include all disclosures including notes required by GAAP for complete financial statements.

The accompanying unaudited interim condensed consolidated financial statements include the accounts of the OpGen and its wholly owned and controlled subsidiaries; all intercompany transactions and balances have been eliminated. The Company operates in one business segment. Certain prior period information has been reclassified to conform to the current period presentation.

Foreign Currency

Foreign Currency

AdvanDx A/S is located in Copenhagen, Denmark and uses the Danish Krone as its functional currency. As a result, all assets and liabilities are translated into U.S. dollars based on exchange rates at the end of the reporting period. Income and expense items are translated at the average exchange rates prevailing during the reporting period. Translation adjustments are reported in other comprehensive loss, a component of stockholder's equity. Foreign currency translation adjustments are the sole component of accumulated other comprehensive loss at September 30, 2015.

Foreign currency transaction gains and losses, excluding gains and losses on intercompany balances where there is no current intent to settle such amounts in the foreseeable future, are included in the determination of net loss.

Unless otherwise noted, all references to “$” or “dollar” refer to the United States dollar.

Use of estimates

Use of estimates

In preparing financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In the accompanying consolidated financial statements, estimates are used for, but not limited to, share-based compensation, allowances for doubtful accounts and inventory obsolescence, valuation of derivative financial instruments, beneficial conversion features of convertible debt, deferred tax assets and liabilities and related valuation allowance, and depreciation and amortization and estimated useful lives of long-lived assets, and the recoverability of long-lived assets. Actual results could differ from those estimates.

Fair value of financial instruments

Fair value of financial instruments

All current assets and liabilities are carried at cost, which approximates fair value, because of the short-term maturities of those instrument s. The carrying value of the Company’s debt is reflective of fair value based on instruments with similar terms available to the Company.

Cash and cash equivalents

Cash and cash equivalents

The Company considers all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company has cash and cash equivalents deposited in financial institutions in which the balances occasionally exceed the federal government agency (FDIC) insured limits of $250,000. The Company has not experienced any losses in such accounts and management believes it is not exposed to any significant credit risk.

Accounts receivable

Accounts receivable

The Company’s accounts receivable result from revenues earned but not collected from customers. Credit is extended based on an evaluation of a customer’s financial condition and, generally, collateral is not required. Accounts receivable are due within 30 to 45 days and are stated at amounts due from customers. The Company evaluates if an allowance is necessary by considering a number of factors, including the length of time accounts receivable are past due, the Company’s previous loss history and the customer’s current ability to pay its obligation. If amounts become uncollectible, they are charged to operations when that determination is made. The allowance for doubtful accounts was $79,697 as of September 30, 2015 and December 31, 2014, respectively.

At September 30, 2015, the Company had accounts receivable from two customers which individually represented 12% and 11% of total accounts receivable. At December 31, 2014, the Company had accounts receivable from two customers which individually represented 79%, and 15% of total accounts receivable.

Inventories

Inventories

Inventories are valued using the first-in, first-out method and stated at the lower of cost or market and consist of the following:

September 30,

December 31,

2015

2014

Raw materials and supplies

$

697,414

$

40,749

Work-in process

222,031

135,625

Finished goods

236,043

193,368

Total

$

1,155,488

$

369,742

Inventories include the Argus Whole Genome Mapping Systems, reagents and supplies used for Argus consumable kits, reagents and components for QuickFISH and PNAFISH kit products, and reagents and supplies used for the Company’s laboratory services. Inventory reserves for obsolescence and expirations were $778,944 and $867,816 at September 30, 2015 and December 31, 2014, respectively.

Product warranty

Product warranty

A warranty reserve is established upon the sale of any Argus System or Whole Genome Mapping product that is covered by warranty based on the estimated cost of replacement parts during the warranty period. Warranty periods are twelve months. The reserve is adjusted during the warranty period to reflect the remaining estimated costs under the warranty. The reserve for warranties was $2,750 as of September 30, 2015 and December 31, 2014, respectively.

Impairment of long-lived assets

Impairment of property and equipment

Property and equipment is reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. Recoverability measurement and estimating of undiscounted cash flows is done at the lowest possible level for which we can identify assets. If such assets are considered to be impaired, impairment is recognized as the amount by which the carrying amount of assets exceeds the fair value of the assets. During the three and nine months ended September 30, 2015 and 2014, the Company determined that its property and equipment was not impaired.

Intangible assets and goodwill

Intangible assets and goodwill

Intangible assets were acquired as part of the Merger, and consist of definite-lived intangible assets and goodwill.

Definite-lived intangible assets

Definite-lived intangible assets include trademarks, developed technology and customer relationships, and are amortized over their useful lives of 10, 7 and 7 years, respectively. Definite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. If any indicators were present, the Company would test for recoverability by comparing the carrying amount of the asset to the net undiscounted cash flows expected to be generated from the asset. If those net undiscounted cash flows do not exceed the carrying amount (i.e., the asset is not recoverable), the Company would perform the next step, which is to determine the fair value of the asset and record an impairment loss, if any. During the three and nine months ended September 30, 2015 and 2014, the Company determined that its definite-lived intangible assets were not impaired.

Goodwill

Goodwill represents the excess of the purchase price for AdvanDx over the fair values of the acquired tangible or intangible assets and assumed liabilities. Goodwill is tax deductible in all relevant jurisdictions. As a result of the Merger, the Company recognized goodwill of approximately $292,000.

The Company will conduct an impairment test of goodwill on an annual basis as of October 1 of each year, and will also conduct tests if events occur or circumstances change that would, more likely than not, reduce the Company’s fair value below its net equity value.

Redeemable convertible preferred stock

Redeemable convertible preferred stock

All shares of Series A redeemable convertible preferred stock, or Series A Preferred Stock (including those shares issued in connection with the conversion of the 2014 and 2015 convertible debt (see Note 6)), were converted into 7,374,852 shares of common stock in connection with the Company’s IPO (see Note 7).

Prior to the IPO, the carrying value of the Series A Preferred Stock was increased by the accretion of related discounts, issuance costs and accrued but unpaid dividends so that the carrying amount would equal the redemption amount at the dates the stock becomes redeemable. At December 31, 2014, the Company had 3,999,864 shares of Series A Preferred Stock, outstanding. The Series A Preferred Stock was redeemable at the option of the holders of 70% of the outstanding shares of Series A Preferred Stock, subject to certain additional requirements. The Company’s redeemable convertible preferred stock was classified as temporary equity due to redemption provisions outside of the Company’s control.

Revenue recognition

Revenue recognition

The Company recognizes revenue primarily from sales of its products and services when the following criteria are met: persuasive evidence of an arrangement exists; delivery has occurred; the selling price is fixed or determinable; and collectability is reasonably assured. At times, the Company sells products and services, or performs software development, under multiple-element arrangements with separate units of accounting; in these situations, total consideration is allocated to the identified units of accounting based on their relative selling prices and revenue is then recognized for each unit based on its specific characteristics.

Amounts billed to customers for shipping and handling are included in revenue when the related product or service revenue is recognized. Shipping and handling costs are included in cost of sales.

Revenue from sales of the Argus System

When an Argus System is sold without the Genome Builder software, total arrangement consideration is recognized as revenue when the system is delivered to the customer. Ancillary performance obligations, including installation, limited customer training and limited consumables, are considered inconsequential and are combined with the Argus System as one unit of accounting.

When an Argus System is sold with the Genome Builder software in a multiple-element arrangement, total arrangement consideration is allocated to the Argus System and to the Genome Builder software based on their relative selling prices. Selling prices are determined based on sales of similar systems to similar customers and, where no sales have occurred, on management’s best estimate of the expected selling price relative to similar products. Revenue related to the Argus System is recognized when it is delivered to the customer; revenue for the Genome Builder software is recognized when it is delivered to the customer.

Revenue from sales of AdvanDx diagnostic products

Revenue from sales of AdvanDx diagnostic products typically is recognized when the product is delivered to the customer.

Revenue from sales of Genome Builder Software and consumables (on a stand-alone basis)

Revenue is recognized for Genome Builder Software and for consumables, when sold on a standalone basis, upon delivery to the customer.

Revenue from extended warranty service contracts

The Company recognizes revenue associated with extended warranty service contracts over the service period in proportion to the costs expected to be incurred over that same period.

Revenue from providing laboratory services

The Company recognizes revenue associated with laboratory services contracts when the service has been performed and reports are made available to the customer.

Revenue from funded software development arrangements

The Company’s funded software development arrangements generally consist of multiple-elements. Total arrangement consideration is allocated to the identified units of accounting based on their relative selling prices and revenue is then recognized for each unit based on its specific characteristics. When funded software development arrangements include substantive research and development milestones, revenue is recognized for each such milestone when the milestone is achieved and is due and collectible. Milestones are considered substantive if all of the following conditions are met: (1) the milestone is nonrefundable; (2) achievement of the milestone was not reasonably assured at the inception of the arrangement; (3) substantive effort is involved to achieve the milestone; and (4) the amount of the milestone appears reasonable in relation to the effort expended, the other milestones in the arrangement and the related risk associated with achievement of the milestone.

Share-based compensation

Share-based compensation

Share-based payments are recognized at fair value. The fair value of share-based payments to employees and directors is estimated, on the date of grant, using the Black-Scholes model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option. For all time-vesting awards granted, expense is amortized using the straight-line attribution method. Share-based compensation expense recognized is based on the value of the portion of stock-based awards that is ultimately expected to vest during the period.

Option valuation models, including the Black-Scholes model, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award.

Income taxes

Income taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the expected future tax consequences attributable to temporary differences between financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred income tax assets to the amount expected to be realized. The Company’s tax provision for the three and nine months ended September 30, 2015 resulted from the deductibility of goodwill for tax purposes.

Tax benefits are initially recognized in the financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions are initially, and subsequently, measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement with the tax authority, assuming full knowledge of the position and all relevant facts.

The Company had federal net operating loss, or NOL, carryforwards of $76,267,809 at December 31, 2014. Despite the NOL carryforwards, which begin to expire in 2022, the Company may have future tax liability due to alternative minimum tax or state tax requirements. Also, use of the NOL carryforwards may be subject to an annual limitation as provided by Section 382 of the Internal Revenue Code of 1986, as amended, or the Code. There can be no assurance that the NOL carryforwards will ever be fully utilized.

Loss per share

Loss per share

Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of shares of common stock outstanding during the period.

For periods of net income, and when the effects are not anti-dilutive, diluted earnings per share is computed by dividing net income available to common shareholders by the weighted-average number of shares outstanding plus the impact of all potential dilutive common shares, consisting primarily of common stock options and stock purchase warrants using the treasury stock method, and convertible preferred stock and convertible debt using the if-converted method.

For periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all dilutive potential common shares is anti-dilutive. The number of anti-dilutive shares, consisting of (i) common stock options, (ii) restricted stock units (in 2014), (iii) stock purchase warrants, and (iv) prior to the IPO, convertible preferred stock and convertible debt, exercisable or exchangeable into common stock which have been excluded from the computation of diluted loss per share, was 5.7 million and 6.1 million for the nine and three months ended September 30, 2015 and 2014, respectively. The Company’s convertible preferred stock, prior to its conversion, contained non-forfeitable rights to dividends, and therefore was considered to be a participating security; the calculation of basic and diluted income (loss) per share excludes net income (but not net loss) attributable to the convertible preferred stock from the numerator and excludes the impact of those shares from the denominator in periods prior to the IPO.

Recent accounting pronouncements

Recent accounting pronouncements

In May 2014, the Financial Accounting Standards Board, or FASB, issued guidance for revenue recognition for contracts, superseding the previous revenue recognition requirements, along with most existing industry-specific guidance. The guidance requires an entity to review contracts in five steps: 1) identify the contract, 2) identify performance obligations, 3) determine the transaction price, 4) allocate the transaction price, and 5) recognize revenue. The new standard will result in enhanced disclosures regarding the nature, amount, timing and uncertainty of revenue arising from contracts with customers. The standard is effective for the Company’s reporting year beginning January 1, 2018 and early adoption is permitted starting January 1, 2017. The Company is currently evaluating the impact, if any, that this new accounting pronouncement will have on its financial statements.

In August 2014, the FASB issued guidance requiring management to evaluate on a regular basis whether any conditions or events have arisen that could raise substantial doubt about the entity’s ability to continue as a going concern. The guidance 1) provides a definition for the term “substantial doubt,” 2) requires an evaluation every reporting period, interim periods included, 3) provides principles for considering the mitigating effect of management’s plans to alleviate the substantial doubt, 4) requires certain disclosures if the substantial doubt is alleviated as a result of management’s plans, 5) requires an express statement, as well as other disclosures, if the substantial doubt is not alleviated, and 6) requires an assessment period of one year from the date the financial statements are issued. The standard is effective for the Company’s reporting year beginning January 1, 2017 and early adoption is permitted. The Company is currently evaluating the impact, if any, that this new accounting pronouncement will have on its financial statements.

In April 2015, the FASB issued accounting guidance requiring that debt issuance costs related to a recognized liability be presented on the balance sheet as a direct reduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected. The standard is effective for reporting periods beginning after December 15, 2015. The Company is currently evaluating the impact, if any, that this new accounting pronouncement will have on its financial statements.

In July 2015, the FASB issued accounting guidance for inventory. Under the guidance, an entity should measure inventory within the scope of this guidance at the lower of cost and net realizable value, except when inventory is measured using LIFO or the retail inventory method. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. In addition, the FASB has amended some of the other inventory guidance to more clearly articulate the requirements for the measurement and disclosure of inventory. The standard is effective for reporting periods beginning after December 15, 2016. The amendments in this pronouncement should be applied prospectively, with earlier application permitted. The Company is currently evaluating the impact, if any, that this new accounting pronouncement will have on its financial statements.

In September 2015, the FASB issued accounting guidance to simplify the accounting for measurement period adjustments resulting from business combinations. Under the guidance, an acquirer will be required to recognize adjustments to provisional amounts identified during the measurement period in the reporting period in which the adjustments are determined. The guidance requires an entity to present separately on the face of the income statement or disclose in the notes to the financial statements the portion of the amount recorded in current-period earnings by line item that would have been recorded in previous reporting periods if the adjustment had been recognized as of the acquisition date. The standard is effective for reporting periods beginning after December 15, 2015. The amendments in this pronouncement should be applied prospectively, with earlier application permitted. The Company is currently evaluating the impact, if any, that this new accounting pronouncement will have on its financial statements.

The Company has evaluated all other issued and unadopted Accounting Standards Updates and believes the adoption of these standards will not have a material impact on its results of operations, financial position, or cash flows.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ References
No definition available.
+ Details

Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 305

-SubTopic 10

-Section 05

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4273-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Financial Reporting Release (FRR)

-Number 203

-Paragraph 02-03

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

+ Details

Name: us-gaap_EarningsPerSharePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for determining the fair value of financial instruments.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13279-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 60

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260

+ Details

Name: us-gaap_FairValueOfFinancialInstrumentsPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895

+ Details

Name: us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16265-109275

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 05

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=51717228&loc=d3e202-110218

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section CC

-Subsection 3

+ Details

Name: us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32840-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 30

-Section 05

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6423966&loc=d3e40913-109327

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 954

-SubTopic 740

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 17

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32809-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e32247-109318

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e32280-109318

+ Details

Name: us-gaap_IncomeTaxPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for major classes of inventories, bases of stating inventories (for example, lower of cost or market), methods by which amounts are added and removed from inventory classes (for example, FIFO, LIFO, or average cost), loss recognition on impairment of inventories, and situations in which inventories are stated above cost. If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28360613&loc=d3e4492-108314

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=28360613&loc=d3e4556-108314

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Financial Reporting Release (FRR)

-Number 206

-Paragraph b

-Subparagraph i, ii

-Chapter 2

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a

-Article 5

+ Details

Name: us-gaap_InventoryPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18823-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18726-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.B.Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section B

-Paragraph Question 1

+ Details

Name: us-gaap_RevenueRecognitionPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (b),(f)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for standard warranties including the methodology for measuring the liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=51674963&loc=d3e12565-110249

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

+ Details

Name: us-gaap_StandardProductWarrantyPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for redeemable preferred stock issued. This disclosure may include the accounting treatment for the difference, if there is any, between the carrying value and redemption amount. For example, describe whether the issuer accretes changes in the redemption value.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.27(b),(c))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 05

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6403650&loc=d3e20905-112640

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 28

-Subparagraph b

-Article 5

+ Details

Name: us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for trade and other accounts receivables. This disclosure may include the basis at which such receivables are carried in the entity's statements of financial position (for example, net realizable value), how the entity determines the level of its allowance for doubtful accounts, when impairments, charge-offs or recoveries are recognized, and the entity's income recognition policies for such receivables, including its treatment of related fees and costs, its treatment of premiums, discounts or unearned income, when accrual of interest is discontinued, how the entity records payments received on nonaccrual receivables and its policy for resuming accrual of interest on such receivables. If the enterprise holds a large number of similar loans, disclosure may include the accounting policy for the anticipation of prepayments and significant assumptions underlying prepayment estimates for amortization of premiums, discounts, and nonrefundable fees and costs.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6378556&loc=d3e10133-111534

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section 50

-Paragraph 15

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=49124121&loc=d3e5212-111524

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=49124121&loc=d3e5093-111524

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3, 4

-Article 5

+ Details

Name: us-gaap_TradeAndOtherAccountsReceivablePolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6061-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6143-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6132-108592

+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 38 R4.htm IDEA: XBRL DOCUMENT v3.3.0.814

Condensed Consolidated Statements of Operations and Other Comprehensive Loss - USD ($)
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Revenue

Product sales $ 929,241 $ 268,854 $ 1,432,592 $ 841,567

Laboratory services 23,765 88,190 87,201 379,339

Collaboration revenue 27,780 477,780 308,340 1,783,340

Total revenue 980,786 834,824 1,828,133 3,004,246

Cost of products sold (excluding depreciation and amortization) 562,694 101,425 712,016 276,831

Cost of services (excluding depreciation and amortization) 46,634 129,120 191,738 336,616

Total costs of sales (excluding depreciation and amortization) 609,328 230,545 903,754 613,447

Gross profit 371,458 604,279 924,379 2,390,799

Operating expenses

Research and development 1,724,127 1,029,650 3,741,247 3,075,420

General and administrative 1,610,828 555,444 3,687,313 1,590,085

Sales and marketing 979,681 459,064 2,815,976 1,486,801

Depreciation and amortization 185,177 141,060 392,404 461,432

Transaction expenses 525,596 0 525,596 0

Total operating expenses 5,025,409 2,185,218 11,162,536 6,613,738

Operating loss (4,653,951) (1,580,939) (10,238,157) (4,222,939)

Other income (expense)

Interest income 2,513 37 9,675 120

Interest expense (17,482) (32,331) (1,746,853) (47,468)

Change in fair value of derivative financial instruments and other 0 4,400 (647,342) 4,400

Total other income (expense) (14,969) (27,894) (2,384,520) (42,948)

Loss before income taxes (4,668,920) (1,608,833) (12,622,677) (4,265,887)

Provision for income taxes 1,662 0 1,662 0

Net loss (4,670,582) (1,608,833) (12,624,339) (4,265,887)

Preferred stock dividends 0 (175,246) (244,508) (458,799)

Net loss available to common stockholders $ (4,670,582) $ (1,784,079) $ (12,868,847) $ (4,724,686)

Net loss per common share - basic and diluted (in dollars per share) $ (0.38) $ (4.92) $ (2.00) $ (13.03)

Weighted average shares outstanding - basic and diluted (in shares) 12,261,238 362,537 6,444,373 362,537

Net loss $ (4,670,582) $ (1,608,833) $ (12,624,339) $ (4,265,887)

Other comprehensive loss - foreign currency translation (49) 0 (49) 0

Comprehensive loss $ (4,670,631) $ (1,608,833) $ (12,624,388) $ (4,265,887)

X

- Definition
Aggregate revenue earned during the period from collaboration agreements entered into in the normal course of business.
+ References
No definition available.
+ Details

Name: opgn_CollaborationsRevenue

Namespace Prefix: opgn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate cost of goods and services produced and sold during the reporting period, excluding depreciation, depletion, and amortization.
+ References
No definition available.
+ Details

Name: opgn_CostOfSalesExcludingDepreciationDepletionAndAmortization

Namespace Prefix: opgn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Aggregate revenue during the period from Laboratory services rendered in the normal course of business, after deducting allowances and discounts.
+ References
No definition available.
+ Details

Name: opgn_LaboratoryServicesRevenue

Namespace Prefix: opgn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 25

-Paragraph 23

-URI http://asc.fasb.org/extlink&oid=34752592&loc=d3e1043-128460

+ Details

Name: us-gaap_BusinessCombinationAcquisitionRelatedCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831223

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e557-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate cost of goods produced and sold during the reporting period, excluding depreciation, depletion, and amortization.
+ References
No definition available.
+ Details

Name: us-gaap_CostOfGoodsSoldExcludingDepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate cost of services rendered during the reporting period, excluding depreciation, depletion and amortization.
+ References
No definition available.
+ Details

Name: us-gaap_CostOfServicesExcludingDepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of expense (income) related to adjustment to fair value of warrant liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 480

-SubTopic 10

-Section 25

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=6939902&loc=d3e20148-110875

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_FairValueAdjustmentOfWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1,2)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_GrossProfit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Income Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6515339

+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.9)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7(b))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_InvestmentIncomeInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1377-109256

+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_NonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1A

-Subparagraph (c)(3)

-URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=51664549&loc=SL4569643-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=51664549&loc=SL4569616-111683

+ Details

Name: us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount before tax, after reclassification adjustments of other comprehensive income (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 1B

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669625-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 323

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=35755396&loc=d3e33775-111570

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669619-108580

+ Details

Name: us-gaap_OtherComprehensiveIncomeLossBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Dividends paid to preferred stock holders that is redeemable solely at the option of the issuer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1377-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_RedeemablePreferredStockDividends

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_RevenuesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregate revenue during the period from sale of goods in the normal course of business, before deducting returns, allowances and discounts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(a))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_SalesRevenueGoodsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate total amount of expenses directly related to the marketing or selling of products or services.
+ References
No definition available.
+ Details

Name: us-gaap_SellingAndMarketingExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
+ References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 39 R12.htm IDEA: XBRL DOCUMENT v3.3.0.814

Series A redeemable convertible preferred stock
9 Months Ended

Sep. 30, 2015

Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]

Series A redeemable convertible preferred stock

Note 7 – Series A redeemable convertible preferred stock

All shares of Series A Preferred Stock (including those shares issued in connection with the conversion of the 2014 and 2015 convertible debt (see Note 6)) were converted into 7,374,852 shares of common stock in connection with the Company’s IPO (see Note 9). Prior to the Company’s IPO, the Series A Preferred Stock was classified as temporary equity due to redemption provisions outside of the Company’s control.

The Company issued 1,999,864 shares of Series A Preferred Stock in December 2013 at $1.00 per share in exchange for $1,999,864 in convertible promissory notes. In February 2014, the Company sold 1,405,096 shares of Series A Preferred Stock for gross proceeds of $1,405,096. In April 2014, the Company sold an additional 594,904 shares of Series A Preferred Stock for gross proceeds of $594,904. At December 31, 2014, the Company had a total of 3,999,864 shares of Series A Preferred Stock outstanding, convertible into 3,999,864 shares of common stock.

The holders of the Series A Preferred Stock had the right to receive non-cumulative dividends, at a rate of 8% per annum, when and if declared by the Board of Directors. The Series A Preferred Stock had preference of payment over all other classes and series of capital stock of the Company with respect to dividends, payment on liquidation and payment on redemption. The liquidation and redemption preferences were at two times the Series A Preferred Stock purchase price. The Series A Preferred Stock holders were entitled to vote on all matters that come to stockholders on an as-converted basis with holders of the common stock. In addition, the Series A Preferred Stock had broad based anti-dilution rights.

The holders of Series A Preferred Stock had the right to convert such shares, at their option and at any time, into shares of common stock at the then-applicable conversion rate, as defined. The initial conversion rate was one common share for each preferred share, which could be adjusted for specified dilutive transactions. Beginning in December 2020, the Company may have been obligated to redeem shares of Series A Preferred Stock, if requested, by holders of at least 70% of the then-outstanding shares of preferred stock. The redemption, if requested, would have taken place in three equal annual installments. Series A Preferred Stock would have been redeemed at two times the original issue price per share plus all accrued and unpaid dividends. The redemptions were subject to certain equity adjustments for specified anti-dilution transactions, as defined.

X

- References
No definition available.
+ Details

Name: us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.
+ References
No definition available.
+ Details

Name: us-gaap_PreferredStockTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 40 R11.htm IDEA: XBRL DOCUMENT v3.3.0.814

Fair value measurements
9 Months Ended

Sep. 30, 2015

Fair Value Disclosures [Abstract]

Fair value measurements

Note 6 - Fair value measurements

The Company classifies its financial instruments using a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:

·

Level 1 - defined as observable inputs such as quoted prices in active markets;

·

Level 2 - defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and

·

Level 3 - defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions such as expected revenue growth and discount factors applied to cash flow projections.

Financial assets and liabilities measured at fair value on a recurring basis

The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the hierarchy. The following tables present the fair value hierarchy for the Company’s financial assets and liabilities measured at fair value on a recurring basis at September 30, 2015 and December 31, 2014:

Fair value at

September 30,

2015

Level 1

Level 2

Level 3

Cash and cash equivalents

$

11,187,129

$

11,187,129

$

-

$

-

Fair value at

December 31,

2014

Level 1

Level 2

Level 3

Cash and cash equivalents

$

749,517

$

748,048

$

1,469

$

-

The Company’s Level 1 securities primarily consist of cash and cash equivalents, including money market funds and U.S. Treasury Notes; the Company determines the estimated fair value for its Level 1 securities using quoted (unadjusted) prices for identical assets or liabilities in active markets.

Prior to its IPO, certain stock purchase warrants contained cash settlement features and, accordingly, the Company considered them to be derivative financial instruments and accounted for them at fair value using level 3 inputs. As a result of the Company’s IPO and elimination of the cash settlement features pursuant to their terms, those stock purchase warrants were reclassified to equity. For periods prior to the IPO, the Company determined the fair value of these derivative liabilities using a hybrid valuation method that consisted of a probability weighted expected return method that values the Company’s equity securities assuming various possible future economic outcomes while using an option pricing method (that treated all equity linked instruments as call options on the Company’s equity value with exercise prices based on the liquidation preference of the Series A Preferred Stock ) to estimate the allocation of value within one or more of the scenarios. Using this hybrid method, unobservable inputs included the Company’s equity value, the exercise price for each option value, expected timing of possible economic outcomes such as initial public offering, risk free interest rates and stock price volatility. The following tables set forth a summary of changes in the fair value of Level 3 liabilities measured at fair value on a recurring basis for the nine months ended September 30, 2015:

Balance at

Balance at

December

Established

Change in

Reclassified

September

Description

31, 2014

in 2015

Fair Value

to Equity

30, 2015

Derivative warrant liability

$

-

$

72,333

$

647,342

$

(719,675)

$

-

Financial assets and liabilities carried at fair value on a non-recurring basis

The Company does not have any financial assets and liabilities measured at fair value on a non-recurring basis.

Non-financial assets and liabilities carried at fair value on a recurring basis

The Company does not have any non-financial assets and liabilities measured at fair value on a recurring basis.

Non-financial assets and liabilities carried at fair value on a non-recurring basis

The Company measures its long-lived assets, including property and equipment and intangible assets (including goodwill), at fair value on a non-recurring basis when they are deemed to be impaired. No such fair value impairment was recognized in the three and nine month periods ended September 30, 2015 and 2014.

See Note 4 for a discussion of the fair value of assets acquired and liabilities assumed in the Merger.

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13537-108611

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13504-108611

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13433-108611

+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 41 R23.htm IDEA: XBRL DOCUMENT v3.3.0.814

Liquidity and management's plans (Details Textual) - USD ($)
3 Months Ended 6 Months Ended 9 Months Ended

Jul. 14, 2015

May. 08, 2015

Jun. 30, 2015

Mar. 31, 2015

Mar. 31, 2015

Sep. 30, 2015

Sep. 30, 2014

Conversion of Stock [Line Items]

Proceeds from Notes Payable $ 1,741,667 $ 0

Stock And Warrants Issued During Period Shares Initial Public Offering 2,850,000

Stock And Warrants Issued During Period Shares Initial Public Offering Purchase Price Per Unit $ 6.00

Proceeds From Issuance Of Units Under Initial Public Offering Gross $ 17,100,000

Proceeds From Issuance Of Units Under Initial Public Offering Net 12,100,000

Debt Conversion, Original Debt, Amount $ 2,100,000

Conversion of Stock, Shares Issued 7,374,852

Proceeds from Issuance of Common Stock 4,958,335 0

Debt Conversion, Converted Instrument, Amount 300,000 0

Merck Global Health Innovation Fund LLC | AdvanDx Inc [Member]

Conversion of Stock [Line Items]

Proceeds From Issuance Of Shares And Debt $ 6,000,000

Common Stock

Conversion of Stock [Line Items]

Stock And Warrants Issued During Period Shares Initial Public Offering 422,500

Proceeds From Issuance Of Units Under Initial Public Offering Gross $ 17,100,000

Proceeds From Issuance Of Units Under Initial Public Offering Net 12,100,000

Common Stock | Merck Global Health Innovation Fund LLC

Conversion of Stock [Line Items]

Sale of Stock, Price Per Share $ 4.40

Sale of Stock, Number of Shares Issued in Transaction 1,136,364

Proceeds from Issuance of Common Stock $ 5,000,000

Initial public offering

Conversion of Stock [Line Items]

Proceeds From Issuance Of Units Under Initial Public Offering Net $ 12,100,000

Debt Conversion, Converted Instrument, Amount 2,100,000 $ 0

Convertible Notes Payable

Conversion of Stock [Line Items]

Proceeds from Convertible Debt 1,500,000

Short-term Demand Notes

Conversion of Stock [Line Items]

Proceeds from Notes Payable $ 2,300,000 800,000

Repayments of Notes Payable $ 200,000

Debt Conversion, Converted Instrument, Amount $ 300,000

Promissory Note | Merck Global Health Innovation Fund LLC

Conversion of Stock [Line Items]

Debt Instrument, Face Amount $ 1,000,000

Promissory Note | Common Stock | Merck Global Health Innovation Fund LLC

Conversion of Stock [Line Items]

Proceeds From Issuance Of Common Stock And Notes Payable $ 6,000,000

X

- Definition
The cash inflow from the issuance of common stock and notes payable.
+ References
No definition available.
+ Details

Name: opgn_ProceedsFromIssuanceOfCommonStockAndNotesPayable

Namespace Prefix: opgn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow during the period from issuance of shares and from additional borrowings.
+ References
No definition available.
+ Details

Name: opgn_ProceedsFromIssuanceOfSharesAndDebt

Namespace Prefix: opgn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from entity's issuance of units under initial public offering.
+ References
No definition available.
+ Details

Name: opgn_ProceedsFromIssuanceOfUnitsUnderInitialPublicOfferingGross

Namespace Prefix: opgn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The net cash inflow associated with the amount received from entity's issuance of units under initial public offering.
+ References
No definition available.
+ Details

Name: opgn_ProceedsFromIssuanceOfUnitsUnderInitialPublicOfferingNet

Namespace Prefix: opgn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Warrants acquired by underwrites on the exercise of over-allotment option in connection with IPO.
+ References
No definition available.
+ Details

Name: opgn_StockAndWarrantsIssuedDuringPeriodSharesInitialPublicOffering

Namespace Prefix: opgn_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the purchase price per unit (common stock and warrants) issued during the period pursuant to initial public offering.
+ References
No definition available.
+ Details

Name: opgn_StockAndWarrantsIssuedDuringPeriodSharesInitialPublicOfferingPurchasePricePerUnit

Namespace Prefix: opgn_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ConversionOfStockLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name: us-gaap_ConversionOfStockSharesIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

+ Details

Name: us-gaap_DebtConversionConvertedInstrumentAmount1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

+ Details

Name: us-gaap_DebtConversionOriginalDebtAmount1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Face (par) amount of debt instrument at time of issuance.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 55

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=34725769&loc=d3e28878-108400

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

+ Details

Name: us-gaap_DebtInstrumentFaceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromConvertibleDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from a borrowing supported by a written promise to pay an obligation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_ProceedsFromNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash outflow for a borrowing supported by a written promise to pay an obligation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3291-108585

+ Details

Name: us-gaap_RepaymentsOfNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockPricePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=opgn_MerckGlobalHealthInnovationFundLlcMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=opgn_AdvandxIncMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShortTermDebtTypeAxis=us-gaap_LoansPayableMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 42 R19.htm IDEA: XBRL DOCUMENT v3.3.0.814

Summary of significant accounting policies (Tables)
9 Months Ended

Sep. 30, 2015

Accounting Policies [Abstract]

Schedule of inventories

Inventories are valued using the first-in, first-out method and stated at the lower of cost or market and consist of the following:

September 30,

December 31,

2015

2014

Raw materials and supplies

$

697,414

$

40,749

Work-in process

222,031

135,625

Finished goods

236,043

193,368

Total

$

1,155,488

$

369,742

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 2

-Paragraph 6

-Subparagraph a,b,c

-Article 5

+ Details

Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 43 R15.htm IDEA: XBRL DOCUMENT v3.3.0.814

Commitments and contingencies
9 Months Ended

Sep. 30, 2015

Commitments and Contingencies Disclosure [Abstract]

Commitments and contingencies

Note 10 - Commitments and contingencies

Operating leases

During the second quarter 2015, the Company extended the term of its Gaithersburg, Maryland office lease, effective May 7, 2015, through January 31, 2021, with one additional five-year renewal at the Company’s election. The Company is responsible for all utilities, repairs, insurance, and taxes under this operating lease. Effective July 1, 2015, the Company further modified its lease agreement to add additional leased space to its headquarters. The Company also leases a facility in Woburn, Massachusetts under an operating lease that expires in January 2016, and provides the Company with options to extend the lease beyond the current expiration date. Additionally, the Company leases office space in Denmark; this lease was extended in September 2015 and is currently on a month-to-month basis. Rent expense under the Company’s facility operating leases for the nine months ended September 30, 2015 and 2014 was $447,007 and $341,862 respectively.

Capital leases

The Company leases computer equipment, office furniture, and equipment under various capital leases. The leases expire at various dates through 2018. The leases require monthly principal and interest payments.

Registration and other shareholder rights

In connection with the Merger and the investment transactions (see Notes 4 and 5), the Company also entered into a Registration Rights Agreement with the AdvanDx stockholders receiving Merger Consideration and with Merck GHI, pursuant to which the investors were granted certain demand registration rights and piggyback registration rights in connection with subsequent registered offerings of the Company's common stock. Merck GHI also received rights to participate on a pro-rata basis in future securities offerings by the Company.

On December 18, 2013, the Company entered into the Third Amended and Restated Investors' Rights Agreement (the "Investors' Rights Agreement") with investors acquiring promissory notes convertible into shares of the Company's Series A Preferred Stock. Following the IPO, the holders of 20% or more of the securities subject to the Investors' Rights Agreement have demand registration rights and piggyback registration rights in connection with subsequent registered offerings of the Company's common stock.

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=51674963&loc=d3e12565-110249

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 44 R13.htm IDEA: XBRL DOCUMENT v3.3.0.814

Debt
9 Months Ended

Sep. 30, 2015

Debt Disclosure [Abstract]

Debt

Note 8 - Debt

All the Company’s outstanding demand notes and convertible notes were exchanged for units in the Company’s IPO or otherwise were converted into Series A Preferred Stock and subsequently converted into shares of common stock in connection with the IPO. A short-term 8% promissory note for $150,000 issued in April 2015 was repaid in cash in June 2015. In July 2015, the Company issued a $1.0 million 8% senior secured promissory note to Merck GHI (see Note 5). As of September 30, 2015, the Company has a total of $1,001,250 debt outstanding.

Demand notes

In the fourth quarter of 2014 and first quarter of 2015, the Company raised a total of $2.3 million through the issuance of short-term demand notes. In the first quarter of 2015, $0.3 million of demand notes, held by an entity controlled by our chief executive officer, were settled as partial payment for a 2015 convertible note. All outstanding demand notes were tendered as payment for 350,000 units in the Company’s IPO (see Note 9). Prior to settlement, the demand notes bore interest at 8% per annum, had a first priority security interest in the assets of the Company, and a term of approximately four months.

2014 convertible debt

In July, August and September 2014, the Company raised $1.5 million through the issuance of convertible debt. All outstanding 2014 convertible debt was converted into Series A Preferred Stock and then into 1,500,000 shares of common stock in connection with the Company’s IPO (see Note 9). Prior to its conversion, the debt was convertible, at the option of the holders or in certain cases at the Company’s option, into shares of Series A Preferred Stock or other potential equity securities, bore interest at 8% and was due in full on July 11, 2015.

2015 convertible debt

In February and March 2015, the Company raised $1.5 million in capital through the issuance of 8% secured convertible notes with detachable stock purchase warrants. All outstanding 2015 convertible debt was converted into Series A Preferred Stock and then into 1,875,000 shares of common stock in connection with the Company’s IPO (see Note 9). Prior to its conversion, the 2015 convertible notes were pre-payable by the Company without penalty at any time following the three-month anniversary of the closing of the IPO (provided that before the six-month anniversary of the closing of an IPO, the 2015 convertible notes could only be prepaid out of newly issued capital subsequent to the IPO), and were puttable by the holder to the Company in the event of a defined default. The 2015 convertible notes were each convertible, at the election of the holder, into (i) shares of Series A Preferred Stock, at a conversion rate of 1.25 shares of Series A Preferred Stock for each $1.00 converted if the conversion occurs prior to closing of an IPO, or (ii) shares of common stock at a conversion rate of one share of common stock for each $1.00 converted if the conversion occurs after the closing of an IPO.

The conversion option embedded in the convertible notes was determined to contain beneficial conversion features, resulting in the bifurcation of those features as an equity instrument (resulting in an additional debt discount) at issuance. After allocation of the gross proceeds to the detachable stock purchase warrants (discussed below) and beneficial conversion feature, the total debt discount recognized was equal to the face value of the 2015 convertible notes. Upon conversion in May 2015, the remaining unamortized beneficial conversion feature of approximately $1.5 million was charged to interest expense in the accompanying condensed consolidated statement of operations. Remaining unamortized deferred financing costs of $71,421 were also charged to interest expense upon conversion.

The 2015 convertible note holders also received detachable stock purchase warrants exercisable for 225,011 shares of common stock at 110% of the IPO price and exercisable only if the IPO occurred, and then exercisable beginning on the six-month anniversary of the closing of the IPO. Prior to the IPO, as a result of net settlement features, the stock purchase warrants were considered derivative liabilities, were initially recorded at fair value (resulting in a debt discount) and were marked-to-market at each balance sheet date through earnings. As a result of the elimination of the net settlement features in the IPO, the stock purchase warrants were marked to fair value of $0.7 million on May 8, 2015 and then reclassified to equity.

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20,22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 45 R14.htm IDEA: XBRL DOCUMENT v3.3.0.814

Stockholders' equity (deficit)
9 Months Ended

Sep. 30, 2015

Stockholders' Equity Note [Abstract]

Stockholders' equity (deficit)

Note 9 - Stockholders’ equity (deficit)

On May 8, 2015, the Company completed its IPO pursuant to which the Company offered and sold 2,850,000 units, each consisting of one share of common stock and a detachable stock purchase warrant to purchase an additional share of common stock, at an initial offering price of $6.00 per unit. Of the total gross proceeds of $17.1 million, approximately $2.1 million was satisfied by exchanging outstanding demand notes. After considering the demand notes, and underwriting discounts, commissions and offering expenses of $2.9 million (which were charged to additional paid in capital), the total net cash proceeds to the Company was $12.1 million. On the IPO closing date, the underwriters exercised a portion of their over-allotment option to acquire an additional 422,500 stock purchase warrants for cash of $4,225. In connection with the IPO, all of the Company’s outstanding Series A Preferred Stock, 2014 convertible notes and 2015 convertible notes were converted into 7,374,852 shares of common stock.

The stock purchase warrants issued as part of the units (including over-allotment option) are exercisable for 3,272,500 shares of common stock at $6.60 per share beginning six months after the closing of the IPO for five years, expiring on May 8, 2020. Additionally, the Company issued additional warrants to its investment bankers to purchase 185,250 shares of common stock, on the same terms as the warrants issued with the units. The warrants were valued using the Black-Scholes option pricing model and are classified as equity.

In July 2015, the Company issued 1,136,364 shares of common stock to Merck GHI for cash consideration of $5.0 million (see Note 5).

Stock options

In 2002, the Company adopted the 2002 Stock Option and Restricted Stock Plan, or the 2002 Plan, pursuant to which the Company’s Board of Directors could grant either incentive stock options or non-qualified stock options, shares of restricted stock, shares of unrestricted common stock, and other share-based awards to officers and employees. In 2008, the Company adopted the 2008 Stock Option and Restricted Stock Plan, or the 2008 Plan, pursuant to which the Company’s Board of Directors may grant either incentive or non-qualified stock options or shares of restricted stock to directors, key employees, consultants and advisors.

In April 2015, the Company adopted, and the Company’s stockholders approved, the 2015 Equity Incentive Plan, or the 2015 Plan; the 2015 Plan became effective upon the execution and delivery of the underwriting agreement for the Company’s IPO. Following the effectiveness of the 2015 Plan, no further grants will be made under the 2002 Plan or 2008 Plan. The 2015 Plan provides for the granting of incentive stock options within the meaning of Section 422 of the Internal Revenue Code to employees and the granting of non-qualified stock options to employees, non-employee directors and consultants. The 2015 Plan also provides for the grants of restricted stock, restricted stock units, stock appreciation rights, dividend equivalents and stock payments to employees, non-employee directors and consultants.

Under the 2015 Plan, the aggregate number of shares of the common stock authorized for issuance may not exceed (1) 1,355,000 plus (2) the sum of the number of shares subject to outstanding awards under the 2008 Plan as of the 2015 Plan’s effective date, that are subsequently forfeited or terminated for any reason before being exercised or settled, plus (3) the number of shares subject to vesting restrictions under the 2008 Plan as of the 2015 Plan’s effective date that are subsequently forfeited. In addition, the number of shares that have been authorized for issuance under the 2015 Plan will be automatically increased on the first day of each fiscal year beginning on January 1, 2016 and ending on (and including) January 1, 2025, in an amount equal to the lesser of (1) 4% of the outstanding shares of common stock on the last day of the immediately preceding fiscal year, or (2) another lesser amount determined by the Board of Directors. Shares subject to awards granted under the 2015 Plan that are forfeited or terminated before being exercised or settled, or are not delivered to the participant because such award is settled in cash, will again become available for issuance under the 2015 Plan. However, shares that have actually been issued shall not again become available unless forfeited. As of September 30, 2015, 528,890 shares remain available for issuance under the 2015 Plan.

For the three months ended September 30, 2015 and 2014, the Company recorded $261,540 and $24,977, respectively, of stock compensation expense. For the nine months ended September 30, 2015 and 2014, the Company recorded $1,172,231 and $80,457, respectively, of stock compensation expense. The allocation of share-based compensation expense by operating expenses is as follows:

Three months ended September 30,

2015

2014

Research and development

$

59,688

$

1,528

General and administrative

156,236

22,460

Sales and marketing

45,616

989

$

261,540

$

24,977

Nine months ended September 30,

2015

2014

Research and development

$

161,819

$

3,903

General and administrative

443,267

74,032

Sales and marketing

567,145

2,522

$

1,172,231

$

80,457

During the nine months ended September 30, 2015, the Company granted stock options to acquire 1,660,387 shares of common stock at a weighted average exercise price of $2.87 per share. The 2015 awards had a weighted average grant date fair value per share of $3.16. The Company has total stock options to acquire 1,948,249 shares of common stock outstanding at September 30, 2015.

Restricted stock units

In March 2014, the Company awarded restricted stock units to acquire 130,640 shares of common stock to its Chief Executive Officer. The restricted stock units were compensation for his service as Chief Executive Officer, or CEO, from October 2013 through June 2014 and were subject to forfeiture if he did not continue to perform management services through October 24, 2014. The restricted stock units vested on October 24, 2014 and 130,640 shares of common stock were issued to the CEO.

Stock purchase warrants

The Company has total stock purchase warrants to acquire 3,716,355 and 33,594 shares of common stock outstanding at September 30, 2015 and December 31, 2014, respectively. In the first quarter of 2015, the Company issued 225,011 warrants in connection with the issuance of its 2015 convertible debt. In the second quarter of 2015 in connection with the Company’s IPO, the Company issued 3,457,750 stock purchase warrants to investors and to its investment bankers. As of September 30, 2015, the warrants are classified as equity.

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityNoteAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 46 R16.htm IDEA: XBRL DOCUMENT v3.3.0.814

License agreements, research collaborations and development agreements
9 Months Ended

Sep. 30, 2015

License Agreements Research Collaborations And Development Agreements [Abstract]

License agreements, research collaborations and development agreements

Note 11 - License agreements, research collaborations and development agreements

OpGen is a party to two license agreements to acquire certain patent rights and technologies. Royalties are incurred upon the sale of a product or service which utilizes the licensed technology. Certain of the agreements require the Company to pay minimum royalties or license maintenance fees. The Company recognized $7,484 and $23,810 of net royalty expense for the three months ended September 30, 2015 and 2014, respectively and ($13,769) and $73,142 of net royalty (income) expense for the nine months ended September 30, 2015 and 2014, respectively. In 2015, future minimum royalty fees are $20,000 under these agreements.

In September 2013, OpGen entered into a technology development agreement in which the Company would receive fixed milestone payments for meeting development milestones under the agreement. Since the milestones are substantive, the Company recognizes revenue in the periods in which the substantive milestones are achieved; the Company attained sixteen milestones during 2014. In addition, the Company received an upfront payment of $250,000, which is recognized on a straight-line basis over the term of the technology development agreement. The Company recognized total revenue of $208,340 and $1,133,340 during the nine months ended September 30, 2015 and 2014, respectively, and $27,780 and $172,220 during the three months ended September 30, 2015 and 2014, respectively, relating to this arrangement.

In July 2003, AdvanDx entered into a non-exclusive, non-sublicensable, worldwide license agreement with Life Technologies, Inc. (“Life Technologies”) to use certain patent rights that allow it to manufacture and sell certain products. The agreement was amended multiple times through 2009 to add additional features and modify certain terms and conditions. Life Technologies is entitled to certain royalties on product sales. The Company expensed royalties of $150,570 since the Merger.

X

- References
No definition available.
+ Details

Name: opgn_LicenseAgreementsResearchCollaborationsAndDevelopmentAgreementsAbstract

Namespace Prefix: opgn_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the entire disclosure pertaining to License agreements, research collaborations and development agreements.
+ References
No definition available.
+ Details

Name: opgn_LicenseAgreementsResearchCollaborationsAndDevelopmentAgreementsDisclosureTextBlock

Namespace Prefix: opgn_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 47 R34.htm IDEA: XBRL DOCUMENT v3.3.0.814

Stockholders' equity (deficit) (Details) - USD ($)
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Allocated share-based compensation expense $ 261,540 $ 24,977 $ 1,172,231 $ 80,457

Research and development

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Allocated share-based compensation expense 59,688 1,528 161,819 3,903

General and administrative

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Allocated share-based compensation expense 156,236 22,460 443,267 74,032

Sales and marketing activities

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Allocated share-based compensation expense $ 45,616 $ 989 $ 567,145 $ 2,522

X

- Definition
Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 48 R21.htm IDEA: XBRL DOCUMENT v3.3.0.814

Fair value measurements (Tables)
9 Months Ended

Sep. 30, 2015

Fair Value Disclosures [Abstract]

Schedule of financial assets and liabilities measured at fair value on a recurring basis

The following tables present the fair value hierarchy for the Company’s financial assets and liabilities measured at fair value on a recurring basis at September 30, 2015 and December 31, 2014:

Fair value at

September 30,

2015

Level 1

Level 2

Level 3

Cash and cash equivalents

$

11,187,129

$

11,187,129

$

-

$

-

Fair value at

December 31,

2014

Level 1

Level 2

Level 3

Cash and cash equivalents

$

749,517

$

748,048

$

1,469

$

-

Summary of change in fair value classified as Level 3 liabilities measured at fair value on a recurring basis

The following tables set forth a summary of changes in the fair value of Level 3 liabilities measured at fair value on a recurring basis for the nine months ended September 30, 2015:

Balance at

Balance at

December

Established

Change in

Reclassified

September

Description

31, 2014

in 2015

Fair Value

to Equity

30, 2015

Derivative warrant liability

$

-

$

72,333

$

647,342

$

(719,675)

$

-

X

- Definition
Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19190-110258

+ Details

Name: us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19279-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 49 R26.htm IDEA: XBRL DOCUMENT v3.3.0.814

Business Combination (Details) - USD ($)

Sep. 30, 2015

Dec. 31, 2014

Fair value of identifiable intangible assets acquired:

Fair value of goodwill $ 291,747 $ 0

AdvanDx [Member]

Business Acquisition [Line Items]

Total purchase price - fair value of common stock issued 2,584,090

Fair value of tangible assets acquired:

Cash 1,367,211

Receivables 557,112

Inventory 1,073,855

Property and equipment 250,636

Other assets 359,587

Fair value of identifiable intangible assets acquired:

Customer relationships 1,094,000

Developed technology 458,000

Trademarks and tradenames 461,000

Fair value of goodwill 291,747

Fair value of liabilities assumed 3,329,058

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net, Total $ 2,584,090

X

- Definition
The amount of trademarks recognized as of the acquisition date.
+ References
No definition available.
+ Details

Name: opgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitieAssumedTrademarks

Namespace Prefix: opgn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The amount of customer relationships recognized as of the acquisition date.
+ References
No definition available.
+ Details

Name: opgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerRelationships

Namespace Prefix: opgn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The amount of developed technology recognized as of the acquisition date.
+ References
No definition available.
+ Details

Name: opgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDevelopedTechnology

Namespace Prefix: opgn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 1

-Subparagraph (b)(4)

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

+ Details

Name: us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_BusinessAcquisitionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4845-128472

+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4845-128472

+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4845-128472

+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The amount of inventory recognized as of the acquisition date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4845-128472

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 55

-Paragraph 37

-URI http://asc.fasb.org/extlink&oid=35744172&loc=d3e2207-128464

+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of liabilities assumed at the acquisition date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4845-128472

+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 55

-Paragraph 37

-URI http://asc.fasb.org/extlink&oid=35744172&loc=d3e2207-128464

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4845-128472

+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The amount of property, plant, and equipment recognized as of the acquisition date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4845-128472

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 55

-Paragraph 37

-URI http://asc.fasb.org/extlink&oid=35744172&loc=d3e2207-128464

+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=opgn_AdvandxMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 50 R5.htm IDEA: XBRL DOCUMENT v3.3.0.814

Condensed Consolidated Statements of Cash Flows - USD ($)
9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Cash flows from operating activities

Net loss $ (12,624,339) $ (4,265,887)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization 392,404 461,432

Deferred tax provision 1,662 0

Noncash interest expense 1,598,312 20,883

Share-based compensation 1,172,231 80,457

Inventory obsolescence 0 (44,595)

Change in fair value of derivative financial instruments and other 647,342 (4,400)

Changes in operating assets and liabilities, net of effects of acquisition:

Accounts receivable 507,066 62,251

Inventory 288,126 (159,174)

All other assets (306,386) 78,311

Accounts payable (814,855) 29,853

Accrued compensation and other liabilities (1,752,790) (42,778)

Deferred revenue (180,311) (121,551)

Net cash used in operating activities (11,071,538) (3,905,198)

Cash flows from investing activities

Cash acquired in business combination 1,367,211 0

Purchases of property and equipment (89,234) (39,537)

Net cash provided by (used in) investing activities 1,277,977 (39,537)

Cash flows from financing activities

Proceeds from issuance of common stock, net of issuance costs 4,958,335 0

Proceeds from issuance of preferred stock, net of issuance costs 0 1,937,902

Proceeds from issuance of convertible notes and warrants, net of issuance costs 1,388,815 1,472,386

Proceeds from issuance of promissory notes, net of issuance costs 1,741,667 0

Proceeds from exercise of stock options and warrants 214 0

Proceeds from initial public offering, net of issuance costs paid in 2015 12,408,285 0

Payments on debt (153,750) (3,750)

Payments on capital lease obligations (112,200) (80,575)

Net cash provided by financing activities 20,231,366 3,325,963

Effects of exchange rates on cash (193) 0

Net (decrease) increase in cash and cash equivalents 10,437,612 (618,772)

Cash and cash equivalents at beginning of period 749,517 1,400,345

Cash and cash equivalents at end of period 11,187,129 781,573

Supplemental disclosure of cash flow information

Cash paid during the period for interest 201,233 26,088

Supplemental disclosure of noncash investing and financing activities:

Acquisition of equipment purchased through capital leases 429,320 0

Common stock issued in business combination 2,584,090 0

Debt Conversion, Converted Instrument, Amount 300,000 0

IPO [Member]

Supplemental disclosure of noncash investing and financing activities:

Debt Conversion, Converted Instrument, Amount 2,100,000 0

Series A Preferred Stock [Member]

Supplemental disclosure of noncash investing and financing activities:

Debt Conversion, Converted Instrument, Amount $ 3,000,000 $ 0

X

- Definition
Represents the information pertaining to cash inflow from issuance of convertible notes and warrants, net of issuance costs.
+ References
No definition available.
+ Details

Name: opgn_ProceedsFromIssuanceOfConvertibleNotesAndWarrantsNetOfIssuanceCosts

Namespace Prefix: opgn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from holders exercising their stock options and warrants.
+ References
No definition available.
+ Details

Name: opgn_ProceedsFromStockOptionsAndWarrantExercises

Namespace Prefix: opgn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash outflow during the period from the repayment of aggregate short-term and long-term obligation for a leases meeting the criteria for capitalization.
+ References
No definition available.
+ Details

Name: opgn_RepaymentsOfCapitalLeaseObligations

Namespace Prefix: opgn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Future cash outflow to pay for purchases of fixed assets that have occurred.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name: us-gaap_CapitalExpendituresIncurredButNotYetPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3179-108585

+ Details

Name: us-gaap_CashAcquiredFromAcquisition

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=49171198&loc=d3e33268-110906

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

+ Details

Name: us-gaap_DebtConversionConvertedInstrumentAmount1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Deferred Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6510177

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 6.I.7)

-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 6

-Section I

-Subsection 7

+ Details

Name: us-gaap_DeferredIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=49171198&loc=d3e33268-110906

+ Details

Name: us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of expense (income) related to adjustment to fair value of warrant liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 480

-SubTopic 10

-Section 25

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=6939902&loc=d3e20148-110875

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_FairValueAdjustmentOfWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayableTrade

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of accrued expenses and other operating obligations not separately disclosed in the statement of cash flows.
+ References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInDeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in other assets used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current assets, other noncurrent assets, or a combination of other current and noncurrent assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInOtherOperatingAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of cash paid for interest during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585

+ Details

Name: us-gaap_InterestPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Charge to cost of goods sold that represents the reduction of the carrying amount of inventory, generally attributable to obsolescence or market conditions.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=28360613&loc=d3e4542-108314

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_InventoryWriteDown

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3574-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3574-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Other expenses or losses included in net income that result in no cash outflows or inflows in the period and are not separately disclosed.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_OtherNoncashExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from entity's first offering of stock to the public.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_ProceedsFromIssuanceInitialPublicOffering

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from a borrowing supported by a written promise to pay an obligation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_ProceedsFromNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.
+ References
No definition available.
+ Details

Name: us-gaap_RepaymentsOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Value of stock issued pursuant to acquisitions during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueAcquisitions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 51 R10.htm IDEA: XBRL DOCUMENT v3.3.0.814

Merck GHI Financing
9 Months Ended

Sep. 30, 2015

Common Stock and Note Purchase Agreement [Abstract]

Common Stock and Note Purchase Agreement [Text Block]

Note 5 – Merck GHI Financing

On July 14, 2015, as a condition to the Merger, the Company entered into a Common Stock and Note Purchase Agreement (the “Purchase Agreement”) with Merck GHI, pursuant to which Merck GHI purchased 1,136,364 shares of common stock of the Company at $4.40 per share for gross proceeds of $5.0 million. Pursuant to the Purchase Agreement, the Company also issued to Merck GHI a 8% Senior Secured Promissory Note (the “Note”) in the principal amount of $1.0 million with a two-year maturity date from the date of issuance. The Company's obligations under the Note are secured by a lien on all of the Company's assets.

The Company incurred issuance costs of approximately $50,000 related to the financing, of which approximately $8,000 was deferred as debt issuance costs and are being amortized as interest expense over the life of the Note, and $42,000 was charged to additional paid-in capital.

X

- References
No definition available.
+ Details

Name: opgn_CommonStockAndNotePurchaseAgreementAbstract

Namespace Prefix: opgn_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for common stock and note purchase agreement.
+ References
No definition available.
+ Details

Name: opgn_CommonStockAndNotePurchaseAgreementTextBlock

Namespace Prefix: opgn_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 52 R27.htm IDEA: XBRL DOCUMENT v3.3.0.814

Business Combination (Details 1) - USD ($)
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Business Acquisition, Pro Forma Information

Revenues $ 1,126,530 $ 1,955,894 $ 3,902,337 $ 6,631,510

Net loss $ (4,650,817) $ (4,517,541) $ (15,623,109) $ (11,784,997)

Net loss per share $ (0.38) $ (4.49) $ (2.29) $ (11.72)

X

- Definition
The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(2)-(3)

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1392-128463

+ Details

Name: us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_BusinessAcquisitionProFormaInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(2)-(3)

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1392-128463

+ Details

Name: us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(2)-(3)

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1392-128463

+ Details

Name: us-gaap_BusinessAcquisitionsProFormaRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 53 FilingSummary.xml IDEA: XBRL DOCUMENT 3.3.0.814 html 111 233 1 false 37 0 false 4 false false R1.htm 101 - Document - Document And Entity Information Sheet http://opgen.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 102 - Statement - Condensed Consolidated Balance Sheets Sheet http://opgen.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 103 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://opgen.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 104 - Statement - Condensed Consolidated Statements of Operations and Other Comprehensive Loss Sheet http://opgen.com/role/CondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveLoss Condensed Consolidated Statements of Operations and Other Comprehensive Loss Statements 4 false false R5.htm 105 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://opgen.com/role/CondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 5 false false R6.htm 106 - Disclosure - Organization Sheet http://opgen.com/role/Organization Organization Notes 6 false false R7.htm 107 - Disclosure - Liquidity and management's plans Sheet http://opgen.com/role/LiquidityAndManagementsPlans Liquidity and management's plans Notes 7 false false R8.htm 108 - Disclosure - Summary of significant accounting policies Sheet http://opgen.com/role/SummaryOfSignificantAccountingPolicies Summary of significant accounting policies Notes 8 false false R9.htm 109 - Disclosure - Business Combination Sheet http://opgen.com/role/BusinessCombination Business Combination Notes 9 false false R10.htm 110 - Disclosure - Merck GHI Financing Sheet http://opgen.com/role/MerckGhiFinancing Merck GHI Financing Notes 10 false false R11.htm 111 - Disclosure - Fair value measurements Sheet http://opgen.com/role/FairValueMeasurements Fair value measurements Notes 11 false false R12.htm 112 - Disclosure - Series A redeemable convertible preferred stock Sheet http://opgen.com/role/SeriesRedeemableConvertiblePreferredStock Series A redeemable convertible preferred stock Notes 12 false false R13.htm 113 - Disclosure - Debt Sheet http://opgen.com/role/Debt Debt Notes 13 false false R14.htm 114 - Disclosure - Stockholders' equity (deficit) Sheet http://opgen.com/role/StockholdersEquityDeficit Stockholders' equity (deficit) Notes 14 false false R15.htm 115 - Disclosure - Commitments and contingencies Sheet http://opgen.com/role/CommitmentsAndContingencies Commitments and contingencies Notes 15 false false R16.htm 116 - Disclosure - License agreements, research collaborations and development agreements Sheet http://opgen.com/role/LicenseAgreementsResearchCollaborationsAndDevelopmentAgreements License agreements, research collaborations and development agreements Notes 16 false false R17.htm 117 - Disclosure - Related party transactions Sheet http://opgen.com/role/RelatedPartyTransactions Related party transactions Notes 17 false false R18.htm 118 - Disclosure - Summary of significant accounting policies (Policies) Sheet http://opgen.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of significant accounting policies (Policies) Policies 18 false false R19.htm 119 - Disclosure - Summary of significant accounting policies (Tables) Sheet http://opgen.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of significant accounting policies (Tables) Tables http://opgen.com/role/SummaryOfSignificantAccountingPolicies 19 false false R20.htm 120 - Disclosure - Business Combination (Tables) Sheet http://opgen.com/role/BusinessCombinationTables Business Combination (Tables) Tables http://opgen.com/role/BusinessCombination 20 false false R21.htm 121 - Disclosure - Fair value measurements (Tables) Sheet http://opgen.com/role/FairValueMeasurementsTables Fair value measurements (Tables) Tables http://opgen.com/role/FairValueMeasurements 21 false false R22.htm 122 - Disclosure - Stockholders' equity (deficit) (Tables) Sheet http://opgen.com/role/StockholdersEquityDeficitTables Stockholders' equity (deficit) (Tables) Tables http://opgen.com/role/StockholdersEquityDeficit 22 false false R23.htm 123 - Disclosure - Liquidity and management's plans (Details Textual) Sheet http://opgen.com/role/LiquidityAndManagementsPlansDetailsTextual Liquidity and management's plans (Details Textual) Details http://opgen.com/role/LiquidityAndManagementsPlans 23 false false R24.htm 124 - Disclosure - Summary of significant accounting policies (Details) Sheet http://opgen.com/role/SummaryOfSignificantAccountingPoliciesDetails Summary of significant accounting policies (Details) Details http://opgen.com/role/SummaryOfSignificantAccountingPoliciesTables 24 false false R25.htm 125 - Disclosure - Summary of significant accounting policies (Details Textual) Sheet http://opgen.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual Summary of significant accounting policies (Details Textual) Details http://opgen.com/role/SummaryOfSignificantAccountingPoliciesTables 25 false false R26.htm 126 - Disclosure - Business Combination (Details) Sheet http://opgen.com/role/BusinessCombinationDetails Business Combination (Details) Details http://opgen.com/role/BusinessCombinationTables 26 false false R27.htm 127 - Disclosure - Business Combination (Details 1) Sheet http://opgen.com/role/BusinessCombinationDetails1 Business Combination (Details 1) Details http://opgen.com/role/BusinessCombinationTables 27 false false R28.htm 128 - Disclosure - Business Combination (Details Textual) Sheet http://opgen.com/role/BusinessCombinationDetailsTextual Business Combination (Details Textual) Details http://opgen.com/role/BusinessCombinationTables 28 false false R29.htm 129 - Disclosure - Merck GHI Financing (Details Textual) Sheet http://opgen.com/role/MerckGhiFinancingDetailsTextual Merck GHI Financing (Details Textual) Details http://opgen.com/role/MerckGhiFinancing 29 false false R30.htm 130 - Disclosure - Fair value measurements (Details) Sheet http://opgen.com/role/FairValueMeasurementsDetails Fair value measurements (Details) Details http://opgen.com/role/FairValueMeasurementsTables 30 false false R31.htm 131 - Disclosure - Fair value measurements (Details 1) Sheet http://opgen.com/role/FairValueMeasurementsDetails1 Fair value measurements (Details 1) Details http://opgen.com/role/FairValueMeasurementsTables 31 false false R32.htm 132 - Disclosure - Series A redeemable convertible preferred stock (Details Textual) Sheet http://opgen.com/role/SeriesRedeemableConvertiblePreferredStockDetailsTextual Series A redeemable convertible preferred stock (Details Textual) Details http://opgen.com/role/SeriesRedeemableConvertiblePreferredStock 32 false false R33.htm 133 - Disclosure - Debt (Details Textual) Sheet http://opgen.com/role/DebtDetailsTextual Debt (Details Textual) Details http://opgen.com/role/Debt 33 false false R34.htm 134 - Disclosure - Stockholders' equity (deficit) (Details) Sheet http://opgen.com/role/StockholdersEquityDeficitDetails Stockholders' equity (deficit) (Details) Details http://opgen.com/role/StockholdersEquityDeficitTables 34 false false R35.htm 135 - Disclosure - Stockholders' equity (deficit) (Details Textual) Sheet http://opgen.com/role/StockholdersEquityDeficitDetailsTextual Stockholders' equity (deficit) (Details Textual) Details http://opgen.com/role/StockholdersEquityDeficitTables 35 false false R36.htm 136 - Disclosure - Commitments and contingencies (Details Textual) Sheet http://opgen.com/role/CommitmentsAndContingenciesDetailsTextual Commitments and contingencies (Details Textual) Details http://opgen.com/role/CommitmentsAndContingencies 36 false false R37.htm 137 - Disclosure - License agreements, research collaborations and development agreements (Details Textual) Sheet http://opgen.com/role/LicenseAgreementsResearchCollaborationsAndDevelopmentAgreementsDetailsTextual License agreements, research collaborations and development agreements (Details Textual) Details http://opgen.com/role/LicenseAgreementsResearchCollaborationsAndDevelopmentAgreements 37 false false All Reports Book All Reports In ''Condensed Consolidated Balance Sheets'', column(s) 3, 4 are contained in other reports, so were removed by flow through suppression. In ''Condensed Consolidated Statements of Operations and Other Comprehensive Loss'', column(s) 1 are contained in other reports, so were removed by flow through suppression. In ''Condensed Consolidated Statements of Cash Flows'', column(s) 1, 2, 4 are contained in other reports, so were removed by flow through suppression. opgn-20150930.xml opgn-20150930_cal.xml opgn-20150930_def.xml opgn-20150930_lab.xml opgn-20150930_pre.xml opgn-20150930.xsd true true XML 54 R20.htm IDEA: XBRL DOCUMENT v3.3.0.814

Business Combination (Tables)
9 Months Ended

Sep. 30, 2015

Business Combinations [Abstract]

Schedule of preliminary allocation of the purchase price

The following represents the preliminary allocation of the purchase price:

Total purchase price - fair value of common stock issued

$

2,584,090

Fair value of tangible assets acquired:

Cash

1,367,211

Receivables

557,112

Inventory

1,073,855

Property and equipment

250,636

Other assets

359,587

Fair value of identifiable intangible assets acquired:

Customer relationships

1,094,000

Developed technology

458,000

Trademarks and tradenames

461,000

Fair value of goodwill

291,747

Fair value of liabilities assumed

3,329,058

$

2,584,090

Schedule of unaudited pro forma financial information

The following unaudited pro forma financial information summarizes the results of operations for the periods indicated as if the Merger had been completed as of January 1, 2014. Pro forma information primarily reflects adjustments relating to (i) elimination of the interest on AdvanDx’s outstanding debt, and (ii) the amortization of intangibles acquired. The pro forma amounts do not purport to be indicative of the results that would have actually been obtained if the acquisition occurred as of January 1, 2014 or that may be obtained in the future:

Unaudited pro forma results

Nine months ended

Three months ended

September 30,

September 30,

September 30,

September 30,

2015

2014

2015

2014

Revenues

$

3,902,337

$

6,631,510

$

1,126,530

$

1,955,894

Net loss

$

(15,623,109)

$

(11,784,997)

$

(4,650,817)

$

(4,517,541)

Net loss per share

$

(2.29)

$

(11.72)

$

(0.38)

$

(4.49)

X

- Definition
Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(2)-(3)

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1392-128463

+ Details

Name: us-gaap_BusinessAcquisitionProFormaInformationTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_BusinessCombinationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1486-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1392-128463

+ Details

Name: us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

Debt (Details Textual)		1 Months Ended		2 Months Ended	3 Months Ended				6 Months Ended	9 Months Ended
Debt (Details Textual)	May. 08, 2015 USD ($)	Jul. 31, 2015 USD ($)	May. 31, 2015 USD ($) shares	Mar. 31, 2015 USD ($) $ / shares shares	Sep. 30, 2015 USD ($)	Jun. 30, 2015 USD ($)	Mar. 31, 2015 USD ($) $ / shares shares	Sep. 30, 2014 USD ($)	Mar. 31, 2015 USD ($) $ / shares shares	Sep. 30, 2015 USD ($)	Sep. 30, 2014 USD ($)
Debt Instrument [Line Items]
Proceeds from Notes Payable										$ 1,741,667	$ 0
Debt Conversion, Converted Instrument, Amount										300,000	0
Fair Value Adjustment of Warrants	$ 700,000				$ 0			$ (4,400)		647,342	(4,400)
Interest Expense, Debt			$ 1,500,000								1,500,000
Amortization of Financing Costs										71,421
Common Stock Percent				8.00%			8.00%		8.00%
Common Stock [Member]
Debt Instrument [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares				225,011			225,011		225,011
IPO [Member]
Debt Instrument [Line Items]
Debt Conversion, Converted Instrument, Amount										2,100,000	$ 0
Debt Conversion, Converted Instrument, Shares Issued \| shares			1,875,000
IPO [Member] \| Common Stock [Member]
Debt Instrument [Line Items]
Debt Conversion, Converted Instrument, Shares Issued \| shares			350,000
2014 Convertible Notes
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage								8.00%			8.00%
Proceeds from Other Short-term Debt								$ 1,500,000
2015 Convertible Notes
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		8.00%		8.00%		0.00%	8.00%		8.00%
Proceeds from Other Short-term Debt		$ 1,000,000		$ 1,500,000		$ 150,000
Convertible Notes Payable					$ 1,001,250					1,001,250
2015 Convertible Notes \| Common Stock [Member]
Debt Instrument [Line Items]
Debt Instrument, Convertible, Conversion Price \| $ / shares				$ 1.00			$ 1.00		$ 1.00
2015 Convertible Notes \| Pre IPO
Debt Instrument [Line Items]
Debt Instrument, Convertible, Conversion Ratio				1.25
2015 Convertible Notes \| Post IPO
Debt Instrument [Line Items]
Debt Instrument, Convertible, Conversion Ratio				1.00
Short-term Demand Notes
Debt Instrument [Line Items]
Proceeds from Notes Payable									$ 2,300,000	$ 800,000
Debt Conversion, Converted Instrument, Amount							$ 300,000
Debt Instrument, Interest Rate, Stated Percentage					8.00%					8.00%

Summary of significant accounting policies (Details Textual) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Jun. 30, 2015	May. 08, 2015
Significant Accounting Policies [Line Items]
Allowance for Doubtful Accounts Receivable	$ 79,697		$ 79,697		$ 79,697
Inventory Valuation Reserves	$ 778,944		$ 778,944		867,816
Operating Loss Carryforwards					76,267,809
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	5,700,000	6,100,000	5,700,000	6,100,000
Cash, FDIC Insured Amount	$ 250,000		$ 250,000
Product Warranty Accrual	2,750		2,750		2,750
Goodwill	$ 291,747		$ 291,747		$ 0
Developed Technology Rights [Member]
Significant Accounting Policies [Line Items]
Finite-Lived Intangible Asset, Useful Life			7 years
Customer Relationships [Member]
Significant Accounting Policies [Line Items]
Finite-Lived Intangible Asset, Useful Life			7 years
Trademarks [Member]
Significant Accounting Policies [Line Items]
Finite-Lived Intangible Asset, Useful Life			10 years
Common Stock [Member]
Significant Accounting Policies [Line Items]
Convertible Preferred Stock, Shares Issued upon Conversion						7,374,852	7,374,852
Series A Convertible Redeemable Preferred Stock
Significant Accounting Policies [Line Items]
Temporary Equity Redemption Request Of Minimum Percentage Of Holders Of Outstanding Preferred Stock Required			70.00%
Temporary Equity, Shares Outstanding	0		0		3,999,864
Accounts Receivable \| Customer One
Significant Accounting Policies [Line Items]
Concentration Risk, Percentage			12.00%		79.00%
Accounts Receivable \| Customer Two
Significant Accounting Policies [Line Items]
Concentration Risk, Percentage			11.00%		15.00%
Maximum
Significant Accounting Policies [Line Items]
Accounts Receivable Period Due			45 days
Minimum
Significant Accounting Policies [Line Items]
Accounts Receivable Period Due			30 days

License agreements, research collaborations and development agreements (Details Textual) - USD ($)	1 Months Ended	3 Months Ended			9 Months Ended
	Sep. 30, 2013	Sep. 30, 2015	Sep. 30, 2014	Jun. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
License Agreements Research Collaborations And Development Agreements [Line Items]
Future Minimum Royalty Payments Due		$ 20,000			$ 20,000
License Upfront Payment Received	$ 250,000
Royalty (Income) Expense		7,484	$ 23,810		(13,769)	$ 73,142
Licenses Revenue		27,780		$ 172,220	$ 208,340	$ 1,133,340
Life Technologies [Member]
License Agreements Research Collaborations And Development Agreements [Line Items]
Royalty (Income) Expense		$ 150,570

Merck GHI Financing (Details Textual) - USD ($)		9 Months Ended
Merck GHI Financing (Details Textual) - USD ($)	Jul. 14, 2015	Sep. 30, 2015	Sep. 30, 2014
Common Stock and Note Purchase Agreement [Line Items]
Proceeds from Issuance of Common Stock		$ 4,958,335	$ 0
Merck GHI Financing Agreement [Member]
Common Stock and Note Purchase Agreement [Line Items]
Sale of Stock, Number of Shares Issued in Transaction	1,136,364
Shares Issued, Price Per Share	$ 4.40
Proceeds from Issuance of Common Stock	$ 5,000,000
Debt Instrument, Interest Rate, Stated Percentage	8.00%
Debt Instrument, Face Amount	$ 1,000,000
Fees Related to Common Stock and Debt Transaction	50,000
Payments of Debt Issuance Costs	8,000
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs	$ 42,000

Business Combination (Details Textual) - USD ($)		3 Months Ended		9 Months Ended
Business Combination (Details Textual) - USD ($)	Jul. 14, 2015	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Business Acquisition [Line Items]
Business Acquisition, Percentage of Voting Interests Acquired	100.00%
Goodwill		$ 291,747		$ 291,747		$ 0
Payments of Merger Related Costs, Financing Activities				500,000
Revenues, Total		980,786	$ 834,824	1,828,133	$ 3,004,246
Net Income (Loss) Attributable to Parent		(4,670,582)	$ (1,608,833)	(12,624,339)	$ (4,265,887)
AdvanDx [Member]
Business Acquisition [Line Items]
Goodwill		$ 291,747		291,747
Revenues, Total				800,000
Net Income (Loss) Attributable to Parent				$ 800,000
AdvanDx [Member] \| Equity Issued in Business Combination [Member]
Business Acquisition [Line Items]
Stock Issued During Period Shares for Meger	681,818
Shareholders' Equity, Fair Value Disclosure	$ 2,600,000

Fair value measurements (Details) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Fair value measurements on recurring basis
Cash and cash equivalents	$ 11,187,129	$ 749,517
Level 1
Fair value measurements on recurring basis
Cash and cash equivalents	11,187,129	748,048
Level 2
Fair value measurements on recurring basis
Cash and cash equivalents	0	1,469
Level 3
Fair value measurements on recurring basis
Cash and cash equivalents	$ 0	$ 0

Fair value measurements (Details 1) - Warrant	9 Months Ended
Fair value measurements (Details 1) - Warrant	Sep. 30, 2015 USD ($)
Changes in the fair value of Level 3 liabilities measured at fair value on recurring basis
Balance at the begining of the period	$ 0
Established in 2015	72,333
Change in Fair Value	647,342
Reclassifed to Equity	(719,675)
Balance at the end of the period	$ 0

Series A redeemable convertible preferred stock (Details Textual) - USD ($)		1 Months Ended			9 Months Ended
	May. 08, 2015	Apr. 30, 2014	Feb. 28, 2014	Dec. 31, 2013	Sep. 30, 2015	Dec. 31, 2014
Class of Stock [Line Items]
Debt Conversion, Original Debt, Amount	$ 2,100,000
Conversion of Stock, Shares Issued	7,374,852
Series A Preferred Stock
Class of Stock [Line Items]
Temporary Equity, Shares Issued		594,904	1,405,096	1,999,864
Temporary Equity, Par or Stated Value Per Share				$ 1.00
Debt Conversion, Original Debt, Amount				$ 1,999,864
Proceeds from Issuance of Convertible Preferred Stock		$ 594,904	$ 1,405,096
Temporary Equity, Shares Outstanding						3,999,864
Temporary Equity Shares Outstanding Convertible Into Common Stock Number						3,999,864
Preferred Stock, Dividend Rate, Percentage					8.00%
Temporary Equity Liquidation And Redemption Preference Multiple Of Purchase Price					2
Conversion of Stock, Shares Issued					1
Temporary Equity Redemption Request Of Minimum Percentage Of Holders Of Outstanding Preferred Stock Required					70.00%
Temporary Equity Redemption Number Of Installments					3
Debt Conversion, Converted Instrument, Shares Issued					7,374,852

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Current assets
Cash and cash equivalents	$ 11,187,129	$ 749,517
Accounts receivable, net	553,938	503,983
Inventory, net	1,155,488	369,742
Prepaid expenses and other current assets	538,312	90,233
Total current assets	13,434,867	1,713,475
Property and equipment, net	1,021,971	587,956
Deferred IPO issuance costs	0	296,041
Intangible assets, net	1,955,769	0
Goodwill	291,747	0
Other noncurrent assets	293,135	57,459
Total assets	16,997,489	2,654,931
Current liabilities
Accounts payable	1,274,657	1,160,081
Accrued compensation and benefits	840,637	423,099
Accrued liabilities	1,232,328	993,657
Deferred revenue	158,860	339,171
Short-term notes payable	1,250	1,505,000
Current maturities of long-term capital lease obligations	227,049	100,499
Short-term convertible notes, net of discounts	0	1,500,000
Total current liabilities	3,734,781	6,021,507
Note payable	1,000,000	0
Long-term capital lease obligations and other noncurrent liabilities	317,854	134,149
Total liabilities	$ 5,052,635	6,155,656
Commitments and contingencies (Note 10)
Redeemable convertible preferred stock
Redeemable convertible preferred stock	$ 0	4,564,899
Stockholders' equity (deficit)
Common stock, $.01 par value; 200,000,000 shares authorized; 12,539,704 and 493,178 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively	125,397	4,932
Additional paid-in capital	121,216,140	88,701,737
Accumulated other comprehensive loss	(49)	0
Accumulated deficit	(109,396,634)	(96,772,293)
Total stockholders' equity (deficit)	11,944,854	(8,065,624)
Total liabilities, redeemable preferred stock and stockholders' equity (deficit)	16,997,489	2,654,931
Series A Convertible Redeemable Preferred Stock
Redeemable convertible preferred stock
Redeemable convertible preferred stock	$ 0	$ 4,564,899

Stockholders' equity (deficit) (Details Textual) - USD ($)			1 Months Ended			3 Months Ended			9 Months Ended
	Jul. 14, 2015	May. 08, 2015	Jul. 31, 2015	Oct. 24, 2014	Mar. 31, 2014	Sep. 30, 2015	Jun. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Mar. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense						$ 261,540		$ 24,977	$ 1,172,231	$ 80,457
Debt Conversion, Converted Instrument, Amount									300,000	0
Stock Purchase Warrants Issued Upon Conversion Over Allotment Option		422,500
Proceeds from Issuance of Warrants		$ 4,225
Proceeds From Issuance Of Units Under Initial Public Offering Gross		17,100,000
Proceeds From Issuance Of Units Under Initial Public Offering Net		$ 12,100,000
Stock Issued During Period, Value, Acquisitions									$ 2,584,090	0
Merck Global Health Innovation Fund LLC [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, New Issues			1,136,364
Over-Allotment Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		3,272,500
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 6.60
Expiration Date of Warrants Issued		May 08, 2020
Demand Notes Payable [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Debt Conversion, Converted Instrument, Amount		$ 2,100,000
2015 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized						1,355,000			1,355,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant						528,890			528,890
Share-based Compensation Arrangement by Share-based Payment Award, Common stock Pecentage									4.00%
Stock Purchase Warrants Issued							3,457,750
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense						$ 261,540		$ 24,977	$ 1,172,231	$ 80,457
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross									1,660,387
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price									$ 2.87
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value									$ 3.16
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number						1,948,249			1,948,249
Restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period					130,640
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period				130,640
Warrant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of Warrant or Right, Outstanding						3,716,355			3,716,355			33,594
Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock and Warrants Issued in Conjunction with Initial Public Offering		2,850,000
Offering Price Per Unit		$ 6.00
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs		$ 2,900,000
Convertible Preferred Stock, Shares Issued upon Conversion		7,374,852					7,374,852
Class of Warrant or Right, Number of Securities Called by Warrants or Rights											225,011
Proceeds From Issuance Of Units Under Initial Public Offering Gross		$ 17,100,000
Proceeds From Issuance Of Units Under Initial Public Offering Net		$ 12,100,000
Common Stock [Member] \| Merck Global Health Innovation Fund LLC [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Value, Acquisitions	$ 5,000,000
Common Stock [Member] \| Over-Allotment Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		185,250

Commitments and contingencies (Details Textual) - USD ($)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Operating Leased Assets [Line Items]
Operating Leases, Rent Expense, Net	$ 447,007	$ 341,862

Summary of significant accounting policies (Details) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Inventories
Raw materials and supplies	$ 697,414	$ 40,749
Work-in process	222,031	135,625
Finished goods	236,043	193,368
Total	$ 1,155,488	$ 369,742

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	12,539,704	493,178
Common stock, shares outstanding	12,539,704	493,178
Series A Convertible Redeemable Preferred Stock
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	6,000,000	6,000,000
Preferred stock, shares issued	0	3,999,864
Preferred stock, shares outstanding	0	3,999,864
Preferred stock, liquidation preference	$ 0	$ 7,999,728

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2015	Oct. 30, 2015
Document Information [Line Items]
Entity Registrant Name	OPGEN INC
Entity Central Index Key	0001293818
Document Type	10-Q
Document Period End Date	Sep. 30, 2015
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	OPGN
Entity Common Stock, Shares Outstanding		12,539,704
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2015

Business Combination (Details) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Fair value of identifiable intangible assets acquired:
Fair value of goodwill	$ 291,747	$ 0
AdvanDx [Member]
Business Acquisition [Line Items]
Total purchase price - fair value of common stock issued	2,584,090
Fair value of tangible assets acquired:
Cash	1,367,211
Receivables	557,112
Inventory	1,073,855
Property and equipment	250,636
Other assets	359,587
Fair value of identifiable intangible assets acquired:
Customer relationships	1,094,000
Developed technology	458,000
Trademarks and tradenames	461,000
Fair value of goodwill	291,747
Fair value of liabilities assumed	3,329,058
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net, Total	$ 2,584,090

Condensed Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Cash flows from operating activities
Net loss	$ (12,624,339)	$ (4,265,887)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	392,404	461,432
Deferred tax provision	1,662	0
Noncash interest expense	1,598,312	20,883
Share-based compensation	1,172,231	80,457
Inventory obsolescence	0	(44,595)
Change in fair value of derivative financial instruments and other	647,342	(4,400)
Changes in operating assets and liabilities, net of effects of acquisition:
Accounts receivable	507,066	62,251
Inventory	288,126	(159,174)
All other assets	(306,386)	78,311
Accounts payable	(814,855)	29,853
Accrued compensation and other liabilities	(1,752,790)	(42,778)
Deferred revenue	(180,311)	(121,551)
Net cash used in operating activities	(11,071,538)	(3,905,198)
Cash flows from investing activities
Cash acquired in business combination	1,367,211	0
Purchases of property and equipment	(89,234)	(39,537)
Net cash provided by (used in) investing activities	1,277,977	(39,537)
Cash flows from financing activities
Proceeds from issuance of common stock, net of issuance costs	4,958,335	0
Proceeds from issuance of preferred stock, net of issuance costs	0	1,937,902
Proceeds from issuance of convertible notes and warrants, net of issuance costs	1,388,815	1,472,386
Proceeds from issuance of promissory notes, net of issuance costs	1,741,667	0
Proceeds from exercise of stock options and warrants	214	0
Proceeds from initial public offering, net of issuance costs paid in 2015	12,408,285	0
Payments on debt	(153,750)	(3,750)
Payments on capital lease obligations	(112,200)	(80,575)
Net cash provided by financing activities	20,231,366	3,325,963
Effects of exchange rates on cash	(193)	0
Net (decrease) increase in cash and cash equivalents	10,437,612	(618,772)
Cash and cash equivalents at beginning of period	749,517	1,400,345
Cash and cash equivalents at end of period	11,187,129	781,573
Supplemental disclosure of cash flow information
Cash paid during the period for interest	201,233	26,088
Supplemental disclosure of noncash investing and financing activities:
Acquisition of equipment purchased through capital leases	429,320	0
Common stock issued in business combination	2,584,090	0
Debt Conversion, Converted Instrument, Amount	300,000	0
IPO [Member]
Supplemental disclosure of noncash investing and financing activities:
Debt Conversion, Converted Instrument, Amount	2,100,000	0
Series A Preferred Stock [Member]
Supplemental disclosure of noncash investing and financing activities:
Debt Conversion, Converted Instrument, Amount	$ 3,000,000	$ 0

Business Combination (Details 1) - USD ($)	3 Months Ended		9 Months Ended
Business Combination (Details 1) - USD ($)	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Business Acquisition, Pro Forma Information
Revenues	$ 1,126,530	$ 1,955,894	$ 3,902,337	$ 6,631,510
Net loss	$ (4,650,817)	$ (4,517,541)	$ (15,623,109)	$ (11,784,997)
Net loss per share	$ (0.38)	$ (4.49)	$ (2.29)	$ (11.72)